Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Sitemap
- COVID-19
- China Approves Covid Vaccines from Two Companies, Sinocelltech and Clover
- Moderna and China at Impasse over Selling mRNA COVID Vaccine in China
- Ascletis Reports Positive Preclinical Data from 3CLpro COVID Therapy
- Brii Bio Partners with Sinopharm to Distribute COVID mAb Therapy in China
- Fosun Sells $157 Million of COVID-19 Vaccine; Still not Approved in Mainland China
- Five China Pharmas to Supply Generic COVID-19 Therapy to Low Income Countries
- Junshi Starts Global Phase III Trial of COVID-19 Therapy
- Stemirna Planning Phase III Trial of COVID mRNA Vaccine in Brazil
- China Approves Pfizer's Oral Antiviral Therapy for COVID-19
- Everest Medicine's mRNA Omicron COVID-19 Vaccine to Start WHO Trials
- Everest and Providence Developing Omicron Variant COVID Vaccine
- CanSinoBIO Signs Deal for Aerosol Delivery of COVID-19 Vaccine
- Clover Bio Stages $260 Million Hong Kong IPO for Vaccine and Oncology Candidates
- Recbio and Rhegen Form JV to Develop mRNA Vaccines including COVID
- Brii Bio Allocates $100 Million to Bring Dual SARS-CoV-2 mAb Therapy to Market
- Brii Bio Says Dual mAb Therapy Effective in Early Stage COVID-19 Patients
- Hyundai Says Preclinical Test of Novel Oral Drug Successful in COVID-19
- Fosun, BioNTech Form $200 Million China JV to Make COVID-19 Vaccine
- WHO Approves Sinopharm's COVID-19 Vaccine for Global Use
- Sinovac Starts Review Process for Approval of COVID-19 Vaccine in Europe
- CanSino Biologics to Start China Trial of Inhaled COVID-19 Vaccine
- Jiangxi Jemincare to Start US Trial of SARS-CoV-2 Neutralizing Antibody
- Sinovac Raises Production of COVID-19 Vaccine to 2 Billion Doses Per Year
- Kintor's Androgen Agonist Reduces COVID-19 Mortality in Hospitals by 92%
- Kintor OK'd to Start US Trial of Androgen Receptor Antagonist for COVID-19
- CanSino Files for China Approval of COVID-19 Vaccine
- Clover Raises $230 Million for Trimer-Tag Vaccines (including COVID-19) and Cancer Therapies
- CanSino COVID-19 Vaccine Approved in Pakistan
- Junshi/Lilly Dual Antibody Treatment Approved in US to Treat COVID-19
- Sinovac Approved to Launch COVID-19 Vaccine in China
- CanSino Reports COVID-19 Vaccine Was Safe in Global Phase III Trial
- Clover to Start Global Trial of S-Trimer COVID-19 Vaccine
- Kintor's Androgen Inhibitor Starts Brazil Trial to Treat COVID-19
- Sinovac to Expand Production of COVID-19 Vaccine to 2 Billion Doses
- Jemincare Starts Phase I China Trial of COVID-19 Antibody
- Advaccine Acquires Inovio COVID-19 Vaccine in $108 Million Deal
- Sinopharm COVID-19 Vaccine is 79% Effective in Phase III Trial
- Fosun Forms JV with BioNTech to Manufacture COVID-19 Vaccine
- Harbour BioMed Out-Licenses SARS-COV-2 Antibody to AbbVie
- Fosun Pharma to Receive 100 Million Doses of COVID-19 Vaccine for China Use
- Sinovac Raises $515 Million to Double COVID-19 Vaccine Production
- Fosun-Partnered COVID-19 Vaccine Approved in UK
- Sinopharm Files for China Approval of COVID-19 Vaccine, Bloomberg Says
- China COVID-19 Vaccines and Antibody Treatments Advancing toward Approvals
- Fosun Pharma's In-licensed COVID-19 Vaccine Scores 90% Efficacy in US-EU Tests
- GenScript's SARS-CoV-2 Antibody Detection Kit OK'd in US
- Sichuan Clover Bio Lands $328 Million Grant for COVID-19 Vaccine
- Carelink Acquires Fujifilm Flu Drug to Treat COVID-19 in China
- Four China COVID-19 Vaccines Safe in 60,000 Phase III Subjects
- Aslan Pharma Repurposes DHODH Inhibitor for Autoimmune, COVID-19 Indications
- Fosun to Start US Trial of COVID-19 Antibody Treatment
- Junshi and Lilly to File for Emergency Use of Paired Antibodies for COVID-19
- Fosun Pharma to Supply COVID-19 Vaccine to Hong Kong and Macau
- BeiGene Acquires Global Rights (ex-China) to Singlomics' COVID-19 Antibodies
- Sinovac Strikes Deal with Bio Farma to Produce CoronaVac for Indonesia
- Harbour Biomed to Test Natural Killer Cells as COVID-19 Treatment
- BioKangtai Strikes Deal to Supply AstraZeneca's COVID-19 Vaccine to China
- Fosun Doses 72 Subjects in China Trial of mRNA COVID-19 Vaccine
- CanSino Publishes Positive Phase II Data on COVID-19 Vaccine
- Sinopharm CNBG Starts Phase III Trial of COVID-19 Vaccine in Abu Dhabi
- Fosun Approved to Start China Trials of mRNA COVID-19 Vaccine
- CanSino Planning Ex-China 40,000-Patient Phase III Trial of COVID-19 Vaccine
- Harbour BioMed Closes $103 Million Financing for Biologic Portfolio
- Clover Bio Raises $66 Million from CEPI for Trimer-Tag COVID-19 Vaccine
- Sinovac Approved to Start Phase III Trial of COVID-19 Vaccine in Brazil
- China Consortium Starts Phase I Trial of mRNA Vaccine for COVID-19
- China Approves CanSino COVID-19 Vaccine for Military
- Beijing's Institute of Medical Biology Starts Phase II Trial of COVID-19 Vaccine
- Taiwan Approves Use of Remdesivir for Severely Ill COVID-19 Patients
- Clover Bio Starts Phase I Trial of Trimer-Tag COVID-19 Vaccine
- Sinopharm Reports COVID-19 Vaccine Produced up to 100% Response in Phase I/II Trial
- Sinovac Says COVID-19 Vaccine Offers Protection in 90% of Subjects
- Sinopharm Reports Positive Preclinical Results for SARS-CoV-2 Vaccine
- Alphamab and Institut Pasteur Shanghai to Develop COVID-19 mAb
- Junshi Bio Starts China Phase I Trial of SARS-CoV-2 Neutralizing Antibody
- Harbour BioMed Partners with AbbVie to Develop SARS-CoV-2 Antibody
- Gilead's Remdesivir Offers Moderately Improved Clinical Results in COVID-19 Trial
- Junshi Reports Positive Preclinical Data from SARS-CoV-2 mAb
- I-Mab Starts Phase Ib Trial of Re-purposed RA Treatment for COVID-19
- Sinovac Raises $15 Million for Phase II Trials of COVID-19 Vaccine
- CanSino Publishes Positive Data from COVID-19 Vaccine Trial in The Lancet
- CanSino Developing mRNA COVID-19 Vaccine with Precision NanoSystems
- Moderna Reports Early Positive Results in Trial of Coronavirus Vaccine
- Sorrento Announces Antibody that Inhibits 100% of SARS-CoV-2 Virus Infection
- Hot Topics
- Search
- Free Newsletter
- About Us
- Top Stories
- Week in Review: Fosun and Sinopharm Announce $1 Billion Drug Logistics JV
- Week in Review: Fosun and TPG Offer $369 Million for Chindex
- China Pharma Foreign Trade Climbed 10% in 2013
- Luye Pharma to Conduct $750 Million Hong Kong IPO
- Week in Review: Mindray Acquires Control of US-China IVD Company
- Zhejiang Wolwo Bio-Pharma Gains 94% Post-IPO
- Jiangsu ASK Pharma Postpones ChiNext IPO
- Eddingpharm Acquires ACT Biotech for $95 Million
- China Restarts IPO Process
- Chugai Pharma Invests $30 Million to Build China Marketing/Distribution
- Shenzhen Hepalink Buys US Heparin API Maker for $338 Million
- Kanghong Pharma Gains CFDA Approval for China’s First Innovative MAb
- Alvogen Pays $210 Million for 67% of Taiwan’s Lotus Pharma
- Consun Pharma Schedules Hong Kong IPO
- Cardinal Health Buys Majority Share of Guangzhou Baiji Xinte Drug Store
- BioPacific to Make Cross-Border Angel Investments in Life Sciences
- PW Medtech Completes $180 Million Hong Kong IPO
- China’s ZDG Options Canadian Medical Devices in a Potential Blockbuster Deal
- Lorem Vascular Pays $531 Million for Rights to Cytori Stem Cell System in China
- 3SBio Acquires Rights to Novel Biologic Drug from SIMM
- Fosun Sells China Rights for Diabetes Drug to Salubris
- Morningside Invests $10 Million in Kona Medical for China Trials of Device
- Eddingpharm Pays $2.7 Million Upfront for China Rights to Bone Drug
- Hutchison MediPharma Out-licenses Cancer Drug to Lilly for $86.5 Million
- Free Articles
- BeiGene Announces $160 Million Agreement for China Rights to Two EUSA Orphan Biologics
- China Excitement at J.P. Morgan Healthcare Conference
- ChinaBio® and Keck Graduate Institute to Offer China Internships
- 8th ChinaBio® Investor Forum Selects Three “Most Promising” Companies
- 7th ChinaBio® Investor Forum Selects Two “Most Promising” Companies
- News & Analysis
- AstraZeneca to Build Global Strategic Center in Shanghai
- Biocytogen Launches New Division to Partner Antibodies and License Mice Platforms
- Fosun Pharma Receives Support for Phase III Trial of Triple Artemisinin Therapy for Malaria
- WuXi Biologics’ Stock Price Falls 24% after Company Reduces H2 Revenue Estimate
- AstraZeneca to Build Hong Kong R&D Center for Cell and Gene Therapies
- Biocytogen Re-organizes into Preclinical Service and Drug Discovery Divisions
- EQRx Gives up on In-licensing Drugs from China for Lower Cost Therapies in the West
- XtalPi/Merck Collaboration Uses AI + Wet Lab to Improve Crystal Morphology
- Everest Starts Operations in New mRNA Vaccine Production Facility
- MilliporeSigma Opens Viral Clearance Lab in Shanghai, Part of a $29 Million Project
- I-Mab to Concentrate on Five Clinical-Stage Candidates, Will Out-license International Rights
- I-Mab to Start $40 Million Company/Management Share Repurchase Program
- AstraZeneca to Build Qingdao Regional Headquarters with Rare Disease Innovation Center
- SonoScape Releases Sonogram Upgrade Based on Deep Learning
- Shanghai STAR Exchange Biologic and Medicine Index Launches May 9
- Moderna to Open Four Asia Subsidiaries to Expand Reach for mRNA Portfolio
- ChinaBio® Partnering Forum Acquired by EBD Group/Informa
- Beroni Group to Build Biopharma R&D Facility in Zhuhai Park
- I-Mab Partners with Hangzhou Qiantang Park to Build Manufacturing Plant
- Clover Bio Starts Construction of R&D Center in Zhangjiang Hi-Tech Park
- Biosyngen Opens Cell Therapy Production Facility in Guangzhou
- BeiGene Launches Guangzhou Innovation Center for Drug/Device Startups
- Denovo Discovers Biomarker for Gene Therapy
- LisenID Says Novel Epigenetics Diagnostic Effective in Early Lung Cancer
- WuXi AppTech Co-Founders Make $20 Million Gift for Cancer Research
- BeiGene to Invest Hundreds of Millions of Dollars in US Manufacturing Site
- EdiGene Forms University Collaboration for RNA Edited Genetic Therapies
- CANbridge Sponsors Gene Therapy Research for Duchenne Muscular Dystrophy
- Shanghai I-Mab to Open San Diego R&D Lab
- Zai Collaborates with Geneseeq to Implement Personalized Cancer Care
- AnchorDx and Twist Launch Pan-Cancer Screening Product Globally
- Chicago's Sparx Therapeutics to Build Biologics Manufacturing Facility in China
- CARsgen to Invest $157 Million in US CAR-T Lab/Manufacturing Facility
- Burning Rock Starts Large Pan-Cancer Early Detection Study
- aTyr Developing Bi-Specific Platform for tRNA Synthetase-derived Targets
- LianBio Hires Cross-Border Industry Veteran as CEO
- PhageLux AgriHealth Acquires New China Manufacturing Site
- BeiGene Approved to Produce anti-PD-1 in New Guangzhou Biologics Facility
- Invesco Launches China Healthcare Equity Fund
- Ascletis to Add Oncology Drugs to Infectious Disease and NASH Portfolios
- Sequoia and Illumina Launch Shanghai Genomics Incubator
- Paratek Closes $60 Million Loan Using Zai Lab Royalties for Pay Off
- Shanghai Pharma to Build $1.8 Billion Novel Drug Facility in Zhangjiang Park
- Hasten Bio Pays $322 Million for China Rights to Five Takeda Drugs
- Genetron to Screen High Risk Individuals for Liver Cancer in Wuxi City
- CHHT-Alvotech JV Signs China Deal to Commercialize Biosimilars
- Corvus Forms $106 Million China Subsidiary with China Rights to Four of its Assets
- Exclusive: The Story Behind How Cirina, a $12 Million Hong Kong Diagnostics Startup, Became Part of Illumina
- Legend Bio's CEO Placed on House Arrest after China Investigation
- MicuRx Receives $7.8 Million for Phase I/II Trials of Novel Antimicrobial
- Germany's Merck Opens Shanghai Collaboration Center
- AnchorDx Developing $100 Diagnostic Test for Six Types of Cancer
- WuXi NextCODE Morphs into Genuity Science Without Shanghai Operations
- GeneQuantum OK'd to Start US Trials of Novel HER2 ADC
- Chime Biologics of Wuhan BioLake Separates its CDMO Operations from JHL Biotech
- GoBroad Healthcare, a Hillhouse Company, Starts Construction of Beijing Research Hospital
- Alphamab and 3D Medicines Choose Simcere to Market Their PD-L1 Candidate
- Sorrento Therapeutics Starts Pre-clinical Tests of SARS-CoV-2 Anti-viral
- Clover Collaborates with GSK on COVID-19 Vaccine
- Lilly-Innovent Veteran to Head Everest Med; Commits to China Despite COVID-19
- Clover Announces Vaccine Candidate for 2019-nCOV
- BGI and Partners Build Emergency Wuhan Coronavirus Testing Lab in Five Days
- Gates Foundation Commits up to $100 Million to Address Coronavirus Outbreak
- Update: Biopharmas Developing Products for Wuhan Coronavirus Outbreak
- Wuhan Coronavirus Continues to Spread; Biopharmas Offer Responses
- Ascentage Building Headquarters, R&D Center, Manufacturing Facility in Suzhou
- Novartis Refocuses Shanghai Research Institute on Drug Development, not Discovery
- WuXi Biologics to Build Facility for $3 Billion Vaccine in Ireland
- New Horizon Health Signs Up Prenetics to Market Colorectal Test
- BJ Bio Selects CMAB for CMC and Manufacturing of Cancer mAb
- CBMG Announces Plans to Build US R&D Facility for Immunotherapies
- Covance Opens New Clinical CRO Facility in Shanghai
- JHL Biotech Settles IP Suit with Genentech, Discontinuing Development of Four Genentech Biosimilars
- AstraZeneca, Wuxi City Partner to Open New China Life Science Park
- Novartis Sells Suzhou API Plant to Zhejiang Jiuzhou for $110.5 Million
- WuXi AppTec Launches DELight, a Self-Service Drug Discovery Hit Finding Kit
- Innovent Reports $46 Million of Revenue for its PD-1 in 2019 First Half
- India's Natco Joins the March to China's Market by Indian Pharmas
- CStone to Build Major R&D and Manufacturing Complex in Suzhou Park
- Accuray-CNNC JV Breaks Ground on China Manufacturing Center
- Yisheng's New $60 Million Rabies Vaccine Facility Approved by NMPA
- Gilead Sciences Plans Western China Ops Center in Chengdu
- J&J Opens JLABS @ Shanghai, a Life Science Incubator with 31 Resident Startups
- MicroPort Ortho Launches Improved Knee Replacement Product
- Pfizer Upjohn Opens Global Headquarters in Shanghai
- WuXi Biologics Starts Building Chengdu Manufacturing Plant, its 12th Globally
- GenScript Starts Construction of Cell Therapy and Antibody Manufacturing Facility
- AstraZeneca Signs MOU to Become Founding Partner of Life Science Park in Wuxi, China
- Lee's Pharm Accelerates Eye Drop Development as Part of New Ophthalmic Division
- Novo Nordisk Launches New Collaborative Innovation Platform in China
- Merck CEO: China Will Have a Top 50 Biopharma Company
- Lonza to Build Biologics CDMO in China Using GE's Prefabricated Factory
- Biohaven Sets Up China Subsidiary for Migraine/CNS Drugs
- WuXi Biologics Starts Construction on Large Shanghai CDMO Facility
- CASI Pharma to Build Manufacturing Plant in Wuxi, China
- Ping An Good Doctor Announces AI-Based Freestanding One-Minute Clinics
- PharmaBlock Acquires China Manufacturing Plant from Porton Pharma
- Shuwen Biotech of Hangzhou Launches PD-L1 Test Kit
- Driver, "A Cure for Cancer Treatment," Launches in US and China
- Adlai Nortye of Hangzhou Opens Boston Innovation Center
- Sanofi Opens $77 Million Clinical Big Data R&D Facility in Chengdu
- CASI Forms Alliance with Yiling to Manufacture Two Generics for China
- Tot Biopharm Opens New Biologics Facility in Suzhou
- Xiangxue to Build Cell-Therapy Manufacturing Plant in Guangzhou
- Shenzhen Breaks Ground on James Watson-led Life Science Research Center
- Chi-Med Expects Approval of First Novel Cancer Drug in 2018
- Is This the Future? China Nanorobots Fight Cancer
- Merck KGaA to Add Mobius® Single-Use Bioreactor to Wuxi Plant
- Krane Offers China Healthcare ETF with China, Hong Kong, US-listed Companies
- Clover Using GE FlexFactory for China Biologic Manufacturing Plant
- Johnson & Johnson Plans JLABS Incubator in Shanghai
- BeyondSpring's Plinabulin Designated "National Major Product" in China
- Genovis Finds Second China Distribution Partner for Enzyme Portfolio
- Beijing is Home to Gates-Backed $100 Million Global Health Institute
- Lilly Announces Plans to Close its Shanghai R&D Center
- Yisheng Biopharma Reports "Breakthrough" Efficacy of Lead Immuno-Oncology Drug
- GSK To Close Shanghai Neurological R&D Operations
- Australia's Cochlear Plans $39 Million Manufacturing Facility in Chengdu
- GSK Forms Respiratory Disease Big Data Project with Guangzhou Institute
- Malaysia's IHH Healthcare Has $1 Billion of China Hospital Projects; Wants More
- Janssen Promises Lung Cancer Drug Initiative in China
- Sorrento Completes Suzhou Manufacturing Plant for ADC Drugs
- Shanghai's CARsgen Opens CAR-T Manufacturing Facility
- Gilead Sciences Building Hangzhou Manufacturing Facility
- Zai Lab Partners with GE Healthcare to Build Suzhou Bio-Manufacturing Facility
- Beijing's Novogene Orders 25 of Illumina's Latest Sequencing Machines
- Seattle's Just Biotherapeutics Building Biologics Facility in Hangzhou
- CloudHealth Announces Genomic Immunotherapy Response Diagnostic
- Qilu Pharma Launches Biosimilar to AstraZeneca's Iressa in China
- WuXi AppTec's STA Pharma to Expand Changzhou Site
- Vexim Starts China Development of Vertebra Fracture Repair Device
- Aslan Pharma Approved to List Shares on Taiwan's Main Board
- CloudHealth Genomics Launches Liquid Biopsy for Very Early China Screening
- German Merck to Open Biologic CRO/CMO Centers in Shanghai and Boston
- BIT Group Opens China JV for Contract Manufacturing of IVD Devices
- Sinovac to Investigate Allegation that its Chairman Bribed the CFDA
- NeuroMetrix Announces China Launch of Peripheral Neuropathy Diagnostic
- Ping An Insurance Adds 10,000 China Medical Clinics for My Doctor Portal
- Merck KGaA Opens $189 Million Nantong Pharma Plant; Plans $89 Million Life Science Center
- DiaCarta Receives Grant to Validate RadioTherapy Efficacy Tests
- TOT Breaks Ground on Biologics Production Facility in Suzhou
- Jackson Laboratory of the US Plans Genomics Partnership in Wenzhou
- GSK Using Collaborations to Build China Neuroscience R&D
- WuXi Opens Cell Therapy Manufacturing Facility in Philadelphia
- Novartis Closes Biologics R&D Ops at its Shanghai Center
- Ascentage Pharma's Lab Passes China National Standards Test
- WuXi AppTec Completes First Phase of $125 Million Biologics Manufacturing Facility
- China Opens China National GeneBank in Shenzhen
- Huons Pharma of Korea Puts China First in Globalization Effort
- China's Vcanbio Opens Boston Offices to Hunt for Cell and Immuno-Therapy Products
- DeltaHealth, Backed by Fidelity, Opens Shanghai Cardiovascular Hospital
- BioDuro Expands its Shanghai CRO Facility
- Hangzhou Cognitive Care and IBM Join to Provide Best Practices in Cancer
- Aspen Pharma Building China Presence for its Generic Drug Portfolio
- Sinopharm Revises Plan to Reform its State-Owned Enterprise Structure
- South Korea's Hanmi Pharma Will Partner with China Innovation
- Pfizer Breaks Ground on $350 Million Biosimilar Plant in China
- Wuhan Humanwell Building $80 Million Production Facility in Ethiopia
- Parkway Pantai Building $70 Million Hospital in Shanghai
- Novartis Opens $1 Billion Shanghai R&D Center
- OrbusNeich Launches Two Peripheral Artery Disease Devices
- WuXi AppTec and Huawei Launch China Big Data Precision Medicine Project
- HemaCare Uses Shanghai Firm to Support Distribution of Blood Cell/Tissue Products in China
- AliHealth to Offer Voluntary Version of China Drug Tracking System
- Ascenta Pharma of Guangzhou Presents Data on Novel Cancer Drug
- BioSciKin Starts US-China Competition for Life Science Start-ups
- Hanmi Pharma Will Build a New $200 Million Plant in China
- GSK Announces New Beijing R&D Center for Infectious Diseases
- Zai Lab Signs Up Boehringer Ingelheim for China Manufacturing of mAb
- ChinaBio® Partnering Forum Returns to Suzhou May 18-19, 2016
- Bristol-Myers Squibb to Alter China Sales Model
- JHL Biotech Wuhan Manufacturing Facility Built in 11 Days Now Operational
- Alibaba: Did the Future of China Healthcare Just Arrive?
- Cocoon Networks, a China Investor, Opens $707 Million Fund in London
- Bayer Completes Phase I of China TCM/OTC Production Plant
- Medtronic to Build Diabetes Pump Plant in Chengdu
- WuXi PharmaTech and PRA Split Their China Clinical Stage JV
- Chi-Med Sells Shanghai Land Rights for $105 Million
- BGI Changes Direction at Complete Genomics; Cuts Staff
- Fresenius Opens Shanghai R&D Center for Renal Products
- BeiGene Named R&D Achievement of 2015 by BayHelix
- Beike Biotech to Supply Cell Therapy Treatments to 11 Shenzhen Hospitals
- Cellular Biomedicine Opens Beijing Facility
- Tsinghua University Sets Up Medical Big Data Center
- JHL Builds Wuhan Biotech Facility in 11 Days
- Roche Plans New $136 Million Innovation Center in Shanghai
- Dr. Jun Wang, Former CEO of BGI, Announces New AI Health Company
- Sichuan Revotek Uses 3D Printer to Make Blood Vessels
- Shenzhen's Direct Genomics Unveils GenoCare Genomic Analyzer
- AbbVie Commits to Bringing Novel Drugs to China
- Zai Lab Expands into Pre-Clinical Research with Shanghai R&D Facility
- China TCM Malaria Drug May Be Effective Cancer Treatment
- CanSino Building $317 Million Ebola Vaccine Production Facility in Tianjin
- Veritas Genetics Sets Up China R&D Center in Hangzhou
- Hengrui to Build $240 Million Biopharma Plant in Jiangsu
- Beijing's BeiGene to Build Manufacturing Facility in Suzhou
- WuXi Announces Successful Test of TruTag Drug ID
- India Plans Park for 50 China Pharmas
- Jun Wang of BGI: 100 Million Genomes + AI = Human Longevity
- Dr. Jun Wang, CEO of BGI, Steps Down
- Jiangsu Hengrui to Build $137 Million Biologic Drug Facility
- BioNano Genomics Signs Up China Distributor
- ASLAN Pharma and ACT Genomics to Collaborate
- China's Desano Pharma to Make API for New HIV Drug for ViiV
- Colorcon Opens Beijing Lab to Offer Drug Formulation Services
- SGS to Expand Shanghai Microbiology Testing Lab
- Fosun Pharma Plans Big Increase in Foreign Drug Revenues
- Pfizer Building $95 Million Production Plant in Suzhou
- CAS to Build $323 Million Genetic R&D Center in Changzhou
- WuXi PharmaTech Announces eCommerce Research Chemicals Service
- SciClone Pharma Reports Higher Q1 Revenues and Earnings
- China's Neusoft Medical Launches 128-Slice CT Scanner
- Korea's Green Cross to Build Cell Therapy Facility in China
- Dongbao Pharma to Build $59 Million Insulin Manufacturing Facility
- UniTao Pharma Puts Planned US Facility on Hold
- GSK to Build New Asia Headquarters in Singapore
- WuXi’s Dr. Steve Yang to Moderate "Biologics: China's New Wave of Innovation"
- Eisai to Build New Oral Solid Dose Plant in Suzhou
- US-China GPCR Research Consortium Adds Two Pharma Members
- China's ChemPartner Opens Lab in South San Francisco
- Waters Opens China Testing Lab with China Pharmacopeia
- Novotech Expands Hong Kong Operations
- PerkinElmer Opens Screening Lab in Suzhou
- Fosun Pharma to Double R&D Budget: $800 Million in 2016-2020
- Tianyin Pharma in Talks to Extend Sales Network
- Ypsomed to Make Diabetes Injection Pens in China
- China Pioneer to Provide NeutroPhase for Free to Patients with Flesh-Eating Disease
- Eisai China Completes Parenteral Facility in Suzhou
- Week in Review: Sinopharm Raises $716 Million in Secondary Offering
- Amgen Completes $200 Million Biologics Facility in Singapore
- WuXi Reports Record Revenues, CapEx Spending
- Daewoong of Korea Opens China Lab
- Roche to Build $466 Million Diagnostics Manufacturing Plant in Suzhou
- Irvine Pharma Building CRO/CMO Facility in Hangzhou
- International GPCR Consortium Includes China Academic Members
- Amerigen Launches First China Product with Sinochem Jiangsu
- Sihuan Pharma: Ebola Drug NDA by Year-End?
- Sanofi Opens Asian R&D Hub in Shanghai
- Week in Review: Blackstone Buys a $100 Million Stake in China Medical Device Company
- Sagent-Hengrui Partnership Launches Second Cancer Drug in US
- Biocept Looks toward China to Market Cancer Diagnosis Technology
- GSK Faces $489 Million Fine in China Bribery Case
- ACM Global Central Lab Opens Facility in Shanghai
- Tasly Pharma Opens US Headquarters in Maryland
- Dehaier to Launch Sleep Apnea Diagnostic System in China
- Fosun Pharma Launches Saladax's MyCare Dosing Assays in China
- Stryker Will Export its China-made Trauson Products to India
- Medtronic Opens Hemodialysis Device Factory in Chengdu
- Sotio Opens Beijing Lab for Cancer Immunotherapy
- SGS Life Sciences to Expand Shanghai Lab
- Gilead Allows China/Indian Pharmas to Make Generic Version of Novel HIV Drug
- Merck KGaA to Begin Construction of $108 Million China Plant
- China Cord Blood to Cooperate with Singapore’s Cordlife
- BGI Tech Announces Inexpensive Whole Exome Sequencing
- Transgene-Tasly JV Reports Immunotherapy Progress
- Cellular Biomedicine Moves to NASDAQ Capital Market
- Fosun Pharma to Buy Several Israeli Medical Device Companies
- Baxter Opens $56 Million R&D Center in Suzhou
- MicroDiag of Suzhou Presents Innovative Cancer Diagnostic at ASCO
- BIG and Zixin Pharma Announce China-Developed Genomics Sequencer
- InSightec Offers Non-Invasive Uterine Fibroid Treatment in Shanghai
- WuXi PharmaTech Starts High-Potency API Operations
- J&J Targets China, Russia to Grow Medical Device Business
- Sixth Annual ChinaBio® Partnering Forum Reports Record Attendance at Suzhou Event
- Concord Medical to Build 400-Bed Cancer Hospital in Shanghai
- Sinovac Receives $9.6 Million Grant to Build E71 Vaccine Facility
- Johnson & Johnson Starts Construction on $300 Million China Plant
- WuXi PharmaTech Adds Key Executive to Management Team
- ChinaBio® Partnering Forum Scheduled for May 7-8 in Suzhou
- Morgan Stanley Further Reduces Sihuan Pharma Stake
- The Global Fund Seeks Partnerships with China Pharmas
- Bayer Plans $138 Million Expansion of Beijing Facility
- Jiangsu Nhwa to Build $64 Million API Plant
- SR-BioPharma Building $32 Million Facility in China Medical City
- Qiagen Launches New-Gen TB Test in China
- Sagent Pharma Will Spend $30 Million to Expand China Plant
- Applikon Biotech Opens Factory in Guangzhou
- Mindray Medical Grows Revenues 14.5% in 2013
- China Researchers Develop Targeted Nanoparticles for Chemotherapy Delivery
- New Strain of Avian Flu Surfaces in China
- GSK Says China Revenues Fell 18% in Q4
- Sagent Opens Research Center in China
- BioTime Starts US-China Test of Cancer Diagnostic
- China Reports Three Deaths from Forty Cases of H7N9 Flu in January
- Abcam of the UK Opens Shanghai Office
- Actavis to Leave China
- GSK Says China Revenues Recovered in Q4
- Shenzhen Kangtai’s Hepatitis B Vaccine Implicated in Six Deaths
- GSK Institutes Changes to Pay Rules for Sales Force and Doctors
- Shanghai Pharmaceuticals Subsidiary Accused of Bribery
- ScinoPharm Completes China Manufacturing Facility
- Shanghai Official Detained in GlaxoSmithKline Scandal
- Helsinn Group Opens China Office
- Gentris Opens Pharmacogenomics Lab in Shanghai
- Catalent Opens Shanghai Clinical Trial Supply Center
- Merck and J&J to Build New Factories in China
- Lilly Will Invest $350 Million in China Diabetes Cartridge Facility
- BGI Health to Form Collaboration with Sidra Medical of Qatar
- China Will Not Bring Charges against GlaxoSmithKline as a Company
- Cellular Biomedicine Offers Stromal Cell Purification Kits in China
- Sanofi’s Q3 China Revenues Increase at Slower 5% Rate
- China Scientists Report Bird Flu Vaccine is Ready for Human Tests
- Kindstar to Offer RNA-based Cancer Diagnostics in China
- GSK Reports 61% Drop in China Revenues for Q3
- Former Head of GSK China Has Been Asked Not to Leave
- CardioKinetix Implants Heart Failure Device in China Patients
- Lilly Says Two ex-China Scientists Sent Secret Drug Info to Hengrui Medicine
- Police Arrest Alleged Bribery Agent in GSK China Scandal
- Sanofi CEO Remains Positive on China and Other Emerging Markets
- Parexel Forms Company Dedicated to China-Specific Approvals
- Boehringer Ingelheim Opens Expanded Shanghai Production Facility
- Shenzhen Proposes Creation of New Biotech Park
- JHL Biotech Building Biologic CMO in Wuhan’s Biolake
- Amgen to Open China R&D Center at ShanghaiTech University
- GSK’s China Revenues May Be Down by 30% in Q3
- Another China Bribery Rumor Involving Novartis
- Boston Scientific Opens Training Center in Shanghai
- BGI Tech Forms Collaboration with San Antonio Cancer Genome Project
- Two China Biopharmas Hit with Accusations of Bribery
- ASLAN Named to Red Herring’s Top 100 Asia List
- China Says GlaxoSmithKline Deserves an “Astronomical” Fine
- Siemens Shanghai Completes New Facility for X-Ray Machines
- J&J Names Top Executive to Lead China Operations
- Lilly Hit with Bribery Charges in China
- BeiGene Signs Up Industry Veterans for Scientific Advisory Board
- Qilu Pharma Announces $1 Billion Biopharma Park in Jinan
- WuXi PharmaTech Reports Excellent Q2; Raises 2013 Guidance
- Whistleblower Says Sanofi Paid Kickbacks to China Doctors
- Mitsubishi Pharma JV Building $20 Million Plant in Tianjin
- Sinopharm to Build China’s Largest Biotech R&D Center in Wuhan East Lake
- GSK Replaces Head of China Operations
- BGI-Shenzhen Sequences IVF Embryos Prior to Implantation
- GSK Researchers Suppressed Data from China Tests of MS Drug
- Ministry of Public Security: GSK Spent $489 Million on Bribes in China since 2007
- Will GSK’s China Scandals Diminish Big Pharma’s Interest in China R&D?
- Details Emerge About China’s Investigation of GSK
- GSK Officials in China Detained over Corruption Charges
- Thermo Fisher Invests $9.5 Million in China Innovation Center
- GSK Fires China R&D Chief for Misrepresenting Data
- Over 750 Life Science Executives Met Potential Partners at ChinaBio® Partnering Forum 2013 in Beijing
- Valeant Pharma Sees Bausch & Lomb Acquisition as China Entry
- WHO Declares China's H7N9 Flu Crisis Over; Cost was $6.5 Billion
- BioDuro Opens Second China CRO Lab, This One in Shanghai
- Want Success in China? Find an experienced Chinese Partner
- Li Ka-Shing Donates $31 Million to Medical Research Institute at Oxford
- China Budgets $48.6 Million to Monitor H7N9 Bird Flu
- OrbusNeich of Hong Kong Wins Patent Suit against Boston Scientific
- China Researchers Clear Blocked Blood Vessels with Lasers
- Eisai Building Second Production Facility in Suzhou
- Merck Opens $120 Million Packaging Plant in Hangzhou
- Weihai Weigao to Distribute TriReme’s Cardiology Devices in China
- GE Healthcare to Double China Production
- Lilly Opens China IT Center to Facilitate Collaboration with Partners
- Shanghai BravoBio Named BioSpectrum Emerging Company of the Year
- WuXi PharmaTech Reports $500 Million in 2012 Revenues
- Sun Yat-sen University, Johns Hopkins Partner to Develop Medical Researchers
- Mindray Medical Tops $1 Billion in 2012 Revenues
- Beijing Double-Crane to Build $43 Million Shanghai Plant
- Janssen Pharma Opens R&D Center in Shanghai
- Luqa Pharma Launches Topical Scar Treatment in China
- Roche Increases Focus on West China with new Center
- Essex Woodlands Opens China Office to Fund Healthcare Deals
- Grupo Insud to Build $55 Million Veterinary Drug Facility
- ChinaBio® Survey Finds Rising Insider Optimism for China Healthcare
- TTY Biopharm Opens $100 Million Manufacturing Plant in Suzhou
- iHuman Institute at ShanghaiTech to Study Cell Signaling
- Thermo Fisher Opens $20 Million Plant in China
- Promega Opens Manufacturing Facility in Shanghai
- In China, Roche and Swiss Re Offer Insurance to Cover Biologic Drugs
- Lundbeck Opens $7.6 Million Production Plant in Tianjin
- Akeso Biopharma, a China Antibody Company, Opens in Zhongshan
- Mindray Medical’s Q3 Financial Report Disappoints
- Fosun Pharma Drops in First Day of Hong Kong Trading
- Xiamen Innovax Launches World’s First Hepatitis E Vaccine
- US Medical Device Makers Target China’s 2nd and 3rd Tier Markets
- Kindstar Diagnostics to Offer BG Medicine’s Cardiac Test
- ChinaBio® Leadership Retreat Brings 120 Senior Life Science Executives Together to “Rethink China”
- Complete Genomics, Soon to Be a BGI Subsidiary, Wins Partial Victory in Illumina Suit
- Legend Capital Invests in Innovative China Medical Device Companies
- WuXi AppTec Opens China’s First GMP Biologics Facility
- Shanghai Starts New Antibody Institute; Names US Researcher as Director
- Tianyin Pharma Says $25 Million Production Facility Nearly Complete
- China Biotech May Soon Sell Vaccine to International Aid Groups
- QPS Qualitix Opens China CRO Office
- BayHelix and Elsevier Announce Four China Drug Development Awards
- BGI to Open Sequencing Facility in Singapore
- Novo Nordisk Opens Second R&D Center in Beijing
- J&J to Establish Innovation Center in China
- ChinaBio® Investor Forum in Beijing Selects Two “Most Promising” Companies
- China Medical Technologies Inc. Has "No Assets" according to Liquidators
- Joincare Pharma to Build $157 Million Antibiotic Facility
- Irish University Sets Up Collaboration with China Organizations
- Takeda Opens China Clinical Trial Center in Shanghai
- Biostar Pharma Says Gelatin Scandal Will Cut Q2 Revenues in Half
- Mindray Medical Beats Estimates with Strong Q2 Report
- Covidien Invests $45 Million into China Technology Center
- Roche to Hire 1,000 New Employees in China
- WIBF and Refine Technology Collaborate on Vaccines
- Chengdu Hoist Selling Animal Health Business
- China Health Resource Announces TCM for Migraine
- Siegfried to Build API and Intermediates Plant in Nantong
- Karl Storz to Spend $31.5 Million on China Headquarters
- SEC Halts Trading in China Medical’s Stock for Two Weeks
- PharmaNet/i3 Named Distinguished Partner by US-China Anti-Cancer Group
- China Medical Technologies Faces Bankruptcy Petition from Bondholders
- Xiamen Innovax Biotech to Launch Hepatitis E Vaccine in China
- GE Healthcare and BGI Team Up to Develop Stem Cell-based Assays
- ChinaBio® and BioCentury Boost News Flow from China’s Life Science Industry
- ShangPharma and Lilly Celebrate Ten Years of China Partnership
- Former WuXi PharmaTech Employee Convicted for Compound Theft
- Roche Diagnostics to Invest $310 Million in China
- GenScript Completes $40 Million R&D Center in Nanjing
- Boehringer Ingelheim Building $69 Million Plant in China Medical City
- Lilly Officially Opens Diabetes R&D Facility in Shanghai
- Partnering Activity Increases 40% at ChinaBio® Partnering Forum
- China Research Team Develops TB/HIV Combination Vaccine
- Shanghai Pharma Faces Media Charges of Accounting Fraud
- China Tops the US – in Drug Reps
- Novozymes Opens Hyaluronic Acid Plant in Tianjin
- BMS Ups Investment in China R&D and Manufacturing
- Partnering Bootcamp Added to ChinaBio® Partnering Forum
- New China-Australia Research Center to Study TCM
- Big Pharma to Meet Chinese Pharma in Suzhou
- China Healthcare Budget Grows 20% in 2012
- Origin Agritech Sets Up Research Institute with Henan Agricultural University
- Research Tool Maker Fluidigm Opens China Office
- China Cord Blood Co. to Build Stem Cell Facility in Chongqing
- Lotus Pharma Runs Out of Cash
- GE Healthcare Targets China's Rural Markets with New Machines
- Bayer Extends and Expands Partnership with Tsinghua University
- Lilly Wants to Double China Revenues; Seeks Distribution Partners
- CSPC Pharma Developing Patented Drugs
- Bayer Seeks $3.3 Billion of China Revenues by 2015
- For Roche, China Is Necessary
- Aslan Pharma Selects PharmaNet/i3 as Clinical Trial Partner
- EntreMed Opens China Office
- GlaxoSmithKline Adopts Multi-Faceted Strategy for China
- Asymchem Opens Large-Scale CMO Facility in Jilin Province
- Tianyin Pharma Builds Larger, cGMP-Compliant Facility
- ChinaBio® and EBD Schedule ChinaBio® Partnering Forum in May
- BGI Opens European Genome Center in Copenhagen
- GSK Devotes Unit to Traditional Chinese Medicine R&D
- Takeda Sets Up China Division to Supervise Clinical Trials
- AstraZeneca Pares 7,300 Jobs; Ups China Spending
- Transgene Starts Two New China Ventures
- Seven Young China Scientists Given $650,000 Howard Hughes Awards
- ShangPharma Achieves First Milestone in Hengrui Biologics Partnership
- Quintiles Opens New Support Center for China Clinical Trials
- Mindray Climbs on Improved 2011 Revenues
- AstraZeneca Wants to Build its Portfolio of Generic Drugs in China
- Darren Ji Steps Down as PharmaLegacy CEO
- China Health Resource, a TCM Maker, Ready to Start M&A Hunt
- Yunnan Baiyao Opens New Production Facility
- J.P. Morgan Healthcare Conference - China Events
- DSM Sinochem JV Building Second China Anti-Infective Facility
- Boehringer Ingelheim Sets $91 Million Shanghai Expansion
- Sihuan Pharma Building $110 Million Facility in Beijing
- Pfizer's Dual R&D Strategy for China
- Merck Will Build Beijing R&D Center; Invest $1.5 Billion in China
- Ascletis Nominated for Financing Deal of the Year
- A Second Life for Bayer’s Diabetes Drug in China
- Lilly Concerned about IP Protection in China
- Novartis Will Invest $25 Million in Zhongshan Facility
- Pfizer’s Shanghai Anti-Infectives Research Unit Delayed
- WuXi PharmaTech to Form $50 Million Venture Fund
- Former Head of Shanghai Pharma Given Death Sentence for Accepting Bribes
- Sanofi Says China Sales Grew 47% to $370 Million in Q3
- Healthgen, a China Startup, Announces Rice-Derived Human Serum Albumin
- Lepu Medical Invests $15.6 Million to Increase Medical Device Capacity
- Novartis Transferring Jobs from Europe/US to China and India
- Modern Hasen Pharma Building $43.6 Million Essential Drug Facility
- CEO of Hutchison MediPharma Quietly Steps Back
- Hepalink Pharma Posts Lower Q3 Results
- Lundbeck Sets Up Research Center in Shanghai
- Sinovac Lands Flu Vaccine Order from Beijing CDC
- China Life Science Leaders Discuss the Future at ChinaBio® Leadership Retreat
- University of Hong Kong and Sinopharm Sign Cooperation Agreement
- AstraZeneca to Build $200 Million Manufacturing Plant in China Medical City
- Merck Names China Expert as Directory of Strategy
- Cardinal Health Seeking to Acquire China Drug Distributors
- AstraZeneca Remains Committed to Partnering in China
- BioBay Investor Forum 2011 Selects Chiva Pharma and Suzhou Biologix Medical Technology as Most Promising Companies
- ProMetic Sells Biotech Product in China
- China Scientist Given Lasker Award for TCM-based Malaria Drug
- Covidien to Build Medical Device R&D Center in Shanghai
- AllCells Expands Primary Cell Services in Shanghai
- GlaxoSmithKline to Use Three Vaccine Distributors to Cover China
- SinoCubate Signs on Biotech Startup Veteran for Incubator
- Merck Serono Opens Beijing Lab
- Nycomed Says Growth in China Helped Revenues
- Sinopharm Beats Estimates for First Half of 2011
- Life Technologies’ Q2 Hurt by Revamping of China Sales Strategy
- WuXi PharmaTech to Add Clinical Trial CRO Services
- ShangPharma Bumps Stock Price 28% Higher with Share Buyback
- WuXi PharmaTech Reports Big Jump in Q2 Manufacturing Revenues
- ShangPharma Touts Growth in its Biologics Division
- BGI and GT Life Sciences Sequence Chinese Hamster Ovary Genome
- Merck Reduces Workforce Globally while Building in China
- Hepalink Pharma’s Shares Fall on Lower Profit
- Boston Scientific to Spend $150 Million in China
- BGI Work on Genomic Structural Variations Published in Journal
- ChinaBio® Investor Forum–Jinan Selects Two “Most Promising” Companies
- Ascletis Adds Support to $100 Million in Startup Capital
- Shanghai Pharma Spending to Build Drug Distribution Business
- Guangzhou Biotech Island Holds Official Opening
- Baiyunshan Pharma Expands Production Facility
- Walvax Will Spend $112 Million to Up Vaccine Capacity
- J&J Opens Innovation Center for Medical Devices in Suzhou
- BGI and Shenzhen Set Up National Gene Bank
- Luoxin Pharmacy to Develop Narrow-Spectrum Antibiotic
- BGI and U. of California Davis Announce Partnership
- Simcere Receives Settlement for Shuttered Rabies Vaccine Facility
- CAS and Univ. of Pennsylvania Set up Brain Mapping Center
- Sinocom Releases Q1 Report before its IPO
- BeiGene Makes Key Hires in Clinical Research and Regulatory Affairs
- Hainan Honz Pharma’s Main Product Faces Partial SFDA Ban
- ShangPharma Reports 26% Increase in Q1 Revenues
- Three Innovative Projects Selected for “Most Promising Technology” Awards at ChinaBio® Partnering Forum
- Shanghai Pharma Affiliate Hit with Allegations of Poor Quality
- ChinaBio® Partnering Forum Attracts Record Crowd
- Takeda Taking Steps for 10-Fold Increase in China Revenues
- Sanofi Expects China to be its Number Two Market by 2015
- WuXi Beats Financial Estimates in Q1
- Columbia University Licenses Autoimmune IP to China Group
- Roche Expects China to be #3 Market by 2015
- Shanghai Pharma Reports Earnings Doubled in Q1
- Roche Expands Shanghai Facility into Third Global Operations Center
- Cachet Pharma Adds to Capacity of Beijing Drug Logistics Center
- Pfizer and Daiichi Sankyo Team Up in China
- Huamin Pharma Plans $168 Million Antibiotic Facility
- Merck Serono Expects M&A to Build China Sales
- ICON Ups China Presence and Posits Double-Standard in China Trials
- Merck Expects to Garner 25% of its Revenues in China by 2013
- Takeda Pharma Ups Commitment to China
- Novartis Will Add China Sales Reps to Gain Market Share
- China Touts Quick Identification of Novel Deadly Pathogen
- SuperNova Diagnostics to Partner with Kang Sheng Bao Bio-Tech
- Pfizer Moving Antibacterial R&D from US to Shanghai
- WuXi PharmaTech Reports 24% Growth in 2010 Revenues
- Thermo Fisher to Build New Factory in Suzhou
- Life Technologies Opens Asia-Pacific Distribution Center
- Bayer to Boost Headcount at Beijing R&D Center
- Aushon Forms Collaboration with Peking University Cancer Hospital
- Dr. Xu Tian and His China Mouse House
- Avacta Signs Device Distribution Deal with Cold Spring Biotech
- China Commits $300 Million to Human Variome Project
- Lilly Files Patent Suit against Hospira and Jiangsu Hansoh Pharma
- Tianyin Pharma Completes Antibiotic Facility
- Sinopharm Building $200 Million Facility in Vietnam
- The Hamner Institutes Forms China Bioscience Bridge with XY Group
- Eisai Opens Trading Company in Suzhou
- United Labs to Spend $150 Million on China Insulin Business
- 2011 J.P. Morgan Healthcare Conference Features China Track
- ChinaBio® Investor Forum Selects Two Most Promising Companies
- Xiangxue Pharma Developing Alzheimer’s Treatment
- Northeast Pharma to Build $750 Million Antibiotic Facility
- China Will Have Second Biggest R&D Spend Starting in 2011
- Lundbeck to Begin China Co-Promotion of Lexapro®
- Steve Yang, Pfizer’s Asia Head of R&D, Leaves for AstraZeneca
- Hengyang to Expand TCM Capacity
- Inflation Hits Prices of TCM Products in Shanghai
- BioTime Inks Progenitor Cell Distribution Deal for China
- Jiangsu Wuzhong Receives $1.8 Million to Develop Cancer Drug
- ShangPharma’s Q3 is Solid, But Investors Still Unimpressed
- Aoxing Pharma’s Narcotic JV Passes Milestone
- Andon Health to Start US Subsidiary
- Guizhou Bailing to Grow Miao TCM Products
- Roche Cuts 4,800 Jobs in the West while Expanding in China
- Sihuan Pharma to Distribute Vascular Drug for Benxi Leilong
- Novo Nordisk to Put $100 Million in its China R&D Center
- Merck Climbs on the Emerging Markets Bandwagon
- Guilin Pharma’s Malaria Drug Meets WHO Standards
- “Most Promising” China Life Science Companies Named at BioBay Investor Forum
- NeoStem Receives Approval for Stem Cell Treatment
- Lilly Announces Major China R&D Center
- Aoxing Reports Progress in its Narcotic API Manufacturing JV
- Lilly to Close Singapore R&D Center This Year
- Sinovac Slashes 2010 Revenue Guidance by One-Third
- Livzon Pharma Plans $300 Million Bio-Tech Park in Zhuhai
- Pfizer Opens Radiation Biology R&D Center in Wuhan
- China-UK Project Seeks to Improve TCM Treatment for Malaria
- China’s Pharmaceutical Sales to Top $50 Billion in 2011
- 13.7% CAGR Predicted for China’s Pharma Market over 5 Years
- Bayer Schering Launches MS Drug Betaferon
- Royal DSM Seeking Asia Partner for Penicillin
- China Pharma Holdings Completes Phase I Trial of Antibiotic
- WuXi PharmaTech Awarded GLP for Suzhou Facility
- Lilly and Parexel Partner on Asia-Pacific Clinical Trials
- Novartis to Start China Trial of Novel Cancer Drug in 2013
- J&J in the Hunt for China M&A
- SIMM to Collaborate with Oslo Cancer Center
- Bohai Pharma Announces New Products
- Merck and BGI Initiate “Substantive” Relationship
- Novo Nordisk to Double China R&D Headcount
- Roche to Ramp Up China Investment, Headcount
- Eisai Begins Marketing Diabetes II Drug in China
- Skystar Updates Progress of New Manufacturing Plant
- Bayer Builds China Diabetes Portfolio with SciLin Launch
- China Sky One Trims Guidance; Stock Drops
- WuXi PharmaTech Subsidiary Passes ISO Environmental Tests
- Wise Sky “Disappointed” by Emergent BioSolutions
- Golden Helix Finds China Distributor for its SNP Software
- Will Roche Job Cuts Include China Positions?
- BGI Deepens Relationship with Denmark
- Boehringer Ingelheim Opens Center of Competence in Shanghai
- Sinopharm Group To Center Antibiotic Production in Shanxi
- Sinovac After 2009’s Flu Scare
- Sinobiopharma Signs Deal for New Hypertension Drug
- WuXi PharmaTech to Build $100 Million R&D Center in Wuhan
- Mindray Reports Higher Q2; Reduces 2010 Guidance
- QIAGEN Hopes to Double China Revenues in 2010
- Affymetrix Announces Array for China-Specific Genotype
- Beike Offers China Rehab Services in Romania
- Bayer Schering and China Hospital to Partner on Women’s Health
- China PharmaHub to Find Life Science Projects for Sichuan Companies
- WuXi PharmaTech Announces Positive Second Quarter Results
- IBM Develops Electronic Patient Record System with Peking University Hospital
- Merck Breaks Ground on $162 Million Hangzhou Facility
- NeoStem Awarded Grant to Test Stem Cells for Wound Healing
- Shandong Lukang Expects Much Improved First Half
- Artepharm Will Use TCM to End Malaria in Comoros Islands
- Shandong Lukang Pharma Announces $514 Million BioMedical Park
- Renhuang to Launch TCM Anti-Depressant
- China’s Stomach Cancer Vaccine to Hit the Market Next Year
- Tiantan Building Large Vaccine Facility in BDA
- Sinovac Announces Government Order for Hepatitis Vaccine
- Radient Pharma Refines Divestiture Plan for Jade Pharma
- Smith & Nephew Opens Beijing Facility
- Charles River CEO Defends WuXi PharmaTech Purchase
- Astellas Plans Sales Push in China
- Dehaier to Market Heyer’s Respiratory Products in China
- GeneNews Finds China Distribution Partner for Cancer Test
- OriGene to Build mAb Production Facility in Wuxi
- GSK Cutting Prices to Gain Market Share in China
- Beijing Genomics Institute to Open Facility in Copenhagen
- Tasly Pharma and Transgene Form JV
- Simcere Wants to Sell OTC Division, Add Prescription Drug Partnerships
- Roche Diagnostics Growing at 50% Rate in China
- J&J Creates R&D Center with Tianjin Cancer Hospital
- Genzyme and TJAB Form Partnership
- WuXi PharmaTech Announces Strong Q1
- Mindray’s Q1 Results a Disappointment
- Boehringer Ingelheim Pursuing M&A in China
- Actavis Opens Beijing Office for Regulatory Affairs and Sales
- Shenzhen Hepalink Rises 27% in First Trading Session
- Roche’s High-End China Strategy
- Evonik Opens New API Plant in Nanning
- Bayer Reports $709 Million in 2009 China Revenues
- China Biologic Eligible for Provincial R&D Financial Support
- Winners Announced for First SEED Business Plan Competition in China
- Sanofi-Aventis to Build China Presence through Partnerships
- ATS Medical Reports Use of Recently Approved Heart Valve
- Singapore Says Biomedical Investment Totals $860 Million in 2009
- Radient Selling its China Subsidiary, Jade Pharma
- Novozymes TEDA Biopharma Facility on Track for Early 2011 Opening
- Sinovac Gives Details on Strong 2009 Results
- Pfizer in Asia Will Focus on Asia-Specific Diseases and Solutions
- Operations of Simcere’s Latest Acquisition Remain Shut Down
- ProMetic Completes Milestone in Tech Transfer to Sinopharm
- Lilly "Aggressively" Investing in China
- Quintiles’ Beijing Lab Receives “Best Central Lab 2009” Award
- AlphaRx to Spin Off China Operations
- Qiagen Sponsors Life Science Professorship in China
- Name Change and Stock Split for China Aoxing
- MDRNA and AstraZeneca China Collaborating on Cancer
- Zhangjiang Park to Cooperate with Swedish Counterpart
- Sinovac Finds India Partner for H1N1 Vaccine
- China Sky One Predicts Improved 2010; Changes Focus
- Vycor Medical to Register Brain Surgery Device in China
- MicuRx Files IND in China for New Antibiotic
- Novartis’ China Revenues Climb 36% in 2009
- Lee’s Pharma to Distribute Recordati Hypertension Drug
- FDA Issues Warning to China API Maker
- Sundia MediTech Founder Receives “Entrepreneur of the Year” Award
- Lotus Pharma Breaks Ground on New Building
- WuXi PharmaTech Reports Solid Performance in 2009
- SEED Competition for China Life Science Announces Finalists
- Sanofi-Aventis Looking for More China Partnerships
- Asymchem Plans Another Facility at TEDA
- Generex Granted China Patent for Cancer Vaccine
- Mindray Medical Reports Stellar 2009 Results
- Biostar Expects 2010 Revenues to Climb Higher
- Dishman Expects Shanghai Facility to be Operating in Q3
- WuXi PharmaTech Granted AAALAC Accreditation for Suzhou Animal Lab
- The Hamner Institutes Adds Europe to its US-China Partnerships
- Narhex Declares Bankruptcy; Involved in Xi’an JV
- CRH Medical Finds China Distribution Partner for Medical Device
- Bayer Seeks Better than 20% Growth in China
- Charles River Labs Disappointed by Weak Demand for its China Lab
- Celsis In Vitro Technologies Finds China Distributor
- Tianyin Pharma Hits Targets for Fiscal Q2
- Gorbec to Open GMP Analytical Lab in China
- Huifeng Bio-Pharma Expects 50% Revenue Increase in 2010
- Response Biomedical Signs Second China Partner
- Sinobiopharma’s Flagship Product OK’d for Insurance Coverage
- Covance Building Pre-Clinical Facility Near Shanghai
- Hong Kong Led Global Exchanges in 2009 IPOs
- Shandong Luoxin Pharma Lists ADSs on OTCQX Exchange
- China Sky One Shifts Emphasis to Generic Western Products
- Pfizer Sees Future Deals as China Biopharma Consolidates
- Sinobiopharma Announces Improved Q2
- Changzhou Begins Construction on Biopharma Incubator
- Jiangbo Pharma’s Bone Drug Included in Basic Medical Directory
- Suven Granted China Patents for Two New Chemical Entities
- ChinaBio® Accelerator to Help Life Science Companies Establish China Operations
- Sinovac’s Sales of H1N1 Vaccine Now Top 20 Million Doses
- Invida to Market Three Dermatology Products in China
- China Sky One Wins National Innovation Award for Diagnostic Kit
- WuXi and QIAGEN Form Biomarker Partnership
- Mindray Medical Reviews New Products and Reveals Future Plans
- China Reports 648 Deaths from Swine Flu in 2009
- China Sky One Qualifies for NASDAQ Global Select Market
- Biostar Pharma to Sell Hepatitis B Treatment in Beijing and Shanghai
- Hutchison Chi-Med to Outsource Development of a TCM
- Syngenta Biotechnology Breaks Ground on Beijing R&D Center
- WuXi PharmaTech and Sundia MediTech Named Again to Fast 500 Asia Pacific
- Alvogen Opens Office in China
- Sinovac Named One of China's Top 10 Most Competitive Companies
- NiTi Reports First China Use of Surgical Device
- Cellonis Biotech Eliminates a Glioma with Stem-Cell-Based Therapy
- Novartis Opens Suzhou Plant and Technical R&D Center
- Pfizer will Co-promote Takeda Diabetes Drug
- aTyr Publishes Groundbreaking Research
- Lilly Aiming at China’s Growing Pharmaceutical Market
- Hubei Guangji Pharma Starts Building Major Biopharma Park
- Medicilon/MPI Accredited to Provide US GLP Services in China
- AlphaRx Incentivized to Locate in Zhangjiang Park
- Tianyin Pharma Calls for 75% Improvement in 2011 Results
- Simcere Shuts Down Production in New Vaccine Subsidiary
- China Sky One to Sell Diagnostic Kits in Southeast Asia through Agent
- Sinovac Receives a 1 Million Dose Order for H1N1 Vaccine
- AstraZeneca to Offshore All API Production
- Pfizer Adds R&D Center in China
- GSK Will Seek to Commercialize Viread in China for Hepatitis B
- Merck Serono to Spend $225 Million on Beijing R&D Center
- GSK to Manufacture Flu Treatment Relenza in China
- Goldman Sachs Puts Pfizer’s 2012 China Sales at $3 Billion
- Students from China Coming to US in Record Numbers
- Tongjitang Reports Another Down Quarter
- American Oriental’s Financials Disappoint Again
- WuXi PharmaTech Reports Higher Q3
- Sinovac’s Q3 Soars; Company Announces New Vaccine Contract
- Early Earnings Season: Medical Devices Flat; Biopharmas Higher
- WuXi PharmaTech Signs LOI to Establish New Company
- China’s Research Output Could Surpass the US in Ten Years
- BMP Sunstone to Distribute Pfizer’s Endometriosis Treatment in China
- Lijun Says Enerxin Capsules Effective in Treating H1N1 Flu
- Pfizer’s Shanghai Operation Saved from Company's R&D Cutback
- ScinoPharm Constructing Facility in Changshu
- Novartis Adds $375 Million in China Investments
- Roche Opens $500 Million Biologics Facility in Singapore
- Novartis to Invest $1 Billion in China
- Sinovac to Move Listing to NASDAQ Global Exchange
- Medicilon/MPI Receives AAALAC Accreditation
- Sinovac Snags Another Large Order for Flu Vaccine
- Boehringer Ingelheim Adds $149 Million to its Investment in China
- Bonovo to Distribute Medical Devices for elliquence in China
- BioTime Investigating Stem Cells to Treat Cancer
- China Biologic Products Receives Forbes Magazine Honor
- California and China Agree to Collaborate on Stem Cells
- Servier Collaborates with SIMM on Cancer Drug Discovery
- China Researchers Use Bioluminescence to Map Eye Cancer
- Biostar Granted Patent for Second TCM Hepatitis B Product
- Tongjitang Completes $20 Million Stock Buyback
- Merial Starts $70 Million China Animal Health Facility Expansion
- Ingen Granted China Patent for Medical Device
- Lilly China to Double Workforce
- Sinovac Receives Big H1N1 Vaccine Order
- China Requires One Divestiture for Pfizer-Wyeth Merger
- Eisai to Market Kyorin's Overactive Bladder Drug in China
- Shenzhen Commits 3.5 Billion RMB for Biotech Development
- Health Robotics Signs IV Robot Deal with SINOPHARM
- Mimotopes China & VPSmart-DDS Biodelivery Centers Opens in WuXi
- Tianyin Pharma Hits 2009 Targets
- China Biologic to Collaborate with Institute of Blood Transfusion
- BioTime Announces China Stem Cell Subsidiary
- AMDL Hopes to Spin-Off Jade Subsidiary to GEM Exchange
- Genzyme Starts Work on $100 Million Beijing R&D Center
- China Medical Announces $30 Million Share Buyback
- Tianyin Pharma’s New Solid Dose Facility Granted GMP
- SFDA Approval Granted to SIBS Swine Flu Vaccine
- LEAD Therapeutics Announces New Antibiotic
- Four of Tianyin Pharma’s Generic Drugs on Essential Drug List
- American Oriental Launches Laryngitis Capsules
- Benitec and Biomics Join to Develop RNAi Drug for Hepatitis B
- Leveraging China to Build a Global Biotech
- China Sky One Selling TCM Pain Relief Patch in Canada
- 20 Guangzhou CROs Form Alliance
- China Orders Flu Vaccine from Sinovac, Hualan; Approves Relenza
- China Medical Technologies Still Stumbling
- Sundia given Growth Potential Award by Zhangjiang Park
- China Sky One Says SAIC Filings Underreported Revenue
- Sinovac To Supply Beijing with Seasonal Flu Vaccine
- China to Sell 10 Million Doses of Swine Flu Vaccine to Mexico
- American Oriental Has Approval for 61 Essential Drug List Products
- 2009 Revenues for Drug Products in China Likely to Top $110 Billion
- Simcere Teams Up with Sun Yat-Sen University Cancer Center
- Sinovac Prospers in Q2 on Large Government Order
- China Sky One’s Q2 Revenue is Up 36%
- US Pharmacopeia Certifies First TCM
- Fosun Ups Tongjitang Stake to 24%
- Welch Allyn Offers General Practitioner Training in Guangzhou
- WuXi PharmaTech Beats Q2 Estimates
- 3SBio Announces Solid Q2; Looks Toward Biosimilar Market
- Mindray Medical Rises After Reporting 10% Increase in Q2 Revenue
- Pasteur Institutes in Shanghai and Paris Discover New Rhinovirus Genomes
- American Oriental’s Q2 is Mixed; New Product Announced
- China Sky One May Raise New Capital for Acquisitions
- Lonza Completes Phase 2 of Nansha Plant Expansion
- Shanghai Biochip Develops DNA Test to Determine Children’s Abilities
- AlphaRx to Conduct R&D inside Venturepharm’s Taizhou Facility
- Commonwealth, Seeking to Acquire Shanghai’s GL Biochem, Faces Delisting
- China Medical Lowers Guidance; Blames False Allegations
- Pfizer and Fudan University Offer Work-Study Graduate Degree
- Lotus Receives Patent for Diabetes Drug
- AlphaRx Signs Cooperation Agreement with Venturepharm
- AlphaRx Seeks Local Partners for China R&D and Pilot Plant Facilities
- American Oriental on China’s Top 20 Pharmas List
- Mindray Medical Releases Product Update
- Sundia Named to Top 100 Fast-Growth Outsourcing List
- Novartis to Offer Management BiMBA in China
- Lijun International Pharma Reports Strong First-Half
- China Medicine Cites Positive Data on Animal Feed Additive
- China-Biotics Reports Gains in FY2009
- China Sky One Receives GMP Renewal
- Neuralstem Sponsors 2nd Stem Cell Research Project in Taiwan
- China Ministry Puts 10 Billion RMB into Health Insurance
- China Wants to Double TCM Production
- Sichuan Hospital and Harvard Collaborate on Transplant Studies
- Rural Heathcare in China to Receive 100 Billion RMB for Facilities
- Micro Imaging Hires OPH for China Expansion
- WuXi Named One of China’s Top 10 Outsourcing Companies
- China’s First Partnering Conference Draws Large Global Audience
- Sinovac Lands H1N1 Flu Vaccine Order
- Pfizer Wants to Do Deals in Emerging Markets
- Guilin Sanjin Pharma Will Be First China IPO of 2009
- China Medical Tech Says 2008 Revenues Climbed 51%
- Tianyin Issues Early Financial Report of Positive 2009
- Vital Images to Offer Scanning Software in China through Chindex
- Lilly Offers Free Testing for Novel Compounds
- Sundia MediTech Says Animal Lab Passes Audit
- Shenyang Officially Opens Pharmaceutical Park
- Sinovac Starts Influenza A (H1N1) Vaccine Production
- Chip-Man Markets Cell-IQ through ChiFi Biomedical
- Tongjitang Chinese Medicines Disappoints Again
- Luminex Opens Asia-Pacific Center in Shanghai
- Sinopharm Medicine Rumored to be Considering October IPO
- Porvair Signs China Microplate Distribution Agreement
- China Set for Quick Development of A/H1N1 Flu Vaccine
- Roche Opens China Application Support Center
- Biostar’s Q1 Revenues Rise 9%
- ChemWerth Teams Up with Tianjin Tianyao for Corticosteroids
- Baxter Commits 1 Billion RMB to Increase Manufacturing in China
- Simcere Buys 35% Stake of Antibody Company, Announces Q1 Results
- BMP Sunstone Reports Large Q1 Revenue Gain and a Non-GAAP Profit
- China Shenghuo Announces Large Loss on Higher Revenues
- China Aoxing’s Revenues Climb; Net Income Still Negative
- Sinovac Announces Much Lower First Quarter
- WuXi PharmaTech Surprises with a 5% Q1 Revenue Increase
- China Sky One Doubles Year-Earlier Revenues in Q1
- China Medicine Corp. Drops on Improved Q1
- Mindray’s Q1 Underwhelms Investors
- Jiangbo Completes Name/Ticker Change from Genesis
- American Oriental Reports Higher Revenue, Lower Profit in Q1
- Tianyin Pharma Expects July Launch for New Manufacturing Facility
- Cuba Begins China Registration of Diabetic Ulcer Drug
- Simcere to Make and Market Flu Drug Zanamivir in China
- WuXi Receives Global Supplier Award from Lilly
- Sinovac Takes Steps toward Producing Swine Flu Vaccine
- Alnylam Granted Additional China Patent for siRNA
- Sinovac Receives $12 Million Vaccine Order
- Novozymes Breaks Ground on New China Manufacturing Facility
- China Biologic Products Lands $5.3 Million Order from India
- Lotus Adds Color to 2008 Financial Report
- Tianyin Reports Successful Tender Process for Major Drug
- Genesis to Launch Three Newly Acquired Products
- Sanofi-Aventis to Build $90 Million China Manufacturing Facility
- Lotus Books Solid 2008; Still Needs Cash
- China Sky One Soars after Releasing Strong 2008 Results
- China Medicine Corp. to Distribute Anti-Adhesive
- New GM for Bridge Labs' Beijing Facility
- Lilly Emphasizes China in Strategic Plan
- China Scientists Challenge Long-Held Fertility Principle
- Sinovac Reports 39% Higher 2008 Revenues
- Sinobiopharma Seeks Patent for new ACE Inhibitor Formulation
- China's Big Hospital/Clinic Construction Plans
- China to Build Major Stem Cell Center in Taizhou
- Biostar Doubles Revenues in 2008
- Covance’s Shanghai Lab Receives CAP Accreditation
- China Sky One Says Financial Reports Await Only a Technical Ruling
- IMCAS and TB Alliance will Search TCM for TB Drug
- China Biologic Keeps Growing
- Zhangjiang Hi-tech Park Sets Up $147 Million Life Science Fund
- Kun Run Reports Strong 2008 Results
- Tiens Biotech Says 2008 Revenues Climbed 41%
- Agilent, Shanghai Institutes and Tongi University Publish Stem Cell Discovery
- China Medicine Corp. Grew Again in 2008
- WuXi PharmaTech’s 2008 Meets Expectations, Though AppTec Disappoints
- SGS Life Science Services Offers API Testing
- Two Biotech Companies Receive “Most Promising Company” Awards in Hong Kong
- Pfizer Works with NGO to Provide Healthcare for China’s Working Poor
- Tongjitang Chinese Medicines Releases Dismal Q4 Report
- Bayer and Tsinghua University to Form Joint Institute
- BMP Sunstone Rides Acquisition to Record 2008 Revenues
- China Pharma Holdings Reports Improved 2008
- China’s First Partnering Conference Set for June
- 3SBio Reports Higher Sales, Flat Earnings
- Simcere’s Q4 Revenues Climb, but Earnings Are Down
- How Does the Merck/Schering-Plough Merger Affect China?
- Biostar to Build Own Raw Material Processing Facility
- American Oriental Reports Solid Numbers; Investors Remain Wary
- Novartis Announces 30% Increase in 2008 China Revenues
- Mindray’s Higher 2008 Results Fail to Impress Investors
- China Medical Announces Higher Q3
- Sinovac’s New Filling Facility Given GMP Cert
- Jingang Andi Officials Detained for Unapproved Additive to Rabies Vaccine
- A Drug Development Update from Obio Pharma
- Beijing Announces $74 million in Biotech Grants for 2009-10
- Sinobiomed, Needing a Turnaround, Replaces Entire Management Team
- Genesis Reports Higher Revenues, Flat Net
- China-Biotics Reports Improved Q3
- Shengtai Pharma’s Second Quarter Disappoints
- Bayer Schering Will Build $129 Million Beijing R&D Center
- China Uses Sinovac Product for Bird Flu Vaccine Stockpile
- Zhangjiang Park and CRO Sundia MediTech Form Incubator
- CRO Sundia Identifies Four Pre-Clinical Candidates for Xcovery
- China Bio-Immunity Recovers Most of Recalled Rabies Vaccine
- Fosun Again Increases Tongjitang Stake
- Lotus Will Build Factory, Pharma Park in Inner Mongolia
- Sinobiopharma Prospers on Muscle Relaxant Drug
- Tianyin Pharma to Start $3 Million Buyback
- Six Cases of Avian Flu in China This Month; Five Deaths
- China YTC Announces Big Increase in Latest Quarter
- China Bio-Immunity Recalls Rabies Vaccines
- China Pharma Holdings Inc. Sees Improvement
- BMP Sunstone Guides 36% Higher for 2009
- Abbott Opens Singapore R&D Center
- Mindray Medical Reviews New Products for 2008/2009
- China-Biotics Says New Plant Delayed
- China Pharma Announces SFDA Approval of Hepatitis B Drug
- Mindray Medical Reports Much Higher 2008
- Simcere Warns that 2008 Net Income Will Miss Forecast By 10%
- e-Therapeutics to Offer Computational Biotech Services from Nanjing Office
- BMP Sunstone Company Granted High Tech Status
- ChinaBio® Stock Index Drops 57% in 2008
- Niusule Lists on Bulletin Board
- Sinovac’s Healive® Vaccine Not Responsible for Infant’s Death
- China Sky One Awarded Science Prize for BPH Drug
- Baiqiang Pharma Builds Cancer Drug Capacity
- China Biologic Announces $1.6 Million International Sale
- Officials Suspect Mutation in Bird Flu Caused Hong Kong Outbreak
- Fountain Medical and ProteLight Receive ChinaBio®'s "Most Promising" Award
- Cook Medical to Open Asia Regional Center in Shanghai
- BioDuro Labs Accredited by AAALAC
- China Shenghuo Resumes Trading; Price Drops 50%
- AnaSpec Signs Second China Distribution Deal
- Sinovac Reports Adverse Effects from Vaccine Limited to One Case
- WuXi Will End Biologics Manufacturing in US
- Sinovac’s Hepatitis A Vaccine Suspended Following Child's Death
- China to Spend almost 5 Billion RMB on Rural Healthcare
- Tongjitang Reports a Down Q3
- China Shenghuo Completes Restatement; Issues Q3 Report
- Syneron Forms Medical Device JV in China
- China Medical Develops Predictor for Biologic Cancer Drug Success
- ChinaBio® Schedules First Partnering Forum for June 2009 in Shanghai
- Sinovac’s Revenue and Profit Slide Lower in Q3
- International Big Pharma Continues China Investment
- Lotus Increases Profit in Q3 while Revenues Drop
- China Medical Releases Selected Q2 Data
- Genesis Pharma Reports Higher Q1
- Shengtai Pharma Begins FY2009 with Small Drop
- China Medicine Reports Lower Q3
- China Biologic’s Revenues and Profits Soar in Q3
- BMP Sunstone Revenues on the Rise in Q3
- Tianyin Pharma Reports Higher Revenues and Costs
- Wall Street Unhappy with Mindray Medical’s Q3
- American Oriental Books Another Good Quarter
- China Pharma Reports Higher Q3; Accounts Receivable also Up
- Novo Nordisk to Build $400 Million China Manufacturing Plant
- Simcere Reports Improved Q3; Starts Buyback
- BioCurex to Offer Cancer Tests in Shanghai
- Roche Expanding in Shanghai; Opens Partnership Office
- Sinovac Included in Deloitte’s Technology Fast 50 China
- 3SBio’s Q3 Hurt by Lehman Bankruptcy
- Tongjitang Can Start $20 Million Share Buyback
- Covance Not Hurrying to Build More China Facilities
- Sundia Named to Deloitte Fast 50 China
- Shengtai Pharma to Seek Growth in International Sales
- Tianyin Boosts Stock Price with Buyback
- Outbreak of CRO and Big Pharma Activity in China
- WuXi Expands J&J Collaboration
- China Aoxing Issues 2008 Financial Report
- Charles River and Shanghai BioExplorer Open CRO Facility
- China Sky One Starts Production at New Subsidiary
- WuXi Misses Q3 Forecast; Guides Lower for Year
- Injectable TCM Blamed for Three Deaths
- Beike Biotech Signs Eight Cooperation Agreements
- China Medicine Guides Lower, Blaming Economic Crisis
- TCM Remains Vital Part of China Healthcare
- Shengtai Receives GMP Certification for Glucose Facility
- The China CRO, CMO and Clinical Trial Markets
- Genesis Pharma Books 31% Higher Revenues in 2008
- Shengtai Pharma Reports Improved Results in 2008
- Tianyin Pharma’s 2008 Results Reach Expectations
- China Sky One Raises 2008 Guidance
- Tianyin to Move to AMEX Exchange
- Phynova Plans Greater China Focus
- China’s Baby Formula Coverup Started 10 Months Ago
- Crown Bio to Build Second China CRO Facility
- Sinovac to Develop Hand, Foot and Mouth Disease Vaccine
- IPEC China Gives Voice to Excipient Industry
- China Pharma says Collection of Accounts Receivable is Improving
- PricewaterhouseCoopers: Where to Outsource in Asia?
- China Sky One Reports Progress on CE Mark
- China Pharma Ups Q3 Revenue Guidance
- China Infant Formula Scandal Tied to Melamine
- Xel Pharma Announces TCM Patch for Alzheimer’s
- China Biopharma Executes 1-for-100 Reverse Split
- Genesis Announces $12 Million in New Orders
- Oculus Launches Dermacyn™ in China
- Sinovac Launches 2008-2009 Version of Flu Vaccine
- BusinessWeek Highlights Sea Turtle Phenomenon
- Tianyin Pharma Reports Higher Fiscal 2008 Revenues and Profits
- Tongjitang Announces $20 Million Stock Buyback
- BioBay Investor Forum 2008: China Pharma to Boost Value with Global Patents
- BioBay Investor Forum 2008: By 2015, Yangtze River Delta Will Boast World’s Largest CRO Cluster
- Mindray Rides Datascope Acquisition for Strong Q2
- Genesis Pharma Completes 40-to-1 Reverse Split
- China Sky One Will Migrate to NASDAQ Global Market
- Smith & Nephew Expanding China Operations
- Sinobiomed: Negative Financials; Vibrant Development Program
- China Shenghuo to Restate Financial Results
- MicuRx Pharma Picks Next-Gen MRSA Antibiotic Candidate
- Lotus Pharma Reports Higher Revenues, Lower Net
- Benda Not Able to Capitalize on Gene Therapy Cancer Drug
- Tongjitang Chinese Medicines Revenues Lower in Q2
- China Sky One to Produce Nasal Spray for Rheumatic Disease
- WuXi Reports Solid Q2 Financials
- 3SBio Reports Higher Q2 Revenues, But Earnings Slip
- Sinovac Q2 Revenues Climb 73%
- China Sky One’s Q2 Beats Estimates
- BMP Sunstone Reports Excellent Q2
- Lonza to Offer Life Science Engineering Services in China
- Pfizer Moving Bioinnovation Center to San Francisco
- China Pharma Holdings’ Growth Moderates in Q2
- Simcere’s Q2 Revenue Below Expectations
- China Medical Reports Higher First Quarter
- Eisai China to Repack and Sell STADA Diabetes Drug
- Huifeng Reports Progress on Diosmin Contract
- Bridge Labs To Build Second China Facility
- MedMira Granted China Patent for Diagnostic Device
- CRO Sundia MediTech Makes Venture 50 List Again
- Bayer Seeks Over 20% Annual China Revenue Growth
- ChinaBio® Makes "Most Promising Company" Awards
- GSK to Double China R&D Staff
- Renhuang Granted “Key Laboratory” Designation
- BIO2008 Panel: Opportunities/Challenges in Asian VC Investment
- Will Bayer AG Be #1 in 2008 China Prescription Drug Sales?
- Doing Business in Asia – Is China Becoming Too Expensive?
- Vibrant Burrill India-China Meeting in San Diego
- China Medical Reports Improved 2007
- Sinovac Receives 80,000 Dose Vaccine Order for Earthquake Victims
- China Sky One Ups Forecast; Hits New High
- Asymchem Keeps Building as API Sourcing Reacts to Heparin Scandal
- ShanghaiBio to Offer siRNA Screening Services
- Tongjitang Chinese Medicine’s Q1 Report Disappoints
- Did AppTec Acquisition Hurt WuXi PharmaTech’s Q1?
- WuXi Reports Improved Quarter, Again
- Sinovac Receives Vaccine Order for China Earthquake Victims
- American Oriental Prepays $16 Million for Acquisitions
- China Sky One Will Move Listing to American Exchange
- Lotus Reports Higher Q1 and New Asthma Drug
- China Yongxin Completes Reverse Merger
- Suven Granted Two Patents for New Neuro Drug Candidates
- Two Announcements from Tongjitang Chinese Medicines
- Calandro Pharma Granted China RNAi Patent
- Oculus Announces China Marketing Plan for Microcyn
- Sinovac’s Q1 Doubles Its Year-Earlier Results
- 3SBio’s Q1 Revenues Rise, Though Net Income Lags
- China Earthquake Shutters Tongjitang Medicines Facility
- China Sky One Reports Record Quarter
- Tianyin Pharma Wins Tenders for Ginkgo Mihuan
- China Medicine Corp. Says Revenues, Profits Climb Again
- Mindray Tops Estimates in Q1
- American Oriental Reports Improved Q1
- Simcere’s Q1: Revenue Increases 26%; Net Up 68%
- GlaxoSmithKline Reorganizes to Emphasize Emerging Markets
- China Pharma Delivers on Improved Financials Promise
- Novo Nordisk Donates Compound Library to China Center
- CRO Service Alliance Expands Again, Adding Tigermed
- China Pharma Holdings Issues Earnings Tease
- Beijing Genomics Institute Expands Sequencing Capacity
- Genzyme to Build $90 Million R&D Center in Beijing
- Aida Reveals Second Anti-Cancer Drug
- WuXi Endows Professorship at Tongji University
- Becton, Dickinson Opens Diagnostic Products Facility in Suzhou
- Aida Pharma Affiliate Developing New Antibiotic
- China Shenghuo Reports Flat Revenues
- Wyeth Complains China IND Process Is Too Slow
- Sanofi-Aventis Seeks China Partnerships, Not a Research Center
- China Sky One Reports Higher 2007 Revenues, Profits
- China Biopharma Stocks Suffer Tough First Quarter
- Boehringer Ingelheim China Profits from Sinopharm Deal
- Sinovac Says 2007 Revenues Up 118%
- China Medicine Corp. Grew by 75% in 2007
- Shanghai GenePharma Licenses Alnylam siRNA Patents
- 3SBio Addresses Falling Share Price with Buyback
- Chi-Med Ups Both Revenues and Losses
- China a Priority for AstraZeneca
- US Journal Says TCM Leukemia Drug is Effective
- WuXi PharmaTech Reports Higher Q4 and 2007 Financials
- CRO Global Research Expands in China
- VisCorp Morphs into Tianyin Pharmaceutical
- Tongjitang Reports Zero Net Operating Income for Q4
- American Oriental Revenues Up 46% in 2007
- Heparin, Baxter, the FDA and China
- Simcere Books Very Strong 2007
- BMP Sunstone Says Propess® Recommended for Induction of Labor in China
- Provectus Granted China Patent for Imaging Drug
- China Pharma Notes Boost from Generic Cold Drug
- Two Japanese Drug Wholesalers Set Up China JVs
- QIAGEN Opens Asia Customer Service Center
- 3SBio Reports Higher Q4 But Misses Estimates
- Omnicare Opens China Offices
- NovaSecta Forms Alliance with Sundia MediTech and HD BioSciences
- Tianyin Pharma Reports 70% Increase in First Half Revenues
- Baxter’s Heparin Problems May Have China Connection
- Charles River: "China Work for China Ops of International Pharma"
- China Shenghuo to Bring TCM-based Cosmetics to US
- WuXi PharmaTech Puts Squeeze on Suppliers
- China VC Investment up 83% in 2007
- PPD Opens Central Lab Services Unit in Beijing
- Renhuang Announces “Major Breakthrough”
- Bridge Labs Lands $18 Million in New Funding
- China Biologic Awarded Innovation Grant
- Benda Begins to Deal with Upcoming Financial Problem
- Access Outlicenses China Rights for Mucositis Product to RHEI
- Calypte’s Receives OK for China HIV Diagnostic Test Facility
- Benda Receives GMP For Expanded Plant
- Agenix Announces Initial China Sales of Hep B Drug YouHeDing
- China’s Gene Therapy Cancer Drugs: Great Science, Slow Acceptance
- Asymchem Labs Ups its China Investment – Again
- Vital Therapies Scores Clinical Success in China
- New US-China CRO Joint Venture Formed
- Novelos Out-Licenses China Rights for Two Compounds
- Contaminated Merck Vaccine Recalled in China
- Sinovac On a Roll
- GSK Ups China R&D Investment
- China’s BioPharma Growth Detailed
- Organogenesis Partners with National Tissue Engineering Center
- Helicon Building Portfolio of Products for China
- ChinaBio® Forum Gives “Most Promising” Award to Two China Biotechs
- Skystar Opens Veterinary R&D Center in Shanghai
- China Biopharma Searches for Mission, Money
- Sanofi-Aventis To Build Flu Plant in Shenzhen
- China Aoxing Given Preferred Status for Cancer Pain Drug
- Genesis Signs Pact with Chinese Academy of Sciences
- Unit Sales Down, Revenues Up at China Biologic
- LEAD Therapeutics and ShangPharma in Strategic Relationship
- WuXi PharmaTech Triples Earnings in Q3
- IBF 15th Annual Biotech Investing Conference
- Novartis to Build $700 Million Plant in Singapore
- Roche Building Fully Functional R&D Center
- MDS Moves to Bigger Lab in Beijing
- AstraZeneca Sourcing Seroquel API in China
- China Biopharma Reports Progress on Topical Antiviral
- TCM Delisheng Shown Effective Against Cancer
- PPD Names Vice President for Asia
- WuXi Begins Building GLP Center in Suzhou
- AstraZeneca and Political Correctness
- Benda Books Record Gendicine Orders
- Russian CRO Synergy Seeks Partner in China
- Sanofi-Aventis Continues Patent Fight with Jiangsu Hengrui
- AMDL Increases Pipeline
- Genentech and Taiwan Company Partner on AIDS Drug
- Lilly Growing in China
- Sanofi-Aventis Will Study Cancer Stem Cells in China
- PATH starts Rotovirus Partnership with Wuhan Institute
- Chongqing Kangwei Expects Approval for H. Pylori Vaccine
- China in Future Plans for Multinational Life Science Companies
- Albumin Shortage in China
- Siemens Medical Park Opens in Shanghai
- AstraZeneca Partners for Clinical Unit in China
- DSM Opens Shanghai R&D Center
- OECD: China Needs More R&D Reforms
- Summit Lifesciences Included on Hot Asia 100 List
- Phillips to Build Molecular Medicine Lab with Shanghai Institute
- Student Engineers Design Medical Diagnostic Device for China
- Top Chinese Drug Producers
- Bridge Pharma's China Lab Gets Accreditation
- China Closes 3 Plants That Produced Lethal Products
- Sinovac and GSK to Co-Promote Flu Vaccine
- China Institutes Heavy Fines for Harmful Products
- China Sky One Puts Eight New Tests in Clinical Trials
- AstraZeneca Cuts Worldwide Workforce While Investing in China
- Beijing Med-Pharm To Distribute Cancer Drug
- Sinobiomed Approaching Launch of Ulceration Drug
- China Shenghuo Completes Phase II Trial of Ulcer Drug
- Chinese National Government Starts Small High Tech Fund
- China Medical Tech Starts US Cancer Trial
- Zhejiang Huahai Approved for Generic HIV Drug
- Conglomerate Fosun Has Hong Kong IPO
- Hansenpharm Co. Begins Selling Generic Zyprexa in China
- Business Leaders Find China Best for Investment
- Cinpathogen Partners with Fudan University in Shanghai
- Adaltis Signs Distribution Agreement for China
- GlaxoSmithKline Will Open Shanghai Research Center
- Hutchison MediPharma Reports Success for Ulcerative Colitis Disease Drug
- Microbix Biosystems Licenses Product to China
- Syngenta To Collaborate with Chinese Institute
- China Aims to Modernize Traditional Chinese Medicine
- China Sets Lofty Goals for its Bioindustry
- Healthcare Park to be Built in Suzhou
- Skystar Cuts Production Costs
- Harbin Pharma Considers Foreign IPO
- China-Biotics Reports Higher Revenues, Profits
- China Sky One Awarded Municipal Grant
- China Meditech Pays $3.3 Million for R&D Facility
- China Medical Climbs on Robust Earnings
- Chindex Signs Management Agreement for Chinese Facility
- Skystar Signs New Orders
- Foreign Investment in China Grows in 2007
- Mindray Gets OK for Two More Devices
- Hi-Tech Angel Fund in Tianjin
- Chengdu Hoist Wins Approval for Liver Cancer Drug
- China Sky One Medical Ups Q1 Revenue by 30%
- CRO Service Alliance Formed in Shanghai
- SinoBiomed Wins Patent Approval for Recombinant Viper Venom
- ChinaBio Today Starts Publication
- SinoBiomed Wins Approval Of Recombinant Growth Factor
- The Week In China: Cancer Therapeutics Sues Partner Peregrine
- The Week In China: Simcere Pharma Files for American IPO
- Industry Insights
- China Biotech Grows Up; Facts and Inferences from an In Vivo Sector Review
- China Showcase Panel: Life Science Investing in China's Golden Age
- 2021 China Life Science Investment Climbs 55% Over 2021's Results
- China Cross-Border Life Science Deals Get 2021 Off to a Fast Start
- ChinaBio® Report: 2020 China Life Science Investment Hits New Records
- ChinaBio at JP Morgan: China Biopharma Books Strong 2020, Despite Pandemic
- AmCham Shanghai Discusses Impact of COVID-19 on China Healthcare Companies
- China's Glut of PD-1/PD-L1 Candidates -- How Can They All Find a Market?
- Investor Survey: US Leads Global Healthcare Innovation, but China to Catch Up by 2025
- HKEX Biotech Summit: Hong Kong Is a Bridge Between East and West for Global Biotech
- The State of China Life Science: Can 2019 Top the 2018 Records?
- The "Cambrian Explosion" of Innovative Drugs in China Biopharma: Five Themes
- China Life Science Investment Hits Record Highs in 2018; What's Next?
- Exclusive Interview with Jonathan Wang of OrbiMed Asia: China's Market is a "Once-in-a-Lifetime Opportunity"
- Loncar Investment Starts China Biopharma Stock Index
- Nanjing Legend/GenScript Bio and Cancer's Next Big Thing: CAR-T
- China Biotech: The Pace of Innovation is Measured in Dog Years
- China's Life Science VC Explosion Continues; Rises 50% Higher in 2017
- China's Top 10 Pharmaceutical Companies
- Ninth ChinaBio® Partnering Forum Celebrates China Life Science "Sea Change"
- The Sanming Model: The Path for China's Healthcare Reform?
- Wall Street Journal: China's Drug Development Goes Global
- China Ranks #1 in Survey of Asian Biopharma Clusters
- Thomson Reuters: China Leads the World in Pharmaceutical Innovation
- China Puts Priority on Biotech
- China's Spending for Drugs to Rise 6-9% during 2016-2020: IMS
- China Generic Drugmakers Poaching Indian Execs
- China Making Its Mark in Global Biopharma Patent Filings
- For Big Pharma in China, Innovation is in the Eye of the Beholder
- Biologics in China: A 3-legged Race between Innovation, Biosimilars
- China's Patent Filings (Including Pharmaceuticals) Up 16% in 2013
- China's Relaxed Currency Conversion Rules Aid China VCs
- IMS: China Pharma Revenues to Total $155-$185 Billion in 2018
- China’s Cross-Border Partnering Deals Set to Break Record in 2014
- Steve Yang Interview: A Returnee’s Perspective
- The Necessity of a China Strategy: Get Started Now
- Wuxi PharmaTech's Steve Yang: Crown Prince of the Returnee Pack
- Chinese Biopharmas Eager to Partner, Differentiation Wanted
- China VCs Actively Backing China's Life Science Companies
- Strategies for Dealing with the CFDA
- Innovative Drug Development Growing in China; Partners Welcome
- China Takes First Place as Asia’s Leading Biopharma Cluster
- Roche and Jiangsu Province Bring Down High Cost of Breast Cancer Drug
- China Pharma Production Rose 18% in 2013
- Asia Registers Big Gain in Global Pharma R&D Spending; US Drops
- CFDA: China Pharma Output Grows, but Profits Lag
- China’s Pharma Market to Reach $310 Billion in Revenues by 2020
- China’s Prescription Drug Market to Reach $315 Billion in 2020
- Pharma Hiring Climbing in China as General Hiring Declines
- CSRC Terminates IPO Applications of 15 China Life Science Companies
- Revenue from China’s Drug Distributors Hits $181 Billion in 2012
- VC Investment, M&A and Cross-border Partnerships Boom in China Life Science
- China Leads Emerging Nations in Pharma M&A
- Barclays Upgrades Outlook on Companies in China Healthcare Sector
- India Unhappy about China’s Dominance in Antibiotic APIs
- ChinaBio® White Paper – China Life Science: From Local to Global
- China’s Pressure on Drug Prices May Hurt Outlook for Pharma
- India Takes Aim at China Pharma's Inroads into the Indian Market
- China’s Pharma Output Climbed 30% in First Seven Months of 2011
- China Leads India on Drug Patents and Academic Drug Research
- Biotech a Priority in China’s $309 Billion Five-Year Plan
- INDs and NDAs Quantify the Innovation in China’s Drug R&D
- Q1 Earnings Review: Healthy Revenue Increases, Smaller Profit Growth
- Latest Round of Cuts in Drug Prices Takes Effect in China
- VC Investment in China Life Science Climbs 300%, Tops $1 Billion
- BMI Ups China’s Pharma Market Short-term Growth Rate
- PwC Expects China to Gain in Medical Device Innovation
- China Expected to be World’s Innovation Leader by 2020
- Monitor Group: China Life Science Will Be Innovative Global Leader by 2020
- 2010 to Set Record for VC Investment in China Life Science
- China 12th Five-Year Plan Calls for Consolidation of Drug Distributors
- China’s Pharmaceutical 2009 Output Tops 1 Trillion RMB
- The Scientific American Devotes Special Section to China Biopharma
- China’s Top Domestic Big Pharmas Increasing Their Dominance
- Survey Puts 2009 Asia-Pacific Life Science Revenues at $111 Billion
- US Healthcare Reform and China
- IMS Health: China Leads Emerging Pharma Markets
- China Pharmaceutical Market Growing at 22% Clip
- Are China CMOs the Next Big Thing?
- The Current State of China Life Science: China Ascendant
- How to Partner with China Life Science Companies
- Successful Partnerships in China – Case Studies
- The Impact of the Financial Crisis on Partnering in China
- A Big Pharma Perspective on Leveraging China’s Resources
- Experts Discuss Potential of Partnering in China at the ChinaBio® Partnering Forum
- US Real Estate Problems Present Opportunities for China Life Science Companies
- China Commits $9 Billion to Biotech and Other New Technology
- The State of China Life Science – IPOs and M&A
- The State of China Biotech – VC Investment
- The State of China Biotech – 2009 – Technology Development
- The State of China Life Science in 2009 – An Introduction
- Cancer Drug Market in China Was $3.6 Billion in 2007
- China Launches “Mega Program” to Fund Drug Development
- Charles River Says CRO Business Slowing
- China’s Hepatitis B Market to Double by 2012
- KPMG: More JVs in 2008, Less M&A
- China CROs: The Agenda is Growth
- VCs Like China and Biotech for 2008
- Nature Biotechnology’s Overview of China Biotech
- ChinaBio® Today Editor Scott on China Life Sciences and IP
- ChinaBio® Investor Forum 2007: China Life Science Investment Growing
- Zero2IPO Reports Jump in China’s Q3 VC/PE Investment and Exits
- China Biomedical Investing Gaining Momentum – Interview with Greg Scott
- China Edges Ahead of India in Clinical Trials
- Rumor Confirmed: SFDA to Speed Approvals
- Taiwan v. China: The MediVas Case Study
- China Innovation: Biotech and Drugs #2
- Asia Pacific Will Supplant US-Europe as Pharma Center
- Does China Have a Short-Sightedness Problem?
- China's Five Year Plan for Biotech
- China Life Science Companies Make Mark at VC Conference
- Food and Drug Safety: Who is Really Responsible?
- Biosimilars and China: Problems and Potential
- Featured Companies
- WuXi Biologics Signs $1.5 Billion Pact with GSK for Four Novel TCE Antibodies
- VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO in Guangzhou
- Exclusive: How Sequencing Firm ReadCoor Came to be Acquired by 10x Genomics
- Gracell Bio Announces Fast, Cost-Effective CAR-T Manufacturing Technology
- Interview: Apollomics Poised to Bring China Developed Checkpoint Inhibitors to the US
- Dr. Zhengqing Li, an Experienced China Pharma Exec, Joins Ascletis
- WuXi Biologics Plans Big Increase in Manufacturing Capacity
- WuXi Biologics to Build Biomanufacturing Facility in Ireland
- Zoetis Starts New Site Construction in Suzhou
- WuXi AppTec Expands Operation Site in New Jersey
- Philip Partners with Digital China Health to Launch Cloud-Based Imaging Services
- Fosun Pharma Stays Committed to Expanding through R&D and M&A
- Chi-Med's Innovative Drug Portfolio: Eight Candidates in 31 Trials
- Exclusive Interview: Dr. Sofie Qiao, CEO of Vivace Therapeutics
- Using Partnerships, Hua Medicine Brings Novel Diabetes Drug to Phase III
- At WuXi AppTec, Partnerships Expedite Drug Development and Approvals: Interview with Dr. Hua Mu
- Jiangsu Hengrui Medicine Uses Partnerships to Advance Novel Drug Programs
- Suzhou's Innovent Biologics: Interview with CEO Michael Yu
- Nuance Biotech Targets China and South Africa
- Interview with Dr. Dan Zhang of Fountain Medical: "Get Started"
- Johnson & Johnson: Translation in Asia
- Roche Seeks Companies with Unique Differentiators for Partners
- Cellular Biomedicine's Stock Price Quadruples in Two Months
- Exclusive Interview with Dr. Jonathan Wang: OrbiMed Asia Seeks Partners for Portfolio Companies
- Exclusive Interview with Dr. Arthur Taveras: ChemPartner Focuses on Science
- Zhejiang Beta’s Conmana, a Cancer Drug, is a Big Winner
- Tianyin Pharma Hopes to Sell Azithromycin API in India
- Fosun Named One of China’s Top Ten Innovative Pharmas
- J&J Touts its Pharma R&D Efforts for China
- GSK Says Lowering Prices in China Caused Higher Sales
- WuXi PharmaTech Reports Higher Q1; Analyzes Prospects for its Business
- Teva's CEO Thinks China is a “Natural Fit”
- WuXi AppTec – "Every Client is a Partner"
- Hangzhou Nurotron Biotech Cuts Cost of Cochlear Implant
- Dream Driven: Exclusive Interview with Dr. Jun Wang, Executive Director of BGI
- DelMar Pharma Partners with Wuzhou Pharma on Cancer Drug
- Sihuan Pharma Doubled its Revenue in 2011
- Steve Yang: AstraZeneca in China Wants to Transform Pharma R&D Models
- For Saladax Biomedical, China Could Be the Largest Market
- SuperNova Developing Point of Care Diagnostics Technology
- China Scientists Given US Award for Cancer Breakthrough
- ASLAN Pharma – A Very Focused Business Plan
- Novo Nordisk Rejects China M&A; Will Grow through Innovation
- Roche’s Strategy for China – Global, Not Local
- SciClone Announces $20 Million Stock Buyback
- Hua Medicine: A China Startup Led by Industry Veterans
- Epitomics Plans Taiwan IPO Later in 2011
- Shanghai Pharma Wants to Acquire US or European Pharma
- Simcere Plans to Triple Headcount in New R&D Facility
- Bristol-Myers Squibb Ups its Plans for China
- AstraZeneca Uses Local Partners to Expand Impact of China R&D
- Cash-strapped Lotus Pharma Explains CapEx Decisions
- Aoxing Pharma: An Exercise in Patience
- Exclusive Interview, Ascletis CEO Says Grants Will Extend $100 Million A Round
- Lilly Sees Big Opportunity in China
- China YCT Bets Company on Botanical Flu Treatment
- American Oriental Bioengineering: All Dressed Up, Nowhere to Go
- WuXi PharmaTech COO Highlights Growth
- JOINN Takes Big Leap into China’s CRO Future
- Interview: China Looms Large for Bayer Growth Strategy
- GeneHarbor Technologies: Novel Enzymes for New Applications
- Sinoasis Develops Proprietary Technology for Therapeutic Antibodies
- aTyr Using Hong Kong to Leverage Development of New Class of Biologics
- Featured Company: HD Biosciences Receives Pfizer’s Top Partner Award
- ProteLight and BioAMPs Take on Antibiotic-Resistant Bacteria
- China Sky One Medical: A Company on the Move
- PharmaLegacy, a Pharmacology CRO, Opens Its Doors
- LEAD Therapeutics: A New US-China Drug Discovery Model
- Beike Uses Research Forum to Showcase its Stem Cell Therapies
- Shenogen Pharma Blends East and West
- Featured Company: Is 3SBio Too Conservative?
- Financial Engineering at American Oriental
- Featured Company: GenePharma Atop Hot siRNA Tool Market
- Lotus Pharma Not Sleepy
- Adaltis Focuses Diagnostic Business in China
- Featured Company: CapitalBio Makes Biochips and VC Investments
- Novartis Reports Higher China Revenues
- Sinobiomed Scores $1.2 Million Grant for Malaria Vaccine
- Dragon’s New Production Process to Cut Costs
- AMDL Launches Anti-Aging Product in China
- Renhuang Seeks Respect
- Shengtai Pharmaceutical: Strong Numbers; Weak History
- Shanghai Century Reports Financials for Acquisition Target
- Featured Company: Beijing Med-Pharm Raises $31 Million
- Bridge Pharma Evolving Quickly
- Featured Company: Beijing Med-Pharm
- Featured Company: American Oriental Stirs Up Controversy
- Featured Company: Sinovac Biotech Is a Bird Flu Play
- Featured Company: Benda Offers Gene Therapy
- Featured Company: Post-IPO Numbers on Simcere
- Deals & Financings
- Boehringer Options Schizophrenia Candidate from Japan’s Sosei in $822 Million Deal
- Hansoh Adds Global Rights for Zhuhai’s Bispecific in $700 Million Deal
- EurekaBio Raises $40 Million for New Lentiviral Vector Production System
- Chengdu Maxvax Bio Raises $40 Million for Vaccines and Immunotherapies
- Zylox-Tonbridge Acquires China Rights to Vascular Devices for $15 Million
- Haihe Out-Licenses Japan/Asia Rights for NSCLC Therapy to Taiho Pharma
- Mabwell Out-Licenses Rare Disease Therapy to Disc in $412 Million Deal
- Biotheus to Develop Antibodies With Bitterroot for Cardio-Immunology
- AstraZeneca to Continue Roxadustat Sales in China; Returns Other Rights
- Nhwa to Distribute Teva’s Movement Disorder Therapies in China
- AlphaGen and ArtBio Form China-US Partnership for Radioligand Therapies
- Biocytogen Signs Three-Year Antibody Discovery Pact with Gilead Sciences
- LianBio to Shut Down Operations; Will Distribute $528 Million to Shareholders
- Yiviva Signs MOU with AstraZeneca to Develop New Drugs based on TCM Therapies
- Bayer Signs Letter of Intent to Market Trinity’s Glucose Monitor in China and India
- China Medical System Acquires China Rights to Phosphate Binder from Winhealth
- I-Mab Divests China Operations to Become Fully US-Based Biopharma
- Anbogen Raises $12.5 Million to Develop Precision Oncology Portfolio
- Inmagene Exercises Option for Two HutchMed Candidates in $460 Million Deal
- Sanofi Invests in Graviton and its Lead Product, a ROCK2 Inhibitor in-licensed from Beijing Tide
- ArriVent Completes $175 Million NASDAQ IPO to Bring Assets from China to the US
- Jiuzhou Pharma Earmarks $42 Million for New CDMO Site in Japan
- Alphamab and 3D Medicines Out-License PD-L1 to India’s Glenmark
- AstraZeneca Signs $26.5 Million Deal to Build Production Line in China for Type-2 Diabetes Drug
- Lee’s Pharma in $138 Million Deal for China Rights to Heart Failure Treatment
- Henlius In-licenses Novel ESR1 Antagonist Therapy for Breast Cancer in $58 Million Deal
- WuXi Biologics to Discover mAbs for BioNTech for $20 Million Upfront
- GSK Pays $1.4 Billion to Acquire Aiolos, which In-Licensed a Hengrui Asthma Candidate
- Bayer Joins $162 Million Round for Ji Xing; Has Preferential Rights for In-Licensings
- OnCusp Completes $100 Million Series A Round for In-Licensed Cancer Candidates
- Kanghua Out-Licenses Norovirus Vaccine Candidate to HilleVax in $270 Million Deal
- Ambrx, a San Diego-China ADC Company, Acquired by J&J for $2 Billion
- Insilico Sells Global Rights for KAT6A Inhibitor to Menarini in $500 Million Deal
- Argo Signs $4.2 Billion Agreement Selling Four RNA Candidates to Novartis
- Tenacia Acquires China Rights to Tremor Therapy from Praxis in $279 Million Deal
- Biocytogen Sells Option for HER2/TROP2 Bispecific ADC to Radiance Biopharma
- Avistone Closes $140 million Series B Round for Precision Medicine Oncology Portfolio
- Novartis Acquires SanReno Therapeutics, a Shanghai Company with Two IgAN Candidates
- Allorion Out-Licenses ex-China Rights for CDK2 Inhibitor to Avenzo in $1 Billion Deal
- IASO and Umoja Partner to Develop Off-the-Shelf CAR-T Gene Therapies
- Ribo Life Science Forms $2 Billion siRNA Collaboration with Boehringer Ingelheim
- MediLink Signs $1 Billion ADC Out-Licensing Rights Agreement with Roche
- JW Therapeutics Extends Development Collaboration with 2seventy for Autoimmune CAR-T
- Elpiscience Out-licenses Bispecific Macrophage Engager to Astellas in $1.7 Billion Deal
- Qilu In-Licenses siRNA Targeting PCSK9 from Ribo in $100 Million Agreement
- Innovent And Sanegene Collaborate to Develop siRNA for Hypertension
- Gracell, a CAR-T Company, to be Acquired by AstraZeneca for $1.2 Billion
- LianBio Sells China Rights for Radioenhanced Drug to Janssen for $30 Million
- Huadong to Promote Impact’s PARP Inhibitor in China in $40 Million Agreement
- Ablaze Medicine Partners with Oncoshot for AI-based Optimization of Clinical Trials
- CStone Sells China Rights for IDH1 Inhibitor to Servier Pharma for $50 Million
- GSK Acquires ex-China Rights to Second ADC from Hansoh in $1.7 Billion Deal
- InxMed Licenses Rights to Escugen’s Linker-Payload Platform for ADC Candidates
- Biocytogen Sells Option for ADC to Barcelona’s Ona Therapeutics
- Nona Out-licenses MSLN-targeting ADC to Pfizer in $1 Billion Agreement
- GeneQuantum and BioMap Form AI Collaboration to Discover Novel ADC Candidates
- Evive and Nona Partner Up to Develop Antibody Drugs
- SystImmune Out-Licenses Rights for ADC to BMS in $8.4 Billion Agreement
- AbelZeta Forms a China CAR-T Collaboration with AstraZeneca
- Aspen Pharma Buys Sandoz’s China Operations for $120 Million
- Innovent Adds Second ADC to Collaboration with Synaffix, an ADC CRO
- Adcentrx Adds $13 Million to A+ Round for Novel Antibody Drug Conjugates
- Abbisko Sells China Rights for CSF-1R Inhibitor to Germany’s Merck in a $605 Million Agreement
- LianBio Receives $465 Million Cash Buyout Plus Contingent Rights Offer From Tang Capital
- Perpetual Raises $8 Million in Seed Financing for AI Discovery of Novel Peptides
- Accutar to Apply its AI Platform to Discover Inflammatory Disease Therapies with Evommune
- Korea’s DxVx Plans Novel Cancer Vaccine In-licensing from its Partner Oxford Vacmedix
- Zhifei Biological to Acquire Chongqing Chenan Bio, a Diabetes/Obesity Company
- Usynova Out-Licenses KRASG12D Inhibitor to AstraZeneca in $419 Million Agreement
- Myriex Bio Acquires Antibody for Novel ADCs Discovered by WuXi Biologics
- BeiGene Acquires Global Rights to CDK2 Inhibitor from Ensem in $1.3 Billion Deal
- Simcere Signs $141 Million Deal for Connect Bio’s Novel Atopic Dermatitis Therapy
- Porton Advanced and Ascle Therapeutics Collaborate on CAR-NK Cell Therapy
- Haisco Out-Licenses Global Ex-China Rights for Bronchiectasis Therapy to Italy’s Chiesi Farma
- SciClone Acquires China Rights to Metastatic Breast Cancer Drug from Menarini
- ChromX Forms Diagnostic Collaboration with Boehringer Ingelheim for Lung Fibrosis
- Nona Collaborates with GeneQuantum to Offer Bioconjugate CMO Discovery Services
- Legend Signs $1.2 Billion Agreement Selling Global Rights for DLL3 CAR-T to Novartis
- AnchorDx and DiaCarta Team Up to Develop Early Cancer Screening Diagnostics
- Eccogene Signs $2 Billion Deal Selling Rights for GLP-1 Agonist to AstraZeneca
- Porton Partners with BioMap for AI Based Gene Therapy Development
- Celest Therapeutics Acquires Novel CAR-NK Cell Therapy from Senti Bio in $156 Million Deal
- Biotheus Out-licenses ex-China BiSpecific Rights to BioNTech in $1 Billion Deal
- Shanghai Argo Biopharma Closes $41 Million Series A+ Round for RNAi Therapies
- Mellow Hope and Rational Vaccines Join to Develop Herpes Simplex Vaccines
- CStone Out-Licenses China Rights for anti-PD-1 to 3SBio for $22 Million
- BioLineRx in $270 Million Deal for China Rights for Stem Cell Mobilizer
- AnHeart Sells Japanese Rights to ROS1 TKI to Nippon Kayaku for $40 Million Upfront
- Hengrui Sells PARP1 Inhibitor to Germany’s Merck in $1.7 Billion Deal
- Henlius Signs $200 Million Deal with Intas for EU/Indian Rights to its Anti-PD-1
- Angita Closes $46 Million Series B Extension for Musculoskeletal Disease Therapies
- LianBio Sells China Rights to Cardiovascular Drug for $350 Million to BMS
- OrbiMed Raises $751 Million for Asia Healthcare Fund; $3.6 Billion for Two Other Funds
- Aiolos Raises $245 Million; Partners Hengrui’s Asthma Drug in $1 Billion Deal
- Sirius Closes $60 Million B Round for Cardiovascular siRNA Portfolio
- Hansoh Out-Licenses ADC to GSK in $1.6 Billion Deal
- Belief BioMed Signs up Takeda to Commercialize Gene Therapy for Hemophilia in China
- KBP Sells Hypertension Candidate for $1.3 Billion to Novo Nordisk
- Hengrui Out-Licenses its PD-1 for Liver Cancer to Elevar in $1 Billion Deal
- EpimAb Out-licenses Use of its Bispecific Platform to Almirall in $210 Million Agreement
- SparX’s Lead Claudin 18.2 mAb Candidate Included in CAR-iNKT Cell Therapy
- MediLink Out-Licenses Novel HER3 ADC to BioNTech in $1.1 Billion Agreement
- Beijing’s BioMap, an AI Drug Discovery Startup, Signs $1 Billion Deal with Sanofi
- Zeifei Biological Partners with GSK to Market Shingles Vaccine in China
- QYuns, an Autoimmune/Allergic Disease Biotech, Files for Hong Kong IPO
- PharmaEssentia Acquires Myeloid Immune Checkpoint Antibody from WuXi Biologics
- Triastek Raises $20 Million for 3D Printing Manufacturing of Pharmaceuticals
- I-Mab Says AbbVie Returns Rights for CD47, Ending $2 Billion Partnership
- Qihan Biotech Raises $16 Million for Gene-Edited Stem Cell Products
- Chime Enters Cooperation with Panolos to Develop Multi-Specific Candidate
- Tonghua Dongbao Out-Licenses US Rights for Three Insulin Biosimilars to Meitheal
- Everest Acquires China Rights to Lupus Nephritis Candidate in $132 Million Agreement
- Lynk Closes $16 Million C2 Round to Advance JAK Inhibitors for Autoimmune Diseases
- Novartis Ends $2.2 Billion Global PD-1 Partnership with BeiGene
- PackGene and Kudo Bio Partner to Provide End-to-End mRNA Services
- Canton Biologics Raises $41 Million in C Round for Biologic CDMO Services
- Cure Genetics to Develop AAV Vectors for Neuro Startup in $60 Million Deal
- Shanghai Pharma Signs MOU to Run China Phase III Trial of Korean Alzheimer’s Drug
- JW Therapeutics to Develop Two Additional 2seventy Cell Therapies in China
- Insilico Out-Licenses Global Rights for USP1 Inhibitor to Exelixis for $80 Million Upfront
- Hasten Biopharma Enters $325 Million Deal for PCSK9 Cholesterol Drug
- ImmuneOnco Stages $30 Million Hong Kong IPO for Innate/Adaptive Immunity Drugs
- Grit Bio Closes $60 Million Round for Tumor-Infiltrating Lymphocyte Oncology Drugs
- Biocytogen Forms ADC Partnership with Myriex, a Cytotoxic Payload Company
- Huadong Pharma Signs $52 Million China Deal for Topical Psoriasis Therapy
- Kangpu Closes $13.8 Million B Round for Protein Ubiquitination Candidates
- GenFleet Partners Three Pre-Clinical RAS Candidates with Verastem in $625.5 Million Deal
- Henlius Collaborates with HanchorBio to Develop Novel Immuno-Biologics
- China Consortium Aims to Acquire Drug Distributor in Poland
- Simcere Acquires Commercialization Rights to Mabpharm’s Colorectal Cancer Therapy
- CirCode Raises “Millions of Dollars” in A Round for Circular RNA Drugs
- Sangon Raises $290 Million for Life Science Tools and Services Business
- Hengrui Out-licenses Ex-China Rights to Asthma/Sinusitis Therapy in $1 Billion Deal
- CytoMed Signs MOU with CNK Therapeutics for Gene Grafting Technology in CAR Therapies
- Zhongmei Huadong In-licenses Skin Disease Therapy in $94 Million Agreement
- Antengene Signs up Hansoh in $101 Million Deal for Commercialization Rights to XPO1 Inhibitor
- Neurophth Closes $95 Million Series C+ Round for Gene Therapy Ophthalmology Therapies
- CanSinoBIO and AstraZeneca Form mRNA Vaccine Collaboration
- Investisbio Out-Licenses KRAS G12C Inhibitor to Sino Biopharm Subsidiary
- BeiGene’s Breakup with Celgene/BMS Now Complete with Return of BeiGene Shares
- Gracell Raises $100 Million in Private Placement for Trials of CAR-T Candidates
- Duality Biologics Adds Third ADC Candidate to BioNTech Partnership
- Mundipharma May Propose Sale of China Operations for $1 Billion
- Oramed and Hefei Tianhui to Form $60 Million JV for Oral Insulin Product
- ABVC Out-licenses China Rights for Two Neurologic Therapies to Xinnovation
- CASI Acquires China Rights to Lymphoma Chemotherapy from Mundipharma
- CirCode Forms Partnership with Pfizer to Develop Circular RNA Therapeutics
- Xinkanghe Biomedical Raises $14 Million for Immunology Drugs
- Mirxes Closes $50 Million Round for miRNA Tests; Will IPO in Hong Kong
- Pyrotech Closes $97 Million Round to Develop Novel Technology for Autoimmune and Cancer Drugs
- Pillar Bio Partners with Illumina to Offer Genomic Profiling Assays for Oncology
- MindRank Raises $20 Million in A+ Round to Support AI Drug Development Operations
- Biotheus Out-Licenses Global Rights for Bispecific Antibody and mAb to BioNTech
- CASI Pharma Acquires VCP/p97 Inhibitor for Myeloid Leukemia and MDS
- Novartis in $1 Billion Deal for DTx Pharma, an siRNA Company Incubated by Viva BioInnovator
- GeneQuantum Licenses Novel Bioconjugation Technology to InxMed
- GeneQuantum Adds Five ADC Candidates to its Collaboration with Aimed, a Korean Biotech
- Biosyngen to Establish Guangzhou-Singapore Translational Center for Cancer Drugs
- Doer Biologics Out-Licenses Global Rights for Candidate to Germany’s BioNTech
- Sinotau Pharma Completes $152 Million E Round for Radiopharmaceutical Portfolio
- BeiGene Options ADC for Solid Tumor Cancer from Duality Bio in $1.3 Billion Deal
- WuXi Biologics Plans Spin-off and $500 Million Hong Kong IPO of Conjugates Subsidiary
- Sirnaomics Provides Capital and RNA Delivery Technology to EDIRNA, an RNA Editing Company
- Brii Bio Expands Rights for VBI’s HBV Therapy to Global in $437 Million Deal
- F-star Signs Third Collaboration with Takeda; This One is Worth up to $1 Billion
- Moderna to Establish Shanghai Operations; May Invest up to $1 Billion
- Worg Pharma Raises $152 Million for Allergy and Autoimmune Immunotherapies
- BCHT Bio Pays $21 Million for 20% Stake in mRNA Vaccine Company; Will Acquire the Rest
- CBMG Out-Licenses Top Two CAR-T Candidates to Janssen for $245 Million Upfront
- Lion TCR Raises $40 Million to Develop HBV-Specific T Cell Receptor Therapy for Liver Cancer
- Brii Bio to Receive $24 Million from Sale of Qpex; Gains Global License to Anti-Infective
- WestGene Biopharma Raises $42 Million in a Series A Funding for its mRNA Portfolio
- AstraZeneca May Create New Company for China Ops and List in Hong Kong or Shanghai
- Cullgen Forms $1.9 Billion Collaboration with Astellas for Protein Degraders
- Cholesgen Collaborates with AstraZeneca to Develop Hypercholesterolemia Candidates
- Simcere to Underwrite up to Eight Research Projects at Mass General Brigham
- HighTide Plans Hong Kong IPO to Support Metabolic and Digestive Portfolio
- Fosun Pharma Lands $107 Million to Build African Production and Distribution Facility
- Impact Sells Rights for Two PARP Inhibitors to Eikon Therapeutics
- invoX Makes 2nd Investment in pHion, a Belfast mRNA Vaccine Company
- Lynk Pharma Closes C1 Round with $28 Million for Oncology and Autoimmune Drugs
- Betta Signs $392 Million Agreement for Lung Cancer Drug Rights with C4 Therapeutics
- Coherent Bio Closes B Round with $100 Million for XDC Candidates
- Keymed and Rona Partner to Discover siRNA Drugs for Severe Kidney Disease
- Amoytop and Aligos Team Up in $109 Million Deal to Develop Novel Drugs for Liver Diseases
- Drug Farm Raises $27 Million for AI-based Immune-modulating Therapies
- LaNova of Shanghai Sells Myeloma ADC Candidate to AstraZeneca for $600 Million
- Reforgene Biotech Completes $15 Million Pre-B Round for Gene Editing Drugs
- Chance Pharma Acquires China Rights for Inhaled Parkinson’s Therapy in $144 Million Deal
- Suzhou Zion Out-Licenses Brain-Penetrating HER2 Candidate to Roche in $680 Million Deal
- Bliss Biopharma Out-Licenses HER2 ADC to Eisai for up to $2 Billion
- Junshi Signs $728 Million Deal Granting Rights for Anti-PD-1 in 21 Countries to Dr. Reddy’s
- Janssen In-licenses CAR-Ts for $245 Million Upfront, its 2nd CAR-T Deal with a China Biotech
- Zai Lab Acquires Global Rights to ADC for Small Cell Lung Cancer from MediLink
- Adcentrx, a San Diego-Shanghai Company, Raises $38 Million for ADC Portfolio
- Hasten Raises $315 Million from CBC and Abu Dhabi's Sovereign Fund for In-Licensings
- Pfizer Partners with Sinopharm to Bring 12 Innovative Drugs to China
- VintaBio Opens Cell and Gene Therapy CDMO after $64 Million Round led by Decheng
- Pierre Fabre Enters $618 Million Deal with Boston’s Scorpion for Two Novel EGFR Candidates
- DualityBio Sells Two ADC Assets to BioNTech for $170 Million Upfront, $1.5 Billion in Milestones
- Apollomics Merges with SPAC to List on NASDAQ; Climbs 121% Higher in Trading
- Ablaze Pharma Acquires China Rights to Targeted Radiotherapy Drug for Liver Cancers
- SciNeuro Signs Up Secarna to Discover Antisense Oligonucleotide Therapies for Neurology Targets
- Pharmaron Receives $186 Million Grant to Expand UK Cell/Gene Therapy Manufacturing
- Junshi Forms Commercialization JV with Rxilient to Market PD-1 in Southeast Asia
- SalubrisBio Reports $35 Million Infusion from Parent for Novel Biologic Drugs
- OncoVent Sells Taiwan Rights to Ovarian Cancer Candidate for $11 Million
- ArriVent Closes $155 Million Round to In-license US Rights for China Drugs
- Everest Forms Renal Research Partnership with Guangdong Medical Academy
- F-star Partners Second Early-Stage Tetravalent Bispecific Antibody with Takeda
- Highlightll Out-licenses Dual Inhibitor for Parkinson’s in $970 Million Deal
- Joincare to Develop TaiGen’s Pan-Flu Therapy in Greater China
- Gracell Closes Cell Therapy Deal with Seagen; No Details Released
- ArkBio and Scripps Research Extend Partnership for Novel Respiratory Candidate
- Base Biotech Raises “Tens of Millions of Dollars” in A1 Round for Base Editing
- Livzon Acquires Rights to GERD Therapy from Onconic for $127.5 Million
- Allorion Raises $50 Million for Oncology/Autoimmune Precision Medicines
- CFIUS Approves Sino Biopharm’s Acquisition of F-Star after Nine Month Wait
- Rinua Gene Raises $14.5 Million in Pre-A+ Round for mRNA Drugs
- Abbisko Out-Licenses Precision EGFR-TKI Medicine to Allist in $188 Million Deal
- TandemAI Raises $35 Million for AI/WetLab Drug Discovery Operations
- Immorna Raises $100 Million for Clinical Trials of Novel RNA Candidates
- Shanghai Oricell Raises $45 Million to Take Cellular Immunotherapies to US
- Chipscreen Signs $72 Million Deal for Eucure Bispecific Immunotherapy
- Keymed-Lepu JV Out-Licenses Claudin 18.2 ADC to AstraZeneca in $1.2 Billion Agreement
- Kinnate, a Precision Oncology Company, Pays $24 Million to Buy Out JV Partners
- InnoCare’s $937 Million MS Deal Falls Apart as Biogen Returns Rights
- Hengrui Signs $706 Million Deal Sending US Rights for EZH2 Inhibitor to Treeline
- Harbour BioMed Out-Licenses US Rights for Bispecific in $588 Million Deal
- CSPC Pharma Out-Licenses Nectin-4 ADC to Corbus in $692 Million Deal
- Wondercell Closes $14 Million in Angel Funding for Immune Cell Therapies
- CANbridge Acquires Global Rights to Rare Disease Therapy from UMass
- GenScript ProBio Forms Partnership to Expedite Novel Products for Bio Immunitas
- Asieris Collaborates with ReviR to Discover RNA Candidates for Genitourinary Tumors
- Zhimeng Biopharma Out-Licenses TLR8 Agonist, an HBV Therapy, to GSK
- JiXing Buys Global Rights for Hypertension Candidate from PhaseBio
- AnHeart to Use Guardant’s Assays for NSCLC Trials of ROS1 Inhibitor
- NeuShen and UMass Partner To Develop Gene Therapy for ALS
- CS Pharma Acquires China Rights to Fibrosis Drug in $336 Million Agreement
- HBMAT, a Harbour Biomed JV, Closes Seed Round for Novel Endocrine Therapies
- HutchMed Out-licenses Rights for VEGFR to Takeda in $1.1 Billion Deal
- Mabwell Out-licenses Rare Disease Drug to Disc Medicine for $412.5 Million
- Tigermed Expands Footprint and Services by Acquiring Marti Farm, a Croatian CRO
- Aprinoia, a Neurodegenerative Company, to be Acquired by $280 Million SPAC
- Nanjing IASO Bio Raises $75 Million to Develop/Commercialize CAR-T Assets
- GenScript ProBio -- a mAb, Cell & Gene Therapy CDMO -- Raises $224 Million
- CARsgen Signs $181 Million Deal to Commercialize CAR-T in China with Huadong
- Ronovo Closes New Funding for Modular Robotic Laparoscopic Surgery Device
- Evopoint Options-Out Rights for Pre-clinical Solid Tumor ADC to AmMax
- Chengdu Qitan Raises $101 Million for Nanopore Sequencing Devices
- Simnova Acquires China Rights to Circular RNA CAR-T Therapies from Orna
- Immune-Onc Adds $25 Million to B Round for Novel Myeloid Checkpoint Inhibitors
- Duality Licenses ADC Platform to Adcendo for Mesenchymal Cancer Program
- HighTide Closes $107 Million Round for Metabolic/Digestive Disease Candidates
- ArriVent in Hunt for $145 Million to Finance US In-licensing Operations
- Biocytogen Out-Licenses Global Rights for mAb Candidates to Hansoh
- 2022 China Life Science Deals: Slow Start, Late Recovery; Top 10 Deals Worth $21.5 Billion
- Ablaze Pharma Forms CDMO Partnership with Yonghe for Radiopharmaceuticals
- Junshi Out-licenses Middle East/North African Rights for PD-1 to Hikma Pharma
- WuXi XDC to Offer GeneQuantum’s Platforms for Bioconjugate Development
- TenNor Raises $10 Million for Conjugate Infectious Disease Products
- Kelun-Biotech Signs $9.5 Billion Deal with Merck for Seven ADC Candidates
- XtalPi Collaborates with Singapore’s EDDC to Discover NSCLC Candidates
- Shanghai Group Leads $20 Million Round for Israel’s Biomica, a Microbiome Company
- Staidson Bio In-Licenses mAb Complement Therapy for COVID in $10 Million Deal
- LianBio Sells Rights for RSV Therapy to Pfizer in $155 Million Deal
- Prenetics Acquires ACT Genomics in $60 Million Cancer Testing Tie-Up
- Innovent Enters $95 Million Agreement to In-License Gout Treatment
- Alternative Bio Lands $15 Million to Develop Oncology Drugs based on Novel Enzymes
- Suzhou 4B Technologies Closes $14 Million Pre-B Financing for Neuro Drugs
- Boston Scientific Pays $523 Million for Control of Acotec, a Beijing Device Company
- Nanjing Biosion Forms ADC Discovery Collaboration with Boston’s ImmunoGen
- HitGen Partners with Nitrase to Develop Novel Enzyme Inhibitors
- WestGene Biopharma Completes $21 Million Funding for mRNA Drugs
- GenAssist Raises “Millions of Dollars” for Novel Base Editing Drugs
- GenScript to Build Synthetic Biology Library with Singapore’s Allozymes
- Akeso Out-licenses ex-China Rights for PD-1/VEGF to Summit in $5 Billion Deal
- Boan Biotech’s IPO Application Accepted by Hong Kong Exchange
- Boston’s Regenta Raises $52 Million for RNA Drugs from China Investors
- Gland Pharma, a Fosun Subsidiary, to Buy French CDMO for $124 Million
- Pediatrix Acquires Atopic Dermatitis Therapy in $96 Million Agreement
- Full-Life Enters $245 Million Deal to Acquire Focus-X, a Radiopharma Company
- Biocytogen Signs Option to Out-License Three Antibodies to ADC Therapeutics
- XtalPi and CK Life Sciences Partner to Discover Therapeutic Tumor Vaccines
- Wanbang Biopharma Adds Animal Rights to Agreement for Diabetes Therapy
- Nona, a Harbour BioMed Subsidiary, to Discovery Immunotherapies for Dragonfly
- Triastek to Start US Trials of Third 3D Printed Therapy
- IASO Forms Collaboration with Umoja for Allogenic CAR-T Therapies
- Fosun Licenses US Rights to PD-1 from Henlius in $840 Million Deal
- Tenacia Signs $266 Million Agreement with Marinus for Seizure Drug
- SynRx Raises $14 Million to Develop Drugs for Solid Tumor Cancers with DNA Damage
- Evive Sells US Rights for Neutropenia Therapy to Aerotech in $236.5 Million Deal
- Simcere Enters $50 Million Deal for China Rights to Novel Insomnia Therapy
- Hansoh Enters $207 Million Agreement for Biotheus EGFR/MET Bispecific
- WuXi Vaccines Acquires Suzhou Manufacturing Facility from Harbour BioMed
- Lupeng Pharma Closes 2nd $35 Million Pre-B Tranche for Small Molecule Drugs
- Harbour BioMed Forms Immunotherapy Discovery Collaboration with Moderna
- Zenas BioPharma Raises $118 Million for Global Autoimmune Portfolio
- Insilico Announces Six-Drug, $1.2 Billion AI Drug Discovery Deal with Sanofi
- XellSmart Raises $27.6 Million for Low-Cost Stem Cell Therapies
- Neurophth Enters $140 Million Gene Therapy Collaboration with Cyagen
- CBC Group Plans $137 Million Shanghai Biopharma Center
- Beijing Immunochina Closes Series D+ with at least $28 Million for CAR-T Drugs
- Eucure Partners CD40 Antibody for Tri-Specific Drug with Korea’s ISU ABXIS
- Beihai Raises $27 Million to Support Increased Solubility Oncology Drugs
- CorreGene Closes $14 Million Pre-A+ round for Novel TCR Drugs
- JHM Bio Closes $28 Million Round for Biologic Product Portfolio
- JW Therapeutics Partners with 2seventy bio to Develop T Cell Immunotherapies
- Salubris and Anlong to Co-develop Nucleic Acid Hypertension Drug
- ImmVira Closes C+ Tranche, Will Keep Round Open for Two Months
- VectorBuilder Raises $57 Million from China Investors for Gene Therapy Delivery
- Celgenyx Closes $14 Million A Round for Off-the-Shelf Cell Therapies
- Maxinovel Raises $14 Million for Novel Small Molecule Portfolio
- Eucure Biopharma Licenses Antibody to Syncromune for Personalized Cancer Therapy
- Harbour BioMed Announces $140 Million Deal to Out-license Autoimmune Therapy to CSPC
- WuXi Biologics to Partner with Toregem to Develop mAb for Tooth Regeneration
- Jemincare Out-licenses Prostate Cancer Drug to Roche in $650 Million Deal
- IASO Signs $162 Million Agreement to Out-License CD19 Binder to Cabaletta For CAR-T
- Simcere Out-Licenses Autoimmune Candidate to Almirall in $507 Million Deal
- NeuShen Raises $20 Million in Pre-A Round for CNS Gene Therapy/Small Molecule Drugs
- SynerK Partners with SciWind to Develop siRNA Drugs for Liver and Metabolic Diseases
- Hansoh Acquires China Rights to Osteoarthritis Therapy in Deal Worth $63 Million-Plus
- Zai Lab In-Licenses Cervical Cancer ADC from Seagen for $30 Million Upfront
- Huisheng Biopharma Closes $70 Million Round for Diabetes Drug Portfolio
- CASI Divests 12% Stake in Juventas, its CAR-T Partner, for $34 Million
- Sino Biopharm Signs $307 Million Deal with Inventiva for NASH Therapy
- Immuno Cure Acquires Partner Teresa Healthcare, an Electroporation Company
- Biocytogen and FineImmune Partner on Cell Therapies Targeting Intracellular Antigens
- Arnatar Biomedical Raises $15 Million in Seed Round for RNAi Therapies
- METiS Acquires Rights to Pan-RAF Inhibitor in $482 Million Agreement
- Great Bay Bio, a Hong Kong CRO, Closes $15 Million Round for AI-based Bioprocessing
- Celregen Therapeutics In-Licenses iPS Therapy for Cornea Transplants in $100 Million Deal
- Worg Pharma Completes $57 Million Series B for Novel Allergy and Autoimmune Therapies
- Advanced MedTech Acquires WIKKON, a Shenzhen Urology Device Maker
- Redbud Closes $10 Million Round for China-US Clinical CRO Services
- Frontier Biotech Raises $29 Million for Novel COVID-19 Therapy
- CanSino Inhaled COVID-19 Vaccine Approved in China as Booster
- CellOrigin and Qilu to Develop Off-the-Shelf CAR-Macrophage Immunotherapies
- BoomRay Raises $43 Million for Novel Diagnostic/Therapeutic Radionuclide Medicines
- Vernalis Collaborates with Unison to Discover Drugs for “Undruggable” Bacterial Target
- Neukio Bio Completes $50 Million Round for Allogenic CAR-T Therapies
- DAC Biotech to Discover Five ADCs in Partnership with Janssen Biotech
- Hangzhou Innoforce and Hibiscus Join to Advance Mayo Clinic’s Cell and Gene Therapies
- E-nitiateBio Closes $15 Million Round to Support Autoimmune Portfolio
- Asieris Acquires Rights to Heart Failure Therapy from Acorda
- UniCar Closes C Funding for “Safe” CAR-T Dual Target Candidate
- Bao Pharma Raises $100 Million in Series B Round for Protein/Antibody Drugs
- Lee’s Pharm Signs $78.9 Million Deal for RDS Drug/Device for Pre-Term Infants
- Hansoh Forms $270 Million Partnership with GHDDI for COVID-19 Therapy
- Porton Advanced Raises $80 Million for Gene and Cell Therapy CDMO Operations
- Jemincare Out-Licenses Prostate Cancer Candidate to Genentech for $650 Million
- Wyze Biotech Closes A Rounds with $30 Million for Universal Immune Cell Products
- Everest Returns Greater China Rights for Trodelvy to Gilead for $455 Million
- Bennu Bio Closes $15 Million Funding for T-Cell Therapies
- GenoImmune, a BGI Company, Completes Funding for NeoAntigen Cell Therapies
- Insilico Closes $35 Million D2 Round; Will Expand AI Beyond Drug Discovery
- Axcynsis Opens Shanghai R&D Center; Raises $15 Million
- Hansoh Enters $170 Million Agreement for Endometriosis/Uterine Fibroid Therapy
- Epigenic Therapeutics Raises $20 Million in Angel and Pre-A Rounds for Epigenetic Drugs
- Innovent to Partner two Sanofi Cancer Assets in China; Sanofi Invests $305 Million in Innovent
- Radiopharm Forms Collaboration to Develop PD-L1 Diagnostic/Therapeutic Antibody
- Ablaze Plans $100 Million Facility in Chengdu Medical City for Targeted Radiation Therapies
- Sironax Closes $200 Million Round for Novel Degenerative Disease Therapies
- Structure Therapeutics Raises $33 Million for Novel Small Molecule Drugs
- OriCell Closes $120 Million Round for Cell Therapies and Bispecific Candidates
- GluBio Completes $22 Million Funding for Protein Degradation Candidates
- Ribo Life Science Closes $40 Million E1 Round for RNA Products
- CSPC Pharma Out-Licenses Claudin18.2 ADC in Deal with $1 Billion in Commercial Milestones
- Maxvax Completes $74 Million Series B for China Vaccine Development
- Kelun-Biotech Out-Licenses Second ADC Candidate to MSD in $936 Million Deal
- BridGene Closes $38.5 Million Funding from China Investors for Novel Small Molecule Targets
- Legend Bio Plans to Raise $250 Million in Public Offering of Shares
- Rona Therapeutics In-licenses Exclusive Global Rights to Sanofi’s siRNA Platform
- WuXi Biologics and WuXi AppTec to Spend $2.8 Billion to Build Separate Singapore Facilities
- Luzhu Biotech Files for HK IPO to Support Shingles Vaccine and Adalimumab Biosimilar
- NeuroFront Acquires Non-Opioid Neuropathic Pain Killer for $130 Million
- Frontera Closes $160 Million B Round for US-China Gene Therapy Development
- Merck’s Uptune Program to Back Asia Health/Technology Startups with €100,000
- Suzhou CStone Pharma Engages Goldman Sachs to Explore Sale of Company
- Epic Bio Completes $55 Million Funding Led by HK’s Horizon to Modify Gene Expression
- Triastek and Lilly to Collaborate on Using 3D Printing for Programed Release of GI Drugs
- Qiming Raises $3.2 Billion in Capital for New China Technology/Healthcare Investments
- Tasly Forms JV to Commercialize Confocal Laser Endomicroscopy Device
- Sinopharm May Bid $1 Billion for Shanghai’s BBI, a Research Products Company
- Precision Autoimmune Therapies Raises $21 Million to Develop Anti-CD38 Program
- BeiGene Collaborates with InnoRNA to Develop mRNA Therapeutics
- Zhiyi Bio Raises $45 Million for Live Biotherapeutic Products Aimed at IBS and Cancer
- Sequoia Raises $9 Billion for Healthcare/Tech Investments in China
- ClinChoice, a Global Clinical CRO, Raises $150 Million from China Investors
- Brii Bio In-licenses China Rights to Second HBV mAb from Vir
- GenFleet to Receive Royalty Rights for Conducting China Trial of BioLineRx Cancer Drug
- Henlius Acquires Two Novel Immunotherapy Candidates in $196.5 Million Deal
- Reistone Completes $100 Million A Round for Inflammatory Disease Drugs
- Genor Partners with Abogen to Develop mRNA Products for Oncology Needs
- Sino Biopharm’s invoX Acquires F-Star, a UK Bispecific Company, for $161 Million
- Xuanzhu Out-Licenses China Rights for Two Antibiotics in $66 Million Deal
- Beijing’s Therorna Raises $42 Million for circRNA Vaccines/Therapies (Including COVID)
- Shenzhen's AxBio Raises $100 Million for Low-Cost, High Precision Sequencing Machines
- MegaRobo Raises $300 Million for Automated Drug Lab Systems and Robots
- I-Mab’s Partner MorphoSys Out-Licenses Ex-China Rights for Two Oncology Candidates to HIBio
- WinHealth Acquires Two Rare Disease Therapies from Quoin Pharma
- Organon Pays $103 Million to Acquire Global Rights for Two Henlius Biosimilars
- META Raises $15 Million to Develop Small Molecule Immunometabolism Drugs
- Shanghai Degron Raises $22 Million for Protein Degradation Drugs
- I-Mab Alters Collaboration with Ferring Pharma for Developing IBD Candidate
- Fosun Acquires 60% Stake in Singapore Medical Center Chain for $158 Million
- OnCusp Acquires Global Rights (ex-China) to CDH6 ADC from Multitude Therapeutics
- Insilico Medicine Completes $60 Million Funding; Will Build Robotic Drug Discovery Lab
- NuProbe Raises $50 Million for Genomics and Molecular Diagnostics
- ProfoundBio Closes $70 Million Series A+ Funding for ADC and Immunotherapy Drugs
- Vivo Capital Closes First Tranche of China Fund at $600 Million; Aiming for $1.5 Billion
- SciNeuro Acquires Rights to Lp-PLA2 Inhibitor from GSK for Alzheimer’s
- Oncotelic Forms $50 Million Hong Kong JV to Develop Antisense Candidate
- Full-Life Closes $37 Million Series A for Radiopharmaceutical Oncology Products
- DongCheng Acquires Imaging Tracer to Predict Immunotherapy Efficacy
- CASI Signs $10 Million Out-licensing of CD38 for Autoimmune Indications to Tianshi
- Fosun Acquires Novel Cancer Immunotherapy in $125 Million Deal
- CTTQ Acquires Global Rights to Clinical Stage Symphogen Immunotherapy
- Hengrui Launches Luzsana to Bring its Novel Medications to Global Markets
- Laekna Raises $61 Million for its 14-Drug Cancer/Liver Disease Portfolio
- Kelun Out-Licenses Global Rights for Candidate to Merck/MSD in $1.4 Billion Deal
- Henlius Out-licenses Latin American Rights for Three Biosimilars in $55 Million Deal
- Coherus Returns Rights for Avastin Biosimilar to Innovent
- Zhaoke Signs $130 Million Deal for Two Eyedrop Near-Vision Treatments
- InxMed Adds $15 Million B+ Funding for China/US Pivotal Trials of FAK Inhibitor
- Jemincare Out-Licenses Global Rights (ex-China) for Novel Pain Drug to Finland’s Orion
- Zhifei Lvzhu In-Licenses Whooping Cough Vaccine from Intravacc
- What Biopharma Slowdown? OrbiMed Raising $1.1 Billion for Asia Companies; $4.75 Billion for Three Funds
- Hansoh Signs $218 Million Agreement with NiKang for Oncology Asset
- Xbiome Acquires Global Rights to Microbiome Product for Ulcerative Colitis
- Chimera Bio Wins $7.5 Million Asia Award for Novel CAR-T Technology
- RVAC Completes B Round for mRNA Drugs, Bringing Total Raised to $140 Million
- Huadong Medicine Acquires Rights to Four Ashvattha Candidates for $45 Million
- Vivo Invests $60 Million in China RNAi JV it Formed with Arrowhead
- Sinorda and Porton Partner to Advance Cell and Gene Therapy Products
- Binhui Raises $47 Million for Oncolytic Virus Products
- I-Mab Seeks Deal – Maybe Partnering a Drug, Maybe Selling the Company
- GeneQuantum Partners with Aimed Bio to Develop ADC for Brain Cancer
- Trevena Closes $40 Million Revenue-based Financing with CBC Affiliate
- Amoy to Develop Companion Diagnostics for AstraZeneca Drugs
- Ji Xing In-licenses China Rights to Eye Drop Therapies for Far-Sightedness
- AnPac Bio-Medical Raises $15 Million to Develop Early Cancer Detection Tests
- Rona Therapeutics Closes $33 Million Series A for RNA Pipeline
- LTZ Completes $17 Million Pre-A Raise for Immunotherapies
- Everest Medicines Signs MOU with CR Pharma to Form mRNA Company
- Harbour BioMed Out-licenses Bispecific to AstraZeneca in $350 Million Agreement
- ENSEM Raises $67 Million in A Round for Structure-Based Oncology Drugs
- GenFleet Out-Licenses CDK9 Inhibitor to Sellas in $150 Million Deal
- Pregene Out-licenses CAR-T to CellPoint for $22 Million in Near-Term Payments
- Hasten Closes $322 Million Deal to Distribute Five Takeda Drugs in China
- InnoRNA Raises $120 Million in B Round for mRNA Candidates
- Biosion Out-Licenses Siglec-15 mAb for Solid Tumors in $226 Million Pact
- Innovent Signs $45 Million Deal to Commercialize Two Lilly Oncology Drugs in China
- Sino Biological Partners AI Antibody Development Prediction Platform for CRO
- Yisheng Bio Raises $40 Million in a Royalty-based Funding from CBC Affiliate
- Nuance In-licenses Adult RSV Vaccine in $225 Million Deal
- Simcere to Commercialize Lynk's JAK1 Inhibitor in China
- EdiGene Licenses IP to Treat Genetically Caused Hemoglobin Diseases
- MediLink Raises $70 Million in B Round for ADC Portfolio
- Shanghai Impact Closes D1 Round for Synthetic Lethality Drugs
- Adiso , a Morningside Company, to Develop Novel Immune Therapies
- WuXi AppTec Partners to Offer Services with UK's Orbit Discovery
- J&J in Partnership Talks with Two China Biopharmas
- Tencent Co-Leads $67 Million Financing for UK's Microbiotica
- SalubrisBio Raises $32 Million from China Parent for Novel Biologics
- Nuance Pharma Acquires Rights to Nasal Spray in $23.5 Million Deal
- InxMed Raises $50 Million for Resistance-Fighting Cancer Therapies
- OBiO Signs MOU to Manufacture Cell Therapy for Korea's Eutilex
- Grit Science Completes $30+ Million Series A for Gene Therapy Products
- Haisco In-Licenses Oral Film Version of Riluzole for ALS
- Adagene to Add Masking Technology to 4 Sanofi Candidates in $2.5 Billion Deal
- Zhongze In-licenses CNS Candidate for Schizophrenia and Parkinson's
- Huadong Strikes $1 Billion Deal for Asia Rights to Four ADC Candidates
- Huadong Pharma Forms $662 Million Collaboration for Anti-Inflammatory Drugs
- Odeon Acquires China Rights for Two Cancer Therapies in $200 Million Deal
- SciNeuro Teams Up with Alamar to Discover Novel CNS Drugs
- AffaMed In-licenses Rights to AMD Therapy, Approved to Start US Trials
- Huadong Med Acquires Rights To Bi-functional Immunotherapy in $75 Million Deal
- EdiGene to Discover Stem Cell/Natural Killer CAR Therapy for Neukio
- HanBio Raises $40 Million for BiSpecific Antibody Portfolio
- Xbiome Signs $139 Million China Deal for Probiotic Diabetic Foot Ulcer Therapy
- Ractigen Closes $30 Million Financing for RNAa Candidates
- Grand Pharma Acquires Rights to Mitral Valve Replacement Device
- Biotime In-licenses Five Adlai Nortye Candidates in $32 Million Deal
- Ignis Acquires China Rights for ADHD Therapy Device from NeuroSigma
- Cure Genetics Raises $60 Million to Advance Universal CAR-T Products
- EdiGene Forms Translational Stem Cell Collaboration with Haihe Lab
- Eluminex Acquires Global Rights to Therapy for Rare Genetic Blindness
- Mabwell Stages $547 Million IPO on STAR Board for Antibody Portfolio
- Novotech Raises $255 Million to Expand Asia-China Clinical CRO Operations
- Abbisko Forms $258 Million Collaboration with Lilly for Cardiometabolic Candidates
- Innovent Options China Rights to Amagma's Inflammatory Disease Inhibitors
- Everest Acquires Global Rights to Protease Inhibitor Therapies for COVID-19
- JYSSBio Closes B+ Round for Single-Use Bioreactor Manufacturing
- Thousand Oaks Bio Completes $235 Million Round for CDMO Ops
- Fosun and Insilico Collaborate to Develop Five Candidates
- Accuredit and N1 Life Form JV to Develop Gene Editing Delivery Technologies
- Shanghai ZhenGe Completes $100 Million Round for Biologic CDMO Services
- Sana In-Licenses BCMA CAR Construct from IASO/Innovent in $204 Million Deal
- Junshi and Coherus Enter $290 Million Agreement for Junshi's TIGIT Antibody
- Junshi Collaborates With DotBio to Discover Multi-Specific Antibodies
- Nuance Acquires Sino Health in a Deal Worth at Least $32 Million
- Accro Raises $50 Million for Regulated Cell Death Drug Candidates
- Jiangsu Atom Closes $45 Million Round for Global Phase III Gout Trial
- AffaMed Signs $145 Million Agreement for China Rights to Ophthalmic Drug
- Sperogenix In-licenses Rare Disease Treatment in $124 Million Deal
- Xuanzhu, a Novel Drug Subsidiary of Sihuan Pharm, Completes $96 Million Round
- Amador Bio Raises $60 Million for Translational/Pharmacology CRO Services
- Great Bay Bio Closes $10 Million Funding for AI CMC Biologic Services
- Sirnaomics Raises $64 Million in Hong Kong IPO for RNA Therapies
- ArkBio In-licenses Novel ADHD Drug in $105 Million Agreement
- SyMap Closes $100 Million Round for Renal Denervation Devices
- Innogen Pharma Closes $120 Million Financing for GLP-1 Diabetes Treatment
- Tasly Acquires China Rights to Sutro ADC in $385 Million Agreement
- GeneSci In-licenses Alzheimer's Patch Therapy from Luye Pharma
- Nuance Announces $213 Million Deal for China Rights to Inhaled RDS Therapy
- ArriVent and Aarvik Form $100 Million Partnership to Develop Oncology Drug
- Ji Xing In-licenses Cytokinetics' Heart Failure Drug in $400 Million Pact
- Suzhou's TandemAI Raises $25 Million for AI-Wet Lab Discovery Operations
- BeiGene Out-Licenses TIGIT Inhibitor to Novartis in $2.8 Billion Agreement
- 3SBio Acquires China Rights to Numab Immunotherapy
- Nanjing Biosion Out-licenses Global Rights for Trop2 mAb to OBI Pharma
- BeiGene In-licenses Rights To LAG-3 mAb from Leads Bio in $772 Million Deal
- AnHeart Closes $61 Million Round for Precision Oncology Therapies
- Qilu Enters $300 Million Deal for Novel RNAi Hepatitis B Therapy
- Hansoh Acquires Cytopenia Therapy in Agreement Worth up to $190 Million
- Shanghai Regor Enters $1.5 Billion Deal with Lilly for Metabolic Therapies
- Avistone of Beijing Raises $200 Million; Will Combine with Pearl Biotech
- METiS, a US-China AI Company, Raises $86 Million in Series A
- Xcovery, a US Affiliate of China's Betta, Acquires Majority Stake in Meryx
- Innoforce Raises $157 Million for Cell Therapy, Gene Therapy and RNA CDMO
- RareStone In-Licenses China Rights to Obesity Therapy in $75 Million Deal
- Sciwind In-licenses Sanofi's Portfolio of GIP Agonists for Obesity and Diabetes
- SanReno, a China JV, Formed with $40 Million and Two Kidney Disease Drugs
- ITabMed Formed as JV to Develop T Cell Engagers; Raises $20 Million
- Suzhou Abogen Raises $300 Million to Support mRNA COVID Vaccine
- Ablaze Closes $75 Million Series for Targeted Radiopharmaceutical Therapies
- Help Therapeutics Raises $25 Million for iPSC Heart Failure/Oncology Therapies
- Tongshu Biotechnology Raises $78 Million for Early Cancer Screening Tests
- Neurophth Closes $60 Million C Round for Ophthalmic Gene Therapies
- Zenas, a US-China Biopharma, Announces $480 Million Deal for Autoimmune Therapy
- Allorion Raises $40 Million in A Round for Novel Oncology and Autoimmune Therapies
- Simcere Collaborates with SIMM to Develop Novel COVID-19 Antiviral Therapy
- CStone Out-Licenses China CTLA-4 Rights to Hengrui in $200 Million Deal
- Livzon Out-licenses PD-1 to Bright Peak for PD-1 Targeted Immunocytokines
- CBC China Life Science Infrastructure Fund Holds First Close with $500 Million
- Clover Receives $38.9 Million CEPI Grant to Finish Development of COVID Vaccine
- Newsoara Expands In-Licensed Territory for BET Inhibitor to Asia
- Ignis Formed with $180 Million to Develop SK Bio's CNS Candidates in China
- I-Mab Announces $315 Million Commercialization Deal for Growth Hormone
- Zai Lab Signs Two In-Licensing Deals with $800 Million Total Value
- Arbor, a US Gene Editing Company, Raises $215 Million Led by Singapore, Hong Kong, US Investors
- Hopstem Bio Completes $40 Million B Round for Neural Stem Cell Therapy
- Ascletis Adds Global Rights to China Deal for Alphamab's PD-L1
- HitGen and Cambridge Molecular Form Alliance to Source Ligands for Targets
- BeiGene Pays $45 Million Upfront for Global Rights to Shoreline Cell Therapies
- HitGen Subsidiary Forms Partnership to Develop Novel Cancer Drug
- Shanghai Pharma Unit Acquires Two Microbiome Therapies in $110 Million Deal
- Novadip's $22 Million B Round for Skeletal Tissue Therapies Includes HK Investor
- Fosun Announces $628 Million Deal for Majority Stake in Chengdu Antejin
- SciNeuro Partners with Mabylon to Discover Antibodies for Neurological Diseases
- Israel's Silenseed Raises $7.8 Million for China RNAi Joint Venture
- CANbridge to Acquire Gene Therapy for Rare Diseases from Scriptr
- Double-Crane In-Licenses Asia Rights to Oral COVID-19 Antiviral
- Antengene and LegoChem to Create ADCs Using Antengene's Antibodies
- ShouTi Closes $100 Million Round for Structure-Based Drug Discovery
- Chase Raises $20 Million from Hong Kong Investor for Novel Neuro Drugs
- Hansoh Signs $1.3 Billion siRNA Deal; Its Second siRNA Deal in a Week
- GV20 Oncotherapy Closes Series B for Genomics/AI-based mAb Portfolio
- BeiGene and Bristol-Myers in Fight over China Abraxane Distribution Deal
- Hansoh Signs $456 Million Agreement for siRNA Products from OliX Pharma
- BioNova Acquires Rights to CD74 Candidate from Sutro in $204 Million Deal
- Hangzhou's Sciwind Closes $70 Million Series C for Metabolic Therapies
- Chance Pharma Completes $30 Million Round for Inhalation Therapies
- Biocytogen Subsidiary Out-Licenses US Rights for CTLA-4 to Tracor
- AffyImmune Raises $30 Million for CAR-T Therapies from HK Investor
- I-Mab in Discussions with Global BioPharmas for a Deal
- CBMG Raises $120 Million for Clinical Trials of Cellular Immunotherapies
- iX Signs Up CRPCC to Distribute Sublingual ED Therapy in China
- Bio-Thera Partners with Intract to Develop Oral mAb for GI Disease
- Newsoara Bio Enters $171 Million Agreement for Oncolytic Viruses
- Worg Pharma Acquires Apitope's Autoimmune Platform and Pipeline
- Innovent Signs $267 Million Deal for Novel Anti-Inflammatory Candidate
- Anji Pharma Closes $70 Million Series B for US-China Drug In-licensing
- Salubris Acquires China Rights to Therapy for Obesity, NASH and Diabetes
- Everest Medicines In-licenses BTK for Renal Diseases in $561 Million Deal
- IASO Completes $108 Million C Round for Novel Cell Therapies
- Cytovia Raises $45 Million for JV to Develop NK Products in China
- Haisco Enters $140 Million Deal for Osteoarthritis Therapy
- Alebund Pharma Raises $54.5 Million for Renal Disease Therapies
- Everest in $500 Million Deal for mRNA Products, including COVID-19 Vaccine
- Huadong and Insilico Partner to Discover Novel Oncology Candidates
- Frontage Acquires Majority Stake in Wuhan Heyan Biomedical, a CRO
- Sanofi Acquires Kadmon, its Novel GVHD Therapy and China JV
- Bio-Thera Out-Licenses Ex-China Rights for Avastin Biosimilar to Sandoz
- Innovent Acquires Rights to KRAS G12C Candidate in $312 Million Pact
- NeuExcell Raises $10 Million For Gene Therapies Aimed at Neurodegenerative Repair
- Jacobio Invests $53 Million into Hebecell and its Stem Cell Based CAR-T Therapies
- ETERN Closes Funding to Advance Novel Technology for Undruggable Targets
- 4B to Partner with Insilico to Develop Small Molecule ALS Treatments
- Ionova Completes $100 Million Round for Targeted and Immuno Therapies
- Microport EP and Stereotaxis Form Robotic Ablation Device Collaboration
- Bio-Thera Sells US Rights to Autoimmune Biosimilar in $150 Million Deal
- Lynk Raises $50 Million to Develop Small Molecule Drug Portfolio
- Ocumension Acquires Two Novartis Products in $35 Million Agreement
- BeyondSpring Signs $200 Million Commercialization Deal with Hengrui
- Alphamab Out-Licenses HER-2 Bispecific to CSPC in $150 Million Agreement
- Abogen Raises a Huge $700 Million for mRNA COVID Vaccine
- Kangle Weishi Completes $157 Million Pre-IPO Round for Recombinant Vaccines
- Scivita Closes $61 Million Round for Advanced Endoscopy Products
- MediTrust Completes $308 Million Funding for China Healthcare Services Platform
- Arthrosi Forms $59 Million China JV with ApicHope for Gout Therapy
- Pulse Raises $100 Million for Imaging Diagnostics of Coronary Artery Disease
- Ranok Closes $40 Million Series B for Protein Degredation Drugs
- InnoCare In-Licenses CD19 Lymphoma Therapy in $117.5 Million Deal
- Gracell Acquires CLDN18.2 Antibodies for CAR-T Candidates
- XtalPi Raises $400 Million for US-China AI Drug Development
- Sorrento Signs $43 Million Term Sheet to Use Dyadic Platform and Develop COVID-19 Vaccine
- RemeGen Out-Licenses HER-2 Candidate to Seagen in $2.6 Billion Agreement
- HutchMed In-licenses Epigenetic Cancer Drug in $310 Million Deal
- Henlius and Promega Form IVD Collaboration for PD-1 Candidate
- Berry Oncology Completes $99 Million Funding for Genomic Testing
- Zai Lab Forms $338 Million Collaboration with Schrödinger to Discover Oncology Drug
- Pacific Bio to Acquire Omniome for $800 Million in Sequencing Tie-up
- Engrail Raises $32 Million From China Investors for CNS Drug Program
- Zentera Raises $75 Million to Develop Three Cancer Candidates in China
- Neukio Bio of Shanghai Raises $40 Million for Universal CAR-T Therapies
- Lupeng Pharma Closes $35 Million Pre-B Funding for Novel Drugs
- Kumquat Announces $2 Billion Deal to Develop Small Molecule IO Drugs with Lilly
- Bota Bio Adds $100 Million to B Round for Synthetic Biotech Manufacturing
- Zion Pharma Raises $40 Million to Develop Therapies for Brain Metastases
- MicroPort CRM Raises $150 Million for Implantable CRM Devices
- Qiming Launches $500 Million Fund to Invest in Listed Healthcare Companies
- ProfoundBio Makes $246 Million Deal for Synaffix Linker-Payload Technology
- Junshi Forms $16 Million mRNA JV with Hangzhou's Immorna
- GenFleet Partners with Insilico for AI-based Drug Discovery
- Eluminex Acquires Synthetic Cornea Product in $108 Million Agreement
- Juventas Closes $62 Million C Round for CAR-T/Stem Cells/Gene Editing
- Hailai Xinchuang Closes $77 Million Round for Tumor Treating Fields Device
- Grit Bio Closes Series A+ Round for its Cell Therapy Oncology Therapies
- Innovent and Ascentage Announce Three-Part, $245 Million Collaboration
- PAQ Therapeutics Closes $30 Million Round for Autophagy-Caused Degredation
- Ji Xing, a Shanghai Pharma, Completes B Round for Cardiovascular Drugs
- InnoCare Out-licenses BTK Inhibitor for MS to Biogen in $937 Million Deal
- Adlai Nortye Completes $100 Million Funding for Immunotherapies
- ProfoundBio Closes $55 Million Round for ADC and IO Candidates
- I-Mab Forms Discovery Partnerships with mRNA and AI Companies
- dMed-Clinipace Raises $50 Million for China-US Clinical CRO Operations
- Abbisko Out-Licenses Rights to Non-Oncology Indications for CSF-1R Inhibitor
- Sirnaomics Closes $105 Million Funding for RNAi Portfolio
- Denovo Acquires Alzheimer's Disease Candidate from Lundbeck
- Zentalis Closes $150 Million Secondary Offering for US-China Operations
- ArriVent Raises $150 Million to In-license China Drugs for Global Markets
- Simcere Acquires China Rights to Alzheimer's Drug in $565 Million Deal
- Eight Roads Launches its Fifth China Healthcare Fund with $400 Million
- Innovent Partners with Synaffix to Create ADC Candidate from Antibody
- Hangzhou Jointech Raises $62 Million for Orthopedic Surgery Robots
- Nanjing's Triastek Completes $50 Million Round for 3D Printing of Drugs
- MindRank Completes $7 Million Angel Round for AI Drug Development
- Hong Kong's Insilico Raises $255 Million for AI Drug Discovery/R&D
- HuiGene, a Shanghai Gene Editing Company, Closes $62 Million B Round
- OncoNano Raises $50 Million from China Investor for pH-based Cancer Products
- Zai Lab Enters $1.4 Billion Deal with MacroGenics for Four Immunoncology Drugs
- HiFiBiO Raises $75 Million for Clinical Trials and Drug Discovery
- Nuance Acquires Rights to Novel COPD Therapy From Verona in $219 Million Deal
- Dingdang Health Raises $220 Million for Online-Offline Health Services
- Shanghai Stemirna Lands $200 Million to Develop mRNA COVID Vaccine
- LianBio Signs $147 Million Deal for Long-Term Rhinosinusitis Product from Lyra
- Phanes Therapeutics Raises $40 Million for mAb and Bi-specific Portfolio
- Neurophth and Hopstem Partner to Develop Stem Cell Therapies for Eye Diseases
- Zai In-licenses KRAS Inhibitor from Mirati in $338 Million Deal
- Guangzhou-Israel Biomed Fund to Raise $300 Million
- Innovent Announces $189 Million Agreement for TKI from Hangzhou Company
- Esco Lifesciences Raises $200 Million to Expand Life Science Tools Portfolio
- NiKang Raises $200 Million from US/China Investors for Oncology Drugs
- HitGen Partners with Dorian to Discover Drugs for Age-Related Diseases
- DualityBio Raises $90 Million for Bispecific and ADC Drugs
- GeneQuantum Completes C Round for Novel ADC Candidates
- BioRay In-licenses Rights to Brain Cancer Drug from Nascent
- Hummingbird Bio Closes $125 Million Financing for Precision Medical Candidates
- LianBio Acquires Two IBD Candidates from Landos in $218 Million Agreement
- Ji Xing Acquires Tachycardia Treatment in $127.5 Million Deal
- BioNovoGene Completes $15 Million Round for Metabolomics Services
- Kinnate Raises $35 Million to Bring Drug Assets to China
- GenScript Raises $1 Billion in Investments from Hillhouse Capital
- Elpiscience Raises $105 Million for Cancer Immunotherapy Portfolio
- Pregene Out-Licenses India Rights for its CAR-T Therapy to Dr. Reddy's
- Hygea Medical Raises $77 Million for Minimally Invasive Surgery Devices
- Fulgent Genetics Invests Another $19 Million in China Testing JV
- Viva Bio and BioMap Form AI Biologic Drug Discovery Collaboration
- Alebund Raises $60 Million for China Development of Novel Renal Drugs
- Shanghai Hope Medicine Closes $56 Million for Novel Drug Development
- Beijing WeMed Completes $46 Million Funding for Angiography Devices
- Shineco Plans to Acquire 51% of Taiwan's Mayah Biological
- CANbridge Acquires Rare Liver Disease Drug in $120 Million Agreement
- Guangzhou Link Health to Form China Clinical CRO with George Clinical
- Adcentrx Raises $50 Million in Initial Funding for Novel ADC Therapies
- Sirnaomics Out-Licenses siRNA Influenza Vaccine Candidate to Walvax
- Clinical CRO Merger: China's dMed Joins Forces with US-Based Clinipace
- Tianhong Shengjie Completes $12 Million Financing for Medical Devices
- CANbridge in $591 Million Deal with LogicBio for Gene Therapies
- VivaVision Completes $46 Million Funding for Ophthalmology Therapies
- Ronovo Closes Series A to Develop Surgical Robotics Devices for China
- RNAImmune Raises $10 Million for mRNA Products and COVID-19 Vaccine
- Zai Lab Raises $750 Million in Public Offering
- EdiGene Completes $62 Million Round for Gene Editing Therapies
- Junshi Bio Completes $50 Million Investment in US Partner, Coherus
- Porton Biologics Raises $61 Million for Cell/Gene Therapy CDMO Services
- Sinopharm to Transfer Six Vaccine Companies (Including Two Covid-19 Vaccines) to Beijing Tiantan Bio
- Qilu In-Licenses Preclinical ADC Candidate from Korea's Peptron
- Ocumension Acquires Implant Therapy for Retina Diseases in $119 Million Deal
- SciNeuro In-Licenses China Rights to Lilly Treatment for Parkinson's
- StoneWise Raises $100 Million to Support AI Drug Development Services
- BDgene Completes $9 Million Round for CRISPR/Cas9 mRNA Candidates
- Shanghai NewMed Medical Raises $100 Million for Heart Repair Devices
- HutchMed Raises $100 Million in Private Placement for Oncology Portfolio
- Biogen Acquires Rights to Bio-Thera RA Biosimilar for $30 Million Upfront
- HitGen and BioAge Identify Alzheimer's, Cardiovascular Candidates
- Sorrento Acquires ACEA, a San Diego-China Drug Developer, in $488 Million Deal
- Long Hill Capital Raises $300 Million for Third China Healthcare Fund
- Immune-Onc Raises $73 Million for Novel Immunosuppressive Checkpoints
- Neuracle Closes $16 Million Round for Brain-Machine Interface
- OnQuality Raises $20 Million for Cancer Side Effect Treatments
- AffaMed Closes $170 Million Financing for In-licensed Portfolio
- LianBio in $200 Million Deal for China/Asia Rights to Tarsus Ophthalmology Drug
- Simcere Announces $292 Million Deal for Novel Glioblastoma Treatment
- Qihan Raises $67 Million for Gene Editing of Cell Therapies, Organ Transplant Drugs
- Chime Biologics Announces $190 Million Round for Wuhan CDMO Operations
- CASI Raises $32.5 Million for China In-Licensing Operations
- Shanghai ImmuneOnco Raises $89 Million for Cancer Immunotherapies
- AllianThera Partners with Insilico to Discover Drugs for Novel Cancer/Autoimmune Targets
- Hutchison China MediTech Sells Stake in TCM Company for $169 Million
- Bioheng Completes $80 Million Funding for Allogenic CAR-T Immunotherapies
- Xtalpi Joins $46 Million Round for PhoreMost in Drug Discovery Tie-Up
- SinoBio Acquires Stake in Belgium Inhaler Company in $200 Million Deal
- Brii Bio Completes $155 Million Financing for Anti-infective/CNS Drugs
- EpimAb of Shanghai Raises $120 Million for Bispecific Antibodies
- Zenas, a China-US Startup, Breaks Cover with Seven Autoimmune Candidates
- Hangzhou Innoforce Raises $96 Million for CRO/CDMO Biopharma Services
- Tavotek Bio Raises $20 Million-plus for Novel US-China Antibodies
- Hanyu Medical Lands $77 Million in D+ Round for Cardiovascular Devices
- Yangtze River Pharma Signs $338 Million Deal for Gastro Reflux Therapy
- Chance Pharma Acquires China Rights to Inhaled PAH Therapy
- WuXi Biologics Acquires 90% Stake in CBC's Suzhou CDMO
- BeiGene Forms Drug Delivery and Patient Communication Partnership with 111
- Beijing Tide Out-Licenses Ex-China Rights to Fibrosis Therapy in $518 Million Deal
- Hansoh Announces $122 Million Agreement to Acquire Rights to Antifungal
- WuXi Biologics Buys Pfizer's Biologics Manufacturing Facility in Hangzhou
- Delonix Bio Raises $14 Million in Seed Financing for Synthetic Vaccines
- Uni-Bio Partners with DotBio to Develop Retinal Therapeutics
- I-Mab Forms Two Novel Drug Discovery Collaborations
- Haohai Acquires China Rights to Eirion Dermatology Products in $527 Million Deal
- Arctic Vision of Shanghai Completes $100 Million Series B Round
- CASI Acquires China Rights to a p97 Inhibitor for Cancer in $85 Million Deal
- WuXi Biologics Out-licenses mAb Panel to Exelixis for Development
- AlphaBio In-licenses Off-the-Shelf NK/T-Cell Technology for Cancer
- Wuhan ABconal Acquires Boston mAb Drug Developer Yurogen
- GenSciences Raises $124 Million for New Drug Development
- Biotheus Completes $100 Million Funding for Biologic Drugs
- Innoforce and dMed Team Up to Develop/Manufacture Novel Biologics
- WuXi AppTec Pays $135 Million to Acquire Oxgene, a Gene Therapy CDMO
- LianBio Acquires China Rights to ReViral's RSV Therapy in $119 Million Deal
- OrbiMed, a Life Sciences Investor, Raises $800 Million for Asia Partners IV
- Suzhou Medilink Closes Initial $50 Million Funding for ADC Drugs
- Junshi Out-Licenses Partial China Marketing Rights for PD-1 to AstraZeneca
- Cullgen Completes $50 Million Round for Protein Degradation Therapies
- YishengBio Raises $130 Million for Immunomodulating Therapies
- Bioelectronica Closes $16 Million Funding from China Investors
- ABclonal Completes $93 Million Round Led by China Investors
- AnchorDx Completes $40 Million Financing for Cancer Diagnostics
- BGI Genomics Raises $300 Million in Private Placement
- Regor Therapeutics Completes $90 Million Round for Novel Drugs
- Sciwind Closes $37 Million Round for Metabolic/Immunological Therapies
- Citrine Acquires China Rights to Therapy for Pediatric Rare Disease
- Yuanxin/Miaoshou Doctor Raises $465 Million for Online Healthcare
- Zhongmei Huadong Forms $180 Million Collaboration for Autoimmune Drug
- BeiGene In-Licenses TNF-based Immunotherapy in $126 Million Agreement
- Qilu Announces $235 Million Deal for Cend's Immunotherapy
- Hansoh Acquires China Rights to Novel Synexis Antifungal
- Apollomics Acquires Immunotherapy for Gastrointestinal Cancers
- Apollomics Acquires Rights to Novel Iterion Oncology Candidate
- Ascletis Participates in $80 Million Funding of US Partner, Sagimet
- Hengrui Acquires PI3kδ Inhibitor Rights from Shanghai Lingli Pharma
- Nuance Acquires China Rights to Osteoarthritis Pain Drug in $100 Million Deal
- Wuhan's Neurophth Raises $62 Million for AAV-delivered Gene Therapies
- Apollomics of Hangzhou Acquires Global (ex-China) Rights to Novel Cancer Candidate
- China Medical System Acquires Luqa Ventures, a China Dermatology Company
- Beijing InnoCare Raises $407 Million in Private Placements with Hillhouse and Vivo
- Beijing neoX Biotech Closes $30 Million A Round for AI Drug Discovery
- Adagene Licenses its mAb Masking Technology to Exelixis in Collaboration
- Syapse, a Cancer Clinical Data Company, Closes $68 Million Round led by Ally Bridge
- Lianya Pharma Completes $62 Million Round for Hard-to-Make Generics
- Shanghai Junshi Bio to Invest $50 Million in Coherus, its US Partner
- Junshi Announces $1.1 Billion Agreement for US-Canada Rights to PD-1
- GenFleet Closes $16 Million B+ Round for China-US Clinical Trials
- Sihuan Pharma Acquires Beijing Combio, an Antibody/Bispecific Company
- Westlake Closes $16 Million A Round for Stem Cell Cellular Therapies
- Matridx Bio Closes $32 Million for Pathogen Metagenomics Analyzers
- Elpiscience Signs $117 Million Deal for TRIGR Bispecific
- Immunotech of Beijing In-licenses Immunotherapy from T-Cure
- Sinovent Completes Pre-IPO Financing of at least $30 Million
- Neurophth to Develop AAV Capsids with AAVnerGene for Ophthalmology
- TenNor and Janssen to Collaborate on Lung Disease Treatments
- EQRx Raises $500 Million to Develop China-Sourced Drugs for US Market
- Raysight Completes $46 Million Funding for Cardiovascular Diagnosis
- CICC Has Second Close of Biomedical Fund at $648 Million
- Henlius In-licenses TPOR-2 mAbs from Chiome in $122.5 Million Deal
- BeiGene Out-Licenses Rights for PD-1 to Novartis in $2.2 Billion Deal
- Visen Pharma Closes $150 Million Financing for Endocrine Drugs
- Inmagene Signs $920 Million Agreement to Acquire Four Chi-Med Immunology Therapies
- BeiGene Acquires Rights to mRNA Cancer Therapy in $320 Million Deal
- EOC Signs $271 Million Agreement for mTor Inhibitor from Aadi Bio
- Abbisko Announces $123 Million Financing for Cancer Portfolio
- Zai Lab Acquires China Rights to Novel Autoimmune Drug in $175 Million Deal
- Kira Closes $53.5 Million B+ Round for Complement-Targeted Drugs
- Keya Medical Completes $46 Million Round for AI-based Scanning Software
- Terns Completes $87 Million Financing to Advance Three NASH Candidates
- Ocumension Invests $15.7 Million In EyePoint of the US
- ImmVira Completes C Round for Oncolytic Virus and Vector Candidates
- Medbanks Closes $305 Million Financing for China Oncology Mega-Data
- DXY.cn Raises $500 Million for On-line Physician Support and Healthcare Services
- Zai Lab In-licenses Novel EGFR Inhibitor in $233 Million Deal
- Oceanpine Raises $400 Million for China-US Technology Companies
- Synyi Closes $61 Million Round for AI-based Medical Data Analysis
- Transcenta of China Raises $105 Million to Develop Antibody Drugs
- 3E Bioventures Forms China JV for Peripheral Neuropathy Therapy with Regenacy
- SciClone Pharma Enters $120 Million Deal for Two Neuroblastoma Treatments
- dMed Completes $100 Million Financing for China-US CRO Operations
- Vivace Closes $30 Million Round for Novel Hippo Pathway Oncology Therapies
- Overland Pharma Announces $117 Million China JV with Allogene Therapeutics
- Singlera Closes $150 Million B Round for Early Cancer Screening
- Overland Forms $50 Million China JV to Develop ADCs with Swiss Biopharma
- 3D Medicines Acquires China Rights to Two Immunotherapies in $202 Million Deal
- Wuzhong Pharma Out-licenses Cancer Drug to Hangzhou's Denovo
- Overland, a China-US Pharma, Starts In-licensing Operations with Hillhouse Backing
- Nuance Pharma Closes $181 Million D Round for In-licensed Drugs
- SciNeuro of Shanghai Launches with $100 Million for CNS Drugs
- Pegbio Raises $122 Million in Pre-IPO Round for Pegylated Drugs
- Tolo Biotech and Sherlock Bio Cross-License CRISPR Diagnostic Platforms
- Beijing Infervision Completes D1 Funding for AI-based Image Reading Products
- HitGen Delivers Candidates to Cedilla for Cancer Caused by Protein Dysregulation
- CANbridge Completes $43 Million E Financing for Rare Disease Drugs
- Xbiome, an AI Company, Completes B+ Round for Microbiome Trials
- Ascentage Acquires Global Rights to Protein Degrader Technology
- PreGene Closes $21 Million Financing for Fusion/Nano-Antibody Drugs
- Eluminex, a Suzhou Startup, Closes $50 Million Round for Ophthalmic Drugs
- Beijing Gene+ Raises $38 Million for Cancer Diagnostics
- RecBio Raises $227 Million for Novel Genetically Engineered Vaccines
- Exclusive Interview: LianBio and Pfizer Create a First-in-Kind Collaboration in Greater China
- Newsoara Forms $135 Million Novel Drug Deal with AUM Bio
- GenScience Acquires Rights to Prostate Cancer Therapy in $132 Million Agreement
- D3 Bio Closes $200 Million Series A to Develop Best-in-Class Precision Medicines
- WuXi Biortus Raises $15 Million for Cryo-EM Drug Discovery CRO
- Zhimeng Biopharma Closes $35 Million Funding for Trials of HBV Therapy
- Tencent Co-leads $50 Million Round for Congenica, a UK Genomics Company
- HitGen Out-Licenses China Rights for Trk/ROS1 Inhibitor to Baiyunshan
- Exclusive: Decheng's Inside View of Merck's $2.75 Billion Acquisition of VelosBio
- Ambrx, a China-owned Biopharma, Completes $200 Million in Crossover Financing
- Pharmaron Beijing Pays Up to $137.5 Million to Acquire Absorption, a US CRO
- Inmagene Closes $21 Million Round for Immune Therapies
- Innoforce Forms Hangzhou CDMO JV with Thermo Fisher
- Apollomics Completes $124 Million C Financing for Cancer Drug Development
- China Grand Pharma in $340 Million Deal for Telix's Radiation Products
- CARsgen Raises $186 Million for CAR-T Portfolio
- AffaMed in $103 Million Deal for Two Ocular Therapeutix Products
- Zylox Medical Completes $45 Million Round for Vascular Devices
- CStone Signs $363 Million Deal for Rights to LegoChem ADC Candidate
- Beijing's Genecast Completes $149 Million E Round for Cancer Diagnostics
- Gracell Closes $100 Million C Funding for Novel CAR-T Technologies
- LianBio Raises $310 Million to Bring Novel Medications to China
- Citrine to Bring Treatment for Narcolepsy, a Rare Disease, to China
- CStone Out-licenses Ex-China Rights for Two Immunotherapies in $1.3 Billion Agreement
- CASI Enters $95 Million China Deal for BioInvent's Checkpoint Inhibitor
- Siranomics Closes $105 Million Funding from China Investors; Plans IPO
- Zhaoke Acquires China Rights to Myopia Treatment in $102 Million Agreement
- Beijing Immunochina Raises $15 Million for CAR-T Portfolio
- 3DMed Completes $225 Million Round for Immunotherapy Candidates
- Huadong Med Acquires ADC for Ovarian Cancer in $305 Million Agreement
- CBC Merges Two Shanghai Companies, AffaMed and EverInsight, into One
- Cue Health Announces $481 Million Grant for Coronavirus Tests
- EdiGene Raises $67 Million for Clinical Trials of Gene Edited Drugs
- ImmuneOnco Completes $25 Million Funding for Immunotherapies
- Curon Announces $149.5 Million Deal for China Rights to Lymphoma Drug
- HitGen Pays $25 Million to Acquire Vernalis, a UK Discovery CRO, from Ligand
- Creative Bio of Guangzhou Raises $90 Million for Oncology Tests
- Chengdu's Hinova Pharma Raises $147 Million for Novel Prostate, Gout Drugs
- 10x Genomics Pays $350 Million to Acquire ReadCoor, a Spatial-Omics Company
- Two China Biopharmas Strike $65 Million Deal for Rights to Cell Therapy
- Virogin Raises $62 Million for Oncolytic Virus Portfolio
- Sumgen Completes $32 Million Round for Immunotherapy Antibodies
- CStone Out-licenses China Rights for PD-1 to Pfizer in $480 Million Deal
- Fosun Closes $182 Million In-licensing of Polyphor Cancer Treatment
- Taimei Tech Completes $176 Million Raise for AI Clinical Trial Software
- BioShin Raises $60 Million to Bring Biohaven's Drugs to China
- XtalPi, a US-China Ai Drug Discovery Company, Closes $319 Million C Round
- InventisBio Completes $147 Million Round for Small-Molecule Drugs
- Sperogenix Acquires China Rights to Rare Disease Candidate in $78 Million Deal
- BioDuro and Sundia Merge to Form China-US CRDMO Backed by Advent
- Viva Biotech to Pay $80 Million to Acquire SYNthesis in CRO Tieup
- ImmVira Raises $10 Million for Genetically Modified Oncolytic Viruses
- Sequoia Capital China Raising $2.2 Billion in RMB for China Fund
- Illumina to Acquire Grail, a Early Cancer Testing Company, for $8 billion
- LinkDoc Raises $103 Million for Oncology AI/Big Data Services
- Tianjin JuveStar Enters $74 Million Deal with Raziel for Body Fat Treatment
- XWPharma Completes $40 Million Round for Neurobiology Candidates
- GenScript ProBio Extends Drug Development Collaboration with REMB
- Biocytogen Raises $142 Million for Gene-Modified Animal CRO Services
- Yufan Bio Partners with Pittsburgh's Abound to Develop Novel CAR-T Therapies
- Singleron Raises $30 Million for Gexscope® Single-Cell Analysis Technology
- Forerunner Closes $28 Million Funding For Medical Devices
- Hualan Genetic to Develop Three Harbour BioMed Antibodies in Return for China Rights
- Baidu Said to Be Raising $2 Billion for AI-based Novel Drug Discovery Company
- Gannex Pharma, an Ascletis Subsidiary, Announces NASH Partnership
- Huadong Medicine Partners with Excientia, a UK-based AI Drug Discovery Company
- AnHeart Acquires Two Additional Cancer Drugs from Daiichi Sankyo
- CANbridge Starts Neuromuscular Gene Therapy Program with UMass
- InxMed Completes $19 Million Series A+ Round for FAK Inhibitor Trials
- I-Mab Partners CD47 with AbbVie in $2 Billion Deal; Raises $414 Million in Private Placement
- CoWin Biosciences Closes $36 Million Financing for Reagents Business
- Carlyle Pays $260 Million for 5% Stake in Shenzhen Salubris Pharma
- Waterstone Completes $63 Million Financing for Generic/Novel Drug Portfolio
- Adlai Nortye Raises $100 Million for Immunoncology Portfolio
- Suzhou Sinovent Raises $145 Million for Biologic Drug Portfolio
- ReViral Raises $44 Million in Funding Led by China Investor
- HitGen Delivers Drug Candidates to Almirall for Skin Disease Targets
- BeiGene Signs $165 Million Deal for China Rights to Bio-Thera's Avastin Biosimilar
- Yuce Bio Completes $43 Million Funding for Clinical Cancer Immunotherapy Testing
- Connect Biopharma Closes $115 Million C Round for Immune Modulators
- Xuanzhu Bio, a Sihuan Novel Drug Subsidiary, Completes $116 Million Funding
- Dizai Pharma, a China AstraZeneca JV, Raises $100 Million
- Keya Medical Closes $22 Million Funding for AI Imaging Software
- JD Health Raises $830 Million from Hillhouse for Online Health Services
- Junshi Bio Invests $43 Million to Partner Impact's PARP Inhibitor in China
- Ocumension Pays $9.5 Million to Add Korean Rights for Two Products
- DK Medtech Closes $14 Million Series B+ for CV Medical Devices
- Galixier Closes $10 Million Pre-A Round for AI Drug Discovery Services
- Innovent Expands Ex-China Alliance with Lilly in $1 Billion Agreement
- Bayer Enters $658 Million Deal to Market Hua's Diabetes Drug in China
- Shanghai Pharma Signs $165 Million Deal for ImmVira Oncolytic Virus Program
- Shanghai Hanyu Completes $72 Million Round for Cardiovascular Devices
- AnHeart Raises $20 Million for ROS1/NTRK Inhibitor to Treat NSCLC
- Cellular Biomedicine Accepts $383 Million Management-led Privatization Offer
- Vision Medicals Raises $29 Million to Support Genetic Testing for Infectious Diseases
- MicuRx Closes $43 Million Round as Antimicrobial Nears Market Approval
- Exclusive Interview: Perceptive Advisors Launches LianBio with a New Model to Take US Assets to China
- LianBio Forms $531.5 Million China Partnership with BridgeBio for Two Oncology Candidates
- LianBio Acquires China Rights to MyoKardia CV Drug in $187.5 Million Deal
- Viva Biotech to Pay $368 Million to Acquire Controlling Stake in China CDMO
- Suzhou Zanrong Completes $20 Million A+ Round for Cancer Drugs
- ABM Therapeutics Completes $20 Million Round for Neural Cancer Drugs
- Biogen Enters $2 Billion Deal to Co-Develop Parkinson's Candidate in US and China
- Lepu Biotech Closes $186 Million B Round for Cancer Immunotherapies
- VistaGen Receives $5 Million Upfront Fee from EverInsight for SAD Therapy
- Sherpa Healthcare Closes $200 Million Life Science Venture/Growth Fund
- Simcere Signs $170 Million Deal for Myelopreservation Therapy
- Qilu Pharma In-licenses Bladder Cancer Drug in $35 Million Deal
- Harbour BioMed and Viva Bio Partner to Offer Incubation Services
- CanSino Enlists Pfizer to Market Meningitis Vaccine in China
- YoFo Medical Raises $7 Million for Novel CT Imaging Technology
- Hansoh In-licenses Novel BCR-ABL Inhibitor for CML in $68 Million Agreement
- Viva Bio and Schrödinger to Collaborate on Structure-based Drug Discovery
- BrosMed Closes C Round for Vascular Devices Led by Hillhouse
- Lynk Pharma Acquires Rights to Novel Japan-Discovered RAS Targets
- HaiHe Bio Completes $171 Million B Round to Advance Novel Candidates
- Thousand Oaks Bio Closes $64 Million Series B for CDMO Operations
- Hansoh Out-Licenses Ex-China Rights for Lung Cancer Drug in $100+ Million Deal
- CASI, a US-China Biopharma, Completes $38 Million Private Placement
- Stroke Medical Raises $10 Million for Minimally Invasive Devices
- Xpect Vision Raises $21 Million for Photon-Counting X-Ray Imaging Devices
- BeiGene In-Licenses Three-Molecules for Hepatitis B in $540 Million Deal
- Antengene Closes $97 Million Round to Develop Hematology/Oncology Portfolio
- Shanghai's JW Therapeutics Acquires Hong Kong Cell Therapy Company
- Ji Xing Pharma In-licenses China Rights to Heart Drug in $425 Million Deal
- BioAtla Closes $72.5 Million Round for Conditionally Active Biologics
- Arctic Vision Raises $32 Million for Ophthalmology Drugs in China
- Venus Medtech Acquires China Rights to Non-implant Heart Valve Treatment
- BeiGene Raises $2 Billion in Private Placement; Amgen Participates
- OBiO Raises $28 Million for Viral Vector CRO/CDMO Operations
- Zai Lab In-licenses NSCLC Candidate from Turning Point in $176 Million Deal
- Livzon In-Licenses Schizophrenia Patch Product from Germany's LTS
- Boehringer Ingelheim Launches Shanghai External Innovation Hub with $500 Million Commitment
- Suzhou CF PharmTech Closes $50 Million F Round for Respiratory Drugs
- CapitalBio Raises $113 Million in Pre-IPO Round for Molecular Diagnostics
- SciClone Acquires China Rights to Immunotherapy in $120+ Million Deal
- Lianchuan Bio Completes $15 Funding for Genomics/Proteomics Services
- Burning Rock Partners with CStone for RET Companion Diagnostic
- Chi-Med Raises $100 Million in Private Placement for Cancer Drugs
- Simcha Raises $25 Million from China Investors for Novel Immunotherapies
- VistaGen Signs $177 Million Deal with EverInsight for China/Asia Rights to VistaGen's Anxiety Drug
- Sophonix of Beijing Closes $14 Million Round for Point-of-Care-Tests
- Genor Signs $46 Million In-licensing Deal for Breast Cancer Candidate
- Betta Pharma Signs $135 Million Deal for China Rights to Two Immunotherapies
- Engrail Raises $32 Million From Nan Fung to In-license Neurological Drugs
- eTheRNA Raises $38 Million for I-O Pipeline; China Grand Pharma to Get China Rights
- Shenzhen Immvira Completes $58 Million Funding for Oncolytic Virus Therapies
- Shukun Raises $28 Million for AI-Based Scan Reading
- Miaoshou Doctor Closes $85 Million Funding for Online-Offline Health Services
- Cygnus Bioscience Raises $14 Million for Gene Sequencing Machines
- JW Therapeutics Raises $100 Million to Support CAR-T Portfolio
- Clover Closes $24 Million B-2 Financing for Novel Biologics and Biosimilars
- Suzhou Innovent Signs $2 Billion-plus Bi-Specific/CAR-T Development Deal with Roche
- Alphamab and Sanofi to Test Dual HER2 Combination; Sanofi Gains Option
- CANbridge Forms Gene Therapy Research Program with UMass for Rare Diseases
- MabPlex Raises $71 Million for Biopharmaceutical CDMO Services
- Everest Medicines of Shanghai Closes $310 Million C Round for In-licensed Drugs
- Beijing Jiushi Shenkang Closes $14 Million Funding for Neurovascular Products
- Deep Informatics++ Closes $14 Million Series B for AI-based Pathology Products
- Jiangsu Atom Raises $30 Million to Support Global Trial of Gout Drug
- Genor Bio Closes $160 Million B Round to Develop Ten Biologic Clinical Candidates
- Jacobio, a Beijing Pharma, Out-Licenses Two SHP2 Candidates to AbbVie
- MGI Tech, a BGI Subsidiary, Raises $1 Billion to Make Gene Sequencing Machines
- Immunochina and EdiGene Team Up to Discover Allogeneic T-Cell Therapies
- Zentalis Raises $20 Million for China Subsidiary, Zentera Therapeutics
- Primedicine In-Licenses China Rights to Heart Attack Treatment
- Innovent and MD Anderson Partner to Test Tyvyt® in Rare Cancers
- Inmagene of Shanghai Partners Affibody's Novel Immunotherapy Candidate
- Simcere Acquires China Rights to Novel Stroke Drug from Canadian Biotech
- Nantong Lianya/Novast Raises $140 Million for Generics and Extended-Release Drugs
- Qujing Hengsheng Closes $14 Million Pre-A Round for Minimally Invasive Imaging
- Sorrento Forms Triple-Antibody Partnership for Protective COVID-19 Product
- Nanjing Immunophage Raises $14 Million for Novel Immune-Regulating Candidates
- Junshi Out-Licenses Ex-China Rights for COVID-19 mAb to Eli Lilly
- TargetRx of Shenzhen Raises $21 Million for Novel Small Molecule Cancer Drugs
- Harbour Bio and Dutch Researchers Discover mAb for SARS-CoV-2
- Atreca, IGM and BeiGene Partner to Develop Novel SARS-CoV-2 Treatment
- OrigiMed and Bayer Partner on Gene Fusion Companion Diagnostic
- SmartNuclide Bio Completes $14 Million B Round for Nuclear Medicine Drugs
- Clover Bio Forms $3.5 Million Collaboration to Test COVID-19 Vaccine
- I-Mab Plans to Partner its CD-47 Immunotherapy in $2 Billion Deal
- Mabwell Bio of Shanghai Closes $278.5 Million Series A Financing
- Denovo to Acquire Gene Therapy Technology for Oncology from Tocagen
- Hansoh In-licenses Novel Anti-Viral from NiKang in Deal Worth up to $100 Million Plus
- APTBIO of Shanghai Completes $28 Million Round for Proteomics Services
- Magpie Pharma Closes $14 Million Funding for Modernized TCM Drugs
- ChosenMed of Beijing Completes B Round for Oncology Precision Medicine
- New Horizon Health Raises $20 Million for China Early-Stage Cancer Tests
- Cloudbreak, a US-China Biopharma, Raises $25 Million for Ophthalmology Drugs
- Beijing Mabworks Closes $160 Million C1/C2 Round for Biologic Drugs
- Leo Pharma Acquires Global Rights to Atopic Dermatitis Treatment in $580 Million Deal
- Guangzhou OptoMedic Raises $14 Million for Medical Devices
- Qiming Closes New China-Focused Fund with $1.1 Billion for Life Science and TMT Companies
- Zai Lab Acquires Greater China Rights to Regeneron Bi-Specific in $190 Million Agreement
- Suzhou Ribo Life Science Completes $66 Million C Round for siRNA Portfolio
- Cytovant Raises $23.5 Million for China Development of Immunotherapies
- RemeGen Closes $100 Million Round for China Launch of Novel Biologics
- Xiamen Innovax Pairs COVID-19 Vaccine Candidates with GSK's Adjuvant
- Shanghai Genechem Raises $56 Million for Biologic CRO/CMO Services
- Nanjing Legend Raises $150 Million for Cell Therapies in an A Round/Pre-IPO Financing
- Boston's Rgenta Raises $20 Million for RNA Therapies from China-Heavy Syndicate
- Ping An Invests $311 Million in Japan's Shionogi for New Drug Development
- Ocumension Enters $77 Million Deal for Stem Cell Therapies from Japan's SanBio
- ZhenGe Biotech Completes $51 Million A Round for CDMO Operations
- Tainuo Signs $42.5 Million China Deal for Knee Osteoarthritis Pain Treatment
- Targene Closes $14 Million A Round for Early Diagnostics and Testing Services
- China's Asieris Pharma Completes C Round for Genito-Urinary Tumor Treatments
- Innovent Acquires China Rights to Novel Immunoncology Candidate from Alector
- Abbisko of Shanghai Raises $70 Million for Novel Oncology-Immunocology Candidates
- Apexigen Adds $65 Million to C Round in Funding Led by China Investors
- Mabpharm Out-Licenses US-EU Rights for COVID-19 Fusion Protein to Sorrento
- Junshi Bio Teams Up with IMCAS to Develop Neutralizing Antibodies for COVID-19
- Laekna Acquires Global Rights to Novartis Clinical-Stage PD-L1
- Shanghai Tyligand Bio to Acquire China Rights to Cancer Drug from Context
- Clover to Add Dynavax's Adjuvant to its COVID-19 Vaccine Candidate
- Nanjing IASO Bio Raises $60 Million in B Round for Cell Therapies
- SciClone Enters $84 Million China Deal for Novel Conjugate Aimed at Solid Tumors
- Yizhun Intelligent Completes $14 Million B Round for AI-based Scaning Diagnosis
- BioNTech and Fosun Partner mRNA Vaccine for COVID-19 in $135 Million Deal
- Harbour BioMed Raises $75 Million to Advance Cancer/Immunological Portfolio
- Exuma, a US-China CAR-T Company, Closes $19 Million B Funding
- Arctic Vision Acquires China Rights to Macular Edema Treatment in $35.5 Million Deal
- OBiO Completes $15 Million B+ Round for Gene Therapy CRO/CDMO Services
- HitGen Forms Second Drug Discovery Partnership with Japan's Kaken
- China Immunotech Completes $6.5 Million Series A for TCR-T and CAR-T Candidates
- GenFleet Closes $57 Million B Round for Oncology/Immunology Portfolio
- Shanghai OPM Bio Raises $14 Million for Biologic CDMO Service Platform
- Harbour BioMed and NYC's Mount Sinai Form mAb Discovery Partnership
- Realbio of Shanghai Lands Majority Investment for Microbiome/Pathogen Testing
- Shenogen Pharma In-licenses Alopexx Fusion CD20 Protein for Lymphoma
- Abpro Bio Announces $1.1 Billion Deal for Asian Rights to Two Abpro Bi-specifics
- 3SBio Contributes to $126 Million MPM/Dana-Farber Fund for Cancer Start-Ups
- Harvard and Guangzhou Institute of Respiratory Health Form $115 Million COVID-19 Collaboration
- Cyagen Closes $41 Million Series B to Expand Animal Research Model Business
- WuXi Biologics and Vir Biotech Team up to Develop COVID-19 Antibodies
- CICC Capital Closes $229 Million Fund for China Biologic Investments
- Invetx Raises $15 Million from Anterra, AbCellear and WuXi Biologics
- Shanghai ImmuneOnco Raises $6.4 Million for Immunotherapies
- WuXi Vaccines Signs $3 Billion, 20-Year Agreement to Manufacture Vaccine
- Anngeen Technolgies Raises $14 Million for Clinical Genetic Diagnosis Operations
- CANbridge Closes $98 Million D Round for Rare Disease/Oncology Portfolio
- TUS-Holdings of China Joins $22 Million Funding for Stilla, a French PCR Testing Company
- Sihuan Pharma Plans to Bring Anti-Infective Generics from India's Hetero Lab to China
- J&J Collaborates with BARDA, a US Agency, to Develop COVID-19 Vaccine
- Beijing Advaccine Raises $4.3 Million for Coronavirus Vaccine Development
- Universal Medical Imaging Raises $86 Million to Expand China Imaging Centers
- Junshi Bio Invests $1.4 Million in Stemirna, a Company Making RNA Cancer Vaccines
- Shenzhen Lachesis Mhealth Raises $21 Million in B+ Round
- Ocumension Acquires China Rights to Ocular Inflammation Product in $12 Million Deal
- Wuhan's BravoVax Signs Letter of Intent with Atlanta's GeoVax to Develop Coronavirus Vaccine
- Sorrento Therapeutics Rejects $933 Million Take-Private Offer
- Biotheus Acquires Rights to TILT Bio's Chimeric Adenovirus
- Ningbo NewBay In-Licenses Novel Genentech Oncology Candidate
- Zai Lab Raises $261 Million; Plans China NDA Filing for Ripretinib in Mid-2020
- Beijing Hengsheng Medical Completes $6 Million Funding for Coronary Devices
- China Medical In-licenses China Rights to Novel Anemia Drug from Zydus Cadila
- Oncologie Collaborates with Genialis to Identify Patients for Clinical Trials
- Celltrion Plans $513 Million Wuhan Biologics Facility; 18 Biologic Launches in China by 2030
- WuXi Biologics Leases German Biologics Manufacturing Facility from Bayer
- Tisenc Medical Raises $12 Million for Point-of-Care Chemiluminescence Testing
- HitGen Collaborates with Kymera to Identify Protein Degradation Targets
- Innovent Out-licenses US-Canada Rights for Avastin Biosimilar to Coherus In $45 Million Deal
- Sino Biopharma Signs Deal to Develop Two Novel Ambrx Biologics in China
- Zhiyun Health Raises $142 Million for Online Diabetes Management Website
- ASK Pharm Announces $51 Million Deal for China Rights to Iron Deficiency Product
- Nantong's IOVaxis Signs $103 Million Deal for RAS Cancer Vaccines
- Adagene Raises $69 Million in D Round for Novel Immunotherapies
- Transcenta of Suzhou Raises $100 Million to Develop 10 Innovative Biotherapies
- RootPath Raises $11 Million for Personalized TCR/CAR-T Solid Tumor Treatments
- Apollomics Enters $189 Million Deal for China Rights to Two GlycoMimetics Immunotherapies
- 3D Med Diagnosis Completes a $40 Million Initial Funding for Cancer Diagnostics
- Yisheng Forms Cancer IO Partnership with US-based Tavotek
- Suzhou's CarrierGene Merges with NuProbe Global of Boston in Diagnostics Tie-up
- BeiGene Forms $132 Million Collaboration for Asia Rights to Leap's DKK1 mAb
- CF Pharma Raises $90 Million in Series E for Inhalation Medicines/Devices
- MyGene, a Guangzhou Diagnostics Company, Completes $14 Million B Round
- Xuanzhu Bio Pays $4.5 Million to Acquire Anti-infective for Drug-Resistant Pathogens
- Elpiscience Completes $100 Million Series B Financing for Immunotherapies
- Geneseeq Completes $114 Million Funding for Cancer Genetic Sequencing
- Shanghai Zerun, a Novel Vaccine Company, Raises $29 Million to Reduce Debt
- Roche Agrees to Nearly $3 Billion Package for ex-US Rights to Sarepta Gene Therapy; China a Major Market
- Innovative Cellular Therapeutics Raises $28.6 Million for Next-Gen CAR-T Drugs
- Tracon Pharma Acquires US Rights to 3D Medicines/Alphamab PD-L1
- Metabomed, a Cancer Metabolism Specialist, Closes $12.5 Million Financing Led by Yonjin Venture
- Frontage Holdings Buys BRI Biopharma, a Canada/US CRO
- Shandong Fontacea In-Licenses IL-17A Candidate from Janssen
- KeChow Completes $45 Million Round for Novel Cancer Drug Development
- FC Capital of Shanghai Leads $20 Million B Round for Switzerland's Cellestia Biotech
- Ally Bridge Leads $140 Million of Investments in Three Medical Device Companies
- 3SBio Has China Rights to Five Numab I-O Therapies following $15.2 Million Investment
- JOINN Bio Raises $60 Million for US-China Biologic CDMO Operations
- Beijing Hygea Medical Closes $28 Million Funding for Cryogenic Cancer Treatment
- Suzhou Ribo Raises $29 Million for siRNA Drug Development
- Luye Pharma to Pay $205 Million to Acquire Shandong Boan Biological
- Aslan Pharma Raises $12.8 Million in NASDAQ Secondary Offering
- EOC Pharma Raises $71 Million in C Round for China Development of In-Licensed Oncology Drugs
- Munich's ViGeneron Closes Series A from WuXi and Sequoia for Gene Therapies
- Clover Biopharma Completes $43 Million Financing for Biologic Drug Development
- Ennovabio Closes $14 Million Series A Round for Novel Drug Development
- GensKey Raises $14 Million for Genetics-based Diagnosis of Pathogens
- Genetron Closes $71 Million D Round for Cancer Diagnostics
- Brii Bio In-licenses Seven Anti-Infectives from Three Companies
- Lansion Bio Closes $14 Million C Round for IVD Portfolio
- 3SBio and Verseau Choose First Candidate in Microphage Immunotherapy Partnership
- Fosun Kite In-licenses CAR-T Candidates for Solid Tumors from Phanes
- Fosun to Pay up to $148 Million for China Rights to MimiVax Glioblastoma Treatment
- GenScript Forms Bispecific Partnership with Korea's ABL Bio
- Shanghai Anovent Closes Funding Led by Sequoia for Respiratory Drugs
- Leo Pharma Licenses Novel Dermatology Molecules Discovered by HitGen
- Hengrui Acquires Rights to Novaliq Dry Eye Treatments in $165 Million Deal
- Antengene Acquires Global Rights to AstraZeneca Cancer Candidate
- Peijia Medical Raises $100 Million for Medical Device Development
- AstraZeneca Plans $1 Billion Fund for China Biopharma Startups
- BeiGene Enters $160 Million Deal for Rights to Seattle Genetics Cancer Molecule
- Genecast Closes $43 Million VC Funding for Cancer Diagnostics
- Simcere In-Licenses China Rights to Clinical-Stage Stroke Treatment
- Akeso Closes $150 Million Series D for Antibody Development
- QYuns Out-Licenses Ex-China Rights for Autoimmune Portfolio to Seneca
- Amgen to Make $2.7 Billion Investment in BeiGene; BeiGene to Develop 23 Amgen Candidates in China
- Denovo Closes $43 Million B Round for Biomarker Driven Drug Development
- OnQuality Pharma Raises $15 Million for Oncotherapy Side-Effect Drugs
- YiXi Biotech Closes Angel Round for Microbial Treatments
- Beijing's Fountain Medical Raises $62 Million for Clinical CRO Services
- NeuroRx Lines Up $95 Million for US-China Trials of Suicide-Prevention Drug
- Taiwan's TLC Completes $27 Million Secondary Offering
- Milu Labs Signs MOU with Thermo Fisher for Women's Health Diagnostics in China
- NovoCodex Acquires China Rights to Second Ambrx ADC Candidate
- Brii Bio In-licenses China Rights to Three Novel Qpex Anti-Infectives
- Verseau Raises $50 Million for Macrophage Immunotherapies; 3SBio Has China Rights
- Merck Opens Shanghai Innovation Hub with $14 Million for China Startups
- Exegenesis Bio Closes $10 Million Initial Funding from China Investors
- Taimei Technology Raises $212 Million to Advance CRO/Life Science Software
- Boji Medical and Great Bay Bio Form JV for Long-Acting Anemia Biologic
- dMed Biopharma, a China, US, EU Clinical CRO, Raises $50 Million
- Shaanxi Micot Raises $16 Million for Bispecific Polypeptide Candidates
- Chengdu's HitGen Partners with Galapagos for Drug Discovery
- San Diego's Ansun Bio Closes $80 Million B Round from China Investors for Novel Antiviral
- China Grand Pharma Pays $30 Million for Majority Stake in US-Based OncoSec
- CTFH and Insilico Form $200 Million AI-Based Drug Discovery Partnership
- Chipscreen Bio Partners with Novogene on Diagnostics for Cancer Drug
- Beijing Gene+ Completes $28 Million B Round for Genetic Test Services
- Innovent Bio Completes $300 Million Secondary Offering in Hong Kong
- Hrain Biotech Raises $28 Million in B Round for Immunotherapies
- CanSino Partners with Ocugen to Develop Gene Therapy Eye Treatment
- Aslan and Bukwang Form JV to Develop Aslan's IO Assets
- Zhentai Completes Funding for Rehab Device Based on Brain-Computer Interface
- Simcere In-licenses Novel Gout Treatment from JW Pharma of Korea
- Changmugu Completes $3 Million Pre-A Round for AI-Orthopedics Plans
- Shandong's Blue Sail Acquires New Valve Technology of Switzerland for $160 Million
- Guanhao Bio Pays $3.1 Million to Acquire Stake in US-based ZY Therapeutics
- Henlius Sells Southeast Asia Rights for PD-1 to Kalbe Genexine in $692 Million Deal
- Sinopharm Invests in US Aesthetics Company; Acquires China Rights to Gel Implant
- Qihan Biotech's Series A Reaches $25.5 Million for Animal-to-Human Transplants
- AllinMD Closes $100 Million Series B for Online/Hospital Orthopedic Services
- China Biologic Products Receives $4.6 Billion Takeover Offer
- Ping An Leads $15 Million Round in Riverain, a US Imaging Software Company
- Shanghai Pharma Forms $250 Million China Antibody JV with Russia's Biocad
- Genecast (Beijing) and US-based Interpace Form Diagnostics Partnership
- EdiGene Adds $11 Million to Pre-B Round for Novel Drugs Based on Gene Editing
- Vision Medicals Closes $14 Million A Round for Early Pathogen Detection
- Jiuzhou Pharma Pays $16 Million to Acquire US-based API CDMO
- Stroke Medical of Shanghai Lands $14 Million for Medical Devices
- Hansoh Forms $1.5 Billion Partnership with Atomwise, an AI Drug Discovery Company
- Genenta Science of Milan Raises $14.6 Million in Funding Led by China Investor
- SoliPharma of Hangzhou Raises $36.5 Million to Develop High End Generics
- Insilico Closes $37 Million Series B for AI Drug Discovery from China Investors
- Laviana Raises $14 Million for CDMO Operations in China
- PAG Pays $540 Million for Majority Stake in Hisun BioRay, a Biologics Company
- Meditool Shanghai Raises Capital for 3D Printed Neuro/Spine Implants
- Just Medical, an Orthopedics Device Company, Raises $14.5 Million
- Quan Capital Closes Second Healthcare Fund at $275 Million
- Temasek, Hillhouse Pay $259 Million for 2% Stake in China's Aier Eye Hospital
- Chunli to Market Novel Orthopedic Implants from Germany's Syntellix in China
- Huimei Closes $30 Million Round for AI-based Hospital Clinical Decision Support
- HiFiBiO Closes $67 Million C Round for Immune Modulators
- CC-Pharming Acquires Rights to Rituxan Biosimilar from Partner iBio
- Zuga Raises Funds for Personalized Dental Implant Products Made in the Dentist's Office
- Yaoyanshe Raises $42 Million for On-Line CRO/CMO Services
- Biotheus Signs $142 Million Deal for Alligator Bio TNFR Antibody
- Innovent Acquires China Rights to Novel Diabetes Drug from Lilly
- Kintor Pharma Starts CDMO Cooperation with CMAB for ALK-1 Cancer Drug
- China's LHHC Signs Up Vancouver's Enlighta to Market AI Early Test for Cancer
- Shenzhen Xpect Vision Closes $14 Million Round for New Imaging Tech
- CMS Acquires China Rights to Seven Generic Drugs from India's Sun Pharma
- Beijing Baicare Closes $9 Million Round for Clinical Diagnostic Devices
- Qiyu Biotech of Shanghai Completes A Funding Round for Novel Biologics
- Shanghai's Stemirna Raises $14 Million for RNA Drug Development
- Vapo Health Completes Series A Round for Medical Device Business
- Kangpu Bio-Pharma Completes $14 Million Pre-B Round for Immuno-Modulators
- Biocytogen, a China Animal Model CRO, Closes $77 Million Series D
- Nanjing King-Friend Acquires Majority Stake in US Generic Injectables Company for $95 Million
- PackGene, a Viral Vector/CRISPR company, Completes Venture Round
- Shanghai Newsoara Signs $78 Million Deal for Cancer Treatment
- Ascletis Leads Second Tranche of Sagimet's $25 Million Financing
- CGene Tech of Suzhou Raises $14.5 Million in Series A+ Round to Develop Small-Molecule Drugs
- Jiangsu Zecheng Completes $26 Million Round to Develop Diagnostics
- Qyuns Therapeutics Announces $20 Million Series B for Autoimmune Treatments
- China's United Family Healthcare Acquired by New Frontier for $1.44 Billion
- Huadong Signs $60 Million Deal for MediBeacon Medical Diagnostic Devices
- Zspeplib Announces $14 Million Round for Novel Peptide Drug Discovery
- TriArm Therapeutics Completes $20 Million Series A Round for Cell Therapies
- Xiamen Weiyang In-Licenses Low-Dose Interferon Alfa Technology for China
- Hinova Pharma Completes $40 Million Series B for US-China Trials of Prostate Cancer Drug
- Sihuan Pharma Forms JV with India's Strides, the Third China-India Pharma JV in Three Months
- Mingdu Tech Completes $14 Million Series A to Develop Efficient Pharma Programs
- Qihan Raises $20 Million for Gene Editing to Enable Xenotransplants
- Wanbang Biopharma In-Licenses Infant Seizure Treatment from Aucta
- Celltrion Forms JV with Nan Fung to Develop Three Biosimilars in China
- Shanghai Fosun Partners In-Vitro Lung Cancer Diagnostic with VolitionRx
- Chengdu New Radiomedicine Raises $14 Million; Will Develop BTG's TheraSphere® in China
- Abbisko Acquires China Rights to Anti-Immunosuppresive Drug from Boston's X4
- Cipla Forms $30 Million China Respiratory Drug JV with Jiangsu Acebright
- EdiGene, a Beijing CRISPR/Cas9 Editing Company, Sells Knockout Cell Line Library to Abcam
- Miaoshou Doctor Completes $73 Million C+ Round at $1 Billion Valuation
- I-Mab Forms $150 Million China Immunotherapy Partnership With MacroGenics
- Fosun Pharma Pays $36 Million to Acquire GSK Suzhou Manufacturing Facility
- Zhongyianke Bio Raises $36 Million to Expand Vaccine Portfolio
- SynyiAI Completes $36 Million Funding for AI Healthcare Big Data
- Ocumension Signs $13.5 Million Deal for China Rights to Nicox Anti-Inflammatory Eye Drug
- Lepu Bio Raises $131 Million in Series A Funding for Immunotherapies
- Zai Lab Announces $77.5 Million Collaboration for Incyte's PD-1 mAb
- Asieris Enters $73 Million Agreement for Global Rights to Cervical Lesion Treatment
- Yuhan Out-Licenses NASH Treatment to Boehringer in $870 Million Deal
- Chi-Med's Parent, C.K. Hutchison, Sells $288 Million of Chi-Med Stock
- China Medical In-Licenses Dry Eye, Psoriasis Treatments from India's Sun Pharma
- Beijing's ChosenMed Partners with Integrated DNA of the US on Cancer Diagnostics
- Terns Enters $228 Million Agreement with Genfit for NASH Candidate
- Sinopharm Leads $20 Million Investment in Singapore's Novena; Plans Joint $150 Million Healthcare Fund
- Eddingpharm In-Licenses Shionogi Thrombocytopenia Treatment
- Akeso Forms $100 Million JV with CTTQ to Develop PD-1 Candidate
- BeiGene and SpringWorks Form MapKure to Test B-RAF Inhibitor in Solid Tumor Cancers
- CASI Acquires Global Rights To CD19 T-Cell Therapy; Will Make $11.6 Million Investment
- BeiGene Books $150 Million as Celgene Returns Rights to BeiGene's PD-1
- Jiangsu Hengrui In-Licenses Treatment for Yeast Infection from Mycovia
- Tessa Forms $120 Million China JV to Develop Cell Therapies for Cancer
- Deepwise Completes C Round for China AI Medical Imaging Diagnostics
- Zai Lab Acquires China Rights to GIST Treatment in $205 Million Deal
- Shanghai's Brii Bio Invests in Artizan; Gains China Rights to Microbiota Treatment for IBD
- Shanghai GT Apeiron Launches; Partners with AI Drug Discovery Company Exscientia
- Vivo Capital Raises $1.28 Billion for Ninth US-China Healthcare Fund
- Everest Acquires China Rights to Kidney Disease Treatment in $121 Million Pact
- Oncologie Completes $80 Million B Round for US-China Oncology Development
- Shanghai's EpimAb Completes $74 Million Series B for Bi-Specific Antibodies
- HitGen Forms Drug Discovery Partnership with Gilead Sciences
- Benchmark Botanics Forms $10 Million Cannabis JV with Yatai Pharma
- Harbour BioMed Signs mAb Discovery Deal with Global Top Ten Biopharma
- Hansoh In-Licenses China Rights to Anti-CD19 mAb in $220 Million Deal
- Suzhou's Alphamab Closes $60 Million Series B for Biologic Oncology Portfolio
- Panacea Venture Raises $180.5 Million to Back Early Stage Healthcare Companies
- New Horizon Health Closes $66 Million C Round for Diagnostics
- Shanghai Allist Pharma Completes $174 Million A Round
- Joinn Labs to Acquire US-Based Biomere, a Pre-clinical CRO, for $27.3 Million
- WuXi Biologics Signs LOI for $3 Billion Vaccine Manufacturing Contract
- Hangzhou's AnHeart Completes $14.6 Million A Funding from Decheng
- ChemPartner Adds B Cell Discovery from Berkeley Lights to Offerings
- Leads Biolabs Grants License for Inhaled Delivery of its Immunotherapies
- Xynomic Closes $191.6 Million Merger with Bison Capital; Now Listed on Nasdaq Exchange
- Winhealth to Market Two Cumberland Pharma Pain Drugs in China
- Mindray Signs Agreement to Use Masimo's Pulse Oximetry Technology in Monitors
- MGI Tech, a BGI Subsidiary that Makes Gene Sequencers, Raises $200 Million
- HanX Biopharma Signs $51.5 Million Agreement for Onconova MDS Treatment
- Harbour BioMed and CTTQ Partner to Discover New Cancer/Immune Drugs
- GeneQuantum Raises $15 Million for Novel ADC Drug Discovery
- India's Alembic Pharma Forms JV to Market Generics in China
- TAKE2 Health In-licenses IP for Nasopharyngeal Cancer Blood Test
- WuXi AppTec Acquires San Diego's Pharmapace, a Biometrics CRO
- Zai Completes $200 Million Follow-on Financing as It Nears Commercialization of Two Products
- QTC Care Raises $7 Million for Online Healthcare in an A Funding Led by Tencent
- CStone Acquires China Rights to Tri-Specific Cancer Immunotherapy from Numab
- Digital China Participates in $17 Million Funding for UK's Congenica
- Everest Pays $65 Million Upfront in $835 Million Agreement for Greater China Rights to Immunomedics ADC
- Luye Pays $5 Million Upfront for China Rights to PharmaMar's SCLC Treatment
- Sirnaomics, a US-China RNAi Company, Completes $47 Million C Funding
- MicroPort Co-Leads $20 Million Investment in Israel's Rapid Medical
- Tencent Trusted Doctors Raises $250 Million for Online/Off-line Healthcare
- Adagene and ADC Therapeutics Partner to Discover Novel Drug Conjugate
- Eddingpharm to Pay $375 Million for Two Lilly Antibiotics and a Suzhou Factory
- WuXi AppTec Pays $46.4 Million to Acquire 15% Stake in its STA Subsidiary
- Golden Meditech Collaborates to Develop Stem Cells for Neurodegeneration
- Realbio Completes $15 Million Series A+ for Genome and Microbiome Screening
- CASI Pharma Pays $7.7 Million for Global Rights to CD38 Immunotherapy
- JF Healthcare Raises $5 Million for AI-Medical Image Diagnoses in Rural China
- I-Mab Forms CDMO Partnership with WuXi Biologics
- BioSense Acquires China Rights to Rexahn's Pancreatic Cancer Drug in $226 Million Deal
- Correction: BioAtla Forms Himalaya Therapeutics to Develop CAB Cancer Drugs in China
- Servier Partners with Mitsubishi to Promote Diabetes Treatment in China
- Creative Bio of Guangzhou Raises $45 Million for Early Colorectal Cancer Test
- Luqa Acquires China Rights to Topical Antibiotic from Spain's Ferrer
- Shiyu Capital Closes Second China Healthcare Fund with $473 Million
- Cullgen of San Diego Raises $16 Million in Series A from China Investors
- Shanghai Miracogen Signs $125 Million Deal to Use Synaffix ADC Technologies
- BeiGene Enters $269 Million Agreement for BioAtla's CTLA-4 Inhibitor
- Fosun Pharma Acquires Rights to ReNeuron Cell Therapies in $113 Million Deal
- HopeMed of China In-Licenses Hair Loss/Endometriosis Treatment from Bayer
- I-Mab Bio and Jiangsu Nhwa Pharma Join China-US-Canada CNS Collaboration
- Cytovant of China Enters $1 Billion Deal for Four Medigene Immunotherapies
- Ally Bridge and LifeTech Form Medical Device JV with France's Quantum
- Miao Jia Announces $74.4 Million C Round for Online Health Management
- Sichuan Haisco Invests $6 Million in eXithera, Gains China Rights to Novel Anti-Coagulant
- Hangzhou Just Biotherapeutics In-licenses China Rights to Bone Disease Biotherapies from Lilly
- Dingdang Raises $89 Million for Online Drug Delivery Service
- Shanghai Fosun Long March Signs MOU with VolitionRx, a Diagnostics Company
- Shuidichou Closes $74 Million Series B for Internet Health Insurance Platform
- Medtronic Launches Collaborative Shanghai Accelerator for Medical Devices
- HitGen Forms Dermatology Lead Discovery Partnership with Spain's Almirall
- Abbisko Completes $42 Million Series B Funding for Oncology Candidates
- BGI's GenoImmune Raises $18 Million for Neoantigen Discovery Services
- Merck Signs MOU with GenScript for China Plasmid and Viral Vector Manufacturing
- Sinopharm Partners with ImmBio on Broad-Spectrum Pneumonia Vaccine
- Yunhu Completes A+ Round for Internet-based China Primary Medical Care
- Shanghai Changren Completes $15 Million Round for IT Health Management
- HitGen to Discover Small Molecule Leads for India's Sun Pharma Unit
- CASI Pharma Signs Up CR Guokang Pharma to Distribute Evomela in China
- Shanghai's InventisBio Closes $70 Million C Round for Novel Drug Portfolio
- BGI Genomics Pays $50 Million for China Rights to Natera Cancer Test
- Newsoara Acquires Asia Rights to NASH Candidate in $26 Million Deal
- Spain's Grifols Acquires Stake in Shanghai RAAS, a Plasma Company, for $1.9 Billion
- Ambrx and BeiGene Form $475 Million Protein Drug Discovery Partnership
- WuXi Biologics Signs $220 Million Bi-Specific Deal with ABL Bio of South Korea
- 3SBio Will Pay $50 Million Upfront for China Rights to Two TLC Products
- Aslan Out-Licenses Korean Rights for Oncology Drug in $13 Million Deal
- Nanjing's NJCTTQ Signs $4 Billion In-Licensing Deal for Bi-Specific Immunotherapies from Abpro
- Beijing Surgerii Completes A Round for Next-Gen Robotic Surgery Device
- Gracell Biotech of Suzhou Completes $85 Million Series B for Immune Cell Gene Therapies
- WuXi STA Pharma Forms Drug Delivery Collaboration with BioLingus
- Happy Life and PPD to Offer China Clinical Trial/Post-Marketing Services
- Hangzhou Sciwind Completes $29.5 A Round for NASH Treatments
- Shukun Raises $29.5 Million for AI-based Hospital Diagnosis in China
- HuaSin In-licenses China Rights to HPV Diagnostic from Spain's Genomica
- Beijing GenomePrecision Raises $15 Million for Molecular Diagnostics
- HaiHe Pharma Forms Drug Development/Marketing JV with CSPC
- Burning Rock of Guangzhou Raises $126 Million for NGS Diagnostics
- Bioheng Closes $15 Million Funding from Decheng Capital for CAR-T Products
- Guangzhou Magpie Pharma Completes $15 Million B Round
- Ascletis Acquires Rights to 3-V Bio's NASH Candidate and Leads $18 Million E Financing
- Shanghai HaiHe Raises $146.6 Million for Innovative Cancer Drugs
- C-Bridge In-Licenses China Rights to Three Samsung Bioepis Biosimilars
- 3SBio Forms China Partnership with Verseau for Macrophage Checkpoint Modulators
- China Resources Launches $300 Million Life Science Fund
- HiberCell Raises $61 Million to Target Cancer Metastases; Hillhouse and 6 Dimensions Participate
- Bolt Bio Closes $54 Million Round Led by Hong Kong's Pivotal/Nan Fung
- MicuRx Acquires China Rights to Gram-Negative Anti-Microbial
- WuXi NextCODE Participates in $68 Million DNAnexus Funding
- Indivior Out-Licenses China Rights To Opioid Treatment in $122.5 Million Pact
- EdiGene Completes $10 Million Round for Gene Editing-based Discovery
- Suzhou GeneQuantum Collaborates with MITRO on ADC Candidates
- Qiming to Raise $250 Million for Second US Dollar Healthcare Fund
- I-Mab Signs Collaboration MOU with Hong Kong's Bio-Cancer Treatment
- Health Hope, an AI Healthcare Company, Completes $15 Million A Round
- Lyndra Raises $55 Million for Long-Acting Drug Delivery; HOPU Participates
- China Medical System Pays $11 Million for 77% Stake in UK's Midatech
- Advent Makes Majority Investment in BioDuro, a US-China CRO
- Circassia Enters $35.7 Million Deal for US/China Rights to Neo-Natal Drug
- Immunochina Closes $20 Million Round for CAR-T Portfolio
- iKang Healthcare Closes $1.4 Billion Privatization, Led by Alibaba
- Nanning Xinzizhu to Distribute AOTI Wound Healing Device in China
- MabPlex, a China Biologic CDMO, Closes $59 million Series A
- Tyto Care Adds $9 Million to Series C for Telehealth Device/Services
- Luye Selects AstraZeneca to Market its Anti-Cholesterol Drug in China
- Ascletis Acquires China Rights to Alphamab's PD-L1 for Hepatitis B
- Bio-Thera Out-Licenses Emerging Marking Rights for Avastin Biosimilar to Cipla
- Medbanks Closes $59 Million D Round for China Oncology Database
- AirDoc of Beijing Completes Series B for AI-Powered Diagnoses and Data-Mining
- Everest Medicines Signs $61.5 Million Deal for Drug Resistant Antibiotic
- Ascentage Out-Licenses Candidate for Age-Related Eye Disease to Unity Bio
- 3SBio to Commercialize Multiple Samsung Bioepis Biosimilars in China
- Ascentage Pharma Forms Clinical Collaboration with MD Anderson Center
- CANbridge and WuXi Biologics Expand Rare Disease Partnership
- Adagene Collaborates with NIH Lab to Develop Novel CAR-T Candidate
- Apollomics, a US-China Company, Raises $100 Million to Develop Cancer Therapies
- Schrödinger Closes $85 Million Round led by Gates Foundation and WuXi AppTec
- Suzhou's BrightGene Bio-Medical Completes $80 Million Pre-IPO Funding
- Apic Bio of Massachusetts Raises $40 Million in Series A, Led by Morningside
- Beijing InnoCare Raises $160 Million for Cancer/Autoimmune Drugs
- Athenex Out-Licenses China Rights to Keratosis/Oncology Drug for $29.5 Million
- Connect Biopharma of Suzhou Raises $55 Million for Immune Disease Therapies
- Thousand Oaks Biopharma Closes $45 Million Series A Funding Round
- Antengene Completes $120 Million Series B for China Clinical Trials
- HJB and MabSpace Merge to Combine Bioprocessing and mAb Discovery Skills
- Betta Acquires China Rights to InventisBio EGFR-Inhibitor for $33.5 Million
- Shanghai Industrial Investment to Launch $7.3 Billion Biomedical Fund Next Year
- Venus Medtech Merges with Keystone in China-Israel Medical Device Tie-up
- Crystal Pharmatech, a China-US Drug Manufacturing Process CRO, Raises $14.5 Million
- Shanghai Cell Therapy Closes $136 Million C Round
- Xynomic Acquires Boehringer Cancer Candidate in $800 Million Deal
- Ascentage and Genor to Collaborate on Immunotherapy Combination
- Anji Pharma Pays $2 Million Upfront for China Rights to Novartis Candidate
- Gan & Lee Out-Licenses Ex-China Rights for Three Diabetes Biosimilars to Sandoz
- GenomiCare Completes $30 Million Round for China Precision Medicine
- Autobio Forms $19 Million China IVD JV with Mobidiag and Invests $11.4 Million in the Company
- Lee's Pharm Enters $22.5 Million Deal for AI-Discovered Preclinical Molecule
- VoxelCloud Raises $50 Million for AI-based Clinical Decision Support
- Innovent Forms Three-Drug $391.5 Million Collaboration with Incyte
- I-Mab Out-Licenses Rights for Diabetes Drug to CSPC for $22 Million
- WuXi Biologics Announces $450 Million Bispecific Deal with Oxford BioTherapeutics
- WuXi Biologics Forms BiSpecifics Collaboration with Brii Bio
- HiFiBiO Forms JV to Develop Novel Cancer Research
- Brii Bio Forms $128.5 Million Collaboration for Therapeutic Hepatitis B Vaccine
- Fosun Pharma Acquires Rights to Next-Gen Botox-type Drug in $260 Million Deal
- Fresenius Building China Dialysis Centers Network through Acquisitions
- Shenzhen Salubris Invests $10 Million in Viracta; Signs $58 Million Deal for Cancer Drug
- Elpiscience of Shanghai Raises $35 Million to Develop Immunotherapies
- Immunochina Collaborates with Sartorius Stedim for CAR-T Production
- Zai Lab Forms $165 Million Cancer Drug Partnership with MacroGenics
- I-Mab Forms Partnership with Tracon for US Development of Immunotherapies
- Zhejiang Bossan Out-Licenses Ex-China Rights for EGFR Drug to CBT Pharma
- BeiGene Forms Cancer Collaborations--Worth up to $1.3 Billion--with Zymeworks
- WuXi NextCODE to Sequence 400,000 Irish Genomes in $400 Million Study; Closes $200 Million C Round
- Shanghai Cell Therapy Closes $40 Million C1 Round for Cancer Drugs
- Ascletis Acquires China Marketing Rights to Roche's Pegylated Interferon
- HitGen Forms Neurological Drug Discovery Partnership with Biogen
- Huadong Medicine Closes $220 Million Acquisition of the UK's Sinclair Pharma
- Alphamab Oncology of Suzhou Closes $100 Million A Round for Cancer Drugs
- Lilly Seeking Up to $300 Million for China Rights to Off-Patent Medications
- I-Mab Acquires China Rights to I-O mAb from MorphoSys in $105 Million Deal
- NextCure Closes $93 Million B Round Led by China Investors for IO Therapies
- Agilent Closes $250 Million Acquisition of ACEA, a US-China Lab Tools Maker
- YITU Raises $15 Million for AI-Supported Cancer Diagnosis
- Shanghai Exuma to Develop Conditionally Active CAR-T Candidates
- Sinovant In-licenses China Rights to HGH Mimetic from Angion
- LG Chem Forms IO Collaboration Worth Up to $1 Billion with Cue Biopharma
- bioMérieux to Pay $114.5 Million for Majority Stake in Suzhou Hybiome
- Denmark's Ascendis Forms $80 Million China Rare Disease JV with Vivo Capital
- Berry Genomics and Prenetics Team up to Offer Consumer Genetic Testing
- HuiyiHuiying Raises Funds from Intel for Medical Imaging AI
- Zhejiang Jingxin Makes $10 Million Investment in Mapi Pharma of Israel
- Ocumension Acquires Rights to Uveitis Drug in $12 Million Deal
- GeneQuantum Forms Cooperation with Biocytogen for Next-Gen Bioconjugates
- Suzhou's Innovent Rises 19% in First Trading Day on the Hong Kong Exchange
- Biotheus of Guangdong Has $140 Million to Develop 8 Candidates
- Terns Closes $80 Million Round to Develop NASH Drugs
- WuXi AppTec and Schrödinger Form Faxian for Novel Drug Discovery
- Insight Capital Raises $72 Million for New China Healthcare Fund
- Fullerton Enters $72 Million of Deals for Shanghai Healthcare
- Xgene Pharma of Shanghai Closes $20 Million B Round for Pain Drugs
- XtalPi Raises $46 Million for Computer-Driven Drug Research
- WuXi AppTec Forms Medical Big Data JV with China Electronics Data
- CANbridge Forms Rare Disease Drug Partnership with WuXi Biologics
- Fosun Acquires China Rights to HCC Diagnostic with $10 Million Glycotest Investment
- CASI Pharma Acquires HBV Treatment for China Use from Indian Pharma
- China Everbright Raises $155 Million for Third Life Science Fund
- Genecast Acquires China Rights to Tumor Test from Cancer Genetics
- iCell Partners with LineaRx for new CAR-T Manufacturing Platform
- HiFiBiO Acquires H-Immune, a French Immunotherapy Biotech
- Suzhou's Amor Medical Collaborates with IME to Develop Resorbable Devices
- BeiGene and MEI Pharma to Test Drug Combination Therapy in B-Cell Malignancies
- Deep Intelligent Pharma Raises $15 Million for AI Drug Development from Sequoia
- Jinxin Fertility Completes Financing Led by Warburg and CNCB
- Biosense Acquires China Rights to Immunotherapy in $75 Million Deal
- Daiichi Sankyo in $32.5 Million Deal for China Rights to Australian Non-Opioid Analgesic
- Ping An Good Doctor Joins with CR Sanjiu to Promote OTC and TCM Products
- Cellular Bio Acquires Rights to Solid Tumor Immunotherapy from National Cancer Institute
- Go Therapeutics Signs $195 Million Licensing Deal with Roche
- HiFiBiO Forms Cell Therapy Discovery Collaboration with Kite Pharma
- Shanghai Aohua Endoscopy Completes $44 Million Series D Funding
- ACEA, a US-China Cell Analysis Device Company, Acquired for $250 Million
- Cellular Bio to Manufacture Novartis CAR-T Drug in China in $40 Million Deal
- Bellen Chemistry of Beijing, a CRO/CMO, Raises $30 Million-Plus in C Round
- Fosun Pharma Acquires China Rights to Stroke Drug in $32.5 Million Agreement
- CSPC Acquires China Rights to Verastem Cancer Drug in $45 Million Deal
- WuXi Biologics Collaborates with I-Mab to Develop Three BiSpecifics
- Flow Pharma Forms JV with Button Capital for China Clinical Trials
- Everest Acquires China/Asia Rights to VenatoRx Drug-Resistant Anti-Infective Drug
- Changchun High & New Forms $200 Million Biosimilar JV with Alvotech of Iceland
- Ping An Leads $70 Million Round in MeMed, an Israeli Diagnostics Company
- Beijing's Hillhouse Closes Latest Fund with $10.6 Billion, a Record
- China Medical In-Licenses China Rights to VAXIMM's Immunotherapies
- General Atlantic Invests $150 Million in Asia Holding, a Hospital/Clinic Company
- Digital China Health to Promote Genomics Diagnostic Support System in China
- CASI Pharma Raises $48.5 Million to Acquire New Drugs
- 111, a Shanghai Online-Offline Pharmacy, Raises $100 Million in US IPO
- Xynomic Pharma to List on Nasdaq via Reverse-Merger at $450 Million Valuation
- Vivo Capital Closes Latest US-China PE Fund at $635 Million
- Shanghai Pharma Signs MOU to Develop BIOCAD's mAb Portfolio in China
- Zai Lab Pays $15 Million for China Rights to Electric Field Therapy for Brain Cancer
- Tianjin Tasly Out-licenses US Rights to TCM Angina Drug in $50 Million Deal
- Cadrock Raises $5 Million from China Investor for Antibiotic CAD Treatment
- Zai Lab Raises $150 Million in US Secondary Offering
- Eccogene of Shanghai Completes $14.6 Million Funding Led by Sinopharm
- BeiGene and SpringWorks to Pair RAF and MEK Inhibitors in Solid Tumor Combo
- Ming Capital Leads $33 Million Round in Belgium's Miracor Medical
- Quan Capital Files to Raise $300 Million for Second Drug Development Fund
- Guangdong Jianke Raises $130 Million for China Online Pharmacy
- Guangzhou Wondfo Forms $16 Million Diagnostics JV with Biocartis
- BI and Tsinghua to Use Immunology for New Infectious Disease Drugs
- Ark Biosciences In-Licenses Pulmonary Fibrosis Candidate from Roche
- WeDoctor and other Investors to Acquire Fertility Company Genea for $510 Million
- Jacobio Pharma of Beijing Raises $55 Million in C Round
- RootPath Completes $7 Million Seed Funding for Next-Gen I-O Development
- Ping An Good Doctor Partners with Jointown for Online/Offline Healthcare
- Huadong Poised to Acquire Sinclair of Britain for $210 Million
- Shenzhen Lachesis Completes $29 Million B Round for Smart Hospital Ward System
- Harbour BioMed, a US-China Company, Closes $85 Million Series B Round
- China Pioneer, a Medical Device Distributor, Pays $33 Million for Stake in Australia's Paragon Care
- Strategia of Boston Forms Drug Development Partnership with Shanghai's JS InnoPharm
- China Biologic Nixes Privatization; Raises $590 Million in PE Deal
- Oxford Biodynamics Raises $12.5 Million from China's GL Capital for Biomarkers
- China Biologic Management Makes $3.9 Billion Take-Private Offer
- Harbour BioMed in $350 Million Deal for Sichuan Kelun PD-L1 Candidate
- Harbin Gloria Partners Four of its Drug Candidates in $53 Million Agreement
- Shanghai ChemPartner Closes Reverse Merger with Quantum
- YiChang HEC Pharm Raises $400 Million from Blackstone Group
- Buck Institute, Insilico and Juvenescence Form Napa to Develop Anti-Aging Drug
- CrownBio Acquires Rights to Drug Development Models from Shanghai Model Organisms
- Haisco Invests $10 Million in Pneuma Respiratory; Acquires Rights to Asthma/COPD Inhaler
- Tot Biopharm of Suzhou Closes $102 Million Round for Cancer Drugs
- Beijing's EdiGene Completes $15 Million Pre-B Round
- Nanjing Sanpower Transfers Dendreon to Cenbest for $868 Million
- Shandong Luoxin Acquires Constipation Drug in $68 Million Agreement
- Harbour to Pay up to $120 Million for China Rights to HER2 Bispecific
- CMS Gains China Rights to Two Can-Fite Candidates in $74.5 Million Agreement
- Cure Genetics (Suzhou) Closes $17 Million Series A Financing
- Impact Therapeutics Closes $30 Million C Round for Cancer Drugs
- CY Biotech Acquires China Rights to Obesity Treatment from Eisai
- China Diagnostics Medical Raises $292 Million led by Legend's $100 Million
- CMS in $70 Million Deal for French Thrombotic Therapy
- Laekna Acquires Exclusive Worldwide Rights to Two Clinical Stage Oncology Assets
- Curon Biopharma of Shanghai Completes $150 Million Initial Financing
- Medlinker Raises $147 Million for China MD-Peer Online Network
- HiFiBiO Forms Drug Discovery Partnership with Takeda
- Omniome Raises $60 Million in Funding Led by China Investors
- HitGen Forms Another Drug Discovery Partnership -- This One with Sanofi
- I-Mab Out-Licenses Bi-Specific to South Korea's ABL Bio in $100 Million Deal
- Gossamer Bio Closes $230 Million Series B Led by Beijing's Hillhouse
- Terumo Pays $130 Million to Acquire Essen, a Beijing Stent Company
- Beijing Allcure Completes $103 Million Funding for China Oncology Centers
- BMS Forms Translation Partnership with Tsinghua University
- Tencent Partners with WebMD to Provide Online China Medical Content
- Long Hill Capital Closes $265 Million Second Fund for China Health Investments
- Shanghai Fosun Pharma Considering $500 Million IPO of Gland Pharma
- Kolon Life Science to Export $207 Million of Gene Therapy Treatment to China's Hainan Province
- China Investors Lead $15.5 Million Round in Quantapore, a US Sequencing Co.
- Laurel VC Acquires Asthma/COPD Technology; Will Form China Biopharma
- Tianjin Tasly in $24 Million Deal for EA Pharma Kidney Disease Drug
- Sinovant Formed with 11 China Drug Candidates and CITICPE Support
- Fosun Pharma to Invest $17.6 Million in EOS Imaging of France
- Ascentage Closes $150 Million C Round to Develop Apoptosis Drugs
- Tasly In-licenses Two Cell Therapy Treatments in $90 Million Deal
- Lyvgen Biopharma Raises $30 Million for IO Drug Candidates
- Cyrcadia Asia Raises $3.8 Million for Breast Cancer Detection Device
- Tasly Biopharma Raises $84.5 Million in Pre-IPO Round
- Haitong Invests in Orig3n, a Boston Genetics/Regenerative Medicine Company
- Merck to Market Xian Janssen's SGLT-2 Diabetes Drug in China
- GT Healthcare and Sonder Invest $26.6 million in Potero Medical
- Hillhouse Capital of Beijing Co-Leads $15 Million Round for Antiva
- Dian Diagnostics to Market Agena's MassARRAY® in China
- Tasly Biopharma Pays $48 Million to Buy Out JV Partner, Transgene
- Adlai Nortye Acquires Global Rights to Novartis Cancer Drug
- CC-Pharming Pays $4.7 Million to be iBio's China Antibody Partner
- IDS Medical Partners with Tencent to Distribute Medical Devices in China
- China's Hybio and Yunfeng Capital Acquire AMW, a German Pharma
- Suzhou Kintor Forms Biomarker Collaboration with Predicine
- Two US Biopharmas -- Stealth and AOBiome -- File for IPOs on Hong Kong Exchange
- China Grand Enterprises in Talks to Acquire Sinclair, a $156 Million UK Company
- Beijing's LinkDoc Completes $151 Million D Round for Big Data
- Sinovac Raises $86.7 Million, Scraps Privatization
- Athenex Forms $145 Million Immunoncology JV with Xiangxue and Raises $100 Million
- Innovent Files for Hong Kong IPO; May Raise $500 Million
- Bain PE to Pay $700 Million to Buy DSM Sinochem Pharma
- China's I-Mab Raises $220 Million in C Round for Biotech Development
- Nuance Raises $35 Million in B Round Led by C-Bridge
- HaploX of Shenzhen Closes B Round for Cancer Liquid Biopsy Products
- WuXi Bio Pays $47 Million to Alter OmniAb Pact with Ligand Pharma
- Amyris Forms Microbiome JV with Shenzhen's BGI Genomics
- CStone Pharma Signs $424 Million Deal for Agios' Cancer Treatment
- Adlai Nortye of Hangzhou Closes $50 Million B Round
- Shanghai's Everest Medicines Acquires Global Rights to Novartis Liver Cancer Treatment
- Ascletis Signs Up with CR Pharma to Distribute Novel HCV Treatment
- Harbour BioMed Collaborates with WuXi Biologic for Supply of Novel Antibody
- CSL Pays $102 Million to Acquire Remaining 20% of China's RuiDe Bio
- Los Altos Pharma In-licenses China Rights to Sedor's Pain Candidate
- Nuance Enters $58 Million Deal for Non-Opioid Pain Treatment in China
- WuXi Biologics to Build $20 Million ADC Facility in Wuxi City
- CITIC Capital Bids $3.6 Billion to Acquire China Biologic Products
- Stealth Bio Raises $100 Million from China Investors for Mitochondrial Candidates
- AlphaBio of Shanghai Announces $65 Million Series A Round
- Baltimore's WindMIL Closes $32.5 Million B Round Led by Qiming
- Aptose Acquires China Rights to Leukemia Candidate in $125 Million Agreement
- Mevion Raises $150 Million from China Investors for Proton Therapy Machines
- Yaoshibang Closes $65.7 Million C Round for Online Pharmacy
- Shanghai Kinetic Acquires US Device Maker Elliquence for $77 Million
- WuXi AppTec Leads Investment in Insilico, an AI Drug Discovery Company
- WuXi Biologics to Build New Biologics Plant Near Boston -- Announces Four New Facilities (a $792 Million Investment) in Two Months
- Oncologie Launches with $16.5 Million for IO Combinations in China and the US
- Hangzhou Just Bio Raises $35 Million for Biologics in B+ Round
- Quantum Surgical Raises Series A Capital from Ally Bridge
- Harbour BioMed Teams Up with Wistar to Discover Novel mAbs
- Denovo Licenses Previously Unknown Use of Cancer Drug for PAH
- CStone of Suzhou Enters $386 Million, Three-Drug Deal with Boston's Blueprint
- CR Pharma to Acquire Jiangzhong Pharma for $667 Million
- Xynomic Pharma Closes Series B from China Investors
- vTv Therapeutics Out-licenses COPD Treatment to China's Newsoara
- Luye Pharma to Bring Elpis CAR-T Therapies to China
- Zai Lab Gains Global Rights to Topical Biologic for Psoriasis
- Link Health In-licenses China Rights to Lidocaine Patch
- Alibaba Sells Online Pharmacy Unit to Ali Health for $1.4 Billion
- JHL Biotech Raises $106 Million in Pre-IPO Funding
- HitGen Closes $39 Million B Round for Drug Discovery/Development
- Shuwen Develops Companion Diagnostics for BlissBio in New Collaboration
- Antengene to Pay $162 Million for China Rights to Four Karyopharm Assets
- Brii Bio Starts Operations with $260 Million to Bring Drugs to China
- Pivotal Partners China Closes $150 Million Fund to Incubate New Companies
- Shanghai Pharma Extends Research Collaboration with Bracco Imaging
- Shanghai Pharma Acquires Majority Stake in JV Techpool in $280 Million Deal
- WuXi Biologics Invests $60 Million in Another New Plant -- In Singapore This Time
- Grail Raises $300 Million from China Investors for Early Cancer Diagnostics
- Legend Capital Closes $156 Million Phase II for RMB Healthcare Fund
- Salubris Acquires China Rights to MedAlliance CV Balloon for $30 Million
- CR Pharma in Talks for $613 Million Acquisition of Jiangzhong Pharma
- Boston's HiFiBiO Raises $37.5 Million from China Investors
- Jiangsu Ambition In-licenses Prostate Treatment from Sweden's Lidds
- Asymchem Starts Fund to Bring Novel Western Drugs to China
- Dongbao Pharma Acquires Two Diabetes Treatments in $135 Million Deal
- Fosun to Bid in $2 Billion Auction for Novartis' US Generic Drug Assets
- Ansun Raises $85 Million for Novel Influenza Therapeutic from China Investors
- Changshan Pharma Signs $9.5 Million Deal for Osteoarthritis Combo Drug
- Unisound Closes $100 Million Round for Medical AI and Voice Recognition
- BangEr Raises $47 Million for its Chain of China Orthopedic Hospitals
- Armo, Backed by China Investors, To Be Acquired by Lilly for $1.6 Billion
- MabSpace Biosciences of Suzhou Closes $40 Million B Round
- WeDoctor Closes $500 Million Pre-IPO Round at $5.5 Billion Valuation
- CStone Pharma Completes Record-Breaking $260 Million B Financing
- Luye Pharma Enters $538 Million Deal for AstraZeneca's Seroquel
- CDH Investments Proposed to Acquire Sirtex Medical for $1.4 Billion
- Refuge Biotechnologies Closes $25 Million Series B from Chinese Investors
- Chinese Medical AI Start-up Synyi Raised $15.7 Million Series B
- Innovent Announced $150 Million Series E
- Tocagen Granted ApolloBio Greater China Rights of Immunotherapy Candidate for $127 Million
- Prenetics Acquires British Consumer Genetic Testing Firm
- Qiming Closes $120 Million US Healthcare Fund; Two General China Funds with $1.2 Billion
- Shuwen Biotech Reports "Multi-Million Dollar" Investment from Tasly
- Beijing's AK Medical Buys JRI Orthopedics of the UK for $24 Million
- DXY Completes $100 Million Series D Round for Academic Portal for China Doctors
- Biocytogen Closes $65 Million Round for Animal Model CRO Services
- Panacea Ventures Files to Raise $150 Million for China Healthcare
- Bliss Biopharma of Hangzhou Licenses Cancer ADC from Morphotek
- New World Development Invests in New Century Healthcare; Plans More China Clinics/Hospitals
- Frontage Labs, a US-China CRO, Acquires Concord Biosciences
- Concord Medical Announces $238 Million Investment from CCIC
- Terns Acquires Three Lilly Candidates; Raises $30 Million from Lilly Asia Ventures
- CMAB Biopharma of Suzhou Announces $34 Million Series B
- GDCC Acquires China Rights to Anti-Seizure Drug from Biscayne Neuro
- Ascentage Chooses Hong Kong Exchange for its IPO
- Roivant Enters $95 Million Deal for China Rights to Novel Antibiotic
- WuXi AppTec Approved for $910 Million Shanghai IPO
- Hua Medicine Completes $117 Million Funding for Novel Diabetes Treatment
- Aslan Pharma of Singapore Files for $86 Million US IPO
- Singlera Raises $60 Million in A+ Round for Cancer Tests
- Adagene Completes $50 Million C Round for Oncology Clinical Trials
- BI Forms $134 Million JV with Two China Partners for Foot-and-Mouth Vaccine
- CBT Acquires Global Rights to CTLA-4 Checkpoint Inhibitor in $46 Million Deal
- Simcere Partners with Agena for Companion Diagnostics in China
- Fosun Acquires China Rights to Dove's Oral Thrombocytopenia Drug
- Senju Acquires China-Japan Rights to Diabetic Macular Edema Treatment
- TCR2 Therapeutics Closes $125 Million B Round for Immunoncology Program
- Oxford Nanopore Completes $140 Million Funding Led by Asian Investors
- CASI Raises $50 Million to Launch Drugs in China
- Akonni and Righton Form Two-Way US-China Diagnostics Deal
- Infervision Closes $47 Million B+ Round for AI-aided CT Scan Analysis
- HitGen to Discover Leads for BASF Crop Protection Products
- United Biopharma of Taiwan to Build $40 Million mAb Manufacturing Facility in China
- Timwell Forms $20 Million JV with ReWalk for China Sales of Exoskeleton
- Alibaba Re-Starts $1.4 Billion Bid to Acquire iKang Healthcare
- Hua Medicine in Hong Kong IPO Queue; Plans to Raise $400 Million
- Adagene to Collaborate with WuXi Biologics for Antibody Manufacturing
- JW, a Juno-WuXi AppTec China JV, Raises $90 Million for CAR-T Drugs
- Oxford Vacmedix Raises $12.5 Million for Therapeutic Vaccines from Asian Investors
- 23Mofang Raises $15.8 Million for China Personal DNA Test
- MicuRx will Receive $5.2 Million to Advance Drug-Resistant Antibiotic
- Shanghai's CARsgen Heads Towards IPO with $60 Million Pre-C Round
- Cullgen Seeded with $15 Million from GNI, a Japan-China Biopharma
- Viela, a New MedImmune Spinout, Raises $250 Million from China Investors
- Shenzhen Hepalink Forms Anti-infective mAb JV with Aridis Pharma
- China's STA Collaborates with Regulus for microRNA Drug Manufacturing
- Everest Acquires China Rights to Tetraphase's Antibiotic in $23.5 Million Deal
- Taiwan Liposome Plans to Stage $50 Million IPO in the US
- Fosun Forms Investment/Commercialization Partnership with Arix, a UK Accelerator
- Oncologie Enters $126 Million Deal for China Rights to Cancer Drug
- Lee's Pharm Acquires China Rights to GC Pharma Anticoagulant
- Harbin Pharma to Acquire 40% of US-based GNC for $300 Million
- NovaBay Raises $6 Million from Hong Kong's OP Financial
- Tsinghua University Commits $276 Million to Cambridge UK Biohub
- Beijing InnoCare Pharma Raises $55 Million in Vivo-led Round
- China's GeneScience Pharma Participates in Rani's $53 Million Funding
- Zhejiang Haichang to Re-formulate Liver Cancer Drug for Rexahn Pharma
- Roivant Strikes $5.5 Million China Deal with ArQule for Cancer Drug
- Jing Medicine Forms $100 Million Collaboration with ShanghaiTech University
- China's Luqa Pharma Closes $15 Million B Round for Dermatology/Aesthetic Products
- Chengdu's NetVation DL Forms Partnership with Pfizer
- CR Pharma In-licenses Rights To Prostate Cancer Drug from Xbrane
- Cellular Biomedicine Raises $30.6 Million from Sailing Capital
- CANbridge Acquires China Rights to Puma Cancer Candidate in $70 Million Deal
- JHL Shareholders Approve Voluntary De-Listing from Taiwan Exchange
- Medopad, a UK Healthcare App, Signs $140 Million of Deals in China
- NCPC GeneTech Acquires China Rights to Anemia Drug from Korean Firm
- Engine Biosciences Raises $10 Million for AI Drug Discovery from Asian/US Investors
- TytoCare Raises $25 Million for Telehealth Devices; Forms China Partnership with Ping An
- C-Bridge Raising $650 Million for Third China Healthcare PE Fund
- CASI Pharma Acquires 29 Generic Drug Candidates from Sandoz
- Shanghai Pharma Plans San Diego Office for US/EU M&A
- Neuspera Raises $26 Million in B Round, Led by China's 6 Dimensions
- XtalPi Closes $15 Million for AI-Aided Drug Design
- Tmunity Closes $100 Million Funding for T Cell Therapies; Ping An Participates
- Taiwan Liposome Forms China Commercialization JV with Jixi Biotech
- Harbour BioMed Raises Additional Capital in Series A+
- BeiGene Completes $750 Million Secondary Offering
- Ascletis Plans $100 Million C Round; Then Hong Kong IPO
- China's Adlai Nortye Acquires Immuno-oncology Candidate from Eisai
- Ping An Raises $1 Billion for Healthcare Management Unit
- 3SBio to Market Japanese Pruritis Treatment in China
- Sinocare Mulls $4 Billion Bid for J&J's Diabetes Device Companies
- CR Pharma Negotiating for China Rights to Two Xbrane Candidates
- Suzhou's Innovent Plans Capital Raise Followed by $200 Million IPO
- BeiGene Acquires Asia Rights to Mirati Cancer Treatment in $133 Million Deal
- Suzhou Zelgen Biosciences Completes $62 Million B Round
- UK's Vaccitech Raises $27 Million, Co-Led by Sequoia China
- Hua Medicine to Raise $200 Million to Support Novel Diabetes Drug
- Suzhou Kintor Raises $44 Million for Novel Drug Portfolio
- Ferring Collaborates with Chinese Academy of Science on Women's Health
- WuXi AppTec Forms Clinical Testing JV with the Mayo Clinic
- Ping An Signs Strategic Oncology Partnership MOU with Varian
- Shanghai Fosun Forms $50 Million US JV -- With Itself
- Fosun Pays $18 Million for China Rights to Novel Parkinson's Disease Drug
- Biostage Raises $4.2 Million from China Investor for Bioengineered Organs
- Sinobioway and F1 Oncology to Build Shenzhen CAR-T Manufacturing Facility
- Shenzhen's HEC Pharm Invests in US Novel Imaging Contrast Company
- Ally Bridge and LifeTech Scientific Join to Invest in MedTech Companies
- Simcere Acquires China Rights to Three Bi-Specific Immunoncology Drugs
- Lepu Medical Pays $23.3 Million for 13% Stake in Australia's Viralytics
- BeiGene to Generate New mAbs Using Harbour BioMed's Mouse Platform
- Berry Genomics Collaborates with 10X Genomics for Next-Gen Prenatal Tests
- Jiangsu Hengrui Out-Licenses Novel Dermatology Drug for $233 Million
- China's KBP Closes $76 Million A Round; Opens Philadelphia Global Headquarters
- Genetron Health Raises $61 Million for Genomics-Oncology Services
- Zhejiang DTRM Completes $60 Million A Round for US-China Clinical Trials
- iCarbonX Leads $200 Million Funding in SomaLogic of Colorado
- Illumina Collaborates with KingMed on China Oncology IVD Assays
- Miracor Closes $30 Million D Round, Led by Shenzhen's Ming Capital
- Genostics Invests $13.5 Million in UK's Oncimmune for China Rights to Lung Cancer Test
- Perennial Real Estate Announces $1.2 Billion China Healthcare Center JV
- Aslan Pharma Pays $129 Million for Global Rights to Lead Asset
- ApolloBio and Inovio Alter $43 Million China Deal for HPV Immunotherapy
- Hong Kong's Xinogen Acquires China Rights to Angiochem Cancer Drug
- Sansure Biotech Raises $77 Million in Funding Led by Lilly Asia
- CMAB, a Suzhou Biologic CRO/CMO, Completes $38 Million A Round
- Laviana Pharma Closes $15 Million Financing for China CRO/CMO Services
- Shanghai Henlius Announces $192.5 Million Funding for Biosimilars, Novel mAbs
- Cellular Biomedicine Raises $14.5 Million for CAR-T Immunotherapy, Stem Cells
- Shanghai's SARI to Acquire NMS, an Italian Oncology Company, for $359 Million
- Kangning to Raise $30 Million in China Psychiatric Hospital IPO
- Merck Serono, WuXi AppTec and Pontifax Form Israeli Life Science Incubator
- Asieris Pharma Closes $15 Million B Round Financing
- CG Capital of Beijing to Acquire 37% of NovaBay for $28 Million
- LP Pharma of Xiamen Raises $30 Million for Drugs with Mucosa/Oral Delivery
- Walgreens Boots Alliance Reduces Stake in China Drug Distribution JV
- China's I-Mab Inks $548 Million Immunoncology Pact with Genexine
- Huadong Medicine Enters $83 Million Deal for GLP-1r Diabetes Treatment
- Yonghua Capital Leads $25 Million B Round in Taris Biomedical
- Nanjing Legend Lands $350 Million Upfront for CAR-T Partnership with Janssen
- JHL Biotech Proposes Voluntary Delisting from Taiwan Exchange
- Ambrx Enters $143.5 Million China Deal for Liver Cancer Treatment
- CrownBio Agrees to be Acquired by JSR of Japan in $400 Million Deal
- Zai Lab Pays $44 Million for China Rights to Gastric Cancer Immunotherapy
- Jacobson Invests $15 Million in Shanghai Henlius; Obtains Hong Kong Rights to Biosimilar
- GBIL Pays $29 Million to Acquire Surgical Robot for China from TransEnterix
- Clover Bio of Chengdu Completes $9.5 Million Series A for Biotech/Biosimilar Portfolio
- Sinopharm Co-leads $18 Million Round in Nebraska's Virtual Incision
- BGI Genomics Forms $7.6 Million JV with TCM Company Kangmei
- Fosun Enters $125 Million China Deal for Ardelyx IBS Treatment
- China Investor Syndicate Acquires Esaote, an Italian Imaging Device Company
- Shenzhen BioScien Acquires China Rights to Generex Cancer Vaccine
- BGI Genomics Partners with Sanguine to Build Databases of Clinical Trial Patients
- Etong Healthcare Completes $30 Million Series B Funding for Online Services
- Genova Biotech (Changzhou) Raises $50 Million in Tasly-led Funding
- MicuRx Raises $15 Million to Complete China Antibiotic Trial
- Everest Enters $224 Million Two-Drug China Partnership with Arena
- Pfizer Enters $226 Million China/Asia Deal for Basilea's Anti-Fungal Drug
- Walgreens Boots Alliance Acquires 40% Stake in Sinopharm Drugstore Chain for $420 Million
- 12 Sigma, a US-China Startup, Raises $30 Million for AI-Imaging
- GenomicCare (Shanghai) Completes Series A; Brings Total Funding to $25 Million
- Zhenxing Biopharma, a Plasma Company, Sells 19% Stake for $322 Million
- I-Mab Obtains China Rights to Myeloma Candidate in $120 Million Deal
- Ping An Good Doctor Plans $1 Billion Hong Kong IPO in 2018
- Fullerton Raises $121 Million for China Healthcare Clinics; Ping An Leads Funding
- HitGen of Chengdu Forms Drug Discovery Partnership with Boehringer Ingelheim
- AstraZeneca Forms $265 Million China Drug Development JV with China Fund
- Aspen Pharma of South Africa to Expand in China via Partnerships
- 3D Medicines Raises $101 Million for Cancer Diagnostics and Drugs
- China Renaissance to Raise Investment Fund Assets to $10 Billion; Healthcare a Focus
- Immunochina Lands $7.5 Million for CAR-T Drug Trials
- Lee's Pharm Forms Second China Cancer Partnership with Beijing Shenogen
- Guangzhou RiboBio Partners with GE to Build Oligonucleotide CRO/CMO Facility
- Shanghai's MicroPort Acquires CRM Business from Liva Nova for $190 Million
- Canada's Acasti Signs $133 Million Non-Binding Term Sheet with China Pharma
- Zensun Raises $76 Million for Novel Drug Portfolio
- Adlai Nortye In-Licenses Oncolytic's Cancer Drug in $86.6 Million Deal
- Shanghai Pharma Plans to Use M&A to Expand Overseas
- Shanghai Pharma Acquires Cardinal's China Drug Distribution Business for $1.2 Billion
- CorestoneBio Plans China JV with Boston's Respiratory Motion
- Cygnus Raises $19.6 Million for Highly Accurate Sequencing Technology
- Arcus Completes $107 Million C Round with China VC Participation
- Pfizer Sells 49% Stake in China-Hisun Generic Drug JV
- Valeant Sells Obagi to Fund that Includes China Regenerative Medicine
- Ark Biosciences Partners with Calibr on Novel COPD Treatment
- US Denies Approval for Creat's $1.5 Billion Acquisition of Germany's Biotest
- Zhejiang Huahai In-licenses Immuno-Oncology Drug in $65 Million Deal
- EOC, an Eddingpharm Spin-out, Closes $32 Million B Round for Oncology Assets
- Guangzhou's AnchorDx Raises $28 Million for Precision Oncology Offerings
- Luye Pharm Leads $11.2 Million Funding of Chicago's Exicure
- Guangzhou Pharma May Form China Generics JV with Teva Pharma
- Shanghai Fosun To Take Control of Taiwan's Henlix for $98 Million
- iPharma in-licenses Global Rights to FAK inhibitor from Boehringer Ingelheim
- Annoroad, a Beijing Gene Services Company, Raises $100 Million in C Round
- Two China Companies to Bid in $765 Million Auction for I-Med Radiology of Australia
- Shanghai Fosun Pays $73 Million for African Drug Distributor
- Cyrano Partners with Shanghai Newsummit to Develop Treatment for Loss of Smell
- Xynomic In-Licenses RAF Inhibitor from Boehringer in $502 Million Deal
- Sumitomo Dainippon Acquires Asian Rights to Poxel's Diabetes Drug in $300 Million Agreement
- Sinotau and Navidea Sign MOU for Beta-Amyloid Imaging Agent
- Maxhealth to Distribute Legacy's Hair Loss Treatment in China
- CR Pharm Files for $368.5 Million China Pharma Fund
- Chi-Med to Raise $301 Million in US Secondary Offering
- Hong Kong's Nan Fung Leads $45 Million Round for US Hearing Device Maker
- GIMDx/Improve Medical Gain China Rights to PD-L1 Quantifying Assay
- Prenetics of Hong Kong Raises $40 Million for Individual DNA Testing
- WuXi AppTec to Acquire Texas-Based Global Clinical Trial CRO
- Shenzhen Hepalink Invests $69 Million in Canada's Resverlogix
- Huawei and Phillips Building AI Healthcare Platform for China
- CASI Pharma Raises $23 Million in Private Placement
- Innovent Licenses Use of Harbour Biomed's Biologic Drug Discovery Platform
- China Biologic to Acquire TianXinFu, a Device Company, in $536 Million Deal
- Gentris and Shanghai Institute Sign MOU for Biomarker Collaboration
- Shanghai Pharma in Second Round Bidding for $1.5 Billion Cardinal China Deal
- Zhejiang Huahai Raises $152 Million for New Biopharma Facility
- Hong Kong's Jacobson Pharma Raises $64 Million for M&A
- Fosun Pharma in $350 Million Auction to Acquire India's Symbiotec Pharma
- CR Gosun In-Licenses Antibiotic from Basilea in $153 Million Deal
- Simcere to Market Four Amgen Biosimilars in China
- Ping An Pays $245 Million for Stake in Japan's Tsumura, a TCM Company
- Chengyuan Genomics to Market Single Cell RNA Sequence Device in China
- Shanghai Pharma May Acquire US Operations of $4 Billion Generic Drugmaker
- Salubris Pharma Invests $5 Million in Boston's GO Therapeutics
- Shandong Weigao Pays $850 Million to Acquire Argon Medical Devices
- Bellen of Beijing Raises $38 Million to Support CRO Operations
- Infervision Raises $18 Million to Develop Automated Scan Readers
- Wuhan's XW Labs Closes $17.5 Million B Round to Develop CNS Drugs
- Fosun Pharma Scales Back Purchase of India's Gland
- Shanghai United Imaging Healthcare Raises Record $500 Million at $5 Billion Valuation
- Spineology Raises $5 Million from Shanghai's Hermed Capital
- China Resources Invests $4.6 Million in Hangzhou's Converd
- Grid Therapeutics Closes A Round from Longview Intl. of Singapore
- Zai Lab Plans $90 Million IPO at $800 Million Valuation
- Ennovabio of Shanghai Raises $10 Million to Develop Brain Cancer Drug
- Shanghai's Harbour BioMed in $81 Million Deal for Two HanAll Biologic Drugs
- Wellem Raises $30 Million for China Pediatric Clinics
- Suzhou Basecare Raises $15.3 Million for Pre-Implantation Genetic Screening Tests
- Fosun In-Licenses Female Sexual Desire Disorder Drug in $106 Million Deal
- HitGen to Discover Lead Molecules for Takeda
- China Medical Systems Invests $8 Million in Destiny; Will Acquire Asia Rights for MRSA Candidate
- TPG Asia Acquires Majority Stake in Taiwan-Asia Clinical CRO
- Suzhou's Innovent Strikes $457 Million Deal with CAS for Immuno-Oncology Candidate
- WuXi NextCODE, a Genomics CRO, Closes $240 Million Series B Round
- Shanghai Sanyou Medical Raises $14 Million for Spinal/Trauma Implants
- SinoVision Raises $29 Million for CT Scanner Technology
- Wuxi Fortune Partners with Andarix to Develop Radiotherapeutic in China
- OrbiMed Raises $551 Million for Third Asia Healthcare Fund
- Sisram, a Fosun Pharma Device Company, Staging a $200 Million Hong Kong IPO
- Fidelity's Eight Roads Launches $250 Million China Healthcare Venture Fund
- 3SBio Acquires CDMO Business from Canada's Therapure for $290 Million
- Fosun Pharma Acquires 65% Stake In SinoMedCare for $40 Million
- Shuidi Raises $24 Million for Healthcare Crowdfunding App
- China's iPharma in $120 Million Deal for Mologen's Immunotherapy Candidate
- Akeso Biopharma of Zhongshan Closes $45 Million B Round
- CF PharmaTech of Suzhou Raises $65 Million for Inhaled Drug Products
- aTyr Pharma, a US-Hong Kong Biotech, Announces $46 Million Private Placement
- Distinct Healthcare Closes $40 Million Round for China Clinics
- Zhejiang Hisun Partners with Seattle's IDRI on Treatment for Drug-Resistant TB
- GSK Teams Up with Ali Health to Promote HPV Vaccine in China
- Columbia China Building $150 Million Hospital in Jiaxing, China
- South Korea's EDGC and China's GPBio Form Genomics Partnership
- Samsung Bioepis Forms Novel Biologics JV with Takeda Pharma
- Fosun Pharma has Plan B to Acquire India's Gland Pharma
- HitGen Forms Immunocology Collaboration with California's Aduro
- Ascletis In-Licenses China Rights to an HCV Treatment from Medivir
- Harbin Gloria, WuXi Biologics Sign $818 Million Deal for Ex-China Rights to PD-1 Candidate
- Zai Lab Files for $115 Million IPO in the US
- Antengene of Shanghai Announces a $21 Million Series A Round
- Lilly Asia Ventures Closes Fourth Fund with $450 Million
- Shanghai Ankon Raises $100 Million to Market Pill-like Endoscopy Device
- Shenzhen Royal Asset to Pay $33 Million for Fibrosis Candidates from Prometic
- Zai Lab of Shanghai Plans $150 Million IPO in the US
- Fosun and Shanghai Pharmas Competing for $700 Million Stake in US-based Arbor
- Biocept Raises $2.2 Million from Ally Bridge; Plans China Expansion
- New Horizon Raises $20 Million for Diagnostics in Qiming-Led B Round
- Shenzhen Salubris May Acquire Liver Cancer Candidate from US NIH
- Hangzhou Just Bio Raises $57 Million for Biologic Drug Development
- Shanghai Pharma Negotiating with DHL on Global Drug Distribution
- China's HitGen to Discover Lead Molecules for LEO of Denmark
- India May Reject Fosun's $1.3 Billion Acquisition of Gland Pharma
- WuXi AppTec Participates in $5.9 Million Series A for Rodeo Therapeutics
- Nanjing Frontier Acquires Rights to Rockefeller University HIV/AIDS Antibody
- Geneseeq Raises "Hundred of Millions of RMB" in C Round to Develop NGS
- Cardinal Health Plans $1.5 Billion Sale of China Drug Distribution Business
- Beijing's Symbow Closes $17 Million Funding for Surgical Navigator
- Uni-Bio Raises $18.2 Million; Partners with HeungKong Group
- iKang Forms $74 Million Partnership for New China Healthcare Clinics
- Shanghai-Israel Fund Co-Leads $9 Million Funding of Rapid Medical
- C-Bridge Closes $400 Million China Healthcare Fund
- Suzhou's PegBio Raises $20 Million from Tasly Pharma
- BGI Genomics Climbs 44% after $81 Million Shenzhen IPO
- ShangPharma Forms Drug Translation Collaboration with UCSF
- Imsight Raises $3 Million for AI Medical Image Reading Product
- Novogene Acquires China Rights to Urine-based DNA Collection Device
- Fosun Pharma to Spend $73.5 Million on Global Technology Incubator
- ChinaBio® Today Exclusive: Licensing agreement between Laekna Inc. and a Major Pharmaceutical Company
- $147 Million Wuhan Healthcare Fund Formed by Leading VC Principals
- QIAGEN (Suzhou) Closes $25 Million A Round for Precision Medicine
- Sino Biological Raises $29 Million in A Round
- BeiGene Signs Blockbuster $1.4 Billion Deal with Celgene for PD-1 Asset
- Sinobioway Raises Offer for Vaccine Maker Sinovac to $459 Million
- Zai Lab Closes $30 Million C Funding Round
- Vivace, a San Francisco Biotech, Raises $40 Million from China-US Investors
- Hong Kong's AGIC Acquires US-based Ritedose for about $700 Million
- Guangzhou Breaks Ground on $800 Million Biopharma Park
- Biological E. In-licenses Two Takeda Vaccines for India/China
- Sinovac Accepts Improved $402 Million Privatization Offer
- CSPC Pharma Signs $118.5 Million Deal for Two Molecules from University of Texas
- China's iCarbonX Invests in HealthLoop's $8.4 Million B Round
- BGI Genomic's $250 Million Shenzhen IPO Scheduled for July
- San Francisco's Sinovas Starts $75 Million China VC Fund
- Baheal to Market IBM's Watson Big Data Health Program to China Hospitals
- Shanghai ChemPartner Plans Reverse Merger with China's Quantum
- Lee's Pharm In-Licenses Asia Rights to RDS Treatment in $40 Million Deal
- Hangzhou's Venus Medtech Acquires InterValve of the US
- Sihuan Pharma Forms China Aesthetic JV with Austria's Croma-Pharma
- Athenex, a US-China Cancer Company, Stages $66 Million US IPO
- China's BeauCare Clinics Closes $29 Million B Financing
- Evasc Neurovascular Closes $7.5 Million Round Led by China Investor
- Australia's CSL Buys 80% Stake in China Blood Products Company for $352 Million
- WuXi Biologics Rises 37% in First Hong Kong Trading Session
- ShangPharma Partners with Scripps Research to Form $15 Million US Accelerator
- Qiming Invests in Boston Startup that Makes Platelets from Stem Cells
- SciClone Pharma Accepts $605 Million Offer from China Investment Consortium
- Jackson Lab Expands into China with Wenzhou Collaboration
- Italy's Chiesi to Distribute Veloxis' Anti-Organ Rejection Drug In China
- WuXi Biologics Prices Hong Kong IPO at $511 Million
- PhiSkin Raises $17 Million for China Aesthetic Clinics
- Essex Bio-Tech to Co-Develop Neurologic Drug with AC Immune
- Taiwan's OBI Pharma Acquires Cancer Drug from Threshold
- Cancer Screening Tie-up: Hong Kong's Cirina Merges With GRAIL, an Illumina Spin-Out
- InventisBio of Shanghai Raises $19 Million from OrbiMed and Lilly
- Shenzhen Institute of Biological Research Signs $440 Million Drug Development MOU with Israel's Zion Medical
- Shanghai's LYFE Capital Closes Second Fund at $420 Million
- VoxelCloud, a California-China startup, Raises $8 Million for Medical Imaging AI
- WuXi Biologics to Raise up to $513 Million in Hong Kong IPO
- Zai Lab Files to Raise $150 Million for Venture Fund
- Symic Raises $30 Million for Matrix Biology Program; Looks for China Partners
- Israel's EarlySense Finds China Partner for Remote Monitoring Device
- WuXi NextCODE in Hunt for $200 Million in Venture Capital
- Beijing's CANbridge Raises $25 Million for Immuno-Oncology Drugs
- Two China-US Life Science Investment Firms, WuXi Ventures and Frontline, Will Merge
- Athenex, a US-China Biopharma, Files for $100 Million US IPO
- Shanghai Pharma May Enter $4 Billion Bidding War for Germany's Stada
- 3SBio will Market Lilly's Recombinant Insulin in China
- Sinobioway Enters $50 Million Deal for Five BioAtla CAB Candidates
- Aslan Pharma Completes Auction Phase of $30 Million Taiwan IPO
- China's CANbridge Partners with Amoy on Diagnostic For Brain Cancer Drug
- Otsuka to Pay $865 Million For Europe and China Rights to Akebia's Anemia Treatment
- Medtronic Signs Option to Pay $28 Million for Balloon Catheter from QT Vascular
- Innovative Cellular in $14 Million Deal for China Rights to Vericel Cell Therapy Products
- Tasly Forges $22 Million Partnership with France's Pharnext
- Fosun Pharma Invests $15 Million in US Early Stage Medical Fund
- Aslan Pharma to Start Taipei Exchange IPO with Three-Day Auction
- Theraclion and Furui Medical Form JV to Market HIFU Surgical Device in China
- Maccura and Qiagen Form Next-Gen Sequencing JV in China
- Ping An Forms $1 Billion Global Investment Fund for Fin-Tec and Healthcare Startups
- WuXi NextCODE Raises $75 Million for Genomics Operations
- Epic Sciences' $40 Million D Round Led by Hermed Capital of Hong Kong
- Digital China Joins State-Owned Enterprises for Big Data Healthcare
- Cathay Fortune to Acquire Germany's Epigenomics for $186 Million
- China's BGI and Healthlink Invest and Make Deal with UK's Congenica
- Aslan Officially Announces $40 Million Taiwan IPO
- Shanghai's EpimAb Closes $25 Million A Round for Bi-Specifics
- Zai Lab Acquires China Rights to Novel Antibiotic from Paratek
- HitGen Enters Drug Discovery Collaboration with Scripps Research Institute
- Denovo Acquires Global Rights to Depression Drug Candidate
- Shaanxi Kanghui Pharma Completes $52 Million Shanghai IPO
- Aire Eye Hospital Offers $166 Million for European Ophthalmology Clinics
- Qiming's US Fund Leads $25 Million Round for Boston's ZappRx
- Suzhou Ribo Forms Broad ssRNAi Collaboration with Ionis Pharma
- Antengene Acquires East Asian Rights to Celgene Cancer Candidate
- Zhejiang POCTech Lands $14.5 Million for Glucose Monitors
- Qiang Sen International Raises $14.5 Million for Community Clinics
- Tianjin CanSino Biologics Raises $65 Million for Vaccine Development
- HitGen Signs Drug Discovery Deal with Pfizer
- BeiGene and Myriad Collaborate on Diagnostic for PARP Inhibitor
- China's Tahoe Offers $75 Million to Privatize Alliance Healthcare
- Aslan Pharma Plans $40 Million Taiwan IPO in May
- China OK's ChemChina's $43 Billion Acquisition of Switzerland's Syngenta
- Phagelux to Develop Phage-Based Skin Care Antibacterials with J&J
- China's CBMG Signs Up GE China to Develop Immunotherapy/Stem Cell Processes
- Dalian Wanda Announces $10 Billion Chengdu Hospital Park
- Beijing's Creat Pays $1.3 Billion for Biotest, a German Plasma Company
- Foresee Pharma of Taiwan Raises $16 Million to Fund Clinical Trials
- South Korea Announces $102 Million Biotech Startup Fund
- Shenzhen's HeliTec to Co-Develop Archer DX Oncology Assays in China
- Fosun Says its M&A/Operating Strategy Designed to Meet Next-Gen Business World
- China Investors Fund Australian Bionic Eye Company with $18 Million
- Shenzhen Investor Forms $23 Million China JV with Montreal's Prometic
- Qilu Pharma In-Licenses China Rights to Herceptin Biosimilar from Alteogen
- Luqa Pharma Gains China Rights to Women's Anti-Fungal
- Creat Offers $1.3 billion for German Blood Plasma Company Biotest
- Tencent Leads $200 Million Round in Haodaifu, a Mobile Healthcare App
- Innovent and Hanmi Form Global Immuno-Oncology Collaboration
- Gene Quantum (Suzhou) Raises $5.8 Million in A Round for ADC Drugs
- Kingdee Healthcare Raises $14.5 Million for Guangzhou Mobile Health App
- Hunan Zhaotai Forms New Zealand JV for Cancer Drug Development
- TaiGen Sells 9% of China JV to HEC ChangJiang for $20 Million
- Week in Review: Two Major China CROs Move Toward China Public Listings
- WuXi AppTec Plans China IPO
- ShangPharma Plans to Merge CRO/CMO Operations with Public Entity
- C-Bridge Capital and Tasly Invest $150 Million in Two China Biopharmas
- Sihuan Pharma Acquires Ambest Pharma China for $160 Million
- Haoeyou Raises $40 Million for its China-US Mobile Health App
- HitGen to Provide Merck with Drug Leads in New Collaboration
- Medical Device Maker Angiotech Acquired by China Investors
- Suzhou Ribo Lands $39 Million B Round for siRNA Portfolio
- Fosun Pharma Closes $90 Million Acquisition of Sweden's Breas Medical
- Kangtai Biological's Stock Price Rises 12-Fold Following Shenzhen IPO
- BGI Genomics Re-Files to Raise $250 Million in Shenzhen IPO
- Ally Bridge Backs $301 Million Privatization of Luoxin Pharma
- Newsummit Acquires Novel HCV Treatment from UK's MRC Technology
- Jiangsu Nhwa In-licenses China Rights to Anti-Psychotic from Zysis
- BeyondSpring Raises $54 Million Via Private Placement and IPO
- Fosun Pharma May Enter $4 Billion Bidding War for Germany's Stada
- Luqa Pharma Acquires Arista, a China Medical Aesthetics In-Licensing Company
- Frontline Bioventures Closes Second China RMB Life Science Fund
- Xynomic In-Licenses Second Oncology Drug Candidate in $60 Million Deal
- BeiGene Forms $330 Million JV for Guangzhou Biologics Manufacturing Facility
- Beijing's BOE Invests $50 Million in Cnoga, an Israeli Medical Device Company
- XW Labs of Wuhan In-licenses Mitochondria Candidates from the University of Pittsburgh
- Hangzhou's Venus Medtech Forms CV Device Partnership with Keystone Heart
- Surefire Medical Raises $12.8 Million in Funding Led by Hong Kong Fund
- OrbiMed to Raise $450 Million for Third Asia Life Science Fund
- ASLAN Collaborates with Singapore Institutes to Develop Cancer Drug
- Pharmaron Acquires US Phase I/II Clinical CRO from Shin Nippon
- Chengdu's HitGen Licenses Cancer Drug Candidates to Cancer Research UK
- Xynomic Pharma In-Licenses Global Rights to HDAC Inhibitor for Cancer
- Fudan-Zhangjiang Bio-Pharma Invests $2 Million in Adgero of the US
- Anxin Doctor, a Mobile Health App, Announces $28 Million Funding
- Hong Kong's Ally Bridge Invests in Two European Biopharmas
- BioSense Inks $68 Million Deal for Neovacs’ Autoimmune Disease Vaccine in China
- Lee's Pharm to Market Solasia's Oral Mucositis Treatment in China
- Eisai to Market Orion’s Two Parkinson’s Disease Drugs in China
- ApolloBio Inks Agreement for Inovio’s HPV Pre-cancer Immunotherapy
- HG Capital Leads $23 Million Round in Nuokangda Pharma
- Maison Capital Leads $10 Million Round in Rainbow Children’s Clinic
- Medtronic-Sequoia China Fund Leads Series B Round in Forerunner Medical
- Genecast of Beijing Raises $18 Million for Cancer DNA Diagnostics
- Fosun Co-Leads $16 Million Round in Yaoshibang, a Mobile Pharmacy App
- Shanghai's Abbisko Therapeutics Raises $28 Million for Cancer Drugs
- Dian Diagnostics In-licenses Metabolon’s Metabolomics Platform
- Shanghai's Ark Biosciences Closes A+ Funding for Anti-Virals
- Vincent Medical Strikes $3 Million Medical Device Deal with Israel's Inovyte
- Yaohua Medical Instrument Inks Agreement for Cervical Cancer Scan in China
- Nhwa Pharma Acquires China Rights to Emergency Treatment for Blood Loss
- Temasek Invests $800 Million in Google's Verily Life Sciences
- WuXi Biologics Files for $300 Million (?) Hong Kong IPO
- Suzhou Connect Biopharma Closes Early Fundings for $25 Million
- Beijing Mabworks Completes $39 Million Series B Funding
- Sanpower and CITIC to Raise $2.9 Billion for Sanpower's Healthcare M&A
- Wondfo Biotech Participates in Atlas Genetics' $35 Million Round
- WuXi AppTec Acquires HD Biosciences, a Biologics CRO
- RMX Acquires China Rights to Novel Antibiotic from LegoChem
- Tencent Leads $55 Million Investment in Indian Mobile Healthcare App
- Renhe Partners with Applied Pharma to Market Migraine Drug in China
- New Century Healthcare Raises $114 Million in Hong Kong IPO
- Yiling Pharma Invests $20 Million in Israel's HealthWatch
- Concord Medical Starts $150 Million Healthcare Fund with Partner
- Cui Yutao Pediatric Online App and Clinic Completes $20 Million C Round
- Sequoia Makes $30+ Million Investment in China Cardiac Hospital Chain
- Beijing's Bioyong Forms $38 Million IVD Collaboration with Biodesix
- China's Sanpower Acquires Dendreon for $820 Million
- Fosun Forms $95 Million China CAR-T JV with Kite Pharma
- AbbVie, GMI, WuXi NextCODE Form Alliance to Sequence 45,000 Irish Genomes
- Week in Review: iCarbonX "Ecosystem" Invests $400 Million in Seven Companies
- MabSpace and Ambrx to Collaborate on Antibody Drug Conjugates
- iCarbonX Forms Health Alliance with Seven Companies; Invests $400 Million
- Lee's Pharm In-licenses AMD Treatment from China's TOT Biopharm
- Frontier Biotech of Nanjing Announces $43 Million Funding
- Ascletis Raises $100 Million in B Round to Expand Liver Disease Portfolio
- New Century Healthcare to Stage $100 Million Hong Kong IPO
- Ascentage Closes $72 Million B Round for Oncology Drug Program
- Berry Genomics to Reverse-Merger at a $619 Million Valuation
- TopGene of Guangzhou Raises $14 Million for DNA Tests
- Shanghai's Harbour BioMed Raises $50 Million; Acquires Discovery Company
- IMAB In-licenses Asia Rights to Anti-Immunology Drug
- China-Focused Investors Acquire Angiotech, a Canadian Device Maker
- CSPC Out-Licenses US/EU Rights to Two Generics for $201 Million
- Suzhou's PegBio Forms China Diabetes Partnership with Pfizer
- China Metallurgical Invests $531 Million to Build Two Kuwait Hospitals
- Tianjin Pharma Closes a $20 Million Neuralstem Investment
- WuXi PharmaTech Invests in $7 Million A Round for Seattle's ApoGen
- China's Aier Eye Hospital Pays $84 Million for 100% Ownership of Nine-Hospital Group
- MicroTech Completes B Round for Diabetes Devices; Qiming Leads
- Mandarin Capital Pays $17 Million for Majority Stake in Italian CMO
- GrandOmics of Beijing Raises $14 Million for Third-Gen Sequencing
- BeiGene and Cancer Genetics Form Precision Medicine Collaboration
- BioAtla and Sinobioway Select Four Drug Candidates: Deal Now Worth $100+ Million
- JHL Forms $257 Million Partnership with Sanofi for Rituximab Biosimilar
- Luye Closes $269 Million Acquisition of Swiss Pharma's Patch Business
- Uni-Bio and Beijing Sun-Novo to Co-Develop Diabetes Treatments
- Beijing's Novogene Closes $75 Million B Round for Genomic Sequencing
- dMed, a Collaborative Shanghai CRO Consulting Startup, Lands $8 Million
- WI Harper and Partners to Form New US-China Early Stage VC Fund
- Innovent Biologics Raises $260 Million in D Round, Setting a Record
- Boehringer Forms Stem Cell Collaboration with China Southeast University
- eimageglobal Adds Medical Imaging to its China Online Healthcare Platform
- Shenzhen Hepalink Invests $36.5 Million in Kymab's C Round
- WuXi Biologics Signs Manufacturing Partnership MOU with Prima Biomed
- Elanix and MEStar Sign LOI for China Drug Marketing JV
- Beijing's BeiGene Raises $200 Million in a Secondary Offering
- Beijing Tinavi Medical Gains China Rights to Spineway's Spinal Devices
- Taikang Buys 26% of China Hospital Operator Harmonicare for $169 Million
- Asymchem Labs, a Tianjin CMO, Raises $125 Million in Shenzhen IPO
- Athenex Teams Up with Lilly for Two-Drug Gastric Cancer Trial
- Omixon and TBG Team Up to Provide HLA Transplant Testing in China
- BeyondSpring, a US-China Pharma, Files for $100 Million IPO
- SciClone Receives $570 Million Acquisition Offer from Ally Bridge Affiliates
- Uni-Bio and Luqa Pharma Partner to Market Dermatology Products in China
- Samsung Biologics Raises $2 Billion in Korean IPO
- BeiGene Files to Raise $150 Million in Secondary Offering
- Korea's Genexine Forms Clinical Research Collaboration with Merck/MSD
- Eddingpharm to Distribute Two Lilly Antibiotics in China
- Qiming Raises $222 Million in China RMB Venture Fund
- Eddingpharm Acquires China Rights to Insomnia Drug from Australia's Suda
- Yisheng Bio to Collaborate with Scripps Institute on AIDS Vaccine
- Betta Pharma Completes $106 Million IPO in Shenzhen
- Fosun Pharma Acquires Cancer Drug Candidate from US-based Kolltan
- BGI's Shenzhen IPO Rejected by China Regulators
- Xbrane Signs Term Sheet for China Distribution of Cancer Drug
- Medbanks Joins Up with IMS for China Oncology Big Data Effort
- TaiGen Forms $102 Million Hepatitis C JV with YiChang HEC Pharma
- Decheng Leads $12 Million Series A in Diagnostics Newco Cirina
- China Resources Pharma Starts Trading Following $1.8 Billion IPO
- WuXi PharmaTech Invests in Unity Biotech's $116 Million Series B
- Kanghua Healthcare to Raise $154 Million in Hong Kong IPO
- Pluristem to Raise $30 Million from China's Innovative Medical
- Athenex to Market Five Oncology Products from Beijing Sciecure in US
- Luye Medical Offers $91 Million for Australian Hospital Chain
- Tamasek Invests $250 Million in Columbia Pacific for China Hospitals
- Zai Lab Acquires Global Rights to Two GSK Anti-Inflammatory Assets
- Quark and China's GF Securities Form $500 Million Life Science Fund
- Veritas Raises $30 Million from China-Connected Investors for Genetic Tests
- FMD K&L Joins with iMEDGlobal in International CRO Merger
- Bloomberg: Samsung and WuXi Plan IPOs for their Biologic CMOs
- TransThera Bioscience, a Nanjing Startup, Raises $10 Million from Morningside
- ASLAN Forms Singapore Partnership to Develop mAb Fragment Drugs
- China Resources Pharma to Start Taking Orders for $2 Billion Hong Kong IPO
- Shanghai's EpimAb Forms Bi-Specific mAb Partnership with Kymab
- 3SBio Pays $100 Million to Market Two AstraZeneca Diabetes Drugs in China
- Singapore's New Silkroutes Group Forms Healthcare PE Joint Venture
- Celltrion and Teva Sign $160 Million Pact to Market Biosimilars in US
- Enable Injections Raises $30 Million Led by Hong Kong VC Fund
- LA's Emmaus Life Science Raises $6 Million from Korean Investors
- Chengdu's HitGen Collaborates with Janssen on Oncology and Metabolics Discovery
- Ramsay Sime Darby in Talks for $500 Million China Hospital JV
- Fosun Forms $100 Million China Medical Device JV with Intuitive Surgical
- Zai Lab Acquires China Rights to TESARO's PARP Inhibitor
- Hanmi Out-licenses pan-RAF Inhibitor to Genentech for $920 Million
- Huanzhong Biotech to Market Concepta's Fertility Product in China
- ReedCoor Raises $23 Million from China Investors for Novel NGS Technology
- Huapont In-Licenses China Rights to Histogen's Stem Cell Hair Growth Injections
- China BioPharma Capital Invests in Quantapore, a Sequencing Device Maker
- Neusoft and Infinity Announce a $250 Million China-Israel Investment Fund
- MicuRx Raises $55 Million for China-US Development of Novel Antibiotic
- FountainVest Raises $2.1 Billion for Third China PE Fund
- Shenzhen Nuokang Raises $10 Million for Continuous Blood Pressure Device
- Jacobson Pharma, a Hong Kong Generic Drugmaker, Stages $85 Million IPO
- PharmaLegacy of Shanghai Forms Alliance with Normalline
- TenNor of Suzhou Raises $25 Million for Dual-Action Antibiotics
- Golden Meditech and MD Anderson Form $20 Million Stem Cell Company
- Luxin Venture Capital Contributes to Boston's Intarcia Therapeutics $215 Million Round
- LIH of Beijing Raises Capital for Rehab Facilities from Qiming
- Aspen Pharma Acquires China Rights to GSK Thrombosis, Anesthesia Products
- China's iCarbonX Buys Israeli Image Recognition Company
- Hisun Pharma Signs Up GeneriCo to Market its Products in US
- Tianjin Pharma Invests $20 Million in Neuralstem of the US
- SciClone Invests $3 Million in Soligenix; Finalizes China Oral Mucositis Drug In-licensing
- China Resources Pharma OK'd to Raise $2 Billion in Hong Kong IPO
- WuXi AppTec Gains China Rights to AutoGenomics' Molecular Diagnostic Platform
- China-Owned iHealth Pays $106 Million for eDevice of France
- China's PharmaLegacy Forms Musculoskeletal Alliance with BioVinc
- Investor Group Says China's Sinovac Worth 75% More than Management's Offer
- ASLAN Gains Global Rights to Immuno-Oncology Candidate from A*STAR
- Fosun Intl. Will Use Healthcare Assets to Create Liquidity
- Beijing's Berry Genomics to Be Acquired by China Auto Parts Company
- Health2Sync of Taiwan Raises $3 Million for Mobile Diabetes Monitoring
- Beijing Allcure Raises $27 Million to Standardize Radiation Treatment
- CBT Pharma, a CrownBio Subsidiary, Raises $9.75 Million for Oncology Drug Trials
- BGI Leads $30 Million Funding in Beijing Gene+ Technology
- Shanghai Kyee Technology Raises $47 Million for Mobile Health Apps
- BioLineRx of Israel and I-Bridge Capital Form China JV for Drug In-licensing
- Shanghai Mab-Venture Raises $35 Million in Funding Led by Prosperico Venture
- Movida Pharma Acquires China Rights to Cancer Drug from Cloaked Therapeutics
- Lee's Pharm and Shenogen to Test Cancer Candidates in Joint Regimen
- Luye Medical Commits $300 Million to Chongqing Hospital Venture
- Singlera Genomics Raises $20 Million in Series A Round Led by Lilly Asia
- Liaison Interactive Invests $20 Million in Beijing's Dehaier Medical
- Berry Genomics And BioNano Genomics Partner for Next-Gen Genome Mapping
- China Developers to Build $1.5 Billion Life Science Park in South San Francisco
- Huapont Life Sciences Invests $6 Million in San Diego's Histogen
- China Sun Pharma Invests in Glucovation, a Glucose Monitoring Company
- Hot China IPO Market Creates New Life Science Billionaire
- China's Maxhealth Invests $1.3 Million in Rex Bionics of the UK
- Zhejiang Hisun Pharma Strikes Deal for China Rights to Celsion Immunotherapy
- ASLAN Pharma says Bristol-Myers Squibb will Reacquire Cancer Drug
- Samsung BioLogics Plans $2.7 Billion IPO in South Korea
- Bio-Techne Acquires Advanced Cell Diagnostics in $325 Million Deal
- ScinoPharm Taiwan and CVie Collaborate on Heart Failure Drug
- Neusoft Xikang Raises $64 Million for Online Healthcare
- Ambrx, a US-China Biotech, Raises $45 Million for Clinical Trials
- Ossen Innovation Proposes Acquisition of China Glucose Monitoring Device Company
- Chengdu Olymax In-Licenses China Rights to Australian Strep Vaccine Candidate
- Sorrento to Form CAR/Killer Cell JV with Korea's CHA Biotech
- Israel's Ornim Raises $20 Million in C Round Led by China Investor
- Hutchison China MediTech Adds $50 Million to AstraZeneca Partnership
- Ligand Out-Licenses China Rights for Three Liver Products to Nucorion
- Shangdong Luoxin Pays $120 Million for China Rights to Lung Cancer Drug
- CrownBio is One of Several Life Science Companies Planning Taiwan IPO
- Frontage Labs and Jiuzhou Pharma Form JV for CDMO of APIs
- China's Yueda Forms China Renal Care Clinic JV with Diaverum
- Fosun Pharma to Pay $1.3 Billion for India's Gland Pharma in Historic Deal
- CR Sanjiu Pharma Acquires Shenghuo Pharma for $280 Million
- Luye Pharma to Acquire Swiss Patch Drug Assets for $269 Million
- Jilin Zixin Pharma to Pay $42 Million for Majority Stake in US Genome Mapping Company
- China Resources Buys Majority Stake in GenesisCare, a $1.3 Billion Australian Healthcare Chain
- Hisun Pharma In-licenses China Rights to mAb Brain Cancer Candidate
- Genexine of South Korea Raises $70 Million for Novel Drug Portfolio
- DiaMedica Raises $4 Million from Fosun Pharma and SK Group
- China Bridge Invests $45 Million in iCarbonX; Plans $1.5 Billion Precision Medicine Fund
- Uni-Bio Signs Up CR Zizhu to Market Recombinant Eye Treatment in China
- Fangyuan Pharma Plans Trials of New-to-China Antibiotic
- Management Offers $228 Million to Privatize Concord Medical
- Huapont Invests $3 Million in Angionetics for Novel CV Treatment
- Medbanks Raises $30 Million for China Oncology Database
- Ali Health Buys China Online Drug Seller for $2.5 Million
- Dehaier Medical Partners with China Sciences to Distribute Sleep Apnea Products
- China's CStone Pharma Raises $150 Million in Series A for Novel Drug Program
- ASLAN Pharma Raises $23 Million In Pre-IPO Round
- Allergan Has $20 Billion for Pharma Deals; China Deals Possible
- Yabao Pharma Acquires China Rights to Albumin Product from LFB Bio of France
- Zhejiang Hisun Licenses Novel Flu Treatment from Fujifilm
- Jiangsu Egens Biotech Gains Rights to Hepatitis C Diagnostic from Israel's BATM
- China Resources Pharma Files for $1 Billion IPO in Hong Kong
- Beijing's CoSci Med-Tech Leads $17 Million Investment in JDP Therapeutics
- Neusoft Closes Investment from Everbright for China Healthcare
- Jiangsu Hengrui Leads $100 Million Investment in US Spin-Off
- Spring Rain Mobile Healthcare App Raises $183 Million, Plans China IPO
- Sinopharm Affiliate Pays $6.5 Million Milestone to Oramed
- Apollo Hospitals of India Signs MOU for Hospital in China's Hainan Province
- Chi-Med Earns $10 Million Milestone from AstraZeneca in Lung Cancer Trial
- China Life Insurance Restarts Takeover Battle for iKang
- Shenzhen Hepalink Invests $60 Million in Latest TPG Biotech Fund
- Gan & Lee Plans $226 Million China IPO
- Response Biomedical of Canada Taken Private by OrbiMed and China IVD Maker
- Vivo Capital Closes $100 Million Fund for Early-Stage US-China Healthcare Companies
- Innovent Expands Adimab Partnership; Second mAb Partnership in a Week
- Yunfeng Capital/Alibaba Wins $1.6 Billion Takeover Battle for iKang Healthcare
- Sorrento Therapeutics Closes $150 Million Financing, Led by Ally Bridge
- 3SBio and Sorrento Therapeutics Form $10 Million China JV for CAR-T Drugs
- Innovent Forms $120 Million Bispecifics Partnership with EpimAb of Shanghai
- Yunfeng Capital Bids $20-$25/ADS for China's iKang Healthcare Group
- Applied StemCell Closes $19 Million Series D for Gene Editing Pipeline
- Sipai Wangluo Raises "Tens of Millions" of Dollars for China Oncology Big Data
- AccuraGen, a US-China Cancer Diagnostics Company, Raises $40 Million
- Guangzhou Link Health in $85 Million Deal for Cancer Drug from 4SC
- PharmaBlock, a Nanjing CRO/CMO, to List on China's Third Board
- Shanghai's HighLight Capital Raising $229 Million for Healthcare Fund
- Hengrui Medicine Signs MOU for China Rights to Oncolytic Virus Drug
- Ping An's China Mobile Health Site Raises $500 Million at $3 Billion Valuation
- WI Harper Closes $175 Million Venture Fund for US-Asia Investments
- Fosun Pharma in $1-$1.5 Billion Bidding War for India's Gland Pharma
- BGI Joins with Clearbridge BioMedics to Develop Liquid Biopsy in China
- Eu Yan Sang, a TCM Maker/Retailer, Receives $196 Million Buyout Offer
- SciClone Pays $20 Million to AbilityPharma for China Rights to Cancer Drug
- ACT Genomics Raises $12.5 Million for Genomic Oncology Testing
- Warburg Pincus Invests in China's UIB, a Hospital Chain
- Harmony Forms Inhaled Insulin JV in China with Dongbao Pharma
- HEC Changjiang Pharma Out-licenses US Rights for Insulin Drug to Lannett
- Ideaya Biosciences Raises $46 Million; WuXi Ventures Participates
- Sirnaomics Raises $10 Million in Series B Funding Led by Hong Kong Firm
- Jiangsu Hengrui Signs Research Deal with MD Anderson Cancer Center
- China's Founder Securities Raises $300 Million for Asia Healthcare with Korean Partner
- CSPC Pharma Out-Licenses Complex Oncology Drug for $108 Million
- Sinocare Pays $200 Million for Second US Diabetes Monitoring Device Company
- Dehaier Medical Announces $20 Million Investment from Hangzhou Liaison
- Beike Biotech of Shenzhen Unveils Cancer Immunotherapy Program
- Collagen Solutions Forms JV to Market Medical Grade Collagen in China
- Nihon Trim of Japan Forms JV for China Hospitals/Dialysis Clinics
- Jiangsu Hengui Forms Cancer Collaboration with Albert Einstein College
- Ascentage Collaborates with UNITY on Treatments to Clear Senescent Cells
- Immune Therapeutics Signs LOI for China CAR-T Technology
- iCarbonX Raises $155 Million for Big Data Healthcare; Company Valued at $1 Billion
- Hua Medicine Lands $50 Million in a Series C Funding
- Yabao Partners with Salus Pharma to Develop Difficult-to-Make Generics
- China's Venus Medtech Buys Rights to Next-Gen Cardiac Valve from Transcatheter of Germany
- Beijing Strong Biotech Grants Technology License to Abbott
- BVCF Raising $400 Million for China Life Science Fund
- DiaCarta to Launch Pangaea Liquid Biopsy Test in the US and China
- WuXi AppTec Buys Germany's Crelux, a Protein Drug CRO
- Shenzhen's BGI Has Revamped Plans for $600 Million China IPO
- Phoenix Healthcare Acquires CR Healthcare's Hospitals for $480 Million
- NMT Pharma of Singapore In-licenses Cancer Drug from US's CAO Pharma
- Shanghai Institut Pasteur-CAS Sets Up Tech Transfer Center with MRC Technology
- WuXi AppTec Forms China Cancer Immunotherapy JV with Juno Therapeutics
- China's Essex Bio Announces $3.5 Million mAb Partnership with Abpro
- Sorrento Lands $150 Million in Private Placement, Led by Ally Bridge
- BioChain Acquires China Rights to Epigenomics' Lung Cancer IVD
- Ally Bridge Participates in Funding of Beijing's LinkDoc Technology
- Alibaba Ends $2.5 Billion Plan to Move Online Pharmacy into Ali Health
- CITIC PE Fund Invests In Beijing Cancer Hospital
- Luye Bids to Acquire France's Ethypharm in Deal Worth up to $900 Million
- Zhongmei Healthcare Plans $150 Million IPO in Hong Kong
- Fujian Thai Hot Acquires Majority Stake in Alliance Healthcare for $103 Million
- Wuhan Humanwell Acquires US Generic Drugmaker for $550 Million
- AliHealth Invests $35 Million for Stake in Remote Medical Imaging Company
- Affymetrix Nixes Origin's Higher China-Backed Takeover Bid
- Facing Two Privatization Offers, Sinovac Adopts Poison Pill
- Yantai Dongcheng Acquires China Ops of Global Medical Solutions for $70 Million
- Venus Medtech of Hangzhou Raises $37 Million from Goldman Sachs
- Lilly Asia Ventures Invests in Millin, a China Hemodialysis Company
- Sequoia Capital China Expects to Raise $1.5 Billion in Two Investment Funds
- China-connected Origin Technologies Bids $1.6 Billion for Affymetrix
- Shenzhen Hepalink Forms $9 Million Cancer JV with Canada's Quest PharmaTech
- China's Ally Bridge Group Participates in Tesaro's $155 Million Private Placement
- Shanghai Pharma Raises $21 Million for Online Pharmacy
- CANbridge of Beijing Pays $134 Million for Rights to AVEO's Cancer Drug
- Human Health, a Hong Kong Clinic Operator, Plans $13 Million IPO
- SK Telecom to Bring Cleveland HeartLab's CV Tests to China
- Bain Capital Buys Controlling Interest in China Hospital Chain for $150 Million
- Chi-Med Completes US Offering at Lowered Price of $13.50/ADS
- Prenetics of Hong Kong Raises $10 Million for Pharmacogenomics Test
- Sinopharm to Distribute Avita Wound Healing Product in China
- China's Hasico Secures China Rights to Microbion's Chronic Wound Product
- Meinian Onehealth Buys Rival China Health Testing Chain for $415 Million
- China Investors Add to Argos Holdings in Latest $60 Million Funding
- Chi-Med to Complete $100 Million US IPO Next Week
- 3DMed and Alphamab Start Joint Development of China PD-L1 Cancer Drug
- Yuhan Forms $10 Million Cancer Immune Checkpoint JV with Sorrento Therapeutics
- Fosun Pharma to Raise $471 Million through Bond Sale
- WuXi AppTec Raises $1.5 Billion From Ping An for China Healthcare
- Gloria Pharma Invests $40 Million in Proteus Digital Health; Gains Option for China JV
- China Medical System Buys Two AstraZeneca Drugs for $500 Million
- WuXi PharmaTech to IPO Biologics Unit in Hong Kong
- Impact Therapeutics of Nanjing Closes $10 Million Funding
- Wanbang Pays $39 Million for China Rights to Renal Disease Treatments
- Korea's Genexine Licenses China Rights for EPO Drug to Fosun Pharma
- Athenex, a US-China Pharma, Lands $225 Million Investment
- Chi-Med Files New Prospectus for $100 Million US IPO
- China CRO Pharmaron Buys Quotient Bioresearch of the UK
- Xizang Haisco Pharma Invests in Regentis, an Israeli Device Maker
- China Resources Pharma Plans $1 Billion Hong Kong IPO
- Cellular Biomedicine Lands $43 Million from Wuhan Dangdai
- Phagelux Raises Capital from Fosun Pharma
- Sinovac Receives Higher Privatization Offer
- BeiGene Prices US IPO at $24; Rises 19% in First Day
- Sinovac Biotech Receives $345 Million Go-Private Offer
- Agena BioScience Forms IVD Collaboration with DaRui Biotech
- Fujian Thai Hot Seeks Control of Alliance Healthcare for $102.5 Million
- Adagene of Suzhou Raises $28 Million in Series B Funding
- Qiming to Close Fifth US Dollar Venture Fund with $650 Million
- Joincare Pharma Invests $30 Million in China Mobile Medical App
- Shanghai's CARsgen Raises $30 Million for CAR-T Program
- Gedeon Richter Buys Out China JV Partner
- WuXi Healthcare Ventures Makes Two US Biopharma Investments
- iCarbonX Raises $106 Million in Series A for Big Health Data
- BeiGene Plans $127 Million US IPO in February
- CASI Pharma Closes $10.3 Million Financing
- Singapore Developer Plans 20-40 China Healthcare Hubs
- Pfizer Buys Treerly, a China OTC Nutritional Company
- 20/20 Gene Systems Raises $4.5 Million in Funding Led by Ping An
- Eye Tech Care of France Reports $27 Million Funding from China
- Yabao Pharma Forms Generics Pact with Sciecure of the US
- Lee's Pharma In-Licenses Ear Infection Treatment from Salvat for China
- Luqa Acquires China Rights to Next-Gen Dermal Filler
- Chengdu's HitGen to Collaborate with Global Blood Therapeutics
- BioAtla, a US-China Biotech, Announces $45 Million Capital Funding
- Zai Lab Raises $100+ Million in a Series B Funding
- China's Nuance Biotech Options Two Cancer Treatments from Celleron
- Simcere to Stage $1 Billion Hong Kong IPO
- J&J In-Licenses Immune Adjuvant from Sino Biopharma
- ChemPartner Adds Peptide Services and Invests in Peptide Startup
- Jiangsu Hansoh Pharma Now Said to Plan $3 Billion IPO
- ASLAN Acquires Rights to Cancer Indications for ASLAN003
- BioAtla to Book $70 Million from Beijing Sinobioway Collaboration
- Wanda Group Invests $2.3 Billion to Build Three China Hospitals
- Taipei Medical University In-Licenses Cancer Drug from US Biotech
- Sagent Pharma to Sell China Subsidiary at $50 Million Loss
- Chongqing Fuan Acquires Yantai Justaware Pharma for $231 Million
- GenScript Stages $68 Million IPO in Hong Kong
- Furen Pharma Pays $1.2 Billion to Acquire Kaifeng Pharma
- Shanghai Kaibao Pays $20 Million for 20% Stake in Shanghai Yizhong Biotech
- Sihuan and Japan's RaQualia to Collaborate on Analgesic Drugs
- Fosun Pharma Plans Hong Kong IPO for IVD Subsidiary
- Shanghai Kehua Acquires Italian IVD Maker in $31.5 Million Deal
- Easton Pharma of Chengdu Partners with Germany's XL-protein
- Novogene of Beijing Forms Diagnostic Partnership with Illumina
- AstraZeneca to Invest $800 Million in China; May Buy WuXi AppTech's Biologics Facility for $100 Million
- WuXi Healthcare Closes Second Venture Fund with $290 Million
- Meinian Ups Bid for Rival iKang Healthcare to $23.50/ADS
- Yisheng Bio and US Army Institute to Collaborate on Ebola Vaccine
- WuXi Leads $30 Million Funding for AltheaDx of San Diego
- Pharmaron, a China-US CRO, Raises $280 Million in Venture Capital
- Jiangsu Hansoh Pharma to Raise $1.5 Billion in Hong Kong IPO
- WuXi PharmaTech Completes $3.3 Billion Privatization
- Luye Medical Buys Australian Hospital Chain for $688 Million
- BioAtla of San Diego and Beijing Forms $1 Billion Collaboration with Pfizer
- ASLAN Pharma of Singapore Announces $34 Million C Funding
- Luqa Pharma In-Licenses China Rights to Vitiligo Treatment
- China's iPharma in $120 Million Deal for Mologen's Immunotherapy Candidate
- Frontline and Sinopharm to Invest in China Life Science Together
- Shuwen to Market Diagnostic in China for Germany's BioNTech
- Eisai Pays $78 Million to Acquire Small China Generic Drugmaker
- Ascletis Raises $20 Million from Goldman Sachs: Exclusive Interview
- Tigermed Expands: Buys Korean CRO and Builds China Central Lab
- 3SBio Acquires Control of CP Guojian in $213 Million Deal
- Sinopharm Affiliate Pays $50 Million for Oramed's Oral Insulin Product
- Meinian Onehealth Tops Management's Offer for iKang Healthcare
- Uni-Bio Science Acquires Rights to Jiangsu Hansoh's Diabetes Drug
- Lee's Pharma to Market Solasia's Anti-Nausea Patch in China
- Shenzhen Hepalink Invests $13 Million in Canada's OncoQuest
- ZAI Lab Acquires China Rights to Hanmi Lung Cancer Drug
- Nantong Jinghua In-licenses Two Cancer mAbs for $50 Million
- Tianjin Tasly Starts $784 Million China Healthcare Fund
- Lee's Pharma Gains China Rights to Liver Cancer Drug from Tragara
- LYFE Capital Closes $298 Million China Healthcare Fund
- Medtronic and Sequoia Start $60 Million China Healthcare Fund
- CRO BioDuro to Merge with Formex, a US CMO
- LEO Pharma Pays $727 Million for Astellas' Global Dermatology Products
- WuXi and Lilly Collaborate on China Development of Cardiovascular Drug
- Hanmi Out-licenses Diabetes Drug to Janssen for $960 Million
- ASLAN and Hyundai Partner on Cancer Drug in Korea
- ACEA Bioscience Closes $30 Million VC Round from China Investors
- Sanofi In-Licenses Three Diabetes Drugs from Korea's Hanmi in $4.2 Billion Deal
- Bloomage Raises $85 Million for Aesthetic Products in China
- China's Tarrex and Aranda of Finland Partner on Prostate Cancer Drug
- Sinocare Pays $273 Million for Nipro's US Diabetes Monitoring Business
- Tianjin CanSino Biotech Raises $30 Million in Venture Capital
- MabSpace of Suzhou Raises $15 Million from Lilly
- Wuxi and Gilead Partner on Dedicated Shanghai Lab for Gilead
- Cipla Sells Stake in China's Biomab for $25 Million
- CITIC in Talks to Acquire Singapore's Biosensors Intl.
- Shandong Luoxin Acquires China Rights to Korean Gastritis Drug
- Xizang Haisco Pharma Invests $10 Million in Endospan of Israel
- WuXi Healthcare Invests in US Genomics Testmaker 23andMe
- ZY Investments and Sundiro Form $473 Million China Healthcare PE Fund
- Yabao Pharma to Develop Second Ely Lilly Diabetes Candidate in China
- BeiGene of Beijiing Files for $100 Million IPO in the US
- Korea's Genexine Out-licenses Three Molecules to Tasly in $100 Million Deal
- Hutchison China MediTech Files for $100 Million IPO in US
- Athenex to Build Two Manufacturing Plants in Chongqing
- Shanghai’s Phagelux Acquires Key Assets of Scithera
- 3SBio In-licenses Cancer Drug from Alteogen
- Helius Enters Strategic Alliance to Commercialize Neuro Stimulator in China
- Astute Signs Distribution Agreement with Fosun with $20 Million Investment
- Innovent/Lilly Expand Collaboration to $1B, Raising Total China Deals to $3.25B This Year
- QuantiHealth Raises $3.2 Million in Pre-A Financing
- TauRx Completes $135 Million Financing for Alzheimer Drug
- CliniCloud Raises $5 million from China's Tencent and Ping An
- OBI Pharma Signs Exclusive Agreement with MSD for Antibiotic Drug
- Curetis Partners with Acumen Research Laboratories
- Elcelyx Secures $40 Million for Diabetes Treatment
- Amoy Enters Diagnostic Collaboration with Illumina
- Tunitas Raises $10 Million from Two China Investors
- Burning Rock Forms Diagnostic Partnership with Illumina
- Genovate to Build $55 Million Insulin Facility in Changzhou
- CARsgen Signs Partnership Agreement with Shanghai Cancer Institute
- Hongene Biotechnology Signs License Agreement with Marina Biotech
- Beijing Clear Biotech to Distribute Curetis Diagnostic Device in China
- Genovate to Build $55 Million Insulin Facility in Changzhou
- GuaHao Raises $394 Million for WeDoctor Healthcare Portal
- Ativa Raises $15 Million from China Investors for Micro Blood Test Device
- Lee's Pharm In-licenses Novel Anticoagulant from Armetheon of the US
- Zai Lab Acquires Global Rights to Inflammatory Disease Drug from UCB
- CASI Pharma Raises $25 Million in Secondary Offering
- BGI and Huawei Collaborate to Build Big Data Storage for Genomics
- Tendcare Medical Raises $40 Million to Expand China Hospital Portfolio
- ShangPharma to Build $60 Million Biologics Campus
- Crystal Pharmatech, a China-US CRO, Raises $10 Million from Renren
- Yabao Gains China Rights to Stroke Treatment from Primary Peptides
- DaVita Healthcare Forms Dialysis JV in China
- Mindray Management Group Lowers Privatization Offer to $27 per ADS
- Yabao Pharma to Support Cancer Drug Research at Australian University
- Hengrui Medicine Licenses Cancer Drug to Incyte in $795 Million Deal
- Ascletis Pharma Raises $35 Million; Seeks More In-Licensings
- iKang Receives $1.1 Billion Go-Private Offer
- Celyad and Medisun Alter Terms of China Stem Cell Deal
- Shanghai Pharma to Form $470 Million China Healthcare VC Fund
- Shanghai Kehua Signs MOU to Acquire Technogenetics of Italy
- Harbin Gloria Pharma to Pay $27.5 Million for Stake in Zhenyang Hospital
- Decheng-Backed Cellular Research is Bought by Becton Dickinson
- ECM Medical Gains China Rights to Novel Spine Fusion Device
- Shenzhen Hepalink Pays $206 Million for Cytovance, a US CMO
- DynoSense Closes $9.4 Million from China-US Investors for Remote Health Monitoring
- Jiangxi Boya Bio-Pharma Makes Two Acquisitions: Will Raise $78 Million
- Lee's Pharm Signs China Deal for Two BioQuiddity Infusion Products
- Eddingpharm In-licenses Second CV Drug from Cardiome
- China's Anpac Lands Series A Investment for Cancer Screening Test
- Janssen Ends Partnership with China's Hutchison MediPharma
- Asian American Medical Plans $57 Million Medical Center in Zhuhai, China
- Burning Rock of Guangzhou Raises $23 Million for Diagnostic Products
- WuXi Accepts $3.3 Billion Go-Private Offer
- Roche Pays $425 Million for GeneWEAVE, a Decheng Portfolio Company
- Ascentage Pharma Lands $15.5 Million in Round A Financing
- FortuneRock to List on China's Third Board
- Sanjiu Medical Buys Zhongyi Pharma for $209 Million
- Luye Pharma Invests in Singapore's Vela Diagnostics
- Xinjiekou Department Store Offers $966 Million for China Cord Blood
- Cold Genesys Raises $10 Million from Ally Bridge and WI Harper
- Mevion Medical's $200 Million Funding Led by China Investors; Will Form China JV
- ResMed Buys Curative, a China Sleep Devices Company
- Sorrento In-Licenses Four China Biobetter/Biosimilars
- Hengrui Medicine In-Licenses China Rights to Nausea/Vomiting Drug
- ZAI Lab Obtains Global Rights to Sanofi NSCLC Drug Candidate
- China's Bloomage Forms Botox JV with Medytox of South Korea
- Boehringer Ingelheim Pays $730 Million for Hanmi Cancer Drug
- Shuwen Signs Companion Diagnostic Deal with Hengrui Medicine
- Yabao Pharma Starts Preclinical Studies on Sepsis Treatment
- Mitsui's Restructured Investment in Chi-Med Worth $84 Million
- 3SBio Pays $85 Million to Acquire Zhejiang Washeng Pharma
- Ally Bridge Starts Hedge Fund for Listed China Healthcare Companies
- Hepalink Acquires China Rights to Resverlogix CV Drug for $27.4 Million
- Shanghai's Phagelux Buys Agricultural Phage Company, OmniLytics
- Frontage Labs, a US-China CRO, Acquires Biostatistics Firm BDM
- CANbridge Acquires China Rights to Apogenix Brain Cancer Treatment
- Phoenix Buys Stake in UMP Healthcare; Will Set Up Beijing Clinic JV
- CORRECTION: WuXi Healthcare Ventures Files for $250 Million China-US Fund
- Zhongzhi Pharma Completes $73 Million Hong Kong IPO
- UPDATED: WuXi Healthcare Ventures Files for $250 Million China-US Fund
- WuXi PharmaTech Raises $80 Million for Manufacturing Subsidiary
- Australia's Benitec Biopharma Buys Out JV Partner, Biomics of China
- Cathay Capital, a China-US-French PE Firm, Invests in Cenexi
- Oramed Pharma Signs $50 Million Diabetes Deal with Sinopharm
- Mindray Medical Buys Rest of Dragonbio Surgical Implant for $73 Million
- Wuzhou Zhongheng Invests $52 Million in Israel's Oramed Pharma
- Provectus Signs LOI for Cancer Drug with Boehringer Ingelheim China
- Israel's Hadasit Bio Receives $2 Million from China Investors
- Materialise Brings 3D Printing to Plan CV Surgery at Fuwai Hospital
- 3SBio Acquires Global Rights to Apexigen RA Drug
- DelMar Pharma to Raise $8 Million in Private Placement
- Livzon Pharma Leads $25.5 Million Funding of Cynvenio Biosystems
- J&J and WuXi AppTec Announce China Life Science Incubator
- BioAtla of San Diego and Beijing Raises $30 Million from China Investors
- Beijing's Annoroad Collaborates with Illumina on Prenatal Diagnostic
- The Pharma Partners Forms Suzhou MedTech Group; Will Raise $30 Million
- 3SBio Climbs 5% in First Trading Day In Hong Kong
- Wandong Medical Raises $147 Million; Alibaba Participates
- Luqa Pharma Announces $15 Million Fundraising
- Huaren Pharma Acquires Hongta Innovation Investment for $550 Million
- Shanghai's Phagelux Raises $10 Million for Anti-Bacterial Phages
- WuXi AppTec Partners with China Academic Genomic Collaboration
- Mindray Medical Receives $3.5 Billion Go-Private Offer
- Luye Pharma Stops $1 Billion Acquisition of Beijing Jialin
- Faes Farma of Spain Forms China JV with Eddingpharm
- 3SBio Sets Target of $712 Million for Hong Kong IPO
- SciClone Pays $6 Million for China Rights to Theravance's Antibiotic
- Youbo Pharma Acquired by Jiuzhitang in $1 Billion Reverse Takeover
- Ambrx of San Diego Acquired by Fosun Pharma, WuXi PharmaTech and Others
- GenorBio Enlists MabSpace to Discover mAbs
- China Medical Systems In-Licenses Respiratory Distress Drug from Faron
- Livzon Pharma to Form China JV with Cynvenio
- MabSpace and Jiangsu Hengrui Collaborate on mAb Development
- Ramsay Sime Darby Forms $135 Million JV with Chengdu Hospital Operator
- BeiGene Raises $97 Million to Develop Cancer Drug Portfolio
- China's Hutchison MediPharma Receives $18 Million in Payments from Lilly
- JHL Biotech Raises $45.6 Million in C Round
- Harbin Gloria to Commercialize Constipation Drug in China
- Provectus and Sinopharm Facing MOU Deadline for Partnership
- FibroGen Receives Milestone from US/China Partner AstraZeneca
- Guizhou Xinbang Pharma Buys Hangzhou Chinese Peptide for $323 Million
- Concord Medical and MD Anderson Collaborate on Cancer Care for China
- BGI to Offer Qiagen Bioinformatics Program
- Week in Review: WuXi PharmaTech Announces $3.3 Billion Go-Private Offer
- WuXi PharmaTech Receives $3.2 Billion Privatization Offer
- Scanadu Raises $35 Million from China Investors for Mobile Diagnostic Device
- China Cord Blood Receives $512 Million Take-Private Offer
- Shenzhen Hepalink Pharma Enters $441 Million Deal for Resverlogix CV Drug
- Alibaba and Partners will Build Cloud Hospital in China
- WuXi PharmaTech and DNAnexus Form Genomic Cloud Partnership; WuXi Invests $15 Million
- Kunming Biomed to Offer its Non-Human Primates in US through BTS Research
- Shanghai Haohai Biological to Stage $305 Million IPO in Hong Kong
- Fosun Pharma Completes $940 Million Private Placement
- Menarini Pays $100 Million for China Rights to 4SC Cancer Drug
- Guided Therapeutics Books Investment, Signs MOU with Potential China Distributor
- Chongqing Lummy Pharma In-licenses China Rights to Cancer Immunotherapy
- Boston Scientific Invests in Suzhou's Frankenman Medical Equipment
- TVM Capital and Chongqing Lummy Pharma Form China In-Licensing Fund
- aTyr Pharma of San Diego and Hong Kong Plans $86 Million IPO
- Ark Biosciences of Shanghai Completes Series A Funding
- Resverlogix Granted Approval of Two China Patents for Cardiovascular Drug
- Hong Kong's Rock-One Forms Medical Device JV with BioLight of Israel
- WuXi PharmaTech to List Shares in CMO Subsidiary on China's Third Board
- Japan's Solasia Pharma Acquires China Rights to Mucositis Treatment
- Merck and China Animal Husbandry Sign Partnership MOU
- Helsinn Out-Licenses China Rights for Cancer Care Drug to MundiPharma
- Concord Medical Buys Singapore Hospital for $40 Million
- Sinophi to Distribute Proton Beam Machines in China
- ZAI Lab In-licenses Potential Liver Cancer Drug from BMS
- Zhejiang ChiMin Pharma Stages $47 Million IPO in Shanghai
- Innovent and Lilly Form Major Cancer Biologics Collaboration
- Hanmi Pharma and Lilly Sign $690 Million Deal for Autoimmune Drug
- Vivo Capital Raises $750 Million for US-China Fund
- Jianshun Bioscience to Distribute Cell-based Vaccine Technology in China
- Green Cross to Form Cell Therapy Company in China
- Porton Fine Chemicals Pays $41.5 Million to Acquire Dongbang Pharma
- Shanghai Pharma Forms Online Drug Distribution JV
- Is Mindray Medical Going Private?
- iKang Buys Majority Stake in China Medical Center Company
- Leica Biosystems to Market Novacyt's Cancer Test in China
- Denovo Biopharma In-licenses Second Drug Candidate from Lilly
- Eddingpharm Gains China Rights To Omega-3 Product in $169 Million Deal
- TWi Pharma Regains US Rights to Products from Teva
- Georgia State University Out-Licenses Leukemia Drug to China's Cisen Pharma
- 3SBio Files for Hong Kong IPO; May Raise up to $500 Million
- Fosun Pharma Rumored to Offer $480 Million for Lumenis of Israel
- Crown Bioscience Buys PDX Unit from Molecular Response
- WuXi PharmaTech Borrows $165 Million for New Ventures
- Rainbow Medical of Israel Raises $25 Million from China Investors
- ACT Genomics of Taiwan Raises $8 Million for Cancer Genomics Tests
- Crown Bioscience Expands Partnership with NRCMM
- NeuroVive Raises $3 Million for Taiwan Subsidiary; Plans IPO
- Cellular Biomedicine Acquires CAR-T Technology from China Hospital
- Response Biomedical Enlists Shanghai Elite as China Distributor
- Merck-Simcere China Drug JV Breaking Apart
- Armetheon Raises $24.3 Million From Taiwan/China Investors
- BBI Life Sciences Stages $37 Million IPO in Hong Kong
- Hainan Shuangcheng Buys Hangzhou Ausia Biotech Stake for $154 Million
- Harbin Gloria Pharma Acquires Shanxi Powerdone for $380 Million
- China's WuXi PharmaTech Leads $15 Million Investment in Claritas Genomics
- MicroConstants In-Licenses China-Discovered Antibody for $16 Million
- China TCM Ltd. Pays $1.3 Billion for 81% Stake in Tianjiang Pharma
- Fosun Pharma Seeking Hospital Partnership in Heilongjiang Province
- 3SBio of Shenyang Buys Italian CMO/CRO
- Hubei Biocause Pharma Buys Guohua Life Insurance Stake for $1.2 Billion
- China's Innovent Biologics Raises $100 Million in C Round
- Mitsubishi Gas Forms Asian Biologics CRO Partnership with Catalent
- Meinian Onehealth Invests in Ciming Health, a Rival
- Kingworld Medicines Forms Marketing/Distribution Alliance with Sinopharm
- Burnet Institute Lands $4 Million from GuoMinXinHe Investment Fund
- Mayo Clinic and Hillhouse Form China Healthcare Delivery Venture
- 3SBio In-licenses Second Anti-Cancer mAb from Korea's PharmAbcine
- Tianyin Pharma Forms TCM Distribution JV with Buchang Pharma
- Biostar to Develop New TCM for Cardiovascular Disease
- Baiyunshan Pharma Raises $1.6 Billion in Secondary Offering
- Hanmi Invests $20 Million in Allegro for Eye Disease Drug
- Roche Acquires Majority Interest in WuXi-Invested Foundation Medicine
- WuXi PharmaTech Acquires Genomics Company NextCODE for $65 Million
- Fosun Pharma Invests $35 Million in Amerigen Pharma
- Shenzhen Hybio Pharma Sells US Rights for Generic MS Drug to Akorn
- Hua Medicine Raises $25 Million for Phase II Trials of Diabetes Drug
- China Medical System Acquires Rights to Novartis Drugs
- Sihuan Pharma and Partners Pay $67 Million for Nanjing Hospital
- Phagelux In-licenses Delivery Systems for Phage-based Products
- What Didn't Happen in 2014: China Life Science IPOs
- Otsuka In-licenses Asian Rights to Cancer Drug from Ariad for $77.5 Million
- Therapix Bio Signs MOU with Nanjing BioSciKin for Antibody
- China Pioneer Extends Marketing Relationships with Polichem
- Eddingpharm to Market AFib Drug in China for Cardiome
- Weijian Pharma to Market Infertility Drug in China for LG Lifesciences
- SciClone Pharma Gains China Rights for Two CV Drugs in $50 Million Deal
- Neusoft Raises $610 Million to Support Healthcare Operations
- Milestone China to Distribute Epidural Device in China
- Cipla Sells Stake in Jiangsu Cdymax Pharma for $18.5 Million
- Luqa Pharma In-licenses Novel Wound Product from Histocell
- Adagene of Suzhou Raises $8 Million for Antibody Discovery
- Guangxi Wuzhou Pharma Invests $3 Million in Israeli Firm Integra
- Shanghai Fosun Buys 65% Stake in Suzhou Erye Pharma
- WuXi PharmaTech Plans to List Subsidiary on China's Third Board
- Oramed Pharma Raises $5 Million from Guangxi Wuzhou Zhongheng
- China Pioneer to Distribute Neoton in China for Alfa Wassermann
- CANbridge Life Sciences of Beijing Raises $10 Million in Series A Funding
- Sinopharm A-Think In-licenses Cancer Drug from Aeterna Zentaris
- Haiyin Capital-Cerevast Deal: China VC Sees Potential in Seattle Device Maker
- Ally Bridge, a Hong Kong VC, Invests in German Biotech
- CARsgen Closes Series A to Take Cancer Immunotherapy to Clinic
- Big Reversal: Actavis Now Plans China Expansion, Post-Allergan
- Sinopharm Raises $716 Million in Secondary Offering
- Nanjing Frontier Biotech In-licenses Novel Patch Pain Product
- BioNano Genomics Closes $53 Million Funding Led by Legend Capital
- Yabao Pharma In-licenses China Rights to Parkinson's Drug Technology
- 3SBio Gains Rights to Korean Cancer mAb for Emerging Countries
- Lee's Pharm In-licenses Neo-Natal Pulmonary Drug for China
- Sino Biopharma Invests in Karolinska; Deals Ahead?
- BeiGene Raises $75 Million to Develop Oncology Drugs in China
- Sinopharm and Provectus Extend MOU Negotiations for Six Months
- BioAtla and BioDuro Team Up to Develop Two Biotech Drugs
- Ascletis In-Licenses China Rights to Second Hepatitis C Drug
- ScinoPharm and Nanjing King-friend Partner on Drug for China
- China's Waterstone Pharma In-licenses Hepatitis C Drug from SCYNEXIS
- Shenzhen Hepalink Pharma Invests $22 Million in TPG Biotech Fund
- Bayer Closes $589 Million Acquisition of China OTC/TCM Maker
- UniTao Pharma of China Buys US Plant from Boehringer Ingelheim
- BioChain to Distribute Clinical Genomics' Cancer Test in China
- WuXi PharmaTech Expands to Israel; Collaborates on Israeli Investments
- FortuneRock Raises $24 Million for Protein Drug Development
- Betta Invests $20 Million in Xcovery; Gains China Rights to Cancer Drug
- Janssen Signs Translational Medicine MOU with Shanghai Ruijin Hospital
- Luye Pharma Pays $390 Million for Remaining 42% of Beijing Jialin Pharma
- Akers Biosciences Forms Diagnostic JV in China with Hainan Savy
- Enigma and Beijing Leadman Form Infectious Disease Diagnostic JV
- WuXi PharmaTech and Foundation Partner to Offer Cancer Test in China
- Powertech to Distribute Pressure BioSciences' Lab Tools in China
- China Materialia Leads $5.7 Million Investment in ZipLine Medical
- Fosun Leads $12 Million Funding for Israeli Medical Device Company
- Sihuan Pharma Announces Second Anti-Virus Partnership with AMMS
- Hangzhou Joinstar and Response Biomedical in $9 Million Deal
- MID Labs of California Raises $51 Million from China Investors
- Yew Bio-Pharm to Distribute Carpal Tunnel Medical Device in China
- Decheng, a China Investor, Participates in Invitae's $120 Million Funding
- China's BravoVax In-Licenses Rotavirus Vaccine for Infants
- Fosun Pays $607 Million for Portuguese Hospital Chain
- ContraFect and China's IVDC Collaborate on Universal Flu Treatment
- Sihuan Pharma Buys Rights to Ebola Drug from China's AMMS
- Hony Capital Invests in Shanghai Private Hospital
- Alliance Boots Pays $91 Million for Stake in Nanjing Pharma
- Lee's Pharm Acquires China Rights to Cancer mAb from Sorrento in $50 Million Deal
- Verisante Revises LOI for China Rights to Cancer Diagnostic Device
- WuXi PharmaTech Buys XenoBiotic, a US-China CRO
- Fosun Bids $584 Million for Portuguese Healthcare Chain
- Livzon Mabpharm to Develop Epirus Biosimilars in China
- iHealth of Tianjin Raises $25 Million for Mobile Health Monitoring
- Blackstone Invests $100 Million In Device Maker Suzhou Xinrong
- CSPC Pharma to Support Drug Discovery Work at Columbia University
- CASI Pharma Pays $11.5 Million for China Rights to Three Spectrum Drugs
- 3SBio Gains China Rights to Pegylated Chemotherapy from JenKem
- Denovo Biopharma In-licenses Cancer Drug from Lilly
- Milestone Scientific Starts Painless Botox Injection JV in China
- BeiGene Books $9 Million Milestone from Merck Serono
- BGI Forms Genomic Partnership with the Vancouver Prostate Center
- Institute Curie and Shenzhen Investor Plan $485 Million Cancer Hospital
- OrbiMed Closes Pan-Asia Healthcare Fund with $325 Million
- Beike Biotech Acquires Altor's Cancer Drug in $200 Million Deal
- Lee's Pharm In-licenses Second Product from Italy's Abiogen
- Zhejiang Huahai and Tianjin Pharma to Form US-Aimed Partnership
- Hainan Sinotau In-Licenses Radiopharmaceutical from Navidea of the US
- China's DXY Lands $70 Million Investment from Tencent Holdings
- Guilin Pharma, a Fosun Subsidiary, Partners with CleveXel of France
- GC-Rise Pharma of Beijing Raises $15 Million from OrbiMed
- Eddingpharm Buys China Rights to Arthritis Drug from Ablynx
- Hony Capital Continues to Sell Holdings in CSPC Pharma
- Luye Pharma Buys Majority Stake in Beijing Jialin for $599 Million
- Amerigen and Ningbo Menovo to Develop Generics for the US
- ZAI Lab of Shanghai Raises Over $30 Million in Series A Funding
- WuXi PharmaTech Invests in Aldea Pharma of California
- FortuneRock(China) Raises $24 Million for Protein Drug Development
- China Biologic Pays $87 Million for Additional 20% Stake in Subsidiary
- Luye In-Licenses China Rights to Cancer Drug from Korea's Hanmi Pharm
- Bao Hao Underwrites China Development of US Lung Cancer Test
- Sinopharm Signs MOU to In-License Cancer Treatment from Provectus
- Miraculins to Distribute Device in China through Cachet Pharma
- TNI Biotech Expands Partnership with Hubei Qianjiang Pharma
- ZAI Lab of Shanghai In-licenses Two Respiratory Drugs from Sanofi
- 3SBio In-licenses Leukemia Antibody from DiNonA of Korea
- China’s Walvax Raises $72.8 Million in Private Placement
- PW Medtech of China Buys Beijing Tianxinfu for $130 Million
- Molecular Targeting Collaborates with Taiwan’s National Health Research Institutes
- Yabao Pharma In-licenses China Rights to Cancer Drug from Le Sun Pharma
- Ventana and Quintiles Team Up to Test Biomarkers in China
- Cellular Biomedicine Pays $22 Million to Acquire Agreen Biotech of China
- Solasia Gains Global Rights to Oncology Drug from Ziopharm
- Cold Genesys Raises $13.8 Million from Hong Kong-US Investment Firm
- China’s Tigermed Acquires 70% Stake in Frontage Labs of US
- Lifetech Scientific to Use Medtronic Technology for China Pacemakers
- Fosun Invests in Miacom; Will Market and Make its Diagnostic Tests
- CANbridge In-Licenses China Rights to Oral Mucositis Treatment
- Welichem Ends Effort to Re-Acquire China Rights to Psoriasis Treatment
- Skystar Bio-Pharm of Xi’an Raises $5 Million
- Week in Review: Sinopharm to Restructure with Private Capital
- China Makes Privatization Plans for Sinopharm
- Morningside’s Gerald Chan Joins Board of Aduro BioTech
- Cellular Biomedicine Raises $10 Million in Private Placement
- Yibai Pharma to Acquire Horus C&K Pharma for $128 Million
- HD Biosciences Forms Drug Discovery Partnership with Marshall University
- Luye Pharma Trades Higher Following IPO in Hong Kong
- Grandhope Announces $48 Million VC Fund for Stem Cell Projects
- Yabao In-Licenses China Rights to Lilly Diabetes Drug Candidate
- Luye Pharma Prices Hong Kong IPO at Top of Range
- MicroPort Forms Medical Device Partnership with MB Innovations
- Fosun Terminates $531 Million Out-licensing Deal with Sellas
- Fosun Pharma Invests $46 Million in US Nutritional Company; Forms JV
- Verisante Sells China Rights to Lung Cancer Diagnostic Device
- Cancer Genetics to Buy Gentris, a US-China Genomics CRO
- Luye Pharma to Stage $764 Million IPO in Hong Kong
- JHL Biotech Raises $35 Million to Fund Drug Development
- Ark Biosciences of Shanghai In-Licenses RSV Treatment from Roche
- 3SBio and US-based Selecta Forge Deal on Gout Treatment
- Meihua Buys Dalian Hissen Biopharm for $96.7 Million
- Medisun Forms China Stem Cell JV with Belgium's Cardio3
- Jackson Lab and Frasergen Sign MOU for China Research Facility
- BGI Raises $320 Million for Prenatal Testing Subsidiary
- RuiYi Forms Collaboration with ShanghaiTech; Raises $4 Million
- Milestone Scientific Forms China JV to Distribute Dental Device
- Shuwen Biotech to Commercialize DiagnoCure’s Colon Cancer Test in China
- Fosun and Sinopharm Form $1 Billion Drug Distribution JV
- Kelun Pharma Purchases 5% of Lijun Pharma for $51.5 Million
- Hutchison Chi-Med JV Gains Rights to Distribute Six TCM Drugs
- MicroPort-Sorin $20 Million Medical Device JV Approved
- Lee’s Pharm In-licenses China Rights to Orphan Drug from Abiogen
- WuXi PharmaTech Forms Biomarker Partnership with Targos
- CrownBio Raises $26.6 Million in Series D Round
- GCA Therapeutics Signs $102.5 Million Deal for China Alzheimer’s Drug Rights
- Life Spine Signs Up Pioneer as China Distribution Partner
- Agenix Sells China Rights for Hepatitis B Treatment to Cinkate
- Inovio Acquires Immune System IP from Fudan University
- AstraZeneca and Tianjin University Form Cardiac Fibrosis Collaboration
- NeoStem Out-Licenses China Rights for Cancer Immunotherapy to Cellular Biomedicine
- Aslan Pharma In-licenses Novel Asthma Therapy from CSL
- Lannett and HEC Pharm Announce US-China Drug Distribution/CMO Plans
- CSPC Pharma Out-Licenses Western Rights for Cancer Drug to Dexcel
- Asia Development Bank Invests $60 Million in Orbimed Healthcare Fund
- ScinoPharm and Lee’s Pharma Partner to Develop High-End Generics
- Livzon Mabpharm Leads $36 Million Funding of Epirus, a US Biosimilar Co.
- Tigermed Pays $50 Million to Acquire Frontage Labs, a US/China CRO
- BeiGene Earns $5 Million Milestone from Merck Serono
- Harbin Gloria and Cumberland Pharmas in Translational R&D Partnership
- Pfizer’s Acquisition of AstraZeneca May Face Anti-Trust Problems in China
- Zhejiang Hisun Enters Cancer Collaboration with Ambrx
- Sinovac In-licenses Sabin Polio Vaccine from Intravacc
- Domain Elite Invests $6.5 Million in SMART for China Commercialization
- Chang Jiang Pharma to Supply Biodel with API for Insulin Aspart
- Eddingpharm In-licenses China Rights to Allergy Products
- Fosun Pharma In-licenses Innovative TB Treatment
- GSK Pays $7.1 Billion for Novartis’s Vaccine Business
- Fosun May Acquire Australian Hospital Operator in $5 Billion Deal
- Beckman Coulter Buys Xitogen of Suzhou
- Chindex Agrees to Higher $24/Share Bid from Insiders
- Changchun BCHT Biotech In-Licenses RSV Vaccine from Mucosis
- Techne Buys Shanghai PrimeGene Bio-Tech
- Wuzhou Zhongheng Raises Money for M&A Fund
- Chindex Announces Higher $23/Share Takeover Offer
- Zhejiang Hisun Pharma Enters Biosimilar Business with Catalent’s Help
- iKang Healthcare Completes $153 Million US IPO
- UCLA to Build Pathology Lab in Shanghai with Centre Testing Intl.
- Novartis, World Bank Invest in BVCF’s $188 Million China Life Science Fund
- BVCF Closes $188 Million China Private Equity Fund
- Royal DSM in Talks to Acquire Aland Neutraceutical of China
- Zhejiang Conba Pays $160.5 Million for Majority Stake in Baite Pharma
- WuXi PharmaTech Invests in Drug Safety Startup
- Lansen Pharma Pays $8 Million for China Rights to a Novartis Dermatology Drug
- AstraZeneca Forms Collaboration with Shenzhen University
- Mapi Pharma Files for IPO
- RuiYi Inc. Raises $15 Million for US-China mAb Development
- Golden Meditech Raises $101 Million
- Simulations Plus Finds China Distributor for R&D Modeling Software
- Hainan Haiyao Announces $41 Million Pharma VC Fund
- Clinipace Acquires Choice Pharma, a Pan-Asia CRO
- WuXi PharmaTech Strikes Deal with Pacific Biomarkers
- Biostar Pharma to Develop Liver Cancer Drug with Shaanxi University
- Shanxi Taxus to Gain Control of Cardium with $5 Million Investment
- PhageLux of China Raises Funds from WuXi PharmaTech
- Lilly-Novast Partnership to Build China Manufacturing Facility
- China Viva Biotech and HQL Pharma Form CRO Alliance
- iKang Healthcare to IPO in the US
- ASPEC Technologies to Distribute CovalX’s Proteomic Tools in China
- Shyndec Pharma Pays $49 Million for 30% of Rongsheng Pharma
- Shanxi Taxus Pharma Plans to Acquire California Pharma
- Bayer Buys Dihon, a China OTC/TCM Pharma
- Essex Medipharma to Distribute Pfizer Glaucoma Eye Drops in China
- BGI Rumored to Stage $400 Million IPO in Late 2014
- Harbin Gloria in $170 Million Deal to Acquire Huatuo Medical Science
- Tonghua Shuanglong Acquires Jinbao Pharma for $178 Million
- Lee’s Pharma Gains China Rights to Labor-Inducing Drug
- Citic Private Equity Rumored to Take Biosensors Intl. Private
- Solentim Announces China Distributors for Drug Discovery Device
- Fosun Pharma and TPG Pay $369 Million for Chindex
- Double-Crane to Distribute Sagent Pediatric Drug in China
- Cachet Signs Term Sheet to Distribute Miraculins’ Diabetes Device in China
- Biogen Idec Signs Up UCB as China Marketing Partner
- Mindray Medical Acquires US-China IVD Company
- Actavis Sells China JV to Zhejiang Chiral Medicine
- AstraZeneca to Collaborate with SIBS on Cardiovascular Disease
- Wanbang In-licenses Diabetes Drug Rights from Sirona of Canada
- Harbin Gloria Pharma In-licenses China Rights to Korean Drug
- TaiGen Raises $36 Million in Taiwan IPO
- Changchun Technology Industries Pays $5 Million for Mucosis Stake
- Thermo Fisher Gains China OK for Life Technologies Buy
- TaiGen Sells Russian Rights for Lead Antibiotic
- Covidien Forms China JV to Address “Value” Market
- Wuhan Kindstar Diagnostics In-licenses Epigenomics’ Lung Cancer Test
- Kunshan RiboQuark Raises $7.5 Million for siRNA Projects
- MicroPort of Shanghai Forms Medical Device JV with Italy’s Sorin
- Bayer Forms Translational Drug Discovery Collaboration with Peking U.
- JHL Biotech and BioLineRx Partner on MAb for Diabetes
- Stellar Biotech Collaborates with Amaran Biotech/OBI Pharma
- DIH Medical Technologies In-licenses China Rights to Stroke Recovery Device
- Nerotron Raises $16.5 Million for Cochlear Implant Business
- Walvax to Gain Majority Control of Genor BioPharma for $49 Million
- Simcere Gains Shareholder Approval for Privatization Offer
- Hutchison MediTech Forms Drug Distribution JV with Sinopharm
- Senhwa Biosciences Raises $17 Million to Develop Cancer Drugs
- Sihuan to Develop CNS Drugs with Dutch Pharma to-BBB
- MTIA In-licenses China Rights to Innovative Glucose Monitoring System
- Omron to Distribute NeuroMetrix’s Diabetic Neuropathy Test Device in China
- Beijing Union Signs MOU for IXICO’s Dementia Neuroimaging Technology
- Zhejiang Hisun to Raise $328 Million to Increase Capacity
- Hebei University Company In-licenses Cancer Molecule from Sareum of Britain
- China Pioneer Pharma to Invest $5.7 Million in NovaBay for Distribution Rights
- ShangPharma Obtains China Rights to Mabspace Antibody Technology
- SIMM and Crown Bioscience to Collaborate on Cancer Center in China
- Lee’s Pharm Finds US Distribution Partner for Short-Acting Anesthetic
- Guangzhou Pharma to Set Up JV with Dr. Ferid Murad, a Nobel Winner
- Golden Meditech to Raise $32 Million from Existing Investors
- China Resources to Distribute Imaging Agent for Mallinckrodt
- Shanghai Kinetic Medical Pays $87 Million for Jiangsu Ideal
- BeiGene Out-Licenses Second Molecule to Merck Serono in $232 Million Deal
- Medifocus Forms China JV to Speed Development of its Medical Devices
- Gansu Duyiwei Pays $16.6 Million for Sichuan Huaji Pharma
- China New Enterprise Invests Additional $25 Million in Shanghai Fudan-Zhangjiang
- Hansen Pharma Buys 80% Interest in Yongzitang Pharma for $45 Million
- WuXi PharmaTech In-Licenses Cancer Models from the Mayo Clinic
- Sichuan Kelun’s Purchase of 20% Stake in Lijun Pharma is Off
- BioChain In-licenses China Rights to Colorectal Cancer Test
- Bristol-Myers Squibb to Market Japanese Hypertension Drug in China
- Charles River Labs Buys Microbial Lab to Offer Services in Asia
- Fosun Sells ex-China Rights for Two Drug Candidates in $531 Million Deal
- Dance Biopharm Forms China Inhaled Insulin JV with Harmony Asset
- Miraculins and Cachet Sign LOI for China Rights to Diabetes Test
- Chipscreen Out-licenses Taiwanese Rights for Cancer Drug to GNT Biotech
- Hutchison MediPharma Receives $6 Million Milestone from Janssen
- ASLAN Pharma Raises $22 Million in B Round
- Eddingpharm Gains China Rights to Cancer Drug from Immutep
- Tasly Pays $25 Million for Stake in New Century Pharma
- Hefei Life Science to Develop Micell’s Stent in China
- Sinochem Jiangsu to Distribute Amerigen Drug in China
- Mindray Buys Australia/New Zealand Medical Device Distributor
- SIMM and Servier Collaborate on China Development for Cancer Drug
- Tianjin CanSino Biotech Raises $10 Million from Lilly Asia Ventures
- Beijing’s CANbridge Gains China Rights to Cancer Drug from Azaya
- Sinopharm and China NT Form $33 Million Acquisition Company
- Genor BioPharma of Shanghai May Be Acquired and IPO’d
- Stratpharma and Luqa Extend China Dermatological Partnership
- MicroConstants China In-Licenses Liver Cancer Drug
- Eddingpharm Gains China Rights for Cancer Drug from Syndax
- Acebright Signs MOU for NasVax's Liver Disease Treatment
- BGI Shenzhen Plans IPO
- Simcere Gains Board Approval for $495 Million Privatization Offer
- Winteam Sells its 51% Ownership in Zhongtai Biological
- Xilong Chemical to Buy Majority Share of Newland Life Tech
- MicuRx Raises $25 Million to Fund US-China Antibiotic Development
- Innovent Pharma Forms Antibody Partnership with Adimab
- Fosun Subsidiary to In-license Diabetes Drug from Canadian Pharma
- OrbiMed Files for $300 Million Asia Fund
- Teva Pharma Wants to Enter China Market via Partnerships
- Mindray Forms US Partnership with MedTest
- ScinoPharm and Sundia Form CRO Alliance in China
- Komtur Forms China JV with HengHeKangJian Pharma
- Zhongyuan Union Announces Stem Cell JV with UK Company
- Apexigen Completes $20 Million Series A Venture Round
- Beijing King Health to Distribute Allium Medical Devices in China
- Shenogen Pharma of Beijing Raises $20 Million in C Round
- Daewoong Pharma Purchases China’s Liaoning Baifeng for $16 Million
- WuXi PharmaTech-Backed Foundation Medicine Files for IPO
- Shanghai Pharma to Fund R&D at Second Military Medical Univ.
- aTyr Pharma of San Diego and Hong Kong Completes $49 Million Venture Round
- Lumenis to Distribute Visionix’s Ophthalmic Products in China
- Zhejiang Hisun Floats $153 Million of Bonds to Build Finished Drug Facility
- Legend Capital Participates in JenaValve's $62.5 Million Venture Round
- GSK in Talks with Potential China Vaccine Partners
- Hisun and Celsion Sign MOU to Expand ThermoDox® Collaboration
- Mindray Closes Zonare Ultrasound Deal at $101.7 Million
- Chongqing Lummy Seeks to Buy Remaining 40% of Sichuan Hygien
- Kunming Pharma Starts TCM Joint Venture in Uzbekistan
- Marinomed Licenses China Rights for Antiviral Portfolio to Unnamed Company
- Luqa Acquires China Rights to Three BMG Pharma Products
- Kinex Gains China Rights to Cancer Program from Hanmi
- Tianjin Weikai In-licenses China Rights to 3D Cell Culture System from Zyoxel
- Wuzhou Pharma Awarded Govt. Grant for DelMar Partnership
- SciClone Collaborates with Soligenix on Oral Mucositis Treatment
- Neusoft Gains Control of Medical Imaging JV from Phillips
- Shanghai RAAS to Acquire Banghe Pharma for $290 Million
- Shanghai Acebright Buys 10% of Israeli Pharma
- Pharming Enters Drug Development Pact with Sinopharm Subsidiary
- Shanghai Pharma to Buy 90% of Dong Ying Pharma
- Shanghai BravoBio Licenses China Rights to Rotavirus Vaccine
- SciClone Acquires China Rights for PAD Drug from Taiwan Liposome
- Biohit Forms China JV for Diagnostic Test
- Shanghai Pharma Ups Stake in Shanghai Sunway
- Simcere Raises $65 Million by Selling its Boda Pharma Subsidiary
- Shanxi CY Pharma Buys Controlling Interest in Baoling Group
- BioClinica Partners with TEDA Cardiovascular Hospital
- Suzhou Ribo Licenses siRNA Delivery System from Life Techologies
- BoXin LaiTe Biotechnology and University of British Columbia Sign MOU
- Zhejiang Medicine Collaborates with Ambrx and WuXi on Breast Cancer Drug
- Simcere Announces Third Drug Development Partnership with BMS
- Mindray Buys Zonare, a US Ultrasound Company, for $105 Million
- Alliance Boots Looking for China M&A
- FortuneRock of China Sells US Technology Rights to Big 10 Pharma
- Chia-tai Tianqing Pharma Gains China Rights for Hepatitis C Drug from BioLineRx
- AngioLight Completes Animal Studies of Cardiovascular Device in China
- Boehringer Ingelheim to Build cGMP Biopharma Facility in Shanghai
- Janssen and Taiwan University Team Up to Fight Hepatitis B
- Genor Biopharma and BioCND to Co-Develop Two Popular Biosimilars
- BeiGene Licenses Ex-China Rights for Cancer Molecule to Merck Serono
- Qiagen and BioBay Announce Translational Medicine JV
- Tongjitang Chinese Medicines Acquired by Winteam for $393 Million
- 3SBio’s Shareholders Approve Go-Private Transaction
- China's Curative Medical to Seek CFDA Approval for ALung's Respiratory Device
- More Details about Hisun-Pfizer and Merck-Simcere JVs
- SciClone Gains China Rights to Zensun’s Heart Failure Drug
- RuiYi and Genor Enter License and Collaboration for Novel mAb
- Amgen's New JV Fulfills Promise to Emphasize China
- RuiYi Selects CMC Biologics to Develop Cell Line for mAb
- Vectura and KingYork Form China Respiratory JV
- ScinoPharm and Coland to Develop Oncology Drugs for China
- Zhejiang Beta Pharma Forms JV with Amgen
- Hutchison Chi-Med in Partner Talks for Cancer Drug
- Zhejiang Huahai and Oncobiologics Sign Biosimilar Pact
- Leadman to Distribute IDS’s Diagnostic Products in China
- Sagent Pharma Pays $25 Million to Buy out China JV Partner
- Zhejiang Huahai Raises $126 Million for New Production Facility
- 3SBio Schedules Take-Private Vote for May 24
- Ascletis In-Licenses China Rights to HIV Drug from Janssen
- Fosun, Chindex and PE Fund Buy Israeli Aesthetic Device Company
- Takeda and Sanofi Strike Diabetes Drug Co-Promotion in China
- 3SBio Ups its Take-Private Offer as Opposition Rises
- Hua Han Bio-Pharma and China National Biotec Announce JV
- WuXi PharmaTech VC Fund Participates in Syros Pharma's Initial Round
- Tasly Pharma Buys 100% of TaslyDiyi Pharma
- Zongyi Group Invests $8.6 Million in ContraFect, a US Biotech
- Wuhan Kindstar Announces Collaboration with Illumina
- Cipla Launches Shanghai CP Guojian’s Biosimilar in India
- Suzhou Ascepion and Debiopharm to Develop Cancer Drug for China
- Thermo Fisher Buys Life Technologies; Aims to Grow in Asia
- Eddingpharm and Chiesi Farmaceutici Form Asthma Drug JV
- Ascletis and Roche to Develop Hepatitis C Treatment for China
- China’s NCDS and PerkinElmer Set Up Biomarker Partnership
- Lilly Invests $100 Million in China Animal Healthcare Ltd.
- TRT Chinese Medicines Expects to IPO on ChiNext
- OriGene Pays $16 Million for Antibody Maker SDIX
- Eddingpharm to Distribute Breast Cancer Drug for GSK in China
- Jiangsu Hengrui In-Licenses China Rights to AMD mAb from X-Body
- Sanofi Pasteur Funds Xiamen University Research on Universal Flu Vaccine
- Baxter Teams with China Officials to Bring Dialysis to Rural China
- China NT Pharma and Sinopharm to Set Up Drug Distribution JV
- Sanofi Looking for China M&A to Increase Revenue
- Sinopharm Sells $515 Million of New Shares
- SK Biopharma Partners with China Companies on Novel CNS Drug
- BGI and H3 Biomedicine to Sequence Pre-Clinical Cancer Models
- OriGene Raises $21.3 Million from China Investors
- Hony Capital Backs Simcere’s Privatization Bid
- Roche May Make a Bid for Life Technologies
- Merck Serono and BMS Team Up to Offer Diabetes Drug to China
- BGI-Shenzhen Closes $118 Million Acquisition of Complete Genomics
- Pathwork Diagnostics Partners with Kindstar to Distribute Cancer IVD
- Domain and Elite Team Up to Bring Life Science Products to China
- Shanghai Pharma Increases Stake in Chiatai Qingchunbao Pharma for $72 Million
- Catalent Pharma Expands in China with Two Deals
- Simcere Pharma Receives $503 Million Buyout Offer from Chairman
- Sinopharm to Raise $640 Million in Bond Offering; Is M&A the Goal?
- China National Biotec and Riboxx Set Up Research Collaboration
- WuXi PharmaTech Adds to OmniRat™ Antibody Technology Agreement
- Viva Biotech of Shanghai Forms Drug Discovery Partnership with Addex
- EntreMed Raises $10.7 Million from KPCB and IDG-Accel China Funds
- Fosun Pharma Buys $22.4 Million of Saladax Stock
- Sinopharm Buys 57% of Winteam Pharma for $252 Million
- Polaris Group of San Diego to Build $50 Million Facility in Chengdu
- Fosun Pharma Forms China JV with Canada’s Atrium Innovation
- OrbiMed Raising $500 Million for Asia Healthcare Fund
- China Grand Pharma Forms JV with HuangShi Feiyun Pharma
- Reckitt Benckiser Buys Golong Medicine of Anhui, a TCM Maker
- China Shenghuo Receives Go-Private Offer from Management
- Amgen will Use Partnerships and M&A to Enter China Market
- Shanshi Medical Device In-licenses Tensys Patient Monitoring System for China
- Lee’s Pharma Subsidiary In-Licenses Dyax Drug for China Use
- 3SBio Signs Official Go-Private Agreement
- Zheijang Hisun Nixes Celsion Deal after Drug Fails Trial
- Cardinal Health Has Acquired Six China Drug Distributors for $120 Million
- Neusoft to Buy Out its Medical Imaging JV Partner, Phillips
- China’s Grandhope Biotech In-licenses Stem Cell Technology from Orthocell
- Hainan Haiyao Pays $10 Million for SinoMab Stake
- Lee’s Pharma Gains Negotiation Option for China Rights to Anticoagulant
- Xceleron and Crystal Pharmatech Team Up on Early-Stage CRO Services
- Huapont Pharma and Yes Biotech to Partner on Psoriasis Ointment
- Wilex Selects GeneDiagnostics to Distribute Cancer Test in China
- Hisun In-Licenses China Rights to Celsion’s Cancer Drug for $100 Million
- Stryker Buys Trauson, a China Orthopedic Company, for $764 Million
- Sanjiu Medical Pays $94 Million for China Medical Patch Maker
- Nanjing Micro-Tech Announces “Significant” Investment from Actis
- China National Biotec’s $1.5 Billion IPO is Rumored Again
- Yunnan Walvax Buys 58% Stake in Vaccine-Maker Zerun Biotech
- China GrandPharma In-Licenses Acetium Capsules from Finnish Company
- Guangdong Dahuanong Animal Health Buys Majority Stake in Competitor
- Joinn Labs of China Buys Bayer’s San Francisco-Area Campus
- Shanghai Fosun Pharma Buys Majority of Hunan Dongting for $93 Million
- China’s Cellular Biomedicine Group Announces Reverse Merger
- China’s BeBetter Medicine and PharmaEngine of Taiwan Form Cancer JV
- Tianjin KingYork and Innovata Announce $190 Million Asthma JV
- Sichuan Kelun Pharma Buys 12% of Lijun Pharma for $135 Million
- Naton Medical Forms Orthopedic Products JV in Malaysia
- Major China Biopharma Buys Bayer's Bay-Area Office/Lab Campus
- HitGen and Viva Biotech Team Up to Provide Early-Stage CRO Services
- ShangPharma Accepts $9/ADS Go-Private Offer
- Techpool In-Licenses China Rights to Bone Cancer Drug from Roche
- AstraZeneca and Fudan Univ. to Collaborate on Cardiovascular Disease
- WuXi PharmaTech Teams Up with PRA to Form Clinical JV
- Sinopharm Lands $6.4 Billion in Support from CDB
- Jiangxi Boya Bio-Pharma to Buy Majority Stake in Haikang Biological
- Fosun Pharma and Dalian Wanchun Announce Partnership
- Shanghai Institute to Collaborate with UK-based MRC Technology
- Guangzhou Pharma Absorbs Guangzhou Baiyunshan Pharma
- Chi-Med and Nestlé Form JV to Develop Chi-Med’s Lead Drug Candidate
- Crown Bioscience and Beijing Purunao Team Up to Develop Cancer Drugs
- Fosun Pharma and SIMM to Co-Develop Oncology Drug
- Stake in China Pharma R&D Center Co. Up for Sale
- Sihuan Pharma In-Licenses Two CCV Products from NeuroVive of Sweden
- Changshan Pharma and ConjuChem Form $3 Million Diabetes JV
- Henan Province Announces $40 Million VC Fund for Biologics
- Innovent Biologics Raises $25 Million for Suzhou cGMP Facility
- Hainan Haiyao Signs LOI for Stake in SinoMab Bioscience
- PerkinElmer Buys Haoyuan Biotech, a Diagnostics Company, for $38 Million
- India’s Orchid Chemicals and Pharma Quits its China Antibiotic JV
- Sinopharm is in M&A Discussions with Foreign Pharmas
- Zhongyuan Union to Set Up Stem Cell JV with Cell Therapy of the UK
- Vivo Ventures Leads $30 Million Funding of Shanghai Jingfeng Pharma
- Pioneer Pharma Completes $2.5 Million Investment in NovaBay
- Charles River Labs Pays $27 Million for China Lab Animals Provider
- DelMar and Guangxi Wuzhou Pharma to Develop Cancer Drug
- MicuRx Lands $9.6 Million to Fund China Trials of Antibiotic
- Fosun Raises $512 Million in Hong Kong IPO
- AstraZeneca Signs $150 Million China Deal with Ironwood Pharma
- LifeTech Scientific to Market Broncus' Pulmonary Medical Devices in China
- TNI BioTech Out-licenses Two Drugs to Hubei Qianjiang Pharma
- Shenzhen Hepalink Signs Two Deals with ProMetic Life Sciences
- Half of Fosun Pharma’s Hong Kong IPO Will Fund Acquisitions
- Medtronic Makes another China Device Deal: LifeTech Scientific
- Pharmaron, a Beijing CRO, Announces Partnership with AstraZeneca
- Fosun Pharma’s $600 Million Hong Kong IPO: Is it a Steal?
- TranS1 to Distribute Spinal Devices in China through Beijing Jiade Sunshine
- LoneStar Heart Raises $20 Million in Round Led by Hong Kong PE Firm
- Cephasonics Signs China Medical Device Distribution Deal with Excelpoint
- RuiYi In-Licenses Cancer/Anti-Inflammatory mAb
- Fosun Pharma’s Hong Kong IPO Set to Raise $600 Million
- Vital Therapies Secures $16 Million for Trial of Artificial Liver Device
- MediStem and Superview to Develop Antibodies that Affect Stem Cells
- Sanofi Signs MOU for Rare Disease Collaboration with Sinopharm
- China Kanghui to be Acquired by Medtronic in $816 Million Deal
- China Nuokang Bio-Pharma Given Board OK to Go Private
- Medicago Licenses China Rights for Flu Vaccine to Phillip Morris Co.
- NovaBay and Pioneer Expand China Partnership to Southeast Asia
- China Cord Blood Lands $50 Million from Golden Meditech
- Two Drug Distributors, Alliance Boots and Nanjing Pharma, Ink $91 Million Deal
- BGI Shenzhen Buys Complete Genomics of the US for $117 Million
- Qiagen and Lepu Team Up to Provide Cardiac Diagnostic Tests in China
- Two Pharma JVs Start Operations in China: Hisun-Pfizer and Merck-Simcere
- 3SBio Receives $337 Million Go-Private Offer
- WuXi AppTec and AstraZeneca Form Drug Development JV
- Triplex, a Diagnostics Company, Lands $50 Million from RRJ Capital
- China National Biotec Approved for $1.6 Billion Hong Kong IPO
- WuXi PharmaTech Licenses OMT’s OmniRat to Aid Biologic Drug Discovery
- Elekta Wins $35 Million Radiation Therapy Contract from China's Military
- Life Technologies and Sino Biological Form Proteomics Partnership
- Fosun Pharma Lands $47 Million Loan from World Bank Unit
- CompanDX, a UK Biomarker Startup, Raises $6.1 Million from China
- Golden Meditech to Distribute Cord Blood Processing Device in China
- CNBG Institute Buys Vaccine Conjugate Technology from FinaBio
- Tigermed Completes $80 Million IPO on the ChiNext Exchange
- Hainan Shuangcheng Pharma Stages $94 Million IPO in Shenzhen
- Cipla Focuses its China Investment, Emphasizes Biosimilars
- Medtronic in M&A Talks with China Medical Device Companies
- S*BIO of Singapore Sells Cancer Drug Rights to MEI Pharma
- PharmaEngine Acquires China Rights to Nanobiotix Cancer Product
- Luqa Pharma In-Licenses Scar Treatment from Stratpharma
- Kinex Pharma of the US Receives Investment from Hong Kong Investor
- Tigermed, a China Clinical Stage CRO, Plans ChiNext IPO - FLASH: Price set
- Transgene and Tasly JV Starts Operations with Four Transgene Molecules
- Suzhou Connect Biopharma Gains Rights to Arena’s Anti-Inflammatory Drugs
- SUMEC to Distribute Breast MRI Machines in China for Aurora
- Fenwal Holdings and Its China JV Bought by Fresenius of Germany
- TJAB Forms Drug Development JV with Antisense of Australia
- Jinhe Biotech Stages a $78.6 Million Shenzhen IPO
- Lee’s Pharma Obtains China Rights to Therapeutic Peptide from RegeneRx
- Ascletis In-Licenses Alnylam’s RNAi Drug for Liver Cancer
- HAO Capital and TCL Group to Set Up Medical Imaging JV
- Walvax Biotech Gains Majority Control of Fengmao Biotech
- ShangPharma's Chairman Offers to Take the Company Private
- China Pharmaceutical Group Pays $1.2 Billion for Robust Sun Holdings
- Sinopharm, Fosun, Meheco Join to Form $157 Million PE Fund
- Cardinal Health Buys Zhejiang Province Drug Distributor
- Zhejiang Medicine In-Licenses Novel Antibiotic from TaiGen
- Gentris of the US to Partner on Genomic Biomarkers with SIPM
- NeoStem Divests its 51% Stake in Suzhou Erye Pharma
- China’s Ascepion Out-licenses Cancer Drug Candidate to Debiopharm
- Quintiles to Spend $14 Million on China Headquarters and Central Lab
- Humanwell Healthcare Buys China Distributor of Roche Diagnostic Tests
- Shanghai Kinetic Medical Debuts on ChiNext Exchange
- Biostar Makes a Deal for New Topical Skin Disease Treatment
- Lilly Invests $20 Million in Novast Labs of China
- Sinopharm to Float $1.3 Billion in Bonds
- Zhifei Biological Expands Vaccine Partnership with Merck
- Mindray Buys Majority Stake in China Orthopedic Implant Maker
- Dongcheng Biochemicals Stages $110 Million IPO in Shenzhen
- Hisun Pharma to Invest $162 Million into its JV with Pfizer
- Xiangxue Pharma Gains China Rights to Kinex’s Glioma Drug
- ASLAN Pharma In-Licenses Rheumatoid Arthritis Treatment from Almirall
- Ventac Partners In-licenses Diabetes Treatments from Guangzhou Institute
- China National Biotech to Raise $1.6 Billion in Hong Kong IPO
- J&J in the Hunt for China Pharma Acquisitions
- IPO of Ningbo David Medical Device Greeted Warmly
- Conba Pharma Plans $148 Million Private Placement
- Mindray Acquires Controlling Stake in Optcla Medical Instrument
- Enzon and Hisun Announce Strategic Alliance for PEGylation Technology in China
- Zhejiang Huahai and Breckenridge Sign Agreement for Generic HIV Drug
- Aeras and CanSino to Collaborate on TB Vaccine Development
- Johnson & Johnson Makes First Medical Device Acquisition in China
- Conba Pharmaceutical Licenses Drug from Evotec for $95M Plus Royalties
- Watson Pharma Buys Actavis in a Marriage of Generic Drugmakers
- Renhe Pharmacy Pays $46 Million for Two Pharma Acquisitions
- SK Pharm and Hanmi Pharm Will Bring Epilepsy Treatment to China
- S*Bio Sells Myelofibrosis Treatment to Cell Therapeutics
- Daiichi Sankyo Buys Shanghai Xinshengyuan Pharma
- Luqa Pharma Out-licenses AfMET Rights for AntiFungal; Keeps China Rights
- Fidelity Targets Healthcare for Half of New $250 Million China Fund
- China Cord Blood Announces $65 Million Investment from KKR
- Fosun Pharma Given OK for Hong Kong IPO
- Lee's Pharma In-Licenses GI-Protective Aspirin
- Henan Taloph Raises $63.4 Million to Fund Projects
- Hubei Minkang Pharma to Gain Stake in Hubei Merryclin Pharma
- Lee’s Pharma to Obtain China Rights for 3 Drugs from Regenerex
- GSK and Hanmi Pharma of Korea to Develop Drugs for China
- Chongqing Huapont to Raise $146 Million in Private Placement
- Fosun Purchases Another $35 Million of Simcere’s Stock
- Anaphore of San Diego Buys RuiYi, a Shanghai Drug Developer
- Qiagen to Partner with Shanghai Jiao Tong University Lab
- Hisun Pharma Diversifies into Animal Health with New Partnership
- Boehringer Ingelheim Plans Shanghai Animal Vaccine R&D Center
- OriGene Buys Zhongshan Golden Bridge Biotechnology
- 3SBio and DaVita Announce $20 Million Dialysis JV for China
- Qiagen and KingMed to Offer HPV Test in China
- Jiangxi Boya Bio-Pharma IPOs on ChiNext Exchange
- Abcam Buys Epitomics for $170 Million
- Shanghai Duyiwei Biotech Strikes mAb Deal with Apexigen
- Wuhan Kindstar Diagnostics Raises $20 Million for Testing Services
- MBK Partners Sells Luye Pharma Stake to Fellow PE Funds
- Yiling Pharma to Spend $22 Million on Three Drug Collaborations
- C3 Jian, a US Dental Company with China Connections, Raises $30 Million
- Cumberland Pharma Out-licenses Products to Harbin Gloria
- Bicon Pharma Lands $250 Million in PE Capital from PAG Asia
- Shanghai Pharma and Guangdong CDC to Research Vaccine Distribution
- Tibet Pharma Plans to End Short Stint as Public Company
- Newsummit Biopharma Files for $80 Million NYSE IPO
- Pfizer Seeks More M&A to Expand China Generic Drug Offerings
- Fosun Pharma Invests in Korean IVD Company
- BGI Collaborates with Big Pharma on Asia’s Most Common Cancers
- Pfizer and Zhejiang Hisun to Invest $545 Million in Generic Drug JV
- Beijing Leadman Biochemistry Completes ChiNext IPO
- Zhejiang Medicine Drops Price on Private Placement
- Changchun BCHT Biotech Acquires Flu Vaccine Technology
- Shanghai Pharma to Spend $80 Million on North China Expansion
- Once Again, Fosun Pharma Plans Hong Kong IPO
- Nanjing Pharma’s Weak Financials Spark Takeover Talk
- Shanghai Biochip Signs MOU with GeneNews of Canada
- Shanghai Pharma Acquires Second API Maker this Year
- Cardinal Health Plans $90 Million in China Acquisitions
- Tasly and SemBioSys Report Progress on their China JV
- WuXi PharmaTech and ShangPharma Are M&A Targets: Bloomberg
- EntreMed Raises $10 Million from China-Connected Investors
- Sanjiu Pharma to Bid up to $110 Million for Shunfeng Pharma
- Jiangsu Kanion Out-licenses 3 Molecules to NewGen Therapeutics
- Xizang Haisco Pharma Completes $127 Million IPO
- Da An Gene and Life Technologies Form JV
- NovaBay® Chooses Pioneer to Market NeutroPhase in China
- Hengrui and Crown Bioscience Announce Antibody Partnership
- Amerigen Pharma Announces Two China-US Deals
- Aeras and CNBG Partner on TB Vaccine
- Shanghai Pharma Subsidiary Buys 51% of Jinhe Biotech
- Ascletis Lands $1.6 Million R&D Grant from Hangzhou Park
- ProteoTech and GSK (China) Collaborate on Parkinson’s Drug Candidate
- Vivo Ventures Closes $375 Million US-China Life Science Fund
- Harbin Pharma Trades $870 Million of Stock for Assets from Parent
- BioTime Options Cell Lines from USCN Life Science China
- Beijing Double-Crane Buys Transfusion Maker Huali
- Sanjiu Expected to Acquire Shungfeng Pharma through Auction
- ForteBio Acquired by Pall Corporation
- Hutchison MediPharma Inks $140 Million Cancer Deal with AstraZeneca
- Hua Medicine In-licenses Diabetes Drug Candidate from Roche
- Beijing SL Pharma Forms US-based Diabetes JV
- China Sky One Partners Up to Form New Stem Cell Company
- Jilin Aodong Defers Investment in Vital Therapies
- Simcere and Bristol-Myers Squibb Partner on Cardiovascular Drug
- ICON Builds China Presence by Acquiring BeijingWits, a Clinical CRO
- Mindray Medical Invests in Healthcare IT Company
- Beijing SL Pharma Buys Stake in Forwell Biopharm
- AstraZeneca Buys China Generic Drug Firm; Announces US Layoffs
- Conba Buys 84% of Yunnan Xiongye Pharma
- Aoxing Pharma Secures $3.2 Million from Bank Loan
- Foci Pharma to IPO in Shenzhen
- Taiantang Pharma Pays $21.4 Million for Stake in TCM Company
- Sihuan Bioengineering Sues Vitapharm to Unwind Deal
- Zhejiang Huahai Pharma to Raise $204 Million
- Fosun Pharma to Float up to $470 Million in Bonds
- Kunming and ZBD to Collaborate on TCM Injection
- BGI Forms Children’s Disease Partnership with Philadelphia Hospital
- Italian Pharma Menarini Buys Invida of Singapore
- Tiantan Biological Receives $24 Million from Gates Foundation
- Lepu Medical Buys Controlling Interest in Dutch Device Maker
- Fosun Pharma Buys 6.5% Stake in Simcere for $30 Million
- China Resources Medications Forms $158 Million JV with Pientzehuang
- Kunming Pharma will Raise $110 Million to Boost Capacity
- China Biotech’s Hong Kong IPO to Raise Up to $2 Billion
- Yabao Pharma Raises $74 Million in Secondary Offering
- China National Biotechnology to IPO on the Hong Kong Exchange
- ImmBio Strikes China Deal with CNBG Unit for TB Vaccine
- Aslan Pharma In-licenses China Rights to BMS Cancer Drug
- Alios Signs Flu Treatment Deal with Univ. of Hong Kong
- Lansen Pharma Inlicenses China Rights to Rheumatoid Drug
- BioBay, Roche and Harvard Form Novel Cancer Drug Partnership
- WuXi PharmaTech Makes Clinical-Stage CRO Acquisition
- ShangPharma Buys Charles River’s Shanghai Lab
- Simcere Partners Up with Suzhou NeuPharma on Cancer Drug
- Medicilon to Complete Pre-Clinical Work on South Korean Anti-Depressant
- Amerigen Finds Partner to Develop Cancer Drugs in the US and China
- Zhuhai Hokai Medical Instruments Completes ChiNext IPO
- Sinocom Pharma Withdraws Nasdaq IPO
- WuXi Buys Abgent, a US-China Antibody Maker
- BeiGene In-Licenses Two Potential Cancer Drugs from Janssen
- SemBioSys Genetics of Canada Forms JV with Tasly Pharma
- Chiva Pharma Acquires Global Rights to Osteoporosis Drug from Ligand
- Biostar Announces $9.6 Million China Acquisition
- GSK Seeking Up to $2B Bolt-on Acquisitions in India
- Guizhou Bailing Buys Another Ethnic-Miao TCM Company
- Nycomed/Takeda Adds Antihistamine to China Portfolio
- Sanjiu Medical Buys Four Small Pharmas
- Newsummit Launches $100 Million Fund for US Medical Device Makers
- Zhongsheng Pharma Commits $3 Million to Three Novel Drugs
- China Grand Pharma Pays $17 Million for Wuhan Kernel Biotech
- Cipla, with Plants in China and India, Goes After Biosimilar Market
- Hua Medicine Raises $50 Million to Develop and Commercialize Drugs
- Lingrui Pharma Raises $60 Million to Expand Capacity
- Pfizer Signs Jointown to Distribute its Drugs in China
- Avenue Capital Plans $313 Million Fund for China Medical City
- ShangPharma Forms mAb Partnership with Hengrui Medicine
- Merck Serono and Pharmaron Partner in Beijing Lab
- Merck Partners with China’s BGI on Genomics
- HealthLinx and CytogenDx to Develop New Ovarian Cancer IVD for China
- Pfizer Starts China Animal Health JV with Jilin Guoyuan
- Fosun Pharma Buys 70% of Jinzhou Ahon Pharma for $219 Million
- Fosun Pharma and Lonza to Start Generic Drug JV
- Royal DSM and Sinochem Close Antibiotics JV Deal
- Vasomedical Buys Two China Medical Device Manufacturers
- Asymchem Announces $39 Million in VC Funds
- Shanghai Pharma Acquires Jiangsu Drug Distributor
- 3SBio Forms Investment Partnership with China Medical City
- Sinopharm Acquires Wuhan Zhongliang Pharma
- Beijing SL Pharma Forms Canadian Vaccine JV
- Bohai Pharma Acquires Yantai Tianzheng Pharma, a TCM Maker
- Mingyuan Medicare Buys Diagnostic Company for $55 Million
- China Medical Technology and Leica to Form IVD Collaboration
- Changshan Biochemical Sets Price for ChiNext IPO
- Hisun Pharma Makes Another US Investment; This One with PharmTek
- Global Pharm Acquires Drug Distributor for $9 Million
- VWR Buys China’s LabPartner, a Fellow Lab Products Supplier
- Shionogi of Japan to Take Control of China’s C&O Pharma
- Shanxi C&Y Pharma to IPO on the ChiNext Exchange
- Yiling Pharma Climbs in Post-IPO Trading
- Meheco Signs Contract for Controlling Interest in Tianshan
- Aeras and China National Biotech Sign MOU for TB Vaccine
- Chi-Med Forming an OTC Drug Distribution JV
- Merck and Simcere Form China JV to Develop and Sell Branded Drugs
- Biolight Meditech and D.A. Diagnostics Debut on ChiNext Exchange
- Shijiazhuang Yiling Pharma Raises Offering Price of ChiNext IPO
- Sihuan Pharma Sells 50% of Drug Distribution Subsidiary to Shandong Buchang
- Chongqing Zhifei Nixes Plan to Buy Bilthoven Biologicals
- Guizhou Bailing Buys Majority Stake in Guizhou Herentang
- Novartis May IPO in China
- Sagent Pharma Adds Lummy Pharma to its List of China Collaborators
- Hikma Pharma Buys Stake in Hubei Haosun Pharma
- Bimeda Sets Up Veterinary JV with Rainbow Labs
- BeiGene Plans a $100 Million to $150 Million Capital Raise
- Baotou Dongbao and Grandhope Biotech Soar after ChiNext IPOs
- MingSight and Relin Medicine Form China Ophthalmology JV
- Mindray Medical Buys Majority Stake in Urinalysis Company
- ARC Capital Invests $13 Million in Buchang Pharma Group
- Boston Therapeutics and Advance Pharma in China Deal for Glucose Product
- Gloria Pharma Loses Out on Bid to Acquire Dilong Pharma
- Jointown Pharma and 360buy.com to Form Online China Pharmacy
- MedicaNova and Zhejiang Medicine Announce Asthma-focused JV
- Wuhan Kindstar Diagnostics Raises $11 Million in Series B Funding
- Microbix and Hunan Influenza JV Looking Doubtful
- Medivir Licenses China Rights for Cold Sore Treatment to Daewoong
- Sirnaomics Names China Partner for siRNA Therapeutic
- Sihuan Pharma Acquires TCM Cardiovascular Drug Maker for $120 Million
- Shandong Jincheng Pharma Completes $72 Million IPO
- China Medical Technology Signs Diagnostic Test Partnership
- Britain and China Announce $155 Million Drug Development Partnership
- Biomatters Partners with Genewiz; Plans Entry into China
- PKU Southwest Synthetic Pharma to Acquire 100% of Distribution Subsidiary
- LabCorp Buys Clearstone Labs, Giving it Access to China
- Nycomed to Market Roche Osteoporosis Drug in China and Asia-Pacific
- GlaxoSmithKline to Buy Out China Vaccine JV Partner
- Conba Pharma Forms Cancer JV with Kite Pharma, a US Startup
- Unigene Ends China Peptide JV; Will Out-License Technology
- Harbor BioSciences in Deal for ex-China Distribution of Sinopharm Generics
- Selected Value Therapeutics Acquires China Rights to Cancer Drug
- Northeast Pharma Announces $370 million Private Placement
- China Medical System Buys 51% of Drug Maker
- KingMed Diagnostics Strikes Second Opinions Deal with U. of Pittsburgh
- Tasly Pharma to Make $40 Million Investment in US Facility
- Pfizer and Zhejiang Hisun Sign MOU for Branded Generics JV
- First China Pharma Progressing on Acquisition of Drug Distributor
- Livzon Pharma to Spend $154 Million on New API Facilities
- D-Pharm Out-licenses China Rights for Epilepsy Drug to Nhwa Pharma
- Hutchison China MediTech Forms Infant Nutrition JV with Hain
- Qiming Shows China Venture Capital Running Strong
- Walvax “Ends Negotiations” with GlaxoSmithKline
- Shanghai Pharma Prices Hong Kong IPO at $2 Billion
- Naviscan Signs Up Chindex as China Distributor of Breast-PET Scanner
- Chongqing Zhifei Bidding to Buy Dutch Vaccine Company
- China Meheco to Sell $939 Million of Drugs to Venezuela
- Sinopharm Xinjiang Unloads Seven Non-operating Subsidiaries
- Sinocom Pharma Plans $58 Million IPO on Nasdaq
- Crown BioScience Raises $28.8 Million in C Round
- C3 Jian to Form Clinical Research Facility with Sichuan Univ.
- Pfizer to Take Stake in $2.2 Billion Shanghai Pharma IPO
- Exclusive Interview: BeiGene Lands “Large” Investment from Merck
- Shenzhen Edan Instruments Stages $146 Million ChiNext IPO
- Aslan Pharma of Singapore Raises $12 Million for In-licensing
- Mitsui Gains Interest in Shenzhen Main Luck Pharma
- Sinopharm Will Raise $440 Million to Build Distribution Network
- Neuralstem and BaYi Brain Hospital Plan Stem Cell Trial in Stroke Patients
- Shanghai Pharma and Pfizer Sign MOU to Expand Collaboration
- Kinex Licenses China Rights for Cancer Molecule to Hanmi Pharma
- Morningside Invests in Aduro Biotech, a US Cancer Immunotherapy Co.
- SciClone to Acquire NovaMed Pharma for up to $105 Million
- Jiangbo Commits Some of its Large Cash Hoard to buy Drug Distributor
- Standard Chemical (Taiwan) and DIA Pharma (Japan) Form China JV
- Shanghai Pharma’s Hong Kong IPO Proceeding Down the Regulatory Path
- Greek Pharma Alapis Signs MoU with CSPC Pharma
- India Tops China in Big Pharma-Generic Deals: Merck Signs up with Sun Pharma
- Jilin Aodong Makes $2 Million Initial Investment in Vital Therapies
- Ascletis Raises $100 Million for US-China Startup
- China Medical System Joins PRC’s Drug Distribution Rollup
- China NT Pharma to Raise $275 Million in Hong Kong IPO
- Shanghai Pharma Bumps Size of Hong Kong IPO by 50%
- Kang Sheng Bao to Develop Immune System Diagnostic Test for SuperNova
- Zhejiang Hisun Pharma Invests in US Biotech Startup
- China Kanghui Acquires Stake in Orthopedic Implant Company
- Competition between Drug Distributors Heats Up in Zhejiang Province
- Chongqing Fuan Pharma Makes Its Debut on ChiNext Exchange
- Jilin Jian Yisheng Pharma IPOs on Shenzhen Exchange
- First China Pharma Acquires Fellow Drug Distributor
- Shanghai Pharma to IPO in Hong Kong in April
- Fenwal and Golden Meditech Agree to Terms for Medical Device JV
- Dahuanong Completes ChiNext IPO
- MediciNova and Zhejiang Medicine to Set Up China JV for Asthma Drug
- Renhe Pharma Plans $140 Million Fund Raise for M&A
- Shijiazhuang Xingbai Pharma Receives $18 Million Investment from Infinity
- Mindray Medical Buys China Infusion Pump Maker
- Fosun Pharma to Raise $913 Million in Hong Kong Listing
- Sanofi-Aventis Closes Acquisition of BMP Sunstone
- Hisoar Pharma Raises $79 Million for Capital Projects
- Shanghai Pharma May Soon Buy Stake in German Drug Distributor
- Pharmaron Raises $40 Million to Expand CRO Operations
- Zhejiang Jolly Pharma Trades Higher after IPO
- Neptunus to Raise $219 Million for New Facilities
- Guangzhou Pharma to Expand in Fuyang City, Anhui Province
- CAS Affiliate to Launch Venture Capital Fund
- Zhejiang Jolly Pharma Starts ChiNext IPO
- Huahai to Supply Novartis with APIs and Intermediates
- Fosun Acquires 75% of Vaccine Maker Aleph Biomedical
- Qianhong Biopharma Starts IPO Process
- Tacere Reacquires Asian Rights to Novel Hepatitis C Treatment
- Yabao Pharma and Frontage Ink $50 Million Collaboration
- Aosaikang Pharma Signs Deal with New Zealand Diabetes Company
- Sinopharm Acquires Stake in Hebei Drug Distributor
- Kelun Pharma Announces Another Acquisition
- Bohai Pharma Announces $1.9 Million Financing
- Golden Meditech Raises $34.7 Million in Taiwan
- First China Pharma Signs Distribution Deal
- Wolters Kluwer and Medicom Form China JV
- Harbor BioSciences Sells China Rights for Three Prospective Drugs to CIPI
- Free Han and Mongolia Pharma Buys French Medical Device Company
- Shanghai Pharma is a Major M&A Player
- PPD Forms JV, Expanding BioDuro to Include Biologic Drug Discovery
- Sinopharm to Acquire 80% of Aurobindo’s China Subsidiary
- Chiva Licenses China Rights to Liver Drugs from Ligand
- Zhendong Pharma Debuts on ChiNext Exchange
- Merck KGaA Buys Lab Equipment Maker Beijing Skywing
- Sihuan Pharma to Invest $208 Million in Tonghua City Facilities
- Golden Meditech to Add Taiwan Listing
- Beijing Double-Crane Buys Enshi Pharma for $13.7 Million
- Emerging Healthcare Inc. Acquires China Rights to Stem Cell Technology
- Kangmei Pharma to Raise $529 Million
- Chindex and Fosun Finalize Medical Device Distribution JV
- Kelun Pharma Buys Qingfa Pharma
- $15 Million VC Fund to Back Israel-Tianjin Transfer Projects
- Hutchinson MediPharma Books $7.7 Million from SBCVC Fund
- Gedeon Richter Forms China JV with Marketing Partner
- Royal DSM Sells Half of Antibiotics Unit to Sinochem
- Shanghai Pharma Spends $570 Million for Two Acquisitions
- Xiangxue Completes ChiNext IPO
- Fosun Pharma to Buy Majority Stake in Hongqi Pharma
- Zhejiang Jolly Pharma to IPO on ChiNext Exchange
- Qinghai Gelatin to Sell TCM Subsidiary to Chongqing Lummy Pharma
- Beike Biotech and SiriCell Dissolve Their JV
- GSK Buys Nanjing MeiRui Pharma for $70 Million
- Sanofi-Aventis Licenses Anti-Angiogenesis Technology from SIBS
- Sumitomo Pays $73 Million for 29% Stake in C&O Pharma
- Ascenta Signs Cancer Drug Deal with Ascentage, Its China Spin-off
- GSK Expected to Buy Nanjing MeiRui Pharma
- Sino Biopharma Ups Ownership of Subsidiaries
- Dongsheng Buys Cardiovascular Drug for $1.5 Million
- Shanghai Pharma Buys Majority Stake in Fellow Drug Distributor
- 3SBio Pays $6.25 Million for Gout Treatment
- Cardinal Health Buys China Drug Distributor Zuellig Pharma
- Two More China Biopharmas to IPO on ChiNext Exchange
- Sihuan Pharma Pays $371 Million to Buy Rival
- Beijing Pharma to IPO in Hong Kong
- Is There Hope for Novartis' $125 MIllion Acquisition of Zhejiang Tianyuan?
- Lansen Buys 20% of Zhejiang Starry Pharma
- Kelun Buys 85% of Guojing Pharma for $37 Million
- Walvax Biotech Soars after ChiNext IPO
- Huifeng Bio-Technic Raises Money for New Production Facility
- Bayer Schering Partners with NPERC on Drug Delivery
- Hutchison MediPharma Raises $12.5 Million from Mitsui
- China Cord Blood Takes Hit on Secondary Offering
- Fibrocell and Hefei Meifu Announce JV
- SOBI Acquires European Rights to Dongbao Anemia Drug
- Simcere To Conduct Human Trial of BMS Cancer Drug
- Tongjitang Chinese Medicine Reaches De-listing Deal
- Nycomed Buys Majority Stake in Guangdong Techpool Bio-Pharma
- Sanofi-Aventis Buys BMP Sunstone for $520 Million
- Sihuan Pharma Climbs 25% In Hong Kong Trading Debut
- Jingxin Pharma In-licenses China Rights to Insomnia Drug
- China Sky One Strikes Deal for 15 New Products
- aTyr Completes $23 Million Funding for Physiocrine Drugs
- Sihuan Pharma Prices Hong Kong IPO at Top of Range
- Takeda Obtains 100% Control of China JV
- Shanghai Pharma to Raise $1.5 Billion in Hong Kong in 2011
- ProMetic Signs Up Allist for China Development of Two Drug Candidates
- Pfizer Invests up to $350 Million in Indian Biosimilar Deal
- ShangPharma Prices New York IPO at $15
- Sihuan Pharma Unwinds Investment from Firm Started by Son of China’s Premier
- Soros to Buy $40 Million of Sihuan Pharma’s Hong Kong IPO
- Burrill and Infinity Announce China Healthcare Fund JV
- MingSight Buys Two Early-Stage Eye Drugs from Pfizer
- Tasly Pharma In-Licenses US Alzheimer’s Drug
- Sihuan Pharma to IPO in Hong Kong
- CRO ShangPharma Plans $90 Million IPO on the NYSE
- CCB $400 Million Healthcare Fund Considering ex-China Investments
- RHEI Pharma to Market Oral Mucositis Treatment in China
- Tongjitang Chinese Medicine Sells Off Divisions
- NeoStem to Acquire Progenitor for $20 Million of Stock
- Eddingpharm Raises $24 Million in Series B
- China Cord Blood Buys into 4th Cord Blood Center
- Yunnan Walvax Biotech to IPO on ChiNext Exchange
- China Cord Blood Modifies Terms for Warrants
- EntreMed Sweetens Private Placement with China Rights to Cancer Drug
- Shanghai Pharma to Raise $1.2 Billion in Hong Kong IPO
- Zhifei Biological Products to IPO on GEM Exchange
- Fosun Completes Half of $30 Million Investment in Chindex
- China PharmaHub to Distribute Liver Cancer Treatment
- 3SBio Buys China Rights to Kidney Transplant Drug
- Golden Meditech Raises $40 Million for Medical Device JV
- Tongjitang Chinese Medicines Buyout Update
- GSK Ups Stake in Neptunus Interlong Vaccine JV
- Accord Pharma to Buy the Rest of Shenzhen Sinopharm TCM
- China Approves Novartis-Alcon Merger with Conditions -- Update
- Kanghui Holdings Prices IPO, Rises in Trading
- Sangon Biotech Raises $10 Million from Qiming Ventures
- China Kanghui Releases Q2 Results, Updates IPO Terms
- Irony: WuXi PharmaTech Guides Higher; Charles River Lower
- WuXi’s CEO Blames Short-term Financial Concerns for Merger’s Demise
- Charles River Calls Off Merger with Wuxi PharmaTech
- Radient Reveals New Divestiture Plan for China Subsidiary
- Kangmei Pharma Continues M&A Initiatives
- Kanghui Files for IPO on NY Stock Exchange
- Merck and Sinopharm to Set Up Vaccine JV
- Lijun Pharma. and Tonghua Dongbao Set Up IV Joint Venture
- CCBI Healthcare Fund Invests in Medical Device Maker
- Lee’s Pharma to Distribute PAH Drug in China
- BioHorizons Seeking SFDA Approval of Dental Implant Products
- BMP Sunstone Rises on Takeover Rumors
- China Life Science IPOs Raise $5.4 Billion in Last 12 Months
- Fosun and Chemo Invest $74 Million in mAbs
- Dehaier Medical Acquires Portable Ventilator Technology
- Charles River Expects $100 Million in Cross-Selling from WuXi Merger
- HEGLN Buys Non-Invasive Urological Diagnostic Technology
- Blackstone Group Helps Raise $45 Million for China Animal Healthcare
- Venturepharm Lab May Announce “Major” Partner Soon
- Swedish Orphan Biovitrum Partners Up with Dongbao Pharma
- China PharmaHub Acquires mAb Platform; Aims toward Reverse Merger
- ULURU Out-Licenses Wound Care Product to Jiangxi Aiqilin Pharma
- Nuokang to Distribute Dianatal® Obstetric Gel in China
- Zhejiang Huahai Pharma to Spin Off US Operations
- NeoStem Announces $5 Million in New Funding
- Trauson Holdings Plans $98 Million IPO in Hong Kong
- Jiangsu Kanion Pharma Gains Control of a Fellow TCM Maker
- Will China Nix the WuXi PharmaTech-Charles River Tie-up?
- Sino Biopharmaceutical Funding Future Acquisition
- Charles River Justifies Purchase of WuXi PharmaTech
- Chindex Forges JV with Fosun Pharma
- Anhui Anke Buys Company with a Hepatitis B Drug
- Qiming Forms RMB Fund for Beijing Biomedical Companies
- Bayer to Collaborate with TauRx on Alzheimer’s
- Fight Brewing over Charles River-WuXi PharmaTech Merger
- Simcere Ups Stake in Boda Pharma to 90%
- Mindray Licenses Patient Monitoring Technology from Pulsion
- Huiheng Acquires Breast Brachytherapy System
- Pfizer Sells Swine Vaccine Subsidiary to Harbin
- Honz Pharmaceutical Completes IPO on GEM Exchange
- Sichuan Kelun Pharma to Stage $735 Million IPO in Shenzhen
- Insulin-maker GanLee Receives Investment from Qiming
- Yu Sheng Tang Pharma to Buy Stake in Japanese TCM Company
- Lilly Buys Stake in Zhejiang BetaPharma
- Shenzhen Hepalink IPO Creates China’s Wealthiest Couple
- S*BIO Lands Another $20 Million from Onyx
- Jiuding Capital Invests 110 Million RMB in PowerdonePude Pharma
- AlphaRx Canada to Merge with Pacific Orient
- China Pediatric Reports Reverse Merger, 2009 Results
- Aoxing and Johnson Matthey Announce China JV for Narcotic APIs
- Charles River Labs Pays $1.6 Billion for WuXi PharmaTech
- Kun Run Biotech Raises $8 Million from OrbiMed
- NeoStem and ImmuneRegen to Collaborate on Stem Cells
- Artepharm Global to Market TCM-Based Malaria Drug
- Eisai Buys China Rights to GI Drug from Almirall
- Beijing YiCheng Bioelectronics Lands $10.3 Million in Series A Funding
- US-based Sagent Pharma Raises $40 Million from China
- Tongjitang Receives Buy-Out Offer from CEO and Fosun
- MicuRx and Cumencor Partner with Pfizer to Develop Antibiotics
- Cord Blood America Licenses Technology to AXM Pharma in China
- Martek Signs Deal to Export Omega-3 to China
- Astellas Obtains China Rights to Teijin Pharma’s Gout Treatment
- China Pharma Inc. Completes Reverse Merger
- WuXi MTLH Out-licenses Innovative Cancer Drug to Shanghai Pharma
- OriGene Completes $16 Million Funding to Build mAb Library
- Chongqing Porton Secures $10 Million for Production Facility
- TCT Medical Books $10 Million Investment from Fidelity
- EA Inc. Raises $6.6 Million from OrbiMed
- AutekBio to Build Largest Biologic CMO in Asia
- Hutchison MediPharma May IPO within Two Years
- Mindray Raises $152.8 Million in Secondary Offering
- Kalen to Offer Lipoprotein Research Products in China
- WuXi PharmaTech Forms Pre-Clinical Collaboration with Janssen
- aTyr/Pangu Announces Second Matching Grant in Hong Kong
- Teva to Market Parkinson’s Drug in China for Lundbeck
- China Aoxing In-Licenses China Rights for Narcotic Drug Combo
- Shenghong Buys New Drug Projects from Tibet Rhodiola
- Merck, Lilly and Pfizer to Construct Asian Cancer Database
- Fosun Increases In-Vitro Presence with Biosino Investment
- Sinovac Acquires New Manufacturing Facility
- NeoStem Raises Cash to Build New Facilities
- 3SBio and Ascentage Form Alliance to Develop Cancer Drugs
- Private Equity Investors Seek Emerging Markets and China
- 3SBio Gains China Rights to Another Drug for Dialysis Patients
- BioMarin Buys LEAD Therapeutics of California and Shanghai
- Tongjitang Pays $18 Million to Acquire Guiyang Liquor
- Zhejiang Hisun Pharma Invests in US-based Sagent Pharma
- GCA Therapeutics to Commercialize Achillion’s HBV Treatment in China
- China Medicine Corp. Closes JPMorgan Funding
- Sanofi-Aventis Forms Another China JV with Minsheng
- Suzhou Nanomed Secures VC Funding from Softbank
- New Summit Bio to be China Partner for Pacgen’s Thrush Treatment
- Morningside Sets Up China Cancer JV with Can-Fite
- Burdica Signs Up Sinopharm to Register, Distribute Products
- bioMerieux Buys Meikang, a China Rapid Test Manufacturer
- China Medicine Raises $69.6 Million in PE from JPMorgan Chase
- $1.5 Billion Fund to Aid VC/PE Investment in Beijing’s Zhongguancun Park
- GL Biochem Reaches Final Terms for Reverse Merger
- Ranbaxy Sells China Manufacturing JV
- Nextchem Pharma Reopens after Capital Infusion
- Fosun to Raise Capital for Expansion
- Hard to Treat Diseases Sells Division to TCM Company
- Pfizer Extends Relationship with Peking University
- Biostar Announces $1 Million Acquisition
- Guangzhou Improve Medical Instruments to IPO on ChiNext
- Sinocom Pharma Raises $15 Million
- Disappointing Pricing for China Nuokang’s Nasdaq IPO
- Sinopharm in Hunt for $3 Billion German Generic Drug Company
- Institut Mérieux Plans China R&D Center
- Milestone Scientific Forms China JV for Injection Devices
- Concord Medical to IPO Next Week on NYSE
- FORMA Therapeutics Closes $25.5 Million Series B
- PPD Paid $77 Million to Acquire BioDuro
- Jiuding Capital Launches PE Fund for China Pharma
- Sinovac Adds Vaccine Capacity by Forming JV
- China Nuokang Bio-Pharma Plans a Nasdaq IPO
- China Cord Blood Completes Secondary Offering on NYSE
- Jennerex Out-Licenses China Rights for Cancer Drug to Lee’s Pharma
- PPD Buys BioDuro, Its Second Major China CRO Acquisition This Month
- Advanced BioMedical Finds Partner for New Use of Medical Device
- China Medicine Corp. Signs Term Sheet to Raise $59.5 Million
- China Establishes $1.3 Billion Emerging Industries VC Program
- D-Pharm Outlicenses Stroke Drug to Wanbang Biopharma
- Simcere Buys Manufacturing License for Statin
- Biostar Raises $3.6 Million
- Beike Biotechnology Invests in Biomaster, a Japanese Stem Cell Company
- Microbix to JV with Hunan Biopharma on $200 Million Flu Facility
- NeoStem Closes China Biopharma Acquisition
- Tianyin Pharma Creates New Antibiotic JV
- China Medicine Acquires Guangzhou LifeTech for $8.3 Million
- Simcere Gains Majority Control of Vaccine Subsidiary
- Chi-Med Ups Ownership of Hutchison Healthcare JV to 100%
- PPD to Acquire China CRO Excel PharmaStudies
- Sanofi-Aventis to Create China Vitamin JV with Minsheng
- Simcere to Develop Cancer Drug from OSI Pharma in China
- Breaking News: California’s $3 Billion Stem Cell Fund Signs MOU with China
- China Pediatric Completes Reverse Merger
- Starr Invests $20.5 Million in Techpool
- NeoStem Moves Forward on China Biopharma Acquisition
- Inviragen and SingVax Merge; Raise $15 Million
- GSK Forms Vaccine JV with Jiangsu Walvax
- CCB Opens RMB Private Equity Fund for Healthcare
- Zhangjiang Hi-Tech Park Buys Stake in Buchang Pharma
- Three Life Science Companies to IPO on New GEM Exchange
- Hualan Biological Signs Middle East Flu Vaccine Deal
- Asia Pharmaceutical Books $10 Million VC Investment from Silicon Paradise
- Cleveland BioLabs Licenses Cancer Drug to Zhejiang Hisun
- PerkinElmer Pays $64 Million for China Diagnostic Company
- Sinopharm Signs Up Big Investors for Hong Kong IPO
- S-Evans Biosciences Obtains China Rights for Stem Cell Technology
- Shenzhen Mellow Hope to Market NCPC Hepatitis B Vaccine Internationally
- Cheezheng Tibetan Medicine to IPO on Shenzhen Exchange
- China Aoxing Sells Shares for $5 Million
- Pfizer Underwrites Basic Research at Shanghai Institutes
- aTyr Pharma of San Diego and Hong Kong Raises $12 Million
- SciClone Buys China Rights to Anti-Nausea Drug
- GSK to Distribute Dr. Reddy’s Generic Drugs in Developing Markets
- Benitec and Biomics to Collaborate on RNAi Treatment for Hepatitis B
- Sinopharm Expected to Raise 7 Billion RMB in Hong Kong IPO
- Bayer Schering to Distribute Bioton's Insulin
- Two China Pharma-Related Companies IPO – Guilin Sanjin and Chemspec
- Novast Receives $25 Million in Series C Round
- NeoStem Raises an Additional $4 Million
- NeoStem Signs China Stem Cell Deal with Enhance BioMedical
- Bio-Bridge Science Begins China JV
- Commonwealth Biotechnologies Acquires China Peptide Producer
- GSK and Shenzhen Neptunus Create Flu Vaccine JV
- China Biologic Raises $9.6 Million
- Simcere Buys Stake in Vaccine Company
- Hamner Institute Builds Biopharma Bridge with China Medical City
- China Sky One Signs Cancer Drug Agreement with Taiwan Company
- Kleiner Perkins Invests $15 Million in CRO Jinsite
- China Aoxing Buys Novel Menstrual Pain Drug
- NeoStem Acquires Asia Rights to Stem Cell Treatment
- NeoStem Licenses Stem Cell Wound Healing Product
- BioVeda May Set Up Guangzhou Life Science Fund
- Pacgen Acquires XPhase, Which Owns Rights to China Anti-Anxiety Drug
- Shanghai ChemPartner Forms Alliance with Japan Pharma
- China Biologic Closes Qianfeng Acquisition
- NeoStem Raises $11 Million from Asian Investors
- BioDuro Expands Discovery Collaboration with Roche
- ReSearch Pharmaceutical Buys China CRO Paramax
- Sinobiopharma Seeking US Partner for Lead Drug
- Tongjitang Chinese Medicines Makes Another Small Acquisition
- Bayer and Bioton Discussing Insulin Distribution Deal for China
- Royal DSM Forms JVs with North China Pharmaceutical Group
- CRO BioDuro Signs Collaboration with AstraZeneca in Beijing
- Nanjing Chuanbo Biotech to Set Up JV in Britain
- Simcere and Epitomics Form mAb Development Partnership
- Lee’s Pharma Acquires Oral Antibacterial Drug from Nippon Shinyaku
- Immtech Signs MOU with Beijing Pharmaceutical Group
- CRO Tigermed Strikes Deal with Biostatistician MacroStat
- Beijing SL Pharmaceutical to Form In-Vitro Diagnostic JV
- China Sky One Out-Licenses Distribution of Prostate Drug
- Frontage Labs Expands Relationship with Beijing Pharma
- Is Pharmacyclics Looking towards China?
- Lotus Purchases Ulcer Drug for $7.9 Million
- OriGene Pays $6.5 Million for Shenzhen P&A Biotech
- Roche Innovates with Deal Making in China
- RHEI Pharma Options China Rights for Invisicare
- Genesis Pharma Buys TCM Manufacturer for $12.2 Million
- NovaMed Buys China Rights for Cancer Pain Drug from Orexo
- SinoGenoMax to Offer Cogenics’ Genotyping Services in China
- S*Bio Licenses Early-Stage Cancer Drug to Tragara
- Hutchison MediPharma Options Program to J&J
- Shares of American Oriental Slide after Real Estate Purchase
- S*Bio Signs $550 Million Deal with Onyx
- Forma Therapeutics, with Significant China Connection, Raises $25 Million
- China Medical Defends HIFU Subsidiary Sale
- Shinva and GE Healthcare Form Medical Device JV
- Tiantan Biological to Acquire Rongsheng Pharma
- Medtronic Buys 15% of Shandong Wiegao; Opens JV
- BMP Sunstone Acquires 50% Stake in Pediatric Drug Maker
- New VC Fund to Back Biopharmas in Jilin Province
- ProGenTech to Develop Diagnostics with China’s CDC
- China Biologic Accepts Smaller Stake in Qianfeng Acquisition
- BMP Sunstone Bumps Non-GAAP Net Income Higher
- China Medical Sells HIFU Business to Chairman/CEO
- 2008 China Biopharma M&A Deals Running Ahead of 2007
- Erye Pharma Invests in NeoStem
- Tigermed Builds Up Phase I CRO Services
- Smiths Group Buys China Device Maker
- AnaSpec Signs Distribution Deal with Shanghai Universal Biotech
- Lilly Adds New Target to Hutchison Meditech Collaboration
- Tigermed Extends CRO Network to Russia and Korea
- GSK Signs Pre-JV Vaccine Pact with Shenzhen Neptunus Interlong
- BMP Sunstone Buys Unique Constipation Drug
- Chiral Quest Closes $13 Million Series B
- China Sky One Pays $2.2 Million for Nine New Drugs
- WuXi PharmaTech Inks New Three-year Deal with Pfizer
- TomoTherapy Buys China Linear Accelerator Company
- NeoStem Announces Two China M&A Transactions
- China Sky One Buys Breast Lesion Drug
- China Medical Wrestles with Accounting for $345 Million Acquisition
- Diagnostics Company Chemclin Closes $16.5 Million Series B
- China Sky One Inks Distribution Deal for Asthma Patch
- American Oriental Announces Two Acquisitions; Terminates a Third
- Fosun Buys 5% Stake in Tongjitang Chinese Medicines
- China Biologic Acquires Another Plasma-based Pharma
- Pioneer to Distribute Spinal Products in China through Bonovo
- InforSense to Market Pharsight’s Products in China
- ProGenTech Aims Entura Machine toward Diagnostic Market
- China Medical Acquires HPV Diagnostic Test for $345 Million
- Huifeng Firms Up Deal to Control Xi’an Qinba
- Three Rivers Buys China Rights to Infergen
- China Biologic to Buy Controlling Interest in Competitor
- WuXi PharmaTech and Covance Nix Partnership
- Qiagen to Help Develop China Food Diagnostic Tests
- Huifeng to Assume Control of Medical Device Maker
- US Stem Cell Banking Company Receives Investment from Asia
- Dermatology Company Profex Announces $15.5 Million Series A
- China Botanic Buys Guangdong Kangli Pharma
- Will Sinopharm and CITIC IPO?
- Biomics Biotech Closes 34 Million RMB B Round
- Beijing Beilu Pharma Raises 67 Million RMB
- More Deals for Venturepharm
- Venturepharm Invests in US CRO and Details Building Plans
- Schering-Plough Takes Sole Possession of its China JV
- American Oriental Reveals Huge Acquisition in Q2 Report
- China Medical to Float $150 Million Note Offering
- HD Biosciences Funded by Lilly, Pfizer and Morningside
- Vaccine Maker JGAD Completes Reverse Merger with China Bio-Immunity
- Sinobiomed Takes in New Capital
- Zhejiang Huahai To Provide Finished Drug Product to Merck
- Lotus Unveils Plans for New Manufacturing Facility
- NovaMed to Distribute Epilepsy Drug for Sanofi-Aventis
- Genelabs to Collaborate on HCV Drug in Taiwan
- GSK Makes Generics Deal to Penetrate Emerging Markets
- GNI In-licenses Hepatitis Drug from EpiCept
- BMP Sunstone Acquires Pediatric Drug Company
- Consortium Formed for Early Stage Biotech Investment
- VCs Turning Their Noses Up at Chinese CMOs
- CRO Tigermed Closes $5 Million Series A Funding
- CRO Consolidation: Indian Firm Veeda Buys US CRO
- China VC Hits Record Level in Q2
- Management Key in Attracting Venture Capital in China
- Shanghai Offers Financing to Early-stage Biotechs
- CRO Tigermed Raises $5 Million in VC from Qiming
- Commonwealth Bio Raises $1 Million for Venturepharm JV
- American Oriental Prices Convertible Notes
- AMDL Acquires Drug Distributor
- Bio-Bridge Raises $2.8 Million for Vaccine Development
- American Oriental to Offer $85 Million in Notes
- Bayer Finally Closes Topsun Acquisition
- Biofield in $365 Million China Breast Cancer Diagnostic JV
- Tongjitang Tanks after Buyout Offer Withdrawn
- NovaMed Will Market Six Cancer Drugs in China for Pfizer
- Pacific Biopharma: Two Parts US; One Part China
- Yunnan Baiyao to Take Lijang Medicine In-house
- Krka Makes Small Investment in Two China Pharmas
- WuXi PharmaTech and Covance Will Partner in JV
- Microbix to Build Flu Vaccine Plant in Hunan
- BioAlliance SA Out-licenses Loramyc in China to NovaMed Pharma
- Oculus to Use Bayer for Approval of Microcyn in Animals
- Immtech to Start CRO with Beijing Capital Medical University
- Cordium Links Launches Cardiac Safety JV in China
- Alpharma Forms Vancomycin JV with Zhejiang Hisun
- China Sky One Makes $7 Million Acquisition
- Daiichi Sankyo to Acquire Control of Ranbaxy
- WuXi PharmaTech and AstraZeneca Sign New Three-Year Collaboration
- Genesis Accepts Strict Terms for $30 Million Financing
- Access Pharma Ties China Clinical Trials to Drug Out-licensing
- NewBiomed Licenses Vaccine Adjuvant to Walvax
- American Oriental To Repurchase $75 Million of Stock
- InSite Visions Signs Essex to Market AzaSite® in China
- China Pharma Raises $10 Million in Secondary Offering
- Kiwa Bio-Tech JV Will Develop Veterinary Anti-Viral Spray
- 3SBio to Commercialize Iron Deficiency Agent in China
- 45% Stake in Shanghai Schering-Plough JV For Sale
- Details Added to Venturepharm Asia JV Plan
- WuXi PharmaTech Postpones Secondary Offering
- Bio-Bridge Buys Majority Interest in China Company
- Frontage Labs Receives $10 Million for China Expansion
- VC Investments in China Biotech/Healthcare Climb in Q1
- US Scientist Forms Changzhou Vaccine Company
- Unigene Breaks Ground for China JV Facility
- Simcere Buys Cancer Drug Company
- Bionet Enters China Alliance with Vita Genomics
- Bio-Bridge Sciences Forms China JV with JR Scientific
- American Oriental Buys Stake in China Aoxing
- AsiaPharm Signs Deals with Two Scottish Pharmas
- Alliance Established between China and India CROs
- SciGen Buys China Rights to Generex Oral Insulin Spray
- China YTC Will Merge Subsidiary with Supplier
- Actavis Buys Controlling Interest in China API Maker
- WuXi Announces 10 Million Share Secondary Offering
- CROs Chemizon and Crown Bioscience Partner Up
- Commonwealth and Venturepharm Form CRO JV
- ProGenTech Closes $21 Million Financing
- Aida Pharma Acquires Jiangsu Institute
- Morgan Stanley to Evaluate Buyout Offer for Tongjitang
- Amarillo Biosciences Signs Deal with CytoPharm of Taiwan
- Tongjitang Buys TCM Company with Respiratory Drug
- Medigen In-licenses Asian Rights for Cancer Drug
- Institutions To Block AsiaPharm Private Equity Deal
- China Aoxing To Acquire TCM Pain Drug Company
- CEO Bids to Take Tongjitang Private
- More Time for Bayer-Topsun Deal
- Hovione Buys Stake in Zhejiang Hisyn
- Valeant Sells Pan-Asia Marketing Rights to Invida
- China Sky One Makes $8.3 Million Acquisition
- Time Runs Out on Bayer-Topsun Deal
- Lotus Private Placement Includes Make Good Clause
- RHEI Licenses China Rights to ADHA Nutraceutical
- Shanghai Century Acquisition Nixes Kelun Pharma Purchase
- Beijing Med-Pharm Completes Sunstone Acquisition
- Chemizon Collaborates with Korean Research Institute
- Mylan Unit Ups Stake in China Subsidiary
- AsiaPharm Accepts Private Equity Offer
- China Sky One Medical Raises $25 Million
- bioMérieux to Move Immunoassay Production to New Shanghai JV
- Baxter Pays $24 Million To Bring JV In-house
- Private Equity Fund Raising for China Up 151% in 2007
- Sinovac Closes $9.8 Million Follow-on Offering
- NovaMed Raises $14 Million to In-license New Molecules
- Shenzhen Chipscreen Received $28 Million for Cancer Drug
- US Venture Capital Investing in China Hits Record in 2007
- Sundia MediTech Rides WuXi IPO to Series B Funding
- Chengdu Tianyin Pharma Completes Reverse Merger
- Biosensors Buys China Stent Maker
- Unigene Sets Up China Biotech JV with Shijiazhuang Pharma
- WuXi PharmaTech Makes US Acquisition
- Yunnan Baiyao Acquires Two Small Pharmas
- China Medical Buys Company to Add ECLIA Testing Products
- Simcere Makes Cancer Acquisition; Misses on Revenue
- Dragon Pharma Sells EPO Unit
- Case Study: Cross-border Investing Works for Life Science Angels
- Newly-Formed Genesis Pharma Buys Patent on Anti-clotting Drug
- LEAD Lands $17 Million to Launch US-China Pharma
- An IPO for ShangPharma?
- Benda Forms JV for HIV Vaccine
- Private Equity Firm Invests in CRO ChemPartner
- Sunway and Genzyme to Collaborate on Gene Therapy
- Beijing Med-Pharm Signs Another Distribution Deal
- China Nepstar Pharmacy Chain Files for IPO
- AMDL Signs Distribution Deal
- Ranbaxy Seeks China Joint Venture
- Laiyang Jiangbo Pharma to Execute Reverse Merger
- Beijing Med-Pharm Buys Remaining 51% of Sunstone
- Simcere Takes Majority Stake in Rival Boda
- China Resources (Holdings) Consolidating China Pharma
- Drug Distributor Jointown Receives Overseas Capital
- Tongjitang Acquires Fellow TCM Company
- NovaMed Pharma Books $5 Million in Venture Capital
- Q2 Investment Activity in China: The Numbers
- Beijing Double-Crane Offers New Shares
- China Biopharma Will Bring Staph Vaccine to China
- DSM Forms Joint Venture with North China
- China Biopharma Strikes Deal for Antiviral
- Benda Adds to Ownership of Cancer Gene Therapy Drug
- Shijiazhuang Pharma Bought by Legend, Goldman Sachs
- China Shenghuo Doubles after its IPO
- Legend Holdings Expected to Win Bidding for Shijiazhuang Pharma
- American Oriental Pays $30 Million to Acquire Rival
- China Biopharma Will Buy Chinese Drug Distributor
- Chi-Med Rumoured Close to Signing Major Deal
- Chemizon Announces Reverse Merger with South Korean Company
- Two Shanghai CROs Join Forces
- PharmEng Makes China Acquisition
- Lilly Contributes $10 Million to BioVeda China VC Fund
- Charles River Labs Enters China
- Amarillo Biosciences Signs Deal with CytoPharma of Taiwan
- Shanghai Century Buys Sichuan Kelun
- J&J Buys Chinese Cosmetics Company For $300 Million
- Beijing Med-Pharm Extends Chinese Distribution Network
- China Is Hot: Venture Capital, Halter Index Soar
- Trials & Approvals
- BeiGene PD-(L)1 Inhibitor Approved in US for Esophageal Carcinoma
- KeChow Approved to Launch Tunlametinib for Melanoma Patients in China
- Aslan Pharma Offers Data Showing Eblasakimab Effective in COPD
- Ranok to Start China Trial of Protein Degrader for Solid Tumors and Lymphomas
- RemeGen Says anti-HER2 ADC Effective for Cervical Cancer
- Akeso Starts China Phase III Trial of PD-1/CTLA-4 Bispecific for NSCLC
- TransThera to Start European Arm of Global Trial for Bile Tube Cancer
- Innovent/AnHeart File China NDA for ROS1 Inhibitor to Treat NSCLC
- Qilu Says PD-1/CTLA-4 Combo Effective Against Cervical Cancer
- CARsgen Approved to Launch BMA CAR-T in China for Multiple Myeloma
- Innovent Starts Trials of Bispecific Antibody for Severe Asthma
- Everest Medicines Approved to Start China Phase IIb Trial of Lupus Therapy
- BioCity Completes Enrollment of ETA Agonist Trial in Patients with IgA Nephropathy
- Longbio of Suzhou Says LP-003 Effective in Patients with Allergic Rhinitis
- CHMP Recommends Approval of Legend’s CAR-T as Second-Line Multiple Myeloma Therapy
- Immunofoco to Start US Trial of CAR-T for Gastrointestinal Tumors
- Simcere Announces Positive Data from Phase III Trial of Dual-Drug Oral Therapy for Stroke
- Innovent’s IGF-1R Antibody Meets Endpoint for Thyroid Eye Disease
- Mabwell OK’d to Begin US Clinical Trials of ADC for Solid Tumors
- Jacobio to Start Phase III Trial of Novel Combination in NSCLC with KRAS G12C Mutations
- CASI Launches Pralatrexate in China for R/R Peripheral T-cell Lymphoma
- AusperBio Updates Clinical Progress of Antisense Oligonucleotide Therapy for HBV
- Chugai Pharma Approved for China Launch of Complement Inhibitor 5 for NPH
- Hengrui Launches Antifungal in China for Vulvovaginal Candidiasis
- Eisai Launches Leqembi, an Alzheimer’s Drug, in China for Early-Stage Disease
- Innovent Says NDA for Dual Agonist Obesity Therapy Accepted for China Review
- Wuhan iRegene Therapeutics Starts China Trial of iPSC Cell Therapy for Parkinson’s
- Fermion OK’d to Start China Trials of Novel JAK inhibitor for Autoimmune Diseases
- Sirius Starts Phase I Trial in Australia of siRNA Aimed at Thromboembolic Disorders
- Biosyngen Nabs US Fast Track Status for TIL Cell Therapy in Liver Cancer
- Bio-Thera Begins China Phase IA/IIB Trial of OX40+ Inhibitor for Atopic Dermatitis
- Biosion Cleared to Start US Trials of Novel anti-SIRPα mAb for Solid Tumor Cancers
- DualityBio and BioNTech announce US Fast Track Status for ADC in Ovarian Cancer
- Data from Qilu Pharma’s Approved ALK Inhibitor for NSCLC Published in Journal
- Gracell Approved for US Trial of FasTCAR in Early Multiple Myeloma
- Vesicure Announces Positive Early Results of Exosome Technology for siRNA Delivery
- Refreshgene’s siRNA Therapy Enables Children with Genetic Deafness to Hear
- Gannex Reports Partner’s US Trial Shows Denifanstat Effective Against NASH
- Guangzhou’s Baird Medical Completes its First Thyroid Microwave Ablation in the US
- Duality and BioNTech Start China Arm of Phase III Trial of ADC for HER2 Breast Cancer
- InnoCare Launches Early Access to CD19 Immunotherapy in China for B-cell Lymphoma
- SineuGene Reports Positive Initial Results of RNA Therapy for ALS
- CARsgen Cleared to Stage China Trial of CAR-T for Hepatocellular Carcinoma
- Adagene Reports Positive Early Results from its anti-CTLA-4 for Colorectal Cancer
- InnoCare to Start BCL2 Inhibitor Trial in US for Hematological Cancers
- Chipscreen NewWay Starts China Trial of PD-1/CD40 Bispecific for Solid Tumor Cancers
- Belief BioMed Starts China Registrational Trial of Gene Therapy for Hemophilia A
- Innovent Will Trial its PD-1 With Xuanzhu’s HER-2 ADC for Solid Tumor Cancers
- Biocytogen and CtM Biotech Identify Tri-Specific T Cell Engager for Cancers
- CellOrigin Starts China Trial of Macrophage-based CAR Therapy
- RNAimmune Approved to Start US Trials of mRNA Vaccine for RSV
- OSAI Bio’s Live Bacteria Capsule Effective In Phase III Trial for Bacterial Vaginosis
- Alebund Reports Positive Phase II Data for Novel Therapy Aimed at Dialysis Side Effects
- Connect Reports Positive Data from Phase IIb Trial of IL-4Rα Inhibitor for Asthma
- CStone Pharma’s PD-L1 Approved as First-Line Therapy for Esophageal Carcinoma
- Yingli Reports Positive Data from Phase III Trial of Linperlisib for T-cell Lymphoma
- Ractigen Files to Start Australian Trials of saRNA Therapy for Bladder Cancer
- Singapore’s CytoMed Plans to Start Investigator Initiated Trials in China of Novel T Cell Therapies
- 280Bio Treats First Patient in US Trial of Small Molecule RAS Signaling Inhibitor
- Coherus Sets US Price of Junshi-Developed PD-1 at 20% Discount to Merck’s Keytruda
- GenFleet Reports KRAS G12C Inhibitor is Under Review in China for NSCLC Approval
- Everest Approved to Launch Nefecon in China for Rare Kidney Disease
- Gracell to Start US Phase I/II Trial of Lead CAR-T for Lupus
- Avistone Biotech Approved to Launch c-Met Inhibitor for NSCLC with Genetic Mutations
- Gritgen’s Gene Therapy for Hemophilia 100% Effective in IIT Trial
- AriBio of South Korea Expands Phase III Trial of Alzheimer’s Therapy
- Viatris and Theravance Report COPD Therapy Effective in China Phase III Trial
- Sirius Files for Australian Trials of siRNA for Thromboembolic Disorders
- Lerna Biopharma to Present New siRNA Therapy for Liver Failure
- Ractigen Reveals Preclinical Results of RNA Therapy for Duchenne Muscular Dystrophy
- Chipscreen Approved to Start China Trials for Novel Oral Psoriasis Therapy
- Innovent Says GLP-1R/GCGR Dual Agonist Lowers Body Weight by 18.6%
- HuidaGene Doses First Patient in Gene Therapy Trial for Inherited Blindness
- Junshi/Coherus Approved for US Launch of PD-1 without US Trials
- Viron and Ocean Begin Trial of Immunotherapy as Functional Cure for HBV
- Kelun-Biotech Releases Positive Data from TROP-2 ADC in Metastatic Breast Cancer
- AnHeart Says ROS1 Inhibitor Effective for NSCLC in Phase II Trial
- BeiGene Reports anti-PD-1 Effective in Phase III Trial for Gastric Cancers
- Ascentage Starts China Phase III Trial of Lead Drug for Acute Lymphoblastic Leukemia
- Skyline Approved to Start China Trials of Gene Therapy for Macular Degeneration
- CANbridge Files Pruritus Therapy NDA for Patients Two Months Old and Up
- Ascentage Pharma to Start Phase III Trial of Bcl-2 Inhibitor for Leukemia
- Akeso Reports Positive Data from PD-1/CTLA-4 Bispecific Published in Lancet
- Kintor Approved to Begin China Phase II Trial for Pulmonary Fibrosis Candidate
- I-Mab and ABL Bio Report Preliminary Efficacy of PD-L1/4-1BB Bispecific
- GenFleet Starts Phase Ib/II Trial of CDK9 Inhibitor for Peripheral T-Cell Lymphomas
- Jiangsu Atom Bio Begins Global Phase IIb/III Trial of Gout Treatment
- Everest Medicines Says Kidney Disease Therapy Effective in Asian Patients
- Transcenta Cleared to Proceed in a US Phase III Trial of CLDN18.2 Antibody
- Arctic Vision Completes China Phase III Enrollment for Macular Edema Candidate
- Biogen-BioThera Biosimilar of Roche Drug Approved in US for Arthritis
- Magpie Pharma Reports Results from Phase II Trial of ALS Therapy
- BioCity Plans Trial of TIM-3 mAb with AstraZeneca’s PD-L1 for Liver Cancer
- AffaMed Approved to Begin China Phase III Trial of Candidate for Dry AMD
- RemeGen Says Dual Targeted B-Cell Drug Meets Endpoints for Rheumatoid Arthritis
- Gracell Reports 100% Minimal Residual Disease Rate for CAR-T in Myeloma Trial
- Ascletis Enrolls 120 Patients for Phase III Trial of Glioblastoma Candidate
- Elpiscience Starts Australian Trial of Anti-Immunosuppressive Candidate
- Asieris Says Drug-Device Combination Effective for Cervical Lesions
- AffaMed Begins China Phase III Trial of Pain Therapy for Cataract Surgery Pain
- Clover Biopharma Starts China Distribution of Quadrivalent Seasonal Flu Vaccine
- Dizal’s JAK1 Inhibitor NDA Accepted for China Review as PTCL Therapy
- BioRay Approved to Launch Anruixi, a CD20 mAb, for B-Cell Lymphoma in China
- Sorrento Reports Positive Topline Results from China Trial of COVID Therapy
- Biosyngen Approved for US Trials of TCR-T Candidate for Solid Tumor Cancers
- Neurophth to Begin Australian Trial of Gene Therapy for Visual Impairment
- AnHeart Starts Global Phase II Trial of mIDH1 Inhibitor for Brain Cancer
- Gloria Bio Approved to Launch anti-PD-1 for Metastatic Cervical Cancer
- Brii Bio Announces Positive Interim Results for Hepatitis B Therapeutic Vaccine
- ABM Therapeutics Begins China Phase I Trial of BRAF Inhibitor for Brain Tumors
- DualityBio and BioNTech to Begin Phase III US Trial of ADC for Breast Cancer
- Genexine/I-Mab Announce Positive Results from Phase III Growth Hormone Trial
- InxMed Will Begin China Trial of FAPα Inhibitor to Lower Immunotherapy Resistance
- Asieris Starts China Trials of Dopamine Beta-Hydroxylase Inhibitor for Ulcerative Colitis
- Akeso Completes Phase III Trial Enrollment of PD-1/VEGF Bispecific for NSCLC
- Harbour BioMed to Start US Trials of its First ADC Candidate
- AusperBio Approved to Start US Trials of Antisense Oligonucleotide for Hepatitis B
- Lynk Pharma Says JAK1 Inhibitor Effective for Ankylosing Spondylitis
- Dizal Approved to Launch EGFR Inhibitor for NSCLC with Exon 20 Mutations
- Hengrui Approved to Launch Antifungal for Vulvovaginal Candidiasis
- HutchMed’s Syk Inhibitor Meets Phase III Endpoints for Immune Thrombocytopenia
- Innovent Approved to Launch PCSK9 Inhibitor in China for High-Cholesterol
- CARsgen and Moderna to Test Dual Claudin18.2 Cancer Therapy Combo
- Akeso Starts Phase III Trial of PD-1/VEGF Bispecific for NSCLC
- OnCusp to Start US Trials of CDH6 ADC In-licensed from China’s Multitude
- Kelun-Biotech’s Lead ADC Meets Endpoint in Phase III Triple Negative Breast Cancer Trial
- AceLink Starts China Phase II Trial of Novel GCS Inhibitor for Fabry Disease
- Jacobio Awarded China Breakthrough Status for KRAS Inhibitor in Pancreatic Cancer
- BioCity Approved to Start US Trial of Bispecific Antibody for Solid Tumors
- LianBio Starts China Trials of SHP2 Inhibitor for NSCLC with EGFR Mutations
- Doer Biologics Starts Trial of Tri-Specific Drug for Obesity
- Leads Biolabs Approved to Start China/US Trials of Bispecific for Multiple Myeloma
- Transcenta to Start Phase II Trial of Osteoporosis Therapy in China
- RemeGen Publishes Data Showing Telitacicept Effective for Sjögren's Syndrome
- Everest Launches Novel Antibiotic in China for Difficult/Drug Resistant Infections
- Viage Says Zhongze-Partnered Gut-Based Therapy Effective for Cognitive Decline
- SunHo Bio Starts China Trials of Immunocytokine for Solid Tumor Cancers
- Ascletis Says PD-L1/Chidamide Combination May Offer Cure for HIV
- Overland ADCT Says Zynolonta BLA Accepted for China Review as Lymphoma Therapy
- Qihan Starts Trial of Gene-Edited iPSC-Derived NK Cell Therapy for Leukemia
- Triastek 3D-Printed Candidate Delivers Active Ingredient to Ulcerative Colitis Target
- Fosun Kite Approved to Launch CAR-T as Second Line Therapy for B-Cell Lymphoma
- HighField Biopharma Starts China Trial of Immune Modulating Liposome for Glioma
- Antengene Doses First Patient in Trial of ERK1/2 Inhibitor Combined with BMS’s PD-1
- Beijing InnoCare Plans Combined Therapy with Arrivent for NSCLC
- Connect Reports Progress in Next-gen IL-4Rα Antibody for Atopic Dermatitis
- Fosun Pharma Files China NDA for Hyperphosphatemia Therapy in Dialysis Patients
- 280Bio, a Yingli Pharma Subsidiary, to Start US Trials of RAS Inhibitor
- Shanghai’s Skyline Approved to Start US Trial of Gene Therapy for Macular Degeneration
- Hansoh Pharma to Start China Trials of Novel Endometriosis Therapy
- Innovent/IASO Candidate is First BCMA CAR-T Approved in China for Multiple Myeloma
- Zai Lab Approved to Launch Fc Receptor Agonist for Myasthenia Gravis Patients
- AusperBio to Start China Trials of Antisense Oligonucleotide for Chronic Hepatitis B Cure
- CStone RET Inhibitor Approved in China for First-Line Treatment in NSCLC Patients
- Insilico Starts China-US Phase II Trials of AI-Discovered Therapy for Lung Fibrosis
- Innovent Collaborates with RemeGen to Test PD-1/ADC Combination for Solid Tumors
- Everest Medicines Reports In-licensed Candidate Effective for Rare Kidney Disease
- BioCity Starts China Phase II Trial of ETA-Receptor Antagonist for Kidney Disease
- Minghui Starts Clinical Trials for Two Novel ADCs Aimed at Solid Tumor Cancers
- MindRank Starts Trial of AI-Discovered GLP-1 Agonist for Obesity and T2DM
- HighField Bio to Start US Trial of Immunoliposome for Solid Tumor Cancers
- Genor Biopharma’s PD-1 Drug Nixed by China Regulators for Rare Lymphoma
- China Medical System’s Novel Nasal Spray Approved to Treat Seizures in China
- Innovent’s anti-CD47/PD-L1 Bispecific Antibody Effective in Hodgkin Lymphoma
- Ractigen Starts China Trials of siRNA Candidate for ALS Patients
- WestVac Biopharma Approved to Launch COVID-19 Vaccine for XBB Variants
- Innovent/IASO Release Strong Long-Term Data on CAR-T for Multiple Myeloma
- iTabMed Approved to Start China Trials of CD3 Bi-specific for Solid Tumors
- Dizal Updates Clinical News of its Two Global Trial Assets at ASCO
- Legend Reports Positive Results for CAR-T as Multiple Myeloma Therapy
- RemeGen Says HER2 ADC Paired with PD-1 Effective for Urothelial Carcinoma
- ASCO: BioNTech and Merck Present Positive Data on China-Sourced Oncology Drugs
- Gracell Reports Positive Data from Trial of BCMA/CD19 FasTCAR-T in Multiple Myeloma
- CANbridge Approved to Launch Pruritus Therapy for Alagille Syndrome in China
- Connect Reports UC Therapy Offers Statistically Significant Improvement
- HighField Biopharma Reports Progression-Free Survival in Glioma Patients
- Unicar-Therapy Publishes Positive Data for Dual-Target CAR T-cell Leukemia Therapy
- ProfoundBio Provides Updates on Two ADC Candidates in US-China Trials
- Ascentage Details ASCO Abstracts for Four Novel Apoptosis Cancer Drugs
- Lynk Doses First Cohort of Psoriasis Patients with Topical Third-Gen JAK Inhibitor
- Accropeutics to Start Phase I Trial of TYK2/JAK1 Inhibitor for Psoriasis
- Allgenesis Reports Positive Data from US Trial of Diabetic Macular Edema Therapy
- BioRay to Start Trials of LIV-1 Targeting ADC for Advanced Malignant Tumors
- Antengene Awarded Orphan Status for Claudin 18.2 ADC in Two Cancer Indications
- Minghui Pharma Doses First Subject in Phase I Trial of Autoimmune Candidate
- Laekna to Start Phase I/II Trials of ATP Inhibitor in US for Lung Cancer
- HanxBio Approved to Start US Trials of anti-CD47/PD-1 for Lymphoma
- CARsgen Starts US Phase II Trial of CLDN18.2 CAR-T for Gastric Cancer
- Boan Bio Approved to Start Trials of Bispecific Antibody for CEA Solid Tumor Cancers
- Hengrui Affiliate Files for US Approval of PD-1 in Early Liver Cancer
- CANbridge Reports Data From Preclinical Test of Gene Therapy for Spinal Muscular Atrophy
- Gracell Announces Trial of FasTCAR Candidate in Autoimmune Diseases
- LianBio Approved to Launch Cardiomyopathy Therapy in Macau
- Innovent Reports Positive Data from GLP-1R/GCGR Agonist in Weight Loss Trial
- GenAssist Says US IND Accepted for Base Editing Product in Duchenne Muscular Dystrophy
- CARsgen CAR-T Approved to Start China Trials for Pancreatic Cancer
- Junshi Bio’s PARP Inhibitor Effective as Maintenance Therapy for Ovarian Cancer
- Bridge Bio Doses First Patient in Phase II Trial of ATX Inhibitor for Fibrosis
- Sirnaomics Starts US Phase I Trial of RNAi Anticoagulant
- China Grand Pharma to Start Phase I Targeted Radiation Trial for Glioblastoma
- OnCusp to Post Data on Lead Candidate, an Anti-CDH6 ADC
- Genor Reports CDK4/6 Inhibitor NDA Under Review in China for Breast Cancer
- JW Therapeutics Starts China Trial of CAR-T for Systemic Lupus Erythematosus
- Nuance Doses First Patient in China Phase III Trial of Novel COPD Treatment
- Mabwell Says Nectin-4 ADC Posts Positive Results in Solid Tumor Cancers
- Evopoint to Start China Trial of EZH2 Inhibitor Combined with Merck/MSD’s Keytruda
- InnoCare Doses First Patient in Trial of Protein Degrader for Myeloma and Lymphoma
- Biosion USA to Start US Phase II Trials of Novel Candidate for Asthma
- Lynk Pharma Reports Third-Gen JAK Inhibitor Meets Safety Goals in Phase I Trial
- HutchMed Completes US Filing of Fruquintinib for Metastatic Colorectal Cancer
- Mabwell Approved to Launch Biosimilar to Amgen's Osteoporosis Therapy in China
- ImmVira Approved to Start Trials of Oncolytic Virus Candidate for Malignant Glioma
- YS Biopharma Says PIKA COVID-19 Vaccine Offers Superior Immunogenicity
- Transcenta Starts US Trials of Gremlin1 mAb for Prostate and Colorectal Cancer
- Boan Biotech Files China BLA for Bone Metastases Biosimilar
- 280Bio Showcases Preclinical Findings for Novel KRAS Inhibitor
- Inmagene Says IL-17A Shows Strong Efficacy for Chronic Skin Disease
- Connect Biopharma’s IL-4Rα Antibody Effective in Atopic Dermatitis Patients
- Everest Approved to Launch Antibiotic in China for Intra-Abdominal Infections
- Mabwell Starts Trials of mAb to Regulate Iron Homeostasis In Vivo
- Simcere to Test TNRF2 mAb in Combination with MSD’s Keytruda for Solid Tumors
- Everest’s In-licensed Kidney Drug Meets Endpoints in Phase III Trial
- Bio-Thera Starts Phase I Trial of Nectin-4 ADC for Solid Tumors
- Luye Enrolls Last Patient in Phase III Trial of Eylea Biosimilar
- AusperBio Starts New Zealand Phase I Trial of Novel Therapy for CHB
- Ambrx Partner Says HER2 ADC Ups Progression-Free Survival in Breast Cancer Trial
- Ractigen Granted Orphan Drug Status for Use of Novel siRNA in ALS
- JW Therapeutics Announces Trial of CAR-T as First-Line B-Cell Lymphoma Therapy
- Harbour BioMed mAb Posts Positive Results in Phase III Myasthenia Gravis Trial
- JW Therapeutics Starts China Trial of T-cell Immunotherapy for Liver Cancer
- Transcenta Reports Immuno-PET Diagnoses CLDN18.2 Levels in Gastrointestinal Tumors
- Atom Bioscience Says Gout Treatment Meets Phase II Efficacy/Safety Endpoints
- Junshi Reports anti-PCSK9 mAb Lowers Cholesterol in Phase III Trials
- BeiGene’s PD-1 Approved in China for Tenth Indication, Gastric Cancer
- InnoCare-Keymed JV Starts China Trial of Novel CCR8 Immunotherapy
- Accutar Starts China Trial of Oral Chimeric Degrader for Prostate Cancer
- Shenzhen Fapon Bio Starts US Trial of CD47 mAb for Advanced Malignancies
- Neurophth Completes Dosing in Phase III Trial of Gene Therapy for Hereditary Blindness
- Frontera Therapeutics Begins Trials for Three Leading Gene Therapy Candidates
- Innovent Starts China Trial of Novel mAb as Extended-Dose Psoriasis Therapy
- Junshi/Coherus Report PD-1 Effective in US Trial for Nasopharyngeal Carcinoma
- Henlius Biotech Reports US Accepts Herceptin Biosimilar BLA for Review
- Clover Launches COVID-19 Vaccine in China as Second Booster Dose
- Boan Biotech Starts China Trial of Anti-CD25 Antibody for Solid Tumor Cancers
- Kintor Reports Positive Data from Trial of Androgenetic Alopecia/Acne Therapy
- ImmVira Posts Positive Data from Trial of Oncolytic Virus Injection for Melanoma
- Technoderma Starts US Trial of JAK1/Tyk2 Inhibitor for Atopic Dermatitis
- Results from InnoCare’s BTK Lymphoma Trial Published in Hematology Journal
- Gracell Biotech to Start US Trial of Dual-Targeting CAR-T Therapy for Myeloma
- Nervtex AI Device Approved in China to Diagnose Parkinson’s
- CARsgen to Test Claudin18.2 mAb with Roche’s PD-L1 for Gastric Cancer
- Help Therapeutics to Start Trial of Universal Cell Therapy for Heart Failure
- HuidaGene’s CRISPR Therapy Approved to Start US Trial for Inherited Retinal Disease
- Legend Reports CAR-T Meets PFS Endpoint as Second-line Therapy for MM
- Ascletis IND Approved to Start China Trials of Prodrug for Monkeypox
- Akeso Approved to Market PD-1 in China as First-Line NSCLC Therapy
- Junshi Bio’s NDA for COVID-19 Therapy Accepted for Review in China
- Henlius anti-PD-1 Approved to Launch in China for Small Cell Lung Cancer
- Harbour Biomed to Start US Trials of Novel B7H7 Immunoncology Asset
- Bio4t2 Starts China Trial of BT-001 Antigen CAR-T for Solid Tumor Cancers
- Visen Pharma Completes Phase III Trial of Therapy for Rare Thyroid Disease
- Takeda Approved for China Launch of Targeted Drug for NSCLC with Mutations
- Dizal’s NDA Filing for NSCLC Therapy Accepted for Review in China
- Innovent Starts China Phase III Trial for Dual Agonist Diabetes Therapy
- Transcenta Approved to Start China Trials of Gremlin1 mAb for Prostate Cancer
- ProfoundBio Starts US Trial of ADC in Solid Tumor Cancers
- InnoCare Approved to Launch Cytolytic CD-19 Immunotherapy in Hong Kong
- MindRank OK’d to Start US Trials of GLP-1 Candidate for Obesity and Diabetes
- IASO Approved to Start US Trials of Lead Drug, a BCMA CAR-T
- Kira Pharma Starts China-Australia Trials of Dual Complement Pathway Candidate
- Jacobio Pharma's KRAS G12C Inhibitor Granted Breakthrough Status in China for NSCLC
- BeiGene Says its BTK Inhibitor Out-Performs Janssen’s Imbruvica
- CARsgen Files NDA for China Approval of CAR-T Based on Phase II Data
- SciClone Pharma’s Neuroblastoma Therapy Approved for China Use
- Ark Biopharma’s China NDA for RSV Therapy Accepted for Priority Review
- Ascletis Pharma to Start China Trials of Protease Inhibitor to Treat COVID-19
- Hexaell to Start China Trial of Novel Drug-Device for Chronic Liver Failure
- Innovent Starts China Trials of In-licensed Oral Therapy for Skin Diseases
- Henlius and Innovent/Lilly: A Tale of Two PD-1 Candidates
- Lyvgen to Start Phase II Trial of mAb with BMS’s PD-1 Keytruda
- AnchorDx Starts US Trial of Non-Invasive Test for Bladder Cancer
- Luye Pharma’s Long-Acting Schizophrenia Drug Meets Endpoints in US Trial
- Everest’s NDA for Renal Disease Therapy Accepted in China
- Nuance Pharma to Start China Phase III Trial of RSV Vaccine in Adults
- YS Biopharma to Start Trials for PIKA COVID-19 Vaccine in US
- NovoCodex Starts China Trial of anti-CD70 ADC in Solid Tumors
- Sirnaomics Starts Trial of Lead siRNA Therapy for Fat Reduction
- Asieris Starts China Phase III Trial of Bladder Cancer Diagnostic
- China Allows BioNTech to Import mRNA COVID Vaccine – for Expats Only
- Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bi-specific
- Kira Says First-in-Human Trial Shows Complement Candidate Effective
- Antengene Ok’d to Start China Trials of CD73 Inhibitor for Solid Tumor Cancers
- Fosun Kite’s NDA Accepted for Second Indication of CAR-T in China
- Ascletis Files US IND to Test COVID Antiviral for Monkeypox
- Akeso Receives Breakthrough Designation for PD-1/VEGF Bispecific
- Everest's Partner Reports mRNA Vaccine Matches Pfizer’s
- Zhiyi Bio to Start US Trial of Live Biotherapy for Chemotherapy-Induced Diarrhea
- Gracell Starts China Trial of Donor-Derived CD-19 CAR-T for Leukemia
- Innovent Publishes Positive Weight Loss Data from Trial of GLP-1/Glucagon Agonist
- BeiGene’s BTK Inhibitor Recommended for EU Approval as Lymphocytic Leukemia Therapy
- Bio-Thera Starts China Trial of mAb Biosimilar for Asthma
- LianBio Stops China Trial of Liver Cancer Drug After Helsinn Asks FDA to Withdraw Approval
- Accutar Starts China Phase I Trial of AI-developed Protein Degrader for Breast Cancer
- JW Therapeutics Approved to Launch CAR-T for Second Lymphoma Indication
- Innovent Approved to Launch Oncology Drug for Cancers with RET Gene Fusions
- Tracon Pharma Says PD-L1 Passes Interim Safety Test in Sarcoma Trial
- SciClone Begins China Phase III Trial of Immunotherapy for Third-Line SCLC
- Ascletis Doses First Patient in China Trial of THRβ Agonist for NASH
- Transcenta OK’d to Start US Trials of MASP2 mAb for Kidney Disease
- Connect Reports Positive Results from Pivotal Trial of its Atopic Dermatitis Therapy
- Kira Pharma to Start Phase II Trials of Biologic Targeting Two Complement Pathways for Severe Lupus
- Biosyngen’s IND Accepted in China for T Cell Treatment of Nasopharyngeal Cancer
- Harbour BioMed Starts Phase I Trial of Biologic Therapy for Asthma
- Bioheng Publishes Positive Results for Universal CAR-T in Hematological Malignancies
- Keymed’s Claudin 18.2 ADC Granted China Breakthrough Status for Gastric Cancer
- RemeGen Reports Positive Results from Confirmatory Trial of Lupus Therapy
- Frontera Approved to Start China Trial of Gene Therapy for Inherited Retinal Degeneration
- Belite Bio Starts China Trial of Therapy for Stargardt, an Inherited Renal Disease
- I-Mab Says CD47 Inhibitor Effective in Myelodysplastic Syndrome
- Genor Doses First Patient in Phase I/II Trial of Bispecific for Lymphoma/Leukemia
- InxMed Starts Pivotal Trial of FAK Inhibitor for Resistant Ovarian Cancer
- CASI and BioInvent Start China Trial of FcγRIIB Inhibitor for NHL
- Sirnaomics Reports 100% Complete Response for Lead siRNA Candidate
- RedCloud Doses NSCLC Patient in China Trial of Next-Gen EGFR TK
- AlphaBio Completes Trials of Therapy for NSCLC with CNS Metastases
- Clover Plans to Add Adolescents to List of Groups Approved for COVID-19 Vaccine
- Ranok Starts Trials of BRD4 Protein Degradation Therapy for Solid Tumors
- Sirnaomics Starts US Trial of siRNA Therapy for Squamous Cell Skin Cancer
- IASO to Start China Trial of Injected CAR-T Therapy for Autoimmune Disease
- Accutar’s Chimeric Degrader OK’d for Prostate Cancer Trials in China
- SinocellTech Says Anti-CD20 mAb Shows Non-Inferiority to Genetech’s Rituxan
- Frontier Reports Positive Results from Early Trial of COVID-19 Therapy
- EQRx Starts US Phase III Trial of Hansoh’s EGFR for NSCLC
- LianBio Completes Enrollment of Phase III Trial for Cardiomyopathy Therapy
- Arbele Starts Australian Trial of CDH17xCD3 Bispecific for GI Cancers
- Inmagene and HutchMed Start Global Trial of BTK Inhibitor
- ImmVira Granted US Orphan Drug Status for Oncolytic Virus Candidate in Glioma
- ProfoundBio Cleared to Start US Trials of ADC for Solid Tumor Cancers
- Zenas to Start China Trials of Thyroid Eye Disease Therapy
- Denovo Starts Global Phase II Trial of Precision Medicine for Resistant Depression
- HanX and Lepu Approved to Launch PD-1 mAb for Colorectal Cancer
- ImmVira Says IV Administration of Oncolytic Herpes Simplex Virus Shows Promise
- Ascentage-Innovent NDA Accepted for Priority Review of Chronic Myeloid Leukemia Therapy
- Innovent Says Type 2 Diabetes Therapy Meets Glycemic/Weight Loss Endpoints
- Antengene to Test its Bispecific with Celularity’s Stem Cell Natural Killer Cell Therapy
- Simcere Approved to Launch Myelosuppression-Prevention Drug in China
- CStone Approved to Launch RET Inhibitor in Hong Kong for NSCLC
- Bio-Thera Starts China Trials of ADC for Solid Tumors
- Connect to Use Early Results from China Phase III Trial of Atopic Dermatitis Therapy
- Overland ADCT Starts China Trial of ADC for B-cell Lymphoma
- SunHo Starts Trial of Dual Immunocytokine Therapy for Solid Tumor Cancers
- Arctic Vision Starts China Phase III Trial of Farsightedness Therapy
- Ascletis Says PD-L1 Induces “Functional Cure” in CHB Patients
- Clover Bio’s COVID Vaccine Effective as Booster Against Omicron Variants
- BeiGene’s Phase III Data Shows PD-1 Effective as First Line Therapy for Esophageal Carcinoma
- Suzhou Ascentage to Start US Trial of Novel EED Protein Inhibitor
- Akeso Approved to Launch Dual Checkpoint Inhibitor for Cervical Cancer
- Innovent/Lilly Announce China Approval for Sixth Indication of PD-1 Drug
- Harbour BioMed to Start US Trials of Novel Bispecific for Solid Tumor Cancers
- InnoCare Starts China Trial of SHP2 Inhibitor for Solid Tumors
- OcuMension Approved to Launch Novel Uveitis Therapy in China
- CANbridge Says Anti-C5 mAb Shuts Down Complement Activity
- Clover Starts Phase III Trial of COVID Vaccine as a Booster to Other Vaccines
- Kangpu Doses First Patient in Phase IIa Trial for Protein Degradation Therapy
- Alphamab Starts China Trial of PD-L1/OX40 Bispecific for Solid Tumors
- Everest Approved to Launch ADC for Triple-Negative Breast Cancer in China
- Chengdu Keymed Starts China Trial of Bispecific for Solid Tumor Cancers
- Innovent and Anheart Report Novel TKI Effective in Phase II NSCLC Trial
- CStone Reports PD-L1 Approved for Stage III NSCLC Following Chemoradiotherapy
- Henlius Releases Positive Results for PD-1 as First-Line Therapy for SCLC
- Insilico Starts China Trial of AI-Discovered Novel Fibrosis Therapy
- Sihuan and CTTQ-Akeso Team up to Test AXL Inhibitor and PD-1 in Solid Tumors
- Hansoh Publishes Positive Results in ASCO Journal for Third-Gen EGFR-TKI Inhibitor
- IASO IND for CAR-T to Treat Autoimmune Disease Accepted in China
- Legend Bio to Launch CAR-T in Europe for Multiple Myeloma
- Laekna Starts China-US Trials of AKT Kinase Inhibitor for Breast Cancer
- Junshi’s Novel SARS-CoV-2 Therapy Out-Performs Pfizer’s Paxlovid
- CanSino One-Shot COVID Vaccine Accepted by WHO
- Belief BioMed Reports Positive Data for Hemophilia Gene Therapy
- Inmagene Approved to Start Phase I Trial of Novel BTK Inhibitor
- Bayer/Merck Cardiovascular Drug Approved for China Use
- Ascentage Oncology Drug Effective in Preclinical Tests for COVID Cytokine Storm
- Green Valley Stops Global Phase III Trial of its Novel China-Approved Alzheimer’s Drug
- Zenas Files China IND for mAb to Treat Thyroid Eye Disease
- Hengrui Reports PD-1 Combo Therapy Effective in Global Trial for Liver Cancer
- CARsgen Reports Positive Results for CAR T Therapy in Solid Tumor Cancers
- Zhimeng Bio Starts US Trials for Novel Epilepsy Therapy
- Ascletis Starts US Trial of PD-L1 as AIDS/HIV-1 Cure
- SCG to Start China/Singapore Trials of Cell Therapy for Hepatocellular Carcinoma
- Tonghua Dongbao Doses First Patient in China Phase III Trial of Ultra-Rapid Insulin
- Elpiscience Cleared for US Trials of Bispecific Immunotherapy in Solid Tumors
- Newsoara Ok’d to Start China Phase III Trial of Bowel Function Drug
- Connect Plans to Partner Ulcerative Colitis Candidate After Disappointing Trial
- BeiGene Approved to Launch Bi-Specific in China for Pediatric Leukemia Patients
- Suzhou Kintor Starts US Trial of ALK-1 mAb for Hepatocellular Carcinoma
- Inmagene Approved to Start US Trials of HutchMed Immune Disease Therapy
- Junshi and Coherus Upbeat Despite US Rejection of Partnered PD-1
- LianBio’s Partner BMS OK’d to Launch Cardiomyopathy Drug in US
- Transcenta Starts China Trials of Osteoporosis Therapy
- Lynk to Start China Trials of Novel Kinase Inhibitor for Psoriasis
- ImmVira to Test its 3-in-1 Virus Delivery Product with Roche’s MEK Inhibitor
- JW to Start China Trials of CAR-T for Pediatric/Young Adult Leukemia
- Bayer's Precision Medicine Approved in China for NTRK Gene Fusion Cancers
- BeiGene Snags 8th Approval for PD-1 mAb in China
- Junshi PD-1 Granted US Orphan Designation for Small Cell Lung Cancer
- CStone Presents Preclinical Data on Tri-specific (PD-L1, 4-1BB, HSA) mAb
- AffaMed and VistaGen Start China Phase III Trial of Social Anxiety Therapy
- BeiGene Says BTK Inhibitor Bests Competitor in Phase III Leukemia Trial
- InventisBio Reports Promising Data from KRAS G12C Trials
- Kintor Reports ACE2 Inhibitor 100% Effective Against COVID-19 Hospitalization/Death
- Innovent Reports Positive Data from Phase III Trial of PCSK-9 Cholesterol Drug
- Sirnaomics Starts US Trial of siRNA Therapy for Liver Fibrosis
- CanSinoBIO Approved to Start China Trials of mRNA COVID Vaccine
- Zhongze Completes China Dose Escalation Trial for Schizophrenia Therapy
- CStone Starts US Trial of ROR1 Conjugate Drug for Lymphoma and Solid Tumors
- CANbridge NDA for Rare Disease Therapy Accepted in Taiwan
- InnoCare Approved to Start Trials of JH2 Inhibitor for Autoimmune Diseases
- Henlius Reports PD-1 Approved for China Use in Solid Tumor Cancers
- Lilly/Innovent Assess New US Trial After PD-1 Rejected by FDA
- Atom Bioscience’s Novel Gout Therapy Meets Efficacy Endpoint
- Ascentage Granted US Rare Pediatric Disease Status for Neuroblastoma Therapy
- Bioheng Approved to Start First China Trial of Universal CAR-T Therapy
- Junshi/Coherus PD-1 Meets Endpoints in US Phase III NSCLC Trial
- Gan & Lee Starts US Trial of GLP Therapy for Type 2 Diabetes
- Eucure-Biocytogen Starts Trial of Dual Drug Combo for Solid Tumors
- China Approves VR Therapy as Medical Device for Acrophobia
- Legend-Janssen CAR-T Therapy Approved in US for Multiple Myeloma
- AnHeart-Innovent Granted China Breakthrough Status for NSCLC Drug
- Transcenta Starts Phase II Trial of Claudin18.2 Therapy for Biliary Tract Cancer
- CANbridge to Launch Rare Disease Therapy in China's Medical Tourism Zone
- Simcere Reports Anti-Neutropenia Oncology Drug Meets Phase III Endpoint
- Sirnaomics Says siRNA Effective in Phase II Basal Cell Carcinoma Trial
- SyMap Starts China Trial of Renal Denervation Device for Hypertension
- Innovent Says China Trial Started for Claudin 18.2 CAR-T Cell Therapy
- Revotek Starts Trial of Stem Cell 3D Printing Product for Arterial Disease
- TransThera to Start US Trials of Novel BTK Inhibitor
- Legend Halts US Trial of CD4+ CAR-T after First Patient Dosed
- Innovent Reports PCSK-9 mAb Meets Endpoint in Hypercholesterolemia Trials
- Gracell's BCMA/CD19 CAR-T Starts China Trial for Non-Hodgkin's Lymphoma
- Sirnaomics Ok'd to Start US Trials of siRNA Therapy for Rare Disease
- IASO/Innovent BCMA CAR-T Granted US Orphan Status for Myeloma
- CStone Approved to Market Precision Medicine Drug for AML Patients
- Everest Approved to Launch Triple-Negative Breast Cancer ADC in Singapore
- Innovent/Lilly PD-1 Rejected by US FDA Panel; Lilly Says Price 40% Below Competition
- Zerun Bio Lands CEPI Grant to Start Trials of Multi-Variant COVID Vaccine
- Innovent/Lilly Face US FDA Setback Due to China-Only PD-1 Trials
- Ascletis Approved to Start US Trials of an Oral PD-L1 for Solid Tumors
- CANbridge Says C5 mAb Effective in Early Trial for Complement Diseases
- Antengene Approved to Start Trial of Oral CD73 Inhibitor for Solid Tumors
- Xvivo Perfusion Approved to Launch Lung Transplant Product in China
- Hutchmed Starts China Trial of Novel FGFR Inhibitor in Solid Tumor Cancers
- Kintor Starts US Trial of Topical Androgen Inhibitor for Alopecia
- Dizal Pharma Awarded US Breakthrough Status for NSCLC Therapy
- Akeso Starts Phase III Trial of Bispecific Immunotherapy for NSCLC
- Applied Pharmaceutical Science to Start US Trial of 2nd Gen RET Inhibitor
- Elpiscience Starts US Trial of Novel CD39 Immunotherapy
- Neurophth Approved to Start Gene Therapy for Hereditary Neuropathy
- CStone Says PD-L1 Meets Overall Survival Endpoint for NSCLC
- CARsgen's Claudin18.2 CAR T-Cell Candidate Granted US RMAT Designation
- Akeso Approved for China Trial of Dual PD-1 Bi-Specifics Therapy
- CStone Approved for US Trial of ROR1 ADC
- CStone Announces Hong Kong Approval of Precision Medicine for GIST
- Kintor COVID-19 Candidate to Target Higher Risk Patients
- CStone Anti-PD-L1 Approved in China for Non-Small Cell Lung Cancer
- Zai Lab's Partner Approved for US Launch of Myasthenia Gravis Therapy
- Antengene Approved to Launch XPO1 Inhibitor for Multiple Myeloma
- Zai Lab Approved to Launch Novel Antibiotic in China for Pneumonia
- Brii Bio Approved to Launch Combination COVID-19 Therapy in China
- I-Mab and Nhwa Announce Novel Alzheimer's Drug Starts US Trials
- Lynk Pharma Starts China Trial of RA Treatment
- Tot Biopharma Approved to Launch Avastin Biosimilar in China
- MingMed Approved to Start US Trial of Immunotherapy
- Ascentage and Innovent Approved to Launch Leukemia Drug in China
- 3D Medicines Approved to Launch Anti-PD-L1 in China
- Apollomics Starts China Phase III Trial of Leukemia Drug
- Connect Bio Reports Positive Data from Phase II Trial of Dermatitis Therapy
- China Expected to Approve Brii Bio COVID-19 Therapy Next Month
- HebaBiz Approved to Start China Trial of Novel Hepatitis B Therapy
- Ascletis Approved to Start China Trial of PD-L1 to Cure HIV-1
- Everest Reports ADC Meets Endpoint for Triple-Negative Breast Cancer
- Gmax Starts China Phase I Trial of 2nd Gen Obesity Therapy
- IASO Starts China Phase I/II Trial of CD19/CD22 CAR-T for Lymphoma
- Nanjing's TransThera Granted US Fast Track for Cholangiocarcinoma Therapy
- Antengene to Start US Trials of PD-L1 Bispecific for B-NHL
- Kintor Starts Taiwan Trial of ALK-1 Antibody in HCC Patients
- Junshi and Coherus File for US Approval of Partnered PD-1
- Alphamab Starts China Phase II/III Trial of PD-L1/CTLA-4 Bispecific
- Innovent and NeoCura to Test PD-1/mRNA Vaccine Combination for Cancer
- CANbridge Doses First Patient in Phase II GBM Trial
- Angel Pharma to Start China Trial of ITK Inhibitor for Lymphoma
- Kintor Approved to Start Phase I Trial of Dual-Targeting Antibody
- Zai Lab Says Novel Antibacterial Effective Against a Drug Resistant Pathogen
- United BioPharma Starts Taiwan-China Trial of Herpes Treatment
- Innovent Says PD-1 Meets Survival Endpoint in Phase III NSCLC Trial
- Sirtex Doses First Patient in China Trial of Microsphere Radiation Therapy
- Kintor Starts China Trial of Combination Therapy for Liver Cancer
- Zai Lab Says HER2 Drug Meets Endpoints in Bridging Trial
- Himalaya Files Four INDs in China for Conditionally Active Biologics
- NovoCodex Reports Positive Data from ADC for Gastric Cancer
- Brii Bio Says mAb COVID Therapy Shows Promise for Later Stage Disease
- Kintor Starts Global Phase III Trial of COVID-19 Therapy
- Harbour BioMed Starts Phase III Trial of mAb for Myasthenia Gravis
- Akeso Files for China Approval of PD-1/CTLA-4 for Cervical Cancer
- Impact Uses Cyclia Platform to Validate Targetivity of Oncology Candidates
- Clover Reports COVID-19 Vaccine Meets Endpoints in Global Phase II/III Trial
- HighTide Says Lead Drug Effective for NASH and Type2 Diabetes
- Hutchmed and Junshi Start Phase III trial of Sulanda/Tuoyi Combination
- InnoCare and Keymed Approved to Start Trials of CD20xCD3 Bispecific
- CStone and EQRx Report Positive Phase III PD-(L)1 Results in NSCLC
- CARsgen Reports Positive Data from China Trial of Claudin18.2 CAR-T
- CStone to Start China Trials of Tri-Specific Immunotherapy in Solid Tumor Cancers
- Harbour Bio to Start China Trials of CLTA-4/PD-1 Combo in Two Additional Cancers
- Legend Bio Starts US Trial of CD4 CAR-T Therapy for Lymphoma
- Sinovac Says Third Dose of COVID-19 Vaccine Protects Against Delta Variant
- Clover Bio Awarded Manufacturing Permit for S-Trimer COVID-19 Vaccine
- JW Therapeutics to Launch CD-19 CAR-T in China for Lymphoma
- Arctic Vision Will Start Phase III Trial of Nearsightedness Therapy in China
- Harbour BioMed to Start China Phase III Trial of Autoimmune Therapy
- GloriaBio Approved to Launch PD-1 in China for Hodgkin's Lymphoma
- Everest Starts China Phase III Trial of ADC for Urothelial Cancer
- LianBio Starts China Trials of Gastric Cancer Therapy
- Reistone Reports Positive Results from Trial of JAK1 Inhibitor for Alopecia Areata
- Zhaoke Says Novel Dry Eye Treatment Hits Endpoint in Phase III Trial
- Innovent's PD-1 Inhibitor Meets Endpoint as First-Line Gastric Cancer Therapy
- Lynk Pharma Starts US Trials of Triple-Kinase Inhibitor for Myelofibrosis
- Junshi Announces Second US Breakthrough Status for PD-1
- Innovent's Anti-Cholesterol Drug Meets Endpoint in Phase III Trial
- Belief Biomed OK'd to Start China Trials of Gene Therapy for Hemophilia
- PhaseBio and SFJ to Start China trial of Reverse Agent for Antiplatelet
- Advaccine to Start China Tests of In-licensed COVID-19 DNA Vaccine
- Akeso and Sino Bio Approved to Launch PD-1 in China
- ImmVira Approved to Start Trials of IV Oncolytic Virus Therapy
- BeyondSpring Says Lead Asset Posts Positive Data in Phase III NSCLC Trial
- Transcenta's anti-Claudin18.2 mAb Granted Orphan Status in US
- IASO Approved to Start China Trials of Dual CAR-T for B-Cell Malignancies
- I-Mab to Start US Phase I Trial of Immunotherapy for Alzheimer's
- Zai Lab and Entasis Complete Enrollment in Global Test of New Antibacterial
- Innovent Starts China Trial of PD-1/TIGIT Bispecific for Solid Tumors
- Ascletis to Start China Phase III Trial of FASN Inhibitor for Brain Cancer
- Antengene to Start Trial of PD-L1/4-1BB Bispecific in Solid Tumors and NHL
- Qilu Pharma Starts China Bridging Trial for Bladder Cancer Drug
- Frontier Says HIV Therapy Effective in Difficult-to-Treat Patients
- Ascletis Starts China Bridging Trial of FXR Agonist for Hepatitis B
- Kintor to Start US Trial of Baldness Treatment
- Innovent Starts China Trial of LAG-3/PD-L1 Bispecific Antibody
- Nhwa Starts China Trial of Novel IV Opioid Analgesic
- Eucure Approved for US Phase II Trials of Combination Therapies
- EpimAb Bio Starts Clinical Trials of Two Bispecific Candidates
- SciClone Files China BLA for Neuroblastoma Treatment
- Harbour BioMed Reports Positive Data from Myasthenia Gravis Trial
- I-Mab Starts Clinical Development of Two 4-1BB Bispecific Candidates
- Neurophth Starts China Trial of Gene Therapy for Hereditary Blindness
- Pulnovo Medical Completes Trial Enrollment for Pulmonary Hypertension Device
- InxMed Says FAK Inhibitor Effective Against Resistance to KRAS Inhibitors
- Lynk Pharma to Start Trials of Novel Therapy for IBD
- HutchMed/AstraZeneca Approved to Launch Partnered MET Inhibitor in China
- Fosun Kite's CAR-T Approved in China for Lymphoma
- BeiGene's Anti-PD-1 Approved in China for 4th and 5th Indications
- Asieris Starts EU Arm in Global Trial of Photodynamic Drug-Device Product
- BeiGene Approved to Launch Brukinsa® for 3rd B-Cell Cancer Indication
- HutchMed's Surufatinib Approved for 2nd Neuroendocrine Tumor Indication
- Bioheng Granted US Orphan Drug Status for Universal CAR-T Therapy
- Jacobio Starts Trial of SHP2 Inhibitor, Triggering $20 Million Payment from AbbVie
- Sirnaomics to Start Clinical Trials of RNAi Candidate in China
- Innovent Starts China Trial of Dual Agonist Obesity Treatment
- Asieris to Start US Combination Trial of MetAP2 Inhibitor for Bladder Cancer
- ImmVira Starts China/US Phase II Trial of Oncolytic Virus Therapy for Cancer
- BeiGene Reports BTK Inhibitor Posts Better Results than the Competition
- CBMG Says Bi-Specific CAR-T Effective in Non-Hodgkin Lymphoma Trial
- Ascentage Reports Bcl-2 Inhibitor Effective in Early Test
- Innovent and HutchMed Report Positive Results from Combo CRC Therapy
- Innovent and IASO Report Positive Data from BCMA CAR-T Trial
- OriginCell Posts Positive Data from Trial of GPC3 CAR-T for HCC
- Ascletis Approved to Start China Trials of FXR Agonist for Hepatitis B
- Junshi Reports PD-1 Effective in Nasopharyngeal Carcinoma
- MicuRx Approved for China Launch of Next-Gen Antibiotic
- IASO BIO to Start Trials of CAR-T in Leukemia Patients
- Innovent Bio and Lilly Announce Third China Approval for PD-1
- Transcenta Reports Positive Results from Phase I Trial of PD-L1
- CStone Reports PD-L1 Meets Endpoint in Phase III NSCLC Trial
- AffaMed Approved to Start China Trial of Parkinson's Candidate
- Sinovant Says Antibiotic Effective for Pneumonia; Transfers China Rights to Sumitomo
- TransThera Starts China Combination Trial of Lead Drug in GI Cancers
- Innovent Doses First Patients in Phase III Cholangiocarcinoma Trial
- Ascletis Says China Accepts Filing of Phase I GBM Trial for Review
- BeiGene's PD-1 Meets Survival Endpoint in Nasopharyngeal Cancer Trial
- InnoCare to Start China Trial of TYK2 Inhibitor for Autoimmune Diseases
- Reistone Starts Global Trial of JAK1 Inhibitor for Atopic Dermatitis
- Antengene Approved to Start China Trial of Endometrial Cancer Therapy
- Connect Doses Asthma Patients in Global Trial of Interleukin Antibody
- BeiGene Announces Approval of PARP Inhibitor in China
- Newsoara Says Lead Drug Effective in Gastrointestinal Surgery Patients
- Asieris and BeiGene to Test Combination Therapy for Bladder Cancer
- Ascletis Reports Initial Success in PD-L1 Trial for Chronic Hepatitis B
- Jacobio to Start US/China Trials of KRAS Inhibitor in Solid Tumor Cancers
- Galmed Adds China Arm to Global Trial of NASH/Fibrosis Treatment
- Nanjing Legend Files for EU Approval of BCMA CAR-T Therapy
- Fosun Pharma Starts China Phase III Trial of Long-Lasting Botox
- I-Mab Reports IL-6 Inhibitor Effective in Phase II Ulcerative Colitis Test
- CStone Reports China to Review NDA for RET Inhibitor in Thyroid Cancer
- Junshi Bio Says PD-1 Meets Endpoints in Esophageal Cancer Trial
- Henlius Reports NDA for its PD-L1 Inhibitor Accepted for China Review
- Transcenta Starts US Arm of US-China Bi-specific PD-1 Trial for Solid Tumors
- Adlai Nortye Starts Phase III Trial of Pan- PI3K Inhibitor in Head and Neck Carcinoma
- Kintor Starts China Trials of Topical Androgen Receptor Inhibitor
- Innovent Reports Positive Data from Phase III Tyvyt Trial in NSCLC
- LintonPharm Starts China Trial of Candidate for Bladder Cancer
- Junshi's PD-1 Approved for Third Indication in China, Bladder Cancer
- Gracell Reports Positive Data from Trial of Off-the Shelf CAR-T Candidate
- Antengene to Start Trial of I PAK4/NAMPT Inhibitor in Solid Tumors/NHL
- Bridge Bio Starts Trial of Novel EGFR Inhibitor for NSCLC with Mutations
- I-Mab and Korea's ABL Bio Start Phase I Trial of Partnered Bispecific
- Zai Lab's GIST Treatment Approved for China Use
- BeyondSpring Files US/China NDAs for Novel Neutropenia Prevention Drug
- CStone Approved to Launch Novel GIST Treatment in China
- Everest Approved for China Phase II trial of Trodelvy® in TROP-2 Cancers
- Henlius Plans to File for China NDA Approval of PD-1 Inhibitor
- Eucure Says anti-CTLA-4 Antibody Effective in Early Tests
- Citrine Approved to Launch Rare Disease Drug in China without Clinical Trial
- Adagene Starts Global Trial of CTLA-4 Inhibitor for Solid Tumor Cancers
- Harbour Bio Starts China Phase III Trial of Novel Dry Eye Treatment
- Lee's Pharm Affiliate OK'd for Phase III Trial of PD-L1 for NSCLC
- BeiGene Starts Trial of HPK1 Inhibitor, a Novel Immunocology Candidate
- Alphamab Approved to Start US Trial of PD-L1/CTLA-4 Bispecific
- Gannex/Ascletis Reports Positive Phase II Data for NASH Treatment
- Apollomics Starts China Trial of Immunotherapy for AML
- Innovent Starts US Trial of CD47/PD-L1 Bispecific Antibody
- Junshi Bio's PD-1 Approved as First-line Therapy for Nasopharyngeal Carcinoma
- Harbour BioMed OK'd to Start China Trial of CTLA-4 Antibody for NSCLC
- Innovent's CAR-T Therapy Awarded Breakthrough Status in China
- I-Mab Doses First Patient in Phase III Trial of Novel Growth Hormone Therapy
- Lee's Pharma to File for China Approval of PD-L1 Under Breakthrough Rules
- I-Mab Approved to Start China Trial of Complement Factor Inhibitor
- Beijing InnoCare to Start Phase III Combination Trial of BTK Inhibitor
- I-Mab Starts China and US Trials of CD73 Immunotherapy
- Innovent's PD-1 Approved in China for First-Line NSCLC Indication
- Kanghong's VEGF Fusion Drug Granted Three US SPAs for Retinal Diseases
- Kira Starts Trial of Candidate for Complement-Mediated Diseases
- Gan & Lee Awarded US Fast Track Status for Glioblastoma Treatment
- BeiGene Says PD-1 Extends Survival in Global Phase III Trial for Esophageal Cancer
- BeiGene Files China BLA for Sylvant, a Rare Disease Therapy
- Eucure Bio Starts China Trial of CTLA4 Treatment for Solid Tumors
- Junshi's PD-1 Candidate Approved for US Fast Track Review
- Seneca Reports Mixed Results from China Stem Cell Trial for Stroke
- Gracell to Start China Trial of CAR-T in Leukemia Patients
- EdiGene Approved to Start China Trial of Gene-Edited Stem Cell Therapy
- Gracell to Start China Trial of Donor-derived CAR-T Therapy for B-ALL
- Everest to Start China Phase III Trial of ADC For Urothelial Cancer
- InnoCare Approved to Launch BTK Inhibitor for Three Indications in China
- Ascletis Doses First Person in US Trial of Novel NASH Treatment
- Chi-Med Approved to Market Surufatinib for Neuroendocrine Tumors
- CASI Granted Breakthrough Status in China for CD19 CAR-T Therapy
- Ascentage's Bcl-xL Inhibitor Starts US Trials for Macular Edema
- Legend Starts Submission for US Approval of BCMA CAR-T Therapy
- CANbridge to Start Trial of Novel Complement Dysfunction Therapy
- Junshi's PD-1 Meets Survival Endpoint as First-Line NSCLC Treatment
- Legend Bio Cleared to Start US Trials of CD4 CAR-T Candidate
- Antengene Approved for Phase III Trial of SINE Candidate for Myeloma
- Innovent Starts Phase II Trial of CTLA-4 mAb for Cervical Cancer
- EOC to Start China Trial of Novel Immunotherapy for Breast Cancer
- JW Therapeutics Releases Positive Data from CAR-T Trial for Lymphoma
- Sinovac Approved to Launch 23-Valent Pneumonia Vaccine in China
- I-Mab Advances AbbVie-Partnered CD-47 Candidate
- Junshi Announces First Patient Dosed in China Trial of TROP2 ADC
- Simcere Approved to Start China Trial of Gout Treatment
- LianBio Cleared to Start China Phase II Trial of FGFR Inhibitor
- Bio-Thera Files for Approval of Avastin Biosimilar in Europe
- Ascentage to Start China Trials of Bcl-2 Apoptosis Candidate
- BeiGene Approved to Market Xgeva for Bone Metastases in China
- Alphamab and 3D Medicines File China NDA for PD-L1 Therapy
- Innovent Bio Reports Novel Bi-Specific is Effective in AMD Trial
- Apollomics to Start China Trial of Multi-Kinase Inhibitor for Solid Tumors
- CStone's China NDA for Anti-PD-L1 Candidate Accepted for Review
- I-Mab Reports Initial Positive Data from US Trial of CD47 Candidate
- BeiGene's BLA for Neuroblastoma Therapy Accepted for Review in China
- Everest's Partner Calliditas Reports Positive Results for Rare Disease Therapy
- Everest Medicines Starts China Trial of Triple-Negative Breast Cancer ADC
- Green Valley to Start US Trial of Algae-based Alzheimer's Drug
- Asieris Approved for Phase III Trial of Bladder Cancer Drug
- LianBio to Start China Phase III Trial of Bile Cancer Drug
- InnoCare Starts US Trial of BTK Inhibitor for MS
- Zai Lab Starts Trial of Anti-PD1 Antibody for Endometrial Cancer
- Aprinoia to Start China Trial of PET Tracing Agent for Alzheimer's
- Reistone Reports Successful Test of JAK1 Inhibitor for Atopic Dermatitis
- Gmax of Hangzhou Starts China-US Trials of Antibody Drug for PAH
- Ascentage Granted China Priority Review of NDA for BCR-ABL Inhibitor
- Innovent and Lilly Announce China Approval for Rituxan Biosimilar
- Ascletis Subsidiary OK'd to Start US Trials of NASH Candidate
- Zai Lab Doses First Patient in China Trial of PD-1 for NSCLC
- Harbour Bio Starts China Trial of Autoimmune Treatment
- CARsgen Granted US Orphan Drug Status for Claudin18.2 CAR-T Drug
- I-Mab to Start China Phase III Trial of Long-Acting Treatment for Dwarfism
- Apollomics to Start China Trials of In-Licensed Leukemia Drug
- Junshi Says its PD-1 Effective Against Nasopharyngeal Carcinoma
- Bioray Lab Starts Tests of Gene Edited PD1-Knockin CAR-T Candidate
- XiangXue Life Sciences to Start US Trial of Novel T-cell Receptor Candidate
- Sinovac Starts Phase III Trial of COVID-19 Vaccine in Turkey
- I-Mab and MorphoSys to Test C5aR1 Antibody in the US
- Everest Med Reports Results from Trial of Antibiotic for MDR Infections
- Fosun-Pfizer Could Complete COVID-19 Vaccine Trials in October
- Ascentage Granted US Orphan Drug Status for Gastric Cancer Treatment
- Junshi Granted US Breakthrough Status for PD-1 in Nasopharyngeal Cancer
- Zai Lab's PARP Inhibitor Approved for First-Line Maintenance in Ovarian Cancer
- Zion Pharma Starts US Trial of Treatment for Breast Cancer Brain Metastases
- CANbridge Approved for China Launch of First Rare Disease Treatment
- Everest Starts China Trial of Treatment for Rare Renal Disease
- Innovent Approved to Launch Humira Biosimilar in China
- Innovent Starts China Trials of Novel Anti-Inflammatory Biologic
- Innovent Reports Positive Data from PCSK9 Anti-Cholesterol Treatment
- CStone Approved to Start US Trial of anti-PD-L1 in Lymphoma
- Ascletis Completes Bridging Study of One-Pill Combination HCV Treatment
- I-Mab Starts China Trial of GM-CSF Inhibitor for RA
- GNI Reports Positive Results from Trial of Liver Fibrosis Drug
- Henlius Biotech Approved to Launch Herceptin Biosimilar in China
- Ascletis Doses Patients in China Trial of PD-L1 for Hepatitis B
- Innovent Reports Positive Data from Phase III Trial of Tyvyt for NSCLC
- NeuPharma Starts Phase II Trial of Novel Treatment for Glioblastoma Multiforme
- CStone Reports Positive Results from Phase III Lung Cancer Trial of Immunotherapy
- Zai Lab Granted China Priority Review for GIST Treatment
- Innovent Starts Phase I Trial of CD47/PD-L1 Bispecific for Solid Tumor Cancers
- Ascletis Approved to Market Dual All-oral HCV Treatment in China
- Henlius' Herceptin Biosimilar Approved for European Use
- NeuPharma Doses First Patient in Phase II Trial of Novel Inhibitor for Cancer
- Chi-Med Starts China Phase I Trial of Ninth Novel Cancer Candidate
- N.B. Quadriga Candidate Starts Australia Trial for LAT1 Cancers
- Ascentage Starts Trial of MDM2-p53 Inhibitor in Hematologic Malignancies
- Asieris Approved to Start Global Phase III Trials of Cervical Lesion Treatment
- Evive Bio Reports Positive Late-Stage Results on Neutropenia Treatment
- Hua Reports Positive Interim Results from Novel Type 2 Diabetes Candidate
- Henlius Approved in China to Launch Osteoporosis Biosimilar
- InxMed Says FAK Inhibitor Effective against Drug Resistance
- Merck Announces China Approval of Fifth Indication for Keytruda
- Innovent Approved to Launch Avastin Biosimilar in China
- Ascentage Files China NDA for 3rd-Gen BCR-ABL Inhibitor
- BeiGene Approved to Launch BTK Inhibitor in China for Two Cancer Indications
- Innovent Reports Trial Data from PD-1 Drug in Three Separate Indications
- Harbour Biomed Approved for China Phase II/III Trials of Graves' Ophthalmopathy Treatment
- Mabspace Reports Positive Data from Phase I Trial of 2nd-Gen PDL1
- CStone Reports Updated Results from Phase I trial of anti-PD-L1 mAb in NSCLC
- Innovent's IBI939 is First TIGIT Inhibitor to Start China Trials
- Apollomics Starts Global Phase II Trial of c-MET Inhibitor
- I-Mab to Start China Phase II Trial of Immunotherapy for GBM
- CARsgen to Start US Trial of CAR-T for Gastric and Pancreatic Cancer
- Zai Lab Doses First Patient in China Trial of Treatment for Drug-Resistant Infections
- SciMount of Chengdu to Start US Trials of Novel Irritable Bowel Treatment
- Zai Lab Approved to Launch Tumor Treating Fields for Glioblastoma in China
- Ascletis Approved to Start China Trials of Second Candidate for NASH
- I-Mab Doses First Patient in China Trial of CD73 Antibody
- Invivoscribe Submits Biomarker Test for Astellas Cancer Drug to China's NMPA
- Ansun Pharma Adds COVID-19 Arm to Trial of Novel Parainfluenza Treatment
- Innovent Reports Positive Results from Phase III NSCLC Trial of PD-1 Drug
- HighTide Says Lead Drug Meets Endpoints in China Phase II Trial for NASH
- CANbridge Approved to Launch HER-2 Cancer Adjuvant in China
- Fosun Partnered mRNA COVID-19 Vaccine Starts US/EU Trials; China Trials to Begin Soon
- Zai Lab Reports China will use Priority Rules to Review Novel Anti-Infective NDA
- Ascentage Granted US Orphan Drug Status for Leukemia Candidate
- RemeGen Cleared to Start US Trials of Novel ADC for HER2 Urothelial Cancer
- Innovent Starts China Trial of PI3Kδ Inhibitor for Indolent Lymphoma
- Shanghai Green Valley Given US Go-Ahead for Phase III Alzheimer's Trial
- Hua Medicine Reports Positive Data from US Trial of Novel Diabetes Treatment
- Innovent's sNDA for Use of PD-1 in NSCLC Accepted for China Review
- CStone Says NDA for GIST Precision Medicine Accepted for Review in China
- Sinovac Reports Positive Animal Data on COVID-19 Vaccine; New Plant to Produce Vaccine
- Harbour BioMed Starts China POC Trial of Novel mAb in Autoimmune Disease
- US Approves Fosun Pharma's COVID-19 Test Kit under Emergency Rules
- Mabspace Cleared to Start US Trial of ADCC Molecule in Solid Tumor Cancers
- Chi-Med Granted US Fast Track Designation for Surufatinib in Pancreatic Neuroendocrine Tumors
- Ansun Starts US Proof-of-Concept Trial for COVID-19 Treatment
- Sinovac Biotech Starts Trial of Inactivated SARS-CoV-2 Vaccine
- Harbour BioMed Approved for China Phase II/III Trial of Autoimmune Candidate
- Antengene Starts Clinical Trial of Novel Lymphoma/Solid Tumor Cancer Treatment
- BeiGene Approved for China Launch of PD-L1 for Urothelial Cancer
- Ascletis Approved for China Phase IIb Test of HIV-Combination Treatment
- Astellas NDA for Leukemia Treatment Accepted for China Review
- CanSino Announces Plan to Start China Phase II Trial of COVID-19 Vaccine
- Sirnaomics Releases Positive Interim Data from Phase II Trial of siRNA Candidate
- Immunomedics Phase III Trial of Breast Cancer Drug Stopped Early; Everest Owns Greater China Rights
- Gracell's IND for Allogenic CAR-T Accepted for Review in China
- Ansun Reports Positive Results from China Trial of Inhaled Antiviral for COVID-19
- Seneca Completes Stem Cell Manufacturing Plant in Suzhou
- BeyondSpring Starts Rolling Application of China NDA for Neutropenia Treatment
- Chi-Med Starts Phase II Trial of FGFR Inhibitor in Mesothelioma Patients
- Shenzhen's BGI Genomics Approved to Launch SARS-CoV-2 Test in the US
- Fosun Long March's COVID-19 Test Approved in China
- CStone Files Taiwan NDA for Precision-Med GIST Candidate
- AnHeart Approved to Start Two China Trials of Cancer Drug
- Zhejiang Hisun Pharma's Anti-Viral Effective Against COVID-19
- Roche Starts Global Trial of Actemra in Seriously Ill COVID-19 Patients
- Hansoh Approved for China Launch of Ameile as Second-Line NSCLC Treatment
- CanSino Bio Approved to Start China Trial for COVID-19 Vaccine
- Zai Files for Approval of PARP Inhibitor as First-Line Maintenance Therapy for Ovarian Cancer
- InxMed of Shanghai Doses First Patient in US Trial of FAK Inhibitor
- Sanofi and Regeneron Start US Trial of Rheumatoid Arthritis Drug for COVID-19
- Moderna Starts Clinical Trial of mRNA COVID-19 Vaccine in Seattle
- I-Mab to Test Anti-Inflammatory for Cytokine Release Syndrome in COVID-19 Patients
- Denovo Discovers Biomarker for Triple-Reuptake Depression Treatment
- Mesoblast to Start Trial of Stem Cell Product to Treat COVID-19 Respiratory Distress
- Ascletis Reports Positive Results from Combination Treatment for COVID-19
- Ascentage Pharma to Start Three Phase Ib/II Trials of Bcl2-Inhibitor
- Shanghai Zhimeng Starts US Phase I Trial of Novel HBV Treatment
- Roche's RA Treatment, Actemra, Approved to Treat Seriously Ill COVID-19 Patients
- Innovent Starts China Phase II Trial of FGFR1/2/3 Inhibitor for Cholangiocarcinoma
- Sihuan Pharma Starts China Trials of Favipiravir to Treat COVID-19
- Merck Announces China Erbitux Approval for Head and Neck Cancer
- Harbour BioMed to Begin US Trials of CLTA-4 Antibody
- MapKure Doses First Patient in Australian Phase I Trial of BeiGene's B-RAF Inhibitor
- Gilead Starts Two Phase III Trials of Remdesivir for COVID-19
- Ascletis Begins China Trial of Combo Treatment for COVID-19
- Harbour BioMed Approved to Start US Trials of PD-L1 in Orphan Disease
- Fosun Kite's NDA Filing for CAR-T Therapy Accepted for China Review
- Moderna Ships Coronavirus Vaccine for Clinical Trials
- Ascentage Approved to Start China Trial of Apoptosis Candidate for Pancreatic Cancer
- Harbour BioMed Reports Successful Phase I Trial of Autoimmune Treatment
- Terns Announces Positive Data from Phase I Trial of NASH Candidate
- Hisun Pharma's Favilavir Approved to Treat Wuhan Coranovirus
- Ascletis Says China Accepts IND Filing for Novel NASH Treatment
- Ascletis to Start Zhejiang Province Trial of Generic HIV/AIDS Drug for COVID-19
- Roche's Tecentriq, a PD-L1, Approved in China for Small Cell Lung Cancer
- Samsung Bioepis OK'd to Start China Trial for Rare Disease Biosimilar
- Genetron Approved to Launch 8-Gene Lung Cancer Assay in China
- Zai Lab's NDA for Novel Antibiotic Accepted for China Review
- Gilead Starts China Phase III Trial of Remdesivir in Coronavirus Patients
- Zai Lab Starts China Trials for Gastric Cancer and Breast Cancer Treatments
- Bio-Thera Reports Positive Results from Phase III Trial of Avastin Biosimilar
- CSPC Starts China Trial of Lymphoma Treatment
- DelMar Reports VAL-083 Increases Progression-Free Survival in GBM
- Ascletis Files for Emergency Use of HIV Anti-Viral Combo as Coronavirus Treatment
- CStone Starts Phase I Trial that Combines its PD-L1 with Bayer's Stivarga®
- Roche's Kadcyla, a Breast Cancer Treatment, Is First ADC Approved in China
- Ascletis Approved to Start China Trial of PD-L1 in HBV Patients
- TenNor Receives Orphan Drug Designation in the US for Biofilm Infection Candidate
- Roche Approved to Market Alecensa, an ALK-Blocker, for NSCLC in China
- Chi-Med Starts China Phase II Trial of Surufatinib/Tuoyi Combo in Solid Tumors
- Innovent Reports Phase III Success of PD-1 in Lung Cancer Patients
- Bio-Thera Approved to Market Humira Biosimilar in China
- Zai Lab Starts China Trial of Tumor Treating Fields Device for Gastric Cancer
- Innovent and Sirnaomics to Test PD-L1-RNAi Combination in Hepatocellular Carcinoma
- Gracell Starts China Trial of Allogenic CAR-T Candidate for ALL
- CStone Starts China Trial of PD-L1/FGFR4 Inhibitor Combination for HCC
- BeiGene's PD-1 Antibody Approved in China to Treat Hodgkin's Lymphoma
- Clover Bio Starts China Phase III Trial of Enbrel Biosimilar
- Zai Lab's PARP Inhibitor OK'd for China Use, the Company's First China Approval
- Luye Pharma Submits NDA in US for Novel Depression Treatment
- Sinovac's Varicella Zoster Vaccine Approved for China Use
- InxMed to Start China Trials of FAK Inhibitor for Gastric Cancer
- AffaMed Ok'd to Begin Phase III Trial of Samsung Bioepis Biosimilar in China
- Everest Approved to Start China Trials of Kidney Inflammation Therapy
- TransThera Approved for US Trials of Heart Failure Treatment
- BeiGene Says BTK Inhibitor Shows Improvement But Does not Meet Clinical Endpoints in WM
- AstraZeneca's Imfinzi, a PD-L1 Immunotherapy, Approved in China for NSCLC
- Zhejiang Medicine Reports Positive Data for HER2 Treatment in Pretreated Patients
- Ascentage Reports 95% Complete Response of BCR-ABL Inhibitor in Leukemia Patients
- Innovent Announces 100% Response Rate for its CAR-T in Multiple Myeloma
- BJ Bio Starts US Trials of Targeted IL-15 Fusion Protein in Solid Tumors
- BeiGene Reports More Clinical Data on BTK-inhibitor Brukinsa
- CARsgen Approved to Start China Trials of Third Oncology Candidate
- Innovent Starts China Trials of Novel LAG-3 Immunotherapy
- AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer
- ICT Approved to Start US Trials of CD-19 CAR-T for Lymphoma
- Bio-Thera Ok'd to Start China Trial of Biosimilar to JNJ Immune Disease Therapy
- CASI's In-licensed CAR-T Candidate to Start China Trials for Leukemia/Lymphoma
- Merck Announces Third Approval of Keytruda for Lung Cancer in China
- Innovent and Hanmi Start China Trials of PD-1/HER2 Bispecific
- Chi-Med's Surufatinib Granted Orphan Status in US
- Lee's Pharm Affiliate Conducting China Phase III Trial of Combo Treatment for Severe Acne
- CStone Starts China Bridging Trial of Leukemia Treatment in China
- Clover Starts Fifth Clinical Trial of TRAIL-Trimer Fusion Candidate
- BeiGene BTK Cancer Drug Approved in US for Lymphoma
- Everest Starts China Phase III Trial of Ulcerative Colitis Treatment
- BeiGene's PD-1 Recommended for Approval by China's CDE
- Chi-Med's NDA for Surufatinib Accepted by China's NMPA for Review
- Aslan's Varlitinib Fails to Meet Goals in Phase III Trial
- Hua Reports Positive Phase III Data for Novel Type 2 Diabetes Drug
- TenNor Announces Positive Results from US Trial of Novel Anti-bacterial
- Akeso Presents Positive Trial Results from PD-1/CTLA-4 Candidate
- CStone's PD-L1 Candidate Shows Positive Results for Lymphoma
- Bio-Thera Approved to Launch Humira Biosimilar in China
- Ark Bio Reports Positive Results from Phase II Trial of Novel RSV Treatment
- CANbridge OK'd to Launch Breast Cancer Drug in Hong Kong
- Harbour BioMed Starts Australian Trial of CTLA-4 Checkpoint Inhibitor
- Ascentage and Henlius to Test Two-drug Combination in China Leukemia Trial
- Shanghai Green Valley Surprises with China Approval for Alzheimer's Treatment
- Terns Granted US Fast Track Status for NASH Candidate
- Ansun Biopharma Reports China Approvals for Two Trials of Anti-Infective
- Visen Pharma Approved for China Phase III Trial of Growth Hormone Drug
- HighTide Completes Enrollment in US Phase II Trial of NASH Candidate
- Eisai Approved to Launch Antiepileptic Drug in China
- Luqa Pharma Approved to Market Adare Diarrhea Treatment in China
- I-Mab Approved for Two China Trials of Multiple Myeloma Treatment
- Harbour BioMed Completes China Phase II Trial of Dry Eye Treatment
- Kangpu Completes Phase I Trial of Cancer Immunomodulator
- Innovent and Chi-Med Add Second Chi-Med Drug to Combo Partnership
- Chi-Med Starts Global Trial of Syk Inhibitor In Lymphoma Patients
- I-Mab Approved to Start China Trials of CD73 Antibody
- Merck's Keytruda Approved as Monotherapy for Lung Cancer in China
- IASO and Innovent Approved to Start Trial of Novel CAR-T Immunotherapy
- Clover Starts Fourth Phase I Trial of TRAIL-Trimer Fusion Candidate
- I-Mab to Test CD47 mAb in Combination with Merck's Keytruda
- CARsgen Announces EU PRIME Review Status for BCMA CAR-T Candidate
- CStone Reports Positive Results from PD-L1 Trial in Solid Tumors
- Chipscreen's NDA for Novel Type 2 Diabetes Drug Accepted for China Review
- Innovent's Avastin Biosimilar Matches Efficacy of Original in Phase III Trial
- CASI Files for China Trials of CD19 CAR-T Candidate
- Gracell Reports Positive Results from FasT CAR-19 Cell Gene Therapy
- Cellular Bio Starts China Trial of Stem Cell Treatment for Arthritic Knees
- I-Mab to Test its CD73 Antibody in Combination with Junshi's PD-1 mAb
- Sichuan Clover Doses First Patient in China Trial of Novel Cancer Biologic
- CANbridge Granted China Priority Review for Rare Disease Treatment
- Chi-Med Starts US-EU Trials of Oral Lymphoma Drug
- AstraZeneca's Tagrisso Approved in China as First-Line Lung Cancer Treatment
- CARsgen Awarded US Orphan Drug Status for BCMA CAR-T Candidate
- Ascletis Pharma's NASH Treatment Approved for China Trials
- BeiGene's US NDA Filing for BTK Inhibitor Accepted by FDA
- CStone to Begin Australian Trials of Solid Tumor Cancer Drug
- Luye Pharma Approved to Start Japan Trials of Novel Anti-depressant
- Abbisko Approved to Start US Trial of CSF-1R Immunotherapy
- Bio-Thera Starts China Trials of a Third Arthritis Biosimilar
- Aslan Presents Progress Update on its Three Clinical Candidates
- CStone Starts China Arm of Global RET Inhibitor Phase I Trial
- DelMar Reports Positive Phase II Data from China Trial of GBM Treatment
- Zai Lab Granted Expedited China Review for Brain Cancer Medical Device
- Gilead Approved to Bring New Three-Drug HIV Treatment to China
- Innovent and Shenogen to Test PD-1/Brain Cancer Candidate Combo
- Eureka Therapeutics Starts US Trial of Liver Cancer T-Cell Therapy
- I-Mab and Tracon Begin US Trials of CD73 Antibody
- Xynomic to Start Two China Pivotal Trials of Novel HDAC Inhibitor
- CANbridge Files China NDA for Hunter Syndrome Drug
- Innovent Tests PD-1 and Avastin Biosimilar Combo in China Lung Cancer Trial
- UCB's Rheumatoid Arthritis Treatment Approved for China
- CStone Approved to Start China Bridging Trial of Leukemia Drug
- Ascentage to Start US Trial of Treatment for Drug-Resistant Leukemia
- I-Mab Ok'd to Start China Trials of CD47 Immunotherapy
- Ascentage Starts China Trial of Apoptosis Cancer Drug
- Novartis Plans to File 50 NDAs in China over the Next Five Years
- CStone Starts China Bridging Trial of GIST Candidate
- BeiGene Granted Second China Priority Review for PD-1 Candidate
- Yisheng Cleared to Start China Trials of PIKA-based Cancer Immunotherapy
- Wuhan's XW Labs Gains US Orphan Drug Status for Narcolepsy Drug
- Gracell Reports Positive Results for FasT CAR-19 in Leukemia Patients
- Henlius is First to have China-Developed Biosimilar Accepted for EU Review
- Cellular Bio Starts Phase I China Trial of CD20 CAR-T
- CARsgen Given Green Light for US Trials of BCMA CAR-T Candidate
- Chi-Med's Surufatinib Meets Survival Endpoint -- Trial Stopped Early
- Innovent's BCMA CAR-T Produces 100% Response Rate in Myeloma Patients
- Reistone Starts Global Trial of China-Discovered JAK1 Inhibitor for IBD
- Terns Starts US Trial of Lead Drug, a NASH Candidate
- Xynomic Completes Pre-IND Conference with US FDA for RAF Inhibitor
- CStone to Start Combo Trial of its PD-L1 with Bayer's Stivarga for Gastric Cancer
- RemeGen Announces Positive Results for HER2 ADC in Urothelial Cancer
- Xynomic Starts US Trial of Abexinostat-Inbruvica Combo for Lymphoma
- CStone OK'd to Start China Combination Trials of PD-L1 in HCC
- Ascentage Reports Positive Trial Data for Two Apoptosis Candidates
- BioMarin's Very-Rare Disease Treatment Approved in China
- Innovent Reports Data on Four China Trials of Approved PD-1 Drug
- Innovent Releases Positive Phase III Data on Avastin Biosimilar at ASCO
- Hengrui Medicine's PD-1 Drug Approved in China for Lymphoma
- Sihuan Pharma Approved to Start China Trials of Third-Gen EGFR Inhibitor
- CStone's In-Licensed Cancer Treatment Meets Endpoints in Phase III Trial
- Xynomic Presents Positive Long-Term Data on Lead Oncology Candidate
- Exuma Reports Positive Early Results from China Trial of Conditionally Active Biologics
- Sandoz Approved to Launch Crestor, a Generic Statin, in China
- Innovent and Lilly Report MabThera/Rituxan Biosimilar Meets Endpoints
- Innovative Cellular Presents Data on Novel CD19 CAR-T Therapy
- Connect Bio Reports Positive Phase I Data for Atopic Dermatitis Treatment
- Ascletis and 3-V Bio Start US-China Trial of NASH Candidate
- I-Mab Starts Second China Trial of CD38 Antibody for Multiple Myeloma
- Sinovant to Start China Trials of Derazantinib for Bile Duct Cancer
- TaiGen and HEC Start China Phase III Trial of Dual-Drug HCV Treatment
- Innovent Starts China Trials of PD-1/PD-L1 Bispecific Antibody
- Hua Medicine Starts New US Combination Trial of GKA Diabetes Candidate
- Sinovac Reports Positive Polio Vaccine Results
- CStone Starts Phase III Trial of PD-L1 Candidate in Gastric Cancer Patients
- Innovent Starts China Trials of Bi-Specific Wet AMD Treatment
- CStone Approved to Start China Bridging Trial of GIST Candidate
- I-Mab and Roche Collaborate on US Trials for Dual Immunotherapy Regimen
- Hengrui and LSK Approved to Start US Trial of PD-1/VEGF-2 Combination
- Junshi and Ascentage Partner to Test PD-1/IAP Combination
- Novartis' First-in-Class Biologic Psoriasis Treatment Approved in China
- Luye Pharma Files for US Approval of Schizophrenia Treatment
- Hefei Tianhui OK'd to Start China Trials of In-licensed Oral Insulin
- Innovent Starts US Trial of "Pivotal" CD47 Immunotherapy
- Xiangxue Approved to Start China Trial of T-Cell Therapy for Solid Tumors
- I-Mab Starts Greater China Trials of CD38 Antibody for Myeloma
- I-Mab Starts US Trial of GM-CSF Immunotherapy for Rheumatoid Arthritis
- Xynomic Extends Phase III Abexinostat Trial to China and Europe
- CStone Approved to Start China Trial of HDAC6 Inhibitor
- CARsgen Approved to Start China Trials of BCMA CAR-T Candidate
- CASI Pharma Approved To Start China Trial of Leukemia Treatment
- I-Mab Starts China Trial of In-licensed Interleukin for Solid Tumors
- Innovent Combines PD-1 with Avastin Biosimilar in China HCC Trial
- Shanghai Henlius' Rituxan Biosimilar is First Biosimilar Approved in China
- Xynomic Starts Phase III Trial of HDAC Inhibitor in South Korea
- Solasia Announces China Approvals for Two Cancer Side-Effect Treatments
- Owlstone to Test Breath Biopsy Diagnostic at Shanghai Renji Hospital
- Innovent to Test Tyvyt, its PD-1 Drug, with Two Chipscreen Drugs
- China to Review IND Filing for CStone/Impact PD-L1/PARP Combo
- Innovent Approved to Start China Trials of Bi-Specific PD-1 Candidate
- Hua Starts US Trial of Lead Type 2 Diabetes Treatment, a GKA Activator
- Innovent Filing for Approval of Avastin Biosimilar is Accepted in China
- CStone to Start China Trial of FGFR4 Inhibitor for Liver Cancer
- CARsgen Cleared to Start China Trials of CAR-T Liver Cancer Treatment
- I-Mab Approved to Start US Trials of Immunotherapy, its Third US Approval This Month
- Bio-Thera Starts Global Phase III Trial of Arthritis-targeted Biosimilar
- I-Mab Approved to Start US Trials of Immunotherapy for Solid Tumors
- Cellular Biomedicine Approved to Start China Stem Cell Trial
- Ironwood/AstraZeneca Approved to Market IBS-C Treatment in China
- Innovent Doses First Patient in China Trial of "Don't Eat Me" Inhibitor
- BeiGene Receives Breakthrough Status in US for BTK Inhibitor
- Aslan Pharma OK'd to Start US Arm of Phase II Trial of AML Treatment
- Cellular Biomedicine Starts China Trial of CAR-T Drug for Multiple Myeloma
- Biohaven's IND Filing for Novel Migraine Drug Accepted in China
- Ascletis's IND Filing for Third HCV Treatment Accepted in China
- Zai Lab Launches Electric Field Treatment for GBM in Hong Kong
- Bio-Thera Files to Start China Trials of Cancer Antibody Drug Conjugate
- FibroGen/AstraZeneca Novel Anemia Drug Approved in China -- Before US/EU Approvals
- Innovent/Lilly PD-1 Approved in China for Hodgkin's Lymphoma
- Xynomic Files Three China INDs for Lead Oncology Candidate
- Junshi Biosciences's Tuoyi is First China-Developed Anti-PD-1 Drug Approved for Marketing
- Cerveau Announces Singapore Test of Neuro PET Imaging Agent
- Innovent Sees Positive Data from China Phase III Trial of Avastin Biosimilar
- Zai Lab's NDA for PARP Inhibitor Accepted for China Review
- China Approves Mundipharma China/Helsinn Anti-Emetic Treatment
- Innovent Approved to Start US Trials of Novel Immunotherapy
- Legend/Janssen CAR-T Therapy Posts Strong Results in Multiple Myeloma Trial
- CASI Pharma Approved to Launch Melphalan in China
- Chi-Med to Start Four Combination Trials of its VEGFR Inhibitors with PD-1 Candidates
- Chi-Med Launches Fruquintinib, First China-Discovered Cancer Treatment
- Gilead Approved in China to Market Vemlidy for Hepatitis B
- Innovent's NDA Filing for Humira Biosimilar Accepted in China
- Generon to Start China Phase I Trial of IO Drug in B Cell Malignancies
- Innovent Starts Phase III Trial of PD-1 Candidate in Lung Cancer Patients
- I-Mab Approved to Start China Trials of Interleukin-7 Immunotherapy
- Bio-Thera Starts China Phase III Trial of HER2 Conjugate Drug
- Adagene Starts US Trial of Lead Molecule; Also Approved for China Trials
- Ark Bio to Release Positive Clinical Data on RSV Candidate
- Alphamab and 3D Medicines Start Phase III Trial of PD-L1 Candidate in China
- Shanghai's Green Valley Files for China Approval of Alzheimer's Drug
- CStone Pharma Approved to Begin US Trial of PD-1 Candidate
- Jiangsu Hengrui Forms Global Clinical Collaboration with LSK BioPharma
- Zai Lab Ok'd to Launch PARP Inhibitor in Hong Kong
- Reistone of Shanghai Approved for US Phase II Trial of UC Treatment
- Ascletis's Second HCV Treatment on Priority Review List in China
- Singlera Reports Positive Results from Blood-based Diagnostic for Colorectal Cancer
- Chi-Med Starts China Trials of Syk Inhibitor in Acute Myeloid Leukemia Patients
- Alphamab to Start US Phase I Clinical Trial of HER2 Bispecific Antibody
- CStone Approved to Start US Trials of PD-L1 Candidate
- I-Mab Starts China Trial of Ulcerative Colitis Treatment
- Alphamab Starts Australian Trial of PD-L1/CTLA-4 Bispecific
- Yisheng Cleared to Start China Phase III Trial of PIKA Rabies Vaccine
- CANbridge Files NDA for Approval of Breast Cancer Drug in China
- Innovent Approved to Start US Clinical Trial of CD47 Immunotherapy
- Innovent's PD-1 Candidate Effective Against NSCLC; Will Start Phase III Trial
- EpimAb Files US/China INDs for Bispecific Cancer Antibody
- CARsgen Reports Positive Results from CAR-T Trial in Solid Tumor Cancers
- Innovent Approved for China Trial of CD47 I-O Drug
- Chi-Med OK'd for China Use of Fruquintinib, its First Drug Approval
- Eisai Announces China Approval for Liver Cancer Treatment
- BeiGene's PD-1 Antibody Accepted for NDA Review in China
- CStone OK'd to Start China Trials of Third I-O Candidate
- Hengrui Medicine Approved to Market Novel HER2 Cancer Drug in China
- BMS to Set China Price of Opdivo, a PD-1 Drug, at 50% of US Cost
- Roche Gets Speedy China Approval for New Lung Cancer Treatment
- Bio-Thera BLA for Humira Biosimilar Accepted in China
- Sirnaomics to Start US Trial of siRNA Treatment for Bile Duct Cancer
- CANbridge Approved for China Phase Ib/III Trial of Esophageal Cancer Drug
- Sihuan Pharma Starts China Phase II Lung Cancer Trial
- BeiGene Starts China Phase III Trial of PD-1 Drug in Squamous NSCLC
- I-Mab Approved to Start China Trials of Novel Diabetes Treatment
- I-Mab Biopharma Files China IND for I-O Multiple Myeloma Treatment
- Gilead Sciences OK'd for China Sales of HIV Combination Drug
- Clover Biopharma Starts China Phase I Trial of Enbrel Biosimilar
- CStone to Start China Trial of its MEK Inhibitor
- CBT Starts Phase Ib Trial of PD-1 Candidate in Australia
- China Uses New Rules for Fast Approval of Keytruda, a Merck/MSD PD-1 Drug
- Innovent Approved to Start Trials of Novel I-O and Osteoporosis Candidates
- BeiGene Reports Positive PD-1 Data; Plans China NDA Filing This Year
- Shanghai Green Valley Reports Positive Results from Phase III Trial of Alzheimer's Drug
- CStone Approved to Start China Clinical Trials of PD-1 Candidate
- Adagene Approved to Begin US Trials of I-O Cancer Candidate
- Zai Lab Starts Phase III China Trial of PARP Inhibitor
- China Accepts Solasia's Filing for Anti-Nausea/Vomiting Patch
- CStone Starts Australian Trial of MEK Inhibitor
- Luye Files to Start China Trials of Class 1.1 Novel Analgesia Candidate
- China Approves First PD-1 Treatment: Bristol-Myers Squibb's Opdivo
- Ascletics' Novel HCV Treatment is Approved by CFDA
- CStone Starts Pivotal China Phase II Trial of PD-L1 Candidate
- Everest Files IND for China Phase III Trial of Novel Antibiotic
- Frontier Biotech's HIV Drug Approved, First China-Developed HIV Treatment
- Legend/Janssen CAR-T Immunotherapy to Start US Trial in Myeloma
- BeiGene Starts China Trial of PARP Inhibitor in Ovarian Cancer Patients
- Innovent Reports Positive Results for PD-1 Candidate; Files China NDA
- CStone Pharma Starts Phase I Trial of PD-1 Molecule
- Suzhou Alphamab to Start China Trial of Bispecific HER2 Inhibitor
- MabSpace Starts US Trial of PD-L1 Drug; China Trial to Begin Soon
- CANbridge to Start China Phase II/III Trial of GBM Treatment
- BeiGene Initiated Global Phase II Clinical Trial for PD-1 Antibody
- Denovo Starts US-China Phase III Study of Lymphoma Treatment
- Guangzhou MaxiNovel Awarded US Orphan Drug Status for AML Treatment
- China Accepts Chugai's NDA Submission for Novel Osteoporosis Treatment
- Avita Medical Starts China Trial of "Spray-on Skin" for Burns
- Cellular Biomedicine Will Focus on China, Closing California Operations
- XW Labs Starts Phase I Trial of Novel Narcolepsy Candidate
- US FDA Approves Drug-Resistant HIV Treatment from Taiwan's TaiMed
- Chi-Med Starts China Trial of Epitinib in Glioblastoma Patients
- Fosun Subsidiary's Aesthetic Laser Approved for US Use
- Yisheng Biopharma Granted US Orphan Drug Status for Immunotherapy
- MabSpace's Second-Gen PD-L1 Candidate Approved for US Trial
- JHL Biotech Approved to Start European Trial of Avastin Biosimilar
- Chi-Med Enrolls 527 Lung Cancer Patients for China Trial of Fruquintinib
- Golden Meditech Gains US OK for Houston T-Cell Processing Center
- BeiGene Launches Third Celgene Cancer Drug in China
- Lee's Pharm to Start China Trials of In-licensed PD-L1 Candidate
- Generon (Shanghai) Says Neutropenia Candidate Meets Phase III Target
- AmoyDx's Plasmid Diagnostic for EGFR Mutations Approved in China
- GSK Launches Triple-Therapy HIV Drug in China at a Low-Cost $450/Month
- Eddingpharm Starts China Trial of Amarin's Hypertriglyceridemia Treatment
- Aslan Says New CFDA Rules Shave One Year Off Development Time for Lead Drug
- 3SBio Approved to Market Once-Weekly Type 2 Diabetes Treatment in China
- CFDA Accepts Ascentage's IND Filing for Lead Drug in Hepatitis B
- CANbridge Files to Start China Trials of Esophageal Cancer Treatment
- BeiGene Starts China Phase II Trial of PARP Inhibitor
- Chi-Med Starts First US Trial of Fruquintinib, an Anti-Angiogenesis Drug
- Xynomic to Start US Trial Combining its Abexinostat with Janssen's Imbruvica
- BMS Reports Successful China NSCLC Trial of PD-1 Drug Opdivo
- Gilead Launches Hepatitis C Treatment in China at 20% of US Price
- Ascentage's IND Accepted in US for Inhibitor of Apoptosis Blocker
- RiboQuark Doses First Patient in China siRNA Trial
- Eye Tech Care's Ultrasound Glaucoma Treatment Approved for China Use
- MabSpace Biosciences Files China IND for Second-Gen PD-L1
- BeyondSpring Starts Phase II/III China Trial of Neutropenia Drug
- China Approves Tianjin CanSino's Ebola Vaccine
- Denovo Approved to Start US-China Phase III Trials of Lymphoma Drug
- Transgene Reports Positive Data on its Tasly-Partnered HBV Therapy
- Suzhou's CStone Pharma Starts Phase I Trial of PD-L1 Candidate
- FibroGen Says CFDA Accepts Novel Anemia NDA for Review
- Chi-Med/AstraZeneca Drug Shows Efficacy Against Lung Cancer
- Generon Announces SPA for US Phase III Trial of Neutropenia Drug
- ImmunoMet, a US HanAll Spinoff, Starts Clinical Trial of Cancer Drug
- MicroPort/LivaNova JV's Pacemaker Approved for China Use
- Zai Labs Starts China Phase III Trial of Lead Drug in Ovarian Cancer
- Novo Nordisk Approved to Launch New Diabetes Treatment in China
- Sinovac Announces Positive Phase III Results for Chickenpox Vaccine
- Gilead Sciences Approved to Market HCV Drug in China
- DelMar Pharma OK'd to Start Trial of Lead Drug in Ovarian Cancer Patients
- Shuwen Biotech Approved for European Use of EGFR Test
- iCAD Gains CFDA Approval to Market Brachytherapy Device in China
- Hong Kong Test Shows Efficacy of Early Cancer Liquid Biopsy Testing
- Korea's ViroMed Starts Trial of Gene Therapy for Diabetic Foot Ulcers
- Sensus Gains China Approval of Radiation Device for Keloids
- DelMar Approved to Start China Phase II Trial of Brain Cancer Treatment
- Lee's Pharm and SillaJen Approved for China Immunotherapy Trial
- Ascentage Approved to Start China Trial of Apoptosis Drug
- CStone Approved to Start China Trials of PD-L1 Candidate
- Resverlogix and Hepalink Start Taiwan/China Trial of CVD/Diabetes Treatment
- BeyondSpring Granted Approval to Start China Trials of Plinabulin
- CFDA Accepts Athenex's IND Filing for Oral Paclitaxel
- BeiGene Starts Second China Pivotal Phase II Trial of PD-1 Drug
- Chi-Med/AstraZeneca Partnership Starts Phase III Trial of c-MET Inhibitor
- Chi-Med Starts China Phase I/II Trial of Novel FGFR Inhibitor
- ACEA Biosciences Reports Positive Phase I Trial of BTK Inhibitor
- Chi-Med Reports CFDA Acceptance of Fruquintinib NDA Filing
- OrbusNeich Launches US Sales with Two Balloon Catheters
- Nanjing Legend Biotech Surprises ASCO with Strong CAR-T Results in Multiple Myeloma
- Celltrion Presents Positive Results from Herceptin Biosimilar Trial
- China to Test Embryonic Stem Cell Treatment for Parkinson's
- Hutchison China MediTech Says Fruquintinib Increased Median Survival 41%
- TaiGen Submits NDA in China for Novel IV Antibiotic
- Celltrion Approved to Start China Trials of Remicade Biosimilar
- Xiangxue Pharma Approved for China Trials of Brain Cancer Drug
- Xynomic Forms Partnership with UCSF for Cancer Drug Trial
- Uni-Bio Launches Oral Type 2 Diabetes Drug in China
- Yisheng Bio Starts Phase I Trial of Immuno-Oncology Candidate
- Impact Therapeutics Granted CFDA Approval for China Test of PARP Inhibitor
- Sirnaomics OK'd to Start China Trial of siRNA Therapeutic
- CFDA Approves Venus Medtech's Minimally Invasive Aortic Valve Implant
- Bristol-Myers Squibb's Oral, Interferon-free HCV Regimen Approved in China
- Aslan to Start Global Phase III Trial of Lead Cancer Drug
- BeiGene Starts China Trial of PD-1 Drug in Hodgkin Lymphoma
- Immunitor Reports Positive Data for Liver Cancer Immunotherapy
- Asieris Pharma Doses First Patient in China Bladder Cancer Trial
- Athenex, a US-China Biopharma, Starts US Trial of Oral Chemotherapy
- JHL Starts European Trial of MabThera/Rituxan Biosimilar for RA
- AstraZeneca's Tagrisso Approved in China Following Priority Review
- Tarrex Biopharma, a US-China Startup, Approved to Start US Cancer Drug Trial
- CFDA Approves Pfizer Oral Arthritis Treatment for China Use
- Chi-Med's Lead Candidate Passes Phase III Colorectal Cancer Test
- Kite's Fosun-Partnered CAR-T Immunotherapy Posts Strong Phase III Data
- Hutchison MediTech Begins Phase II Study of Its PSC Drug Savolitinib in China
- Denovo Biopharma Plans to Initiate a Global Phase III Trial of DLBCL Drug
- Medigus’ First Multi-center Clinical Study for MUSE™ Approved by CFDA
- ASLAN Pharma Published Positive Phase I Data for It's Bone Loss Drug, ASLAN002
- Hutchison MediTech Launches Phase I Trial of Novel FGFR Inhibitor in Australia
- ASLAN Pharma Initiates Enrollment for HER-2 Cancer Drug Phase I Study in Japan
- Aslan Pharma Reports Positive Data for HER-2 Cancer Drug
- Sirnaomics, a US-China Biopharma, Starts Trial of RNAi Candidate
- FibroGen's Novel Anemia Treatment Meets Phase III Endpoints in China
- BeiGene Starts Global Phase III Trial of BTK Inhibitor
- Neovia, a Seattle-Beijing JV, Starts US Trial of Cancer Drug
- WuXi-MedImmune RA Biologic Approved for China Trials
- Chi-Med Starts China Phase I Trial of Syk Inhibitor
- Alphamab/3DMed Announce China Approval for PD-L1 Antibody Trial
- Taiwan's TLC Reports Positive Data on Long-Acting Steroid for Arthritis
- Yisheng Granted US Orphan Drug Designation for Rabies Vaccine
- BeiGene Starts China Clinical Trial of PD-1 Candidate
- CFDA Accepts NDA for Hepatitis C Drug from Ascletis
- Ascentage's Cancer Drug Candidate Advances toward US/China Trials
- BeiGene Doses First Patient in China Phase I PARP Trial
- US-Based Mederi Approved to Market GERD Treatment in China
- China-Prevalent Form of NSCLC Responds to AstraZeneca Drug
- Alphamab/3D Medicines PD-L1 Antibody Approved for US Trial
- CBMG, a China-US Biopharma, Starts China Trial of CAR-T Immunotherapy
- MicuRx Tests Oral/IV Versions of its Anti-Infective in US Trial
- Yisheng Completes Successful Phase I Test of Hepatitis B Vaccine
- Chi-Med Reports Positive Data from Phase I Trial of Syk Inhibitor
- China Team is First to Inject CRISPR-edited Genes into Human
- Sirnaomics Given OK for US Trials of Anti-Fibroid siRNA Therapeutic
- Suzhou Alphamab to Start China Trial of Biologic Infertility Treatment
- CFDA to Start Priority Reviews of Medical Devices in January 2017
- Pfizer Granted China Approval for Children's Pneumonia Vaccine
- Biohit Oyj OK'd to Start China Production of Cancer Screening Test
- CFDA Addresses "80% of China Trials are Based on Fraudulent Data" Story
- Yisheng Granted US Orphan Drug Designation for Cancer Immunotherapy
- MicuRx Starts China Phase III Trial of Novel Antibiotic
- Taiwan's TLC Granted Orphan Status in US for Lymphoma Drug
- CFDA Accepts CStone's IND Submission for PD-L1 Candidate
- Hua Medicine's GKA Diabetes Treatment Passes Proof-of-Concept Trial
- Taiwan's TLC Approved to Begin US Clinical Trials of Cancer Drug
- China's CANbridge Starts Taiwan Trial of Novel Brain Cancer Drug
- SciClone Starts Clinical Trials for Two China Portfolio Products
- Hua Medicine Completes Phase II Trial of Type 2 Diabetes Drug
- Innovent Starts China Trials of Two Biologic Drug Candidates
- BeiGene Approved to Start China Trial of PD-1 Drug
- BeiGene OK'd to Test PARP Inhibitor in China
- Ambrx to Start US Clinical Trials of HER2 Cancer Drug
- Ark Bio of Shanghai Starts Phase II Trial of Novel RSV Treatment
- Magellan Awarded China Approval for Blood Lead Test
- ViroMed Approved to Start Trial of Gene Therapy for Ischemic Heart Disease
- China to Test CRISPR-Edited Cells in Lung Cancer
- GSK's Cervarix is First HPV Vaccine Approved for China Use
- Yisheng Bio Reports Early Success for its Adjuvant in Ebola Vaccine
- Hengrui Medicine OK'd to Start China Trials of Autoimmune Drug
- China's BeiGene Starts Combination Trial for Two Novel Cancer Drugs
- BeyondSpring Starts China-US Phase III Trial of Lung Cancer Drug
- ASLAN Receives Second US Orphan Drug Designation for Cancer Drug
- Taiwan Liposome Completes Trial Enrollment for Arthritis Treatment
- Nanjing Frontier's NSAID Patch Meets US Trial Endpoints
- Ascletis Reports Positive Phase II Data from Interferon-free HCV Regimen
- TaiGen Biotech's Novel Antibiotic Approved for Use in China
- Galmed Pharma Adds China Arm to Phase IIb Trial of Liver Disease Drug
- Frontier Biotech Reports Positive Data from HIV Treatment Trial
- Lee's Pharm and RegeneRx Use New China Rules to Speed Eye Drug Development
- ViroMed of Korea Receives US Fast Track Status for Gene Therapy
- Solasia Files for China-Japan Trials of Oral Mucositis Treatment
- Chi-Med Completes Enrollment of Fruquintinib Phase III Trial in CRC
- CASI Approved to Start Fourth China Phase II Trial of Cancer Drug
- China's Innovative Cellular Therapeutics Reports 90% Remission Rate in CAR-T Trial
- China Jo-Jo Drugstores Approved to Start Virtual Doctor Service in Pharmacies
- Germany's Merck Says Erbitux Meets Endpoints in China Phase III Trial
- BeiGene Presents Positive Interim Data from Trial of RAF-Inhibitor
- Chi-Med Starts Phase I Trial of Cancer Drug in Australia
- CANbridge Files IND in Taiwan for Novel GBM Treatment
- Zhejiang and Ambrx Start Phase I Trial of HER2 Cancer Drug
- Bird Rock Bio Reports Encouraging Data on Inexpensive RA Treatment
- Quark and Suzhou Ribo Start China Trial of Anti-Blindness RNAi Drug
- Asieris Pharma Announces Positive Data from Bladder Cancer Drug Trial
- Roche Cervical Cancer Diagnostic Test Approved in China
- BeiGene Approved to Start China Phase of Global BTK-Inhibitor Trial
- 3SBio Approved for Trials of PEG-Irinotecan
- Chi-Med Starts Trial of Sulfatinib in Thyroid Cancer Patients
- Aurinia/3SBio Drug Effective against Lupus Nephritis
- BMS Reports Positive China Phase III Data of Hepatitis C Treatment
- Golden Grand Starts China Trial of Minimally Invasive GERD Device
- Athenex to Start US Trial of Oral Docetaxel Product
- NeuroMetrix's Peripheral Neuropathy Test Approved for China
- Hutchison MediPharma Begins Trial of Lymphoma/Leukemia Drug
- BeiGene OK'd to Start US Trial of PD-1 Cancer Drug
- CANbridge Completes Biomarker Study of Cancer Drug; Gains Taiwan Rights
- Suzhou Connect Reports Positive Data from Autoimmune Drug Trial
- Yisheng Pharma's Rabies Vaccine Passes Phase I Test
- Sinovac's Vaccine for Enterovirus 71 Earns CFDA Approval
- BeyondSpring Approved for China Arm of Global Phase III Cancer Trial
- SciClone Pharma to Begin Developing Oral Mucositis Treatment in China
- Chi-Med Starts China Phase III Trial of Sulfatinib
- Celsion OK'd for China Phase III Trial of Liver Cancer Treatment
- BeiGene Posts Encouraging Early Data on Cancer Drug
- Sinovac Obtains Trial Approval for Polio Vaccine in China
- TaiGen Reports Positive Taiwan-China Data for Novel Antibiotic
- Hutchison MediPharma Starts US Trial of Cancer Drug
- Akers Awarded CFDA Approval for Heparin-Reaction Diagnostic
- Hutchison MediPharma to Receive $10 Million Milestone from Lilly
- Sinovac Given CFDA Go-Ahead for Trial of Chicken Pox Vaccine
- US FDA Confirms Luye Pharma’s 505(b)(2) NDA Submission
- Advance Pharmaceutical Completes Enrollment for HTI-320 Clinical Trial
- Ark Completes Phase I Trial of Antivirus Drug
- iNeedMD Gains CFDA Approval for EKG Medical Device
- RuiYi's Autoimmune Treatment Starts Clinical Trial
- Beijing Shenogen Granted Fast Track Status for Novel Cancer Drug
- ASLAN Approved to Start Singapore-Taiwan Trial of Cancer Drug
- China Issues Rules for Approval of Stem Cell Clinical Trials
- DelMar Reveals Plan for China Trial of Lung Cancer Drug
- Chi-Med Says Fruquintinib Successful in Lung Cancer Trial
- MicuRx Says Novel Antibiotic Passes China Phase II Test
- Ascletis Approved for Taiwan Trial of Interferon-Free HCV Regimen
- ASLAN Pharma Granted US Orphan Drug Status for Cancer Drug
- Hua Medicine’s Diabetes Drug Shows Efficacy in Phase Ic Trial
- BeiGene Starts China Clinical Trial of Melanoma Drug
- Suzhou Connect Reports Positive Results for Trial of Autoimmune Drug
- Eddingpharma to Start China Trial of Cardiome AFib Drug
- Micell Technologies Enrolls First Patients in China Stent Trial
- OrbusNeich Starts China Trial of COMBO™ Dual Therapy Stent
- CASI Pharma Gains Hong Kong OK for Cancer Drug
- Biohit Oyj's Diagnostic Starts Large China Gastric Cancer Screening Study
- Aoxing Pharma Advances Two Opioid Products in China
- AstraZeneca/Ironwood Drug for IBS-C Passes China Phase III Test
- Zhejiang Kanglaite to Start US Phase III Trial of TCM Cancer Drug
- PharmaEngine's Cancer Drug Granted Priority Review by the FDA
- Exclusive Interview: Ascletis First to File for China Trials of Interferon-Free Hepatitis C Treatment
- BeiGene Gains US OK to Start Trial of Cancer Drug
- UCB Patch Product for Parkinson's Passes China Phase III Test
- Suzhou NeuPharma Starts Phase I Trial of Cancer Treatment
- CASI Files for Fourth China Trial of Lead Cancer Drug
- AstraZeneca and Chi-Med Report Positive Data from Cancer Drug Combo
- Cellular Biomedicine Reports Positive China CAR-T Cancer Data
- Luye Pharma Completes US Trials of Anti-Psychotic
- Bayer Granted Additional Approvals for Xarelto Based on Global Trials
- PharmaEngine's Pancreatic Cancer Drug Seeks Approval in Europe
- Shanghai Generon to Start US Trial of GvHD Biologic Drug
- TaiGen Starts China Trial of Novel Chemotherapy Sensitizer
- Uni-Bio Files for China Approval of Novel Osteoporosis Drug
- PerkinElmer Gains China OK for Neonatal Test Analyzer
- China's NHWA Pharma to Start Trial of In-Licensed Epilepsy Drug
- Sihuan Pharma Starts US Trial of Novel Cancer Drug
- Cytori and Lorem Announce China Approval of Regenerative Medicine Device
- Pfizer Shuts Down its China Vaccine Unit
- Luye Pharma Reports Successful Phase I Trials of Novel Anti-depressant
- Hutchison MediPharma's Cancer Drug Meets Endpoint in Phase II Trial
- Berry Genomics Granted China Approval for Birth Defect Test
- WuXi-MedImmune Biologic Drug Begins China IND Review
- China Ebola Vaccine Passes Phase I Test
- CASI Starts China Arm of Phase II Breast Cancer Trial
- Critical Diagnostics Gains China Approval for Heart Risk Assay
- CardioKinetix Announces Positive Data from Heart Failure Device Trial
- Ascletis Reports Strong Phase II Data for Hepatitis C Drug
- Yisheng Biopharma Starts Clinical Trial of Novel Rabies Vaccine
- ZAI Lab Begins Trial of Novel Respiratory Disease Drug
- ASLAN Reports Positive Phase I Results from Cancer Drug
- Luqa Pharma to Launch Italian Wound Healing Product in China
- Hua Medicine Files to Start US Trial of Novel Diabetes Drug
- Wanbang Biopharma's Oral Diabetes Drug Passes Tox Study
- Hutchison Chi-Med to File for Approval of Two Cancer Drugs in 2016
- MicuRx Pairs US Phase II Trial of Novel Antibiotic with China Test
- Qiagen's TB Test Cuts Estimate of Latent TB Incidence in China
- Hua Medicine Reports Single Oral Drug Controls Diabetes for 24 Hours
- UCB to File for China Approval of Parkinson's Disease Patch
- Moberg Pharma's Fungal Nail Product Approved in China
- China Approves World's First Inactive Sabin Strain Polio Vaccine
- Chipscreen's Treatment for Lymphoma Approved in China
- Ascentage Pharma to Start China Clinical Trial of Novel Cancer Drug
- Sirnaomics and China Partner File to Begin China Trials of siRNA Drug
- AMMS-CanSino to Start Clinical Trial of China Ebola Vaccine
- Hutchison MediPharma Starts Phase III Trial of Cancer Drug
- Taiwan's TWi Biotech to Start Clinical Trial of Gout Treatment
- BeyondSpring to Start China-US Phase III Trial of Novel Cancer Drug
- CFDA Approves BioChain's Colorectal Cancer Diagnostic Test
- CFDA Approves Three Diagnostic Tests for Ebola
- Suzhou Connect Biopharma Starts Phase I Trial of Autoimmune Drug
- CASI Obtains Permission for China Phase II Cancer Trial
- STAAR Surgical Ophthalmic Device Approved in China
- CardioKinetix Starts China Trial of Heart Failure Device
- TWi Pharma Granted US Orphan Drug Designation for Lead Molecule
- China Biologic Awarded CFDA Approval to Manufacture Plasma Product
- BSD Medical and Dalian Orientech Gain China Approval for Cancer Hypothermia Device
- Guangzhou Baiyunshan is First-to-China-Market with Generic Viagra
- Mazor Robotics Gains China Approval for Surgical Guidance System
- Aslan Pharma Starts Phase I Trial of Lead Molecule in Taiwan
- NovaBay Cleared to Market NeutroPhase Wound Cleanser in China
- SciClone Pharma Gains CFDA Approval for Liver Cancer Treatment
- Amerigen's First Generic Product OK'd in China
- WuXi PharmaTech FDA Approved to Manufacture API
- Cook Medical Starts China Trial of Drug Eluting Stent for PAD
- Pfizer Reports China Trial Results for Lyrica
- Celltrion files for Approval of Remicade Biosimilar in US
- Berry Genomics Awaits CFDA Approval of Noninvasive Prenatal Test
- CASI Pharma to Start China Trial of Cancer Drug
- Hamilton Thorne’s Laser is CFDA-Approved for Fertility Clinics
- Beike Biotech Applies for China Use of Stem Cells in Lupus Patients
- Henlius Biotech Files for Fourth Biosimilar IND in China
- CFDA Approves BGI’s Prenatal DNA Test, Reversing Ban on Genetic Testing
- Uni-Bio Announces Positive Results from Osteoporosis Drug Trial
- NHWA Pharma Gains China Fast-Track for Epilepsy Drug
- Bruker Cleared by CFDA to Market Microorganism-Identification Device
- Hengrui Medicine Granted Approval to Market Cancer Drug in US
- Chia-Tai Tiangqing Files IND for Biotech Product Licensed from Alphamab
- Omron, NeuroMetrix File for China Approval of Peripheral Neuropathy Test
- Waters Announces CFDA Approval for Diagnostic Device
- Biomerica Approved to Distribute Two Diagnostic Tests in China
- Jiangsu Hengrui Reports Positive Phase III Data for Cancer Drug
- DelMar Advances China-partnered Cancer Drug in Clinical Trial
- Jiangsu Hengrui Approved to Start Trial of Biosimilar Cancer Drug
- WuXi Approved to Supply TaiMed Biologic Drug for US Trials
- TaiGen On-Track for 2014 China Approval of Novel Antibiotic
- Hutchison MediPharma Starts Phase II Trial of Lilly-Partnered Cancer Drug
- TWi Pharma of Taiwan Gains US Approval for Calcium-Channel Blocker
- Lee’s Pharma and Partners Plan Global Phase III trial of Cancer Immunotherapy
- MicroPort’s Third-Gen Drug Eluting Stent Approved in China
- Hua Medicine Reports Strong Results for Early Diabetes Drug Trial
- TaiGen Biotech Granted Taiwanese Approval for Novel Antibiotic
- BioLight Approved to Market Glaucoma Medical Device in China
- Aslan Pharma Opens Clinical Trial Office in Taiwan
- Abiomed Lands China Approval for Cardiac Device
- Sinovac Files to Begin Trials of H7N9 Avian Flu Vaccine
- Neuralstem Begins Trial of Stem Cell Product to Treat Stroke Disability
- EntreMed Files to Start China Arm of Phase II Ovarian Cancer Trial
- Adimmune Plans to Sell its Flu Vaccine in China This Year
- TaiGen Expects China Launch of Novel Antibiotic in 2014
- MicuRx Pharma Starts China Trial of Drug-Resistant Antibiotic
- Nanjing Frontier Biotech Begins China Phase III Trial of HIV Treatment
- China Researchers Develop Novel Cancer Biomarker
- Qiagen Gains China Approval for Next-Gen TB Test
- Shanghai Sundise Reports Positive Results from TCM Liver Fibrosis Trial
- Boston Scientific Gains China OK for Non-drug Asthma Treatment
- Adimmune of Taiwan Readies Flu Vaccine for China
- Sihuan Pharma Approved for China Trials of Innovative Cancer Drug
- CNBG’s Japanese Encephalitis Vaccine Prequalified by WHO
- Lee’s Pharma Completes Successful China Test of Anti-Depression Drug
- Huahai Pharma China-Approved to Produce AIDS Treatment
- Wanbang to Begin Clinical Trial of Fast-Acting Insulin Analogue
- Ironwood and AstraZeneca Begin Phase III China Trial for Linaclotide
- Ventana Test Approved by CFDA as Diagnostic for Pfizer Cancer Drug
- DelMar and Guangxi Wuzhou Pharmas Form Advisory Board for Cancer Drug
- Hua Medicine Begins Phase I Trial of Novel Diabetes Treatment
- Cosmederm Gains CFDA Approval for Topical Skin Treatment
- Zoetis/Jilin Guoyuan JV Gains China Approval for Swine Vaccine
- Takeda’s DPP-4 Treatment for Type 2 Diabetes Approved in China
- InSightec Granted CFDA Approval for Fibroid Treatment Device
- Sihuan Pharma Receives OK from CFDA for Trials of Novel PPI Drug
- EntreMed Files for China Arm of its Sarcoma Clinical Trial
- Sinovac Files for Approval of its EV71 Vaccine
- Beijing Vigoo Biological Says EV71 Vaccine Passes Phase III Test
- Aslan Pharma Reports Positive Results for Gastric Cancer Treatment
- Zensun Announces Positive Data from Phase II Trials of Neucardin
- CFDA Approves Clinical Trials for Novel China AIDS Treatment
- Injex Pharma Given China Approval for Needle-Free Delivery Device
- Shenzhen Chipscreen Reports Phase II Success of Cancer Drug
- Furui Subsidiary Receives US Approval for Liver Testing Device
- China’s SFDA Ready to Fast-Track Approvals of Peramivir, a Flu Treatment
- Agenix to File for Clinical Trial of Hepatitis B Drug by June
- Life Technologies Gene Sequencer SFDA Approved for Diagnostic Use
- Cellular Biomedicine Starts China Trial of Liver Cancer Treatment
- Amoy Diagnostics Approved to Market IVD for Lung Cancer
- Antisense and TJAB Advance MS Drug
- Taiwan Liposome’s Liver Cancer Drug Put on Fast Track in China
- Sinovac Biotech’s Hand, Foot and Mouth Vaccine Succeeds in Phase III Trial
- Pfizer Gains China Approval of Kinase-Specific Lung Cancer Drug
- Sihuan Granted SFDA Approval to Test New Diabetes Drug
- Regeneron and Bayer Start Phase III Trial of Macular Edema Drug in China
- Luye Pharma Completes US Phase II Trial of Cardiovascular TCM
- Celgene Gains SFDA Approval for Multiple Myeloma Treatment
- OxOnc to Partner with Pfizer on China Cancer Drug Trial
- Solasia to Start China Clinical Trial of Anti-Nausea Patch Product
- Aoxing Pharma Receives License for Narcotic Cough Treatment
- Sihuan Given SFDA Approval to Start Clinical Trial of Innovative Antibiotic
- Shenzhen Neptunus Bioengineering Files for US Test of TCM
- Sihuan Pharma Gains OK for Opioid Inhibitor
- Zhifei's TB Vaccine Approved to Begin Phase III Trial
- EntreMed Files to Begin Clinical Trial of Cancer Drug in China
- Omega Diagnostics Secures SFDA Approval for Food Allergy Test
- Mauna Kea Technologies Wins China Approval for Endoscopy Device
- Veridex, a J&J Company, Gains OK for Cancer IVD Test in China
- Neusoft Medical Gains US Approval for 64-slice CT Scanner
- Covance’s Shanghai Lab Given GLP Certification by SFDA
- Edwards Lifesciences Wins SFDA OK for Heart Valve Replacement
- AstraZeneca Wins China Approval of Heart Drug
- Qiagen Gains SFDA Approval for HPV Test Aimed at Rural Areas
- Hua Medicine Advances Diabetes Treatment toward Trial
- Simcere Pharma Given OK to Start China Trial of Cancer Drug
- Hutchison MediPharma Starts Clinical Trial on Fourth Cancer Drug
- Sihuan Pharma Announces SFDA Approval for Ulcer Drug
- Neuralstem to Begin Clinical Trial of Stem Cell Product in Beijing
- Shanghai Kinetic Medical Spinal Device OK’d in US
- China’s Generon Starts Clinical Trial of Biologic Anti-Inflammatory Drug
- Dainippon Sumitomo Seeks SFDA Approval for Cancer Drug
- FortuneRock Given Go-Ahead to Begin China Trials of Long-Acting Interferon
- Biostar Moves Closer to Launching Topical Pain Relief Product
- 3SBio Files China IND for Anti-Autoimmune mAb from Apexigen
- Shanghai Jia Fu Medical Apparatus Starts Stem Cell Clinical Trial
- Ironwood Pharma Files to Begin China Phase III Trial of Linaclotide
- Oculus Announces SFDA Approval of Wound Healing Product
- 3SBio Given SFDA Permission for Phase III Trial of Anti-Rejection Drug
- Hutchison MediPharma Releases Phase I Data on Two Cancer Molecules
- Sihuan Pharma Passes Inspection for New GI Drug
- Sanofi to Start China Clinical Trial of Cancer Drug In-licensed from SIBS
- Baxter Gains SFDA Approval for Recombinant Hemophilia Treatment
- Shanghai Generon Initiates a Phase II Trial for Breast Cancer in the US
- TCM Treatment for Angina Approved for Use in Europe
- ThermoGenesis Gains SFDA Approval for Stem Cell Processing Device
- Zhejiang Hisun Pharma Files for US Approval to Start Clinical Trial of Statin
- PhytoCeutica of the US to Advance Clinical Trials of TCM for Cancer
- Agenix to File for China Clinical Trials of Hepatitis Treatment
- Zhejiang Hisoar Given Japanese Approval for Antibiotic
- InflammaGen Begins Clinical Trial of Treatment for Multi-Organ Failure
- Sihuan Pharma Files IND for New Anti-Hypertensive Drug
- Access Pharma Gains SFDA Approval for Oral Mucositis Treatment
- SFDA Approves Dynex Tech’s ELISA Analyzer
- Hutchison MediPharma Starts Phase I Trial of Fourth Molecule
- Syneron Announces SFDA Approval for Five Aesthetic Machines
- Novartis Announces China Launch for Lucentis and Galvus
- Xiamen Innovax Biotech Gains Approval for Hepatitis E Vaccine
- China Kanghui Granted FDA Approval for Two Joint Replacements
- Hengrui Gains FDA Approval for Cancer Drug
- LDR Given China Approval for Two Medical Devices
- Haibin Pharma Announces European Approval for Bulk Antibiotic
- Regeneron/Bayer Start China Trial of Wet AMD Drug
- Tasly Pharma Selects ICON for Global Phase III Trial of TCM Heart Drug
- Hutchison MediPharma Starts Clinical Trial of Cancer Drug
- Sinovac Biotech’s EV71 Vaccine Passes Phase II Test
- Jennerex/Lee’s Pharma Report Positive Phase II Data for Cancer Drug
- SFDA Annual Report of Drug Registration Approvals -- 2010
- ViroMed’s Gene Therapy Drug Given SFDA Approval for Phase II Trial
- Sinovac Given Final Go-Ahead for Animal Rabies Vaccine
- Daiichi Sankyo Given OK for Prostatic Hyperplasia Drug in China
- NexBio Reports Positive Data from Test of Biologic Flu Drug
- Simcere Obtains SFDA Approval for Rheumatoid Arthritis Treatment
- WuXi AppTec Certified by European Authorities for Bioanalytical Services
- Simcere Passes EU-GMP Inspection for OTC Diarrhea Treatment
- BeiLu Pharma Gives Up on Melatonin-based Depression Drug
- 3SBio Given OK for High-Dose EPIAO
- Sinovac Starts Phase II Trial of EV71 Vaccine
- Rhei Pharma Gaining on SFDA Approval of MuGard™
- Agenix Discloses Plans for Clinical Trial of Hepatitis B Drug
- Zhejiang Huahai Obtains FDA Approval for Alzheimer’s Drug
- Sinovac Announces Success for Phase I Trial of EV71 Vaccine
- Tianyin Pharma Approved to Launch Diabetes Treatment
- Simcere Subsidiary Given SFDA Approval for anti-TNF Biosimilar
- Beijing Second Pharma Wins US Approval for Anti- Hypertensive
- Novo Nordisk Wins China Approval for Diabetes Drug
- Simcere Files to Test Innovative Cancer Drug from US Biopharma
- Sinovac Files to Start Clinical Trial of Infant Pneumococcal Vaccine
- Poniard Given SFDA Approval for Phase III Cancer Trial
- Biomics and Benitec Advance RNAi Treatment for Hepatitis B
- NS8 to Launch Generic Zoloft in China
- Takeda Begins Phase III Trial of Diabetes Drug in China
- Hutchison MediPharma Starts Clinical Trial of Second Cancer Drug
- Sinovac Files to Start Trial of Bacterial Vaccine
- Boston Scientific Starts China Trial of New Stent
- 3SBio Announces OK of Additional Indication for TPIAO
- United Labs Announces Lower Cost Insulin Drugs
- Mingyuan Medicare Starts Test of Updated Cancer Microarray
- Sinovac Also Receives OK for EV71 Vaccine Trials
- CNBG Given Go-Ahead to Test HFMD Vaccine
- China Pharma Holdings Completes Trial of Generic Crestor®
- China Medical Tech. Receives Approval for Cancer Drug Test
- Roche’s Tarceva Effective in China Lung Cancer Trial
- Vital Therapies Says Liver Device Shows Long-term Benefit in China Trial
- OrbusNeich Completes Enrollment of China Stent Trial
- Roche Officially Launches Avastin after Fake Version Caused Problems
- FibroGen Earns SFDA Approval for China Trials of Anemia Drug
- Lotus Pharma Starts China Clinical Trial of Asthma Drug
- Aoxing Receives Approval for Trial of Drug Dependence Therapy
- Hepatitis E Vaccine from Xiamen Innovax Passes Phase III Test
- Jiangbo Predicts $8-$12 Million First Year Sales of Hypertension Drug
- Simcere Given SFDA Approval of Anti-Nausea Drug
- Tasly to Start Phase III Trial of TCM Angina Treatment in US
- SFDA Approves Rasilez, a Novartis Hypertension Drug
- Stallergenes Reports Successful Asthma Trial in China
- Kun Run Biotech OK’d to Produce Hepatitis B Drug
- SFDA Approves China Medical Technologies’ HPV Test
- Tarceva Effective in Asians with Specific Form of Lung Cancer
- Hemispherx and Fountain to Start China Trial of Flu Drug
- Sinovac Applies to Begin Mumps Vaccine Trial
- China Medical Announces New ECLIA Analyzer
- Lotus Expects Approval to Begin Trials of Asthma Drug
- Simcere Garners European Approval for Diarrhea Drug
- NeoStem Subsidiary Receives SFDA Approval for Antibiotic
- Milestone Awaits China Approval of Dental Anesthesia Device
- Simcere’s Cancer Drug Endostar Passes Phase IV Test
- OrbusNeich Begins China Clinical Trial of Bio-Engineered Stent
- Simcere Given OK by SFDA for Flu Drug Relenza
- NeoStem’s Eyre Subsidiary Approved to Use New Manufacturing Facility
- Novo Nordisk Awaits China Approval of Type 2 Diabetes Treatment
- Bayer Schering to Conduct Phase IV Hypertension trial in China
- China Aoxing Completes Trial of Pain Drug
- NeoStem Receives SFDA Approval for Proton Pump Inhibitor
- Sinobiopharma to Launch ACE Inhibitor
- China Pharma Holdings Seeks Approval of Generic Hypertension Drug
- 3SBio Files to Begin Trial of Anemia Drug
- China Aoxing Completes Trial of TCM Product for Menstrual Pain
- TCM Treatment Announced for H1N1 Flu
- Sinovac Files to Begin Trial of Vaccine for Hand, Food and Mouth Disease
- Astellas Given SFDA Approval for Overactive Bladder Treatment
- Merck KGaA Starts China Trial of Cancer Vaccine
- Bayer Schering Receives SFDA Approval for MS Drug
- Tianyin Pharma Announces Two TCM Product Approvals
- China Sky One Close to Approval on Two Diagnostic Tests
- Shanghai Biolaxy Given SFDA OK for Oral Insulin IND
- Oculus Receives China OK for Animal Wound Product
- China Medical’s FISH Probe for Leukemia Approved
- Hutchison MediPharma Says HMPL-004 Meets Trial Endpoints
- Hutchison MediPharma Starts Phase I Trial of Auto-Immune Candidate
- Mycenax Finishes Phase II Trial of Biosimilar Drug
- Sinovac’s Swine Flu Vaccine OK’d in Mexico
- Advanced BioMedical Reports Progress on Orthopedic Screw
- China Medicine Registers Vascular Drug in Pakistan
- China Medical Given SFDA Approval for SPR Diagnostic System
- Celsion Granted SFDA Approval for China Cancer Trial
- Sinobiopharma Given Certificate for Anti-Coagulant
- Jiangsu Yanshen’s Swine Flu Vaccine Approved by the SFDA
- China Aoxing Given OK for Trial of Narcotic Drug
- Abbott Granted China Approval for Drug Eluting Stent
- China Aoxing Submits Codeine Product for Approval
- Sinovac Approved to Produce H1N1 Vaccine
- Experts Recommend Approval of Sinovac’s H1N1 Flu Vaccine
- Hengrui Medicine to Put New Diabetes Drug in US Trials
- China Pharma Holdings Receives SFDA Approval for Proton Pump Inhibitor
- TCM OK’d to Begin US Clinical Trials for Hepatitis C
- Avita Granted China Approval for Wound Healing Kit
- Sinovac First Vaccine Maker to Complete Swine Flu Test
- TCM Shown Effective for Rheumatoid Arthritis
- Tianyin Granted Two SFDA Approvals
- Access Pharma to Start China Trial of US Cancer Drug
- Sinovac Releases Positive Update on A/H1N1 Flu Vaccine Trial
- Neusoft Medical Granted FDA Approval for High-End CT Scanner
- SFDA Grants Green Channel Approval to Market Drug without China Trials
- Sinovac, Hualan Biological Test Swine Flu Vaccines
- Biostar to Introduce Three New TCM Products
- Uni-Bio to Begin Phase III Trial of Diabetes Drug
- TCM May Be Best Treatment for Endometriosis
- Bayer Launches Novel Anti-Clotting Drug in China
- China Pharma Holdings Given OK for Generic Crestor® Trials
- China Aoxing Completes Trial of Codeine Product
- NeuroLogical Given SFDA Approval for Portable CT
- Solasia Files to Begin China Tests of its Anti-Emetic Patch
- China Sky One Receives Another New Product Approval
- Neusoft Positron, a China-US JV, Given FDA OK for PET Scanner
- China Sky One Receives Two New Approvals
- China Sky One Moves Ahead on Diagnostic Kit for Cardiac Problems
- China Aoxing Given SFDA OK for Angina Drug
- China Medical Tech’s Test for Bladder Cancer Approved
- China Sky One Given OK for Two New Products
- China Medical’s SPR Diagnostic System Passes Test
- American Oriental to Begin US Clinical Trial of TCM Drug
- SciGen Receives OK to Sell Recombinant Human Insulin in China
- China Sky One Granted One Approval, Two Drug Trial OKs
- Biocomposites Synthetic Bone Graft Product is SFDA Approved
- China Pharma Starts Clinical Trial for Hypertension Drug
- Sinovac Expands into Animal Health
- China Medical Approved for Two More FISH Probes
- China-Biotics Adds Four Probiotic Products
- 3SBio Now Has Three Drugs Seeking SFDA Approval
- LDR Wins China Approval for Artificial Disc
- Hutchison MediTech Puts Radiation Drug on Hold
- Q-Med Granted China Registration for Dermal Filler
- China Sky One Receives 4 More Product Approvals
- Tianyin Pharma Given SFDA OK to Launch Constipation Drug
- China Aoxing Granted Approval for Stroke Product
- China Sky One Announces Two More Approvals
- China Aoxing Granted Approval for OTC Pain Drug
- Crucell Advances Hepatitis B Vaccine in China
- China Sky One Receives Two New SFDA Approvals
- RHEI Begins Final China Trial for Oral Cadidiasis Product
- China Sky One Adds TCM Nasal Spray Product
- China AIDS Vaccine Passes Phase I Test
- SFDA Approves China Medical’s HER2 FISH Probe
- China Sky One Wins SFDA Approval for Two More Products
- China Pharma Antibiotic OK’d for Trial
- 3SBio Files for SFDA Approval of High-Dose EPIAO
- Phytomedics Testing TCM Drug for Rheumatoid Arthritis
- China Biologic to Start Trial of New Plasma Product
- Sinovac Strikes Deal for Healive® in the Ukraine
- Tianyin Receives SFDA Approval for TCM Asthma Product
- China Sky One Has Another 26 Products Awaiting Approval
- Positive Interim Data from Phase IV Test of Simcere’s Endu
- FDA Accepts Data from Bridge Labs’ China Facility
- Roche’s Xeloda Approved in China for Gastric Cancer
- SL Pharma Wins SFDA Approval for New Drug and a Clinical Trial
- Tianyin Receives SFDA Approval for Statin
- CompuMed Granted SFDA Clearance for Osteoporosis Diagnostic
- Bayer Given China Approval for Nexavar
- Genesis’s TCM Flu Treatment Approved by SFDA
- Abraxis Given China Approval for Cancer Drug ABRAXANE
- China Sky One Reports 11 Drugs in Clinical Trials
- China Sky One to Launch Clot Buster Injection
- Helicon Announces SFDA Approval for ReCell®
- Chindex Complains about Slow China Medical Device Approvals
- Sinovac Starts Phase II Trial of Second Pandemic Flu Vaccine
- China Sky One Receives Four More Approvals
- Hong Kong Researchers Identify Promising Avian Flu Treatment
- TCM Effective Against Heart Attacks and Cancer
- China Sky One Receives Approval for Two New Products
- Sinobiomed to Start Phase II Malaria Vaccine Trial
- Simcere Given SFDA Approval for Generic Antibiotic
- BMP Sunstone Given Go-Ahead for Trials of Enablex®
- Takara Bio Reports on Cancer Drug Trial in China
- China Biologic Reports Two SFDA Successes
- Frontier Biotechnologies Approved to Test HIV Drug
- Sinovac Granted SFDA Approval for Avian Flu Vaccine
- Oculus Announces SFDA Approval of Microcyn
- China Med Granted CE Mark for ECLIA Analyzer
- Tianyin Wins SFDA Approval for Antibiotic
- Pharmaxis Seeks to Run China Trial of Mucus Clearing Drug
- SurExam Has China Rights to New Ovarian Cancer Test
- Lotus Readies Generic Angina Drug
- AlphaRx to Seek China Approval of Arthritis Drug Indaflex™
- China Pharma Wins Approval for Generic Diuretic
- Calypte Oral HIV Test Nears SFDA Approval
- Sirnaomics on Track for 2008 Phase I in China
- Immtech Puts Hold on Clinical Trials of Pafuramidine
- Bird Flu Vaccine from Sinovac Reports Success
- AlphaRx Receives SFDA Approval for Topical Arthritis Product
- Second HIV/AIDS Vaccine from China to Start Phase I
- Immtech Conducts Joint US/China Trials for Pneumonia Drug
- GNI/Shanghai Genomics to Start China Clinical Trials of Liver Drug
- Qiagen Reports Positive Trial for FastHPV Test in China
- Tongjitang to Seek FDA Approval for TCM Drug
- Aida Updates Progress on Gene Therapy Cancer Drug
- China Medical Receives Approval for HIFU Device in Korea
- China Pharma Wins FDA OK for Generic HIV Pill
- Generex Will Test Cancer Vaccine in China
- WEX Publishes Results from Pain Drug Trial
- Immtech Wins Fast-Track for Pafuramidine from SFDA
- Sinobiomed Says Recombinant Batroxobin Effective in Trial
- Sinovac Starts Phase II Test of Pandemic Flu Vaccine
- China Aoxing Begins Trial for Codeine-based Cold Drug
- Gov't & Regulatory
- BIO Switches Gears, Forcing WuXi AppTec Out of Organization
- US Legislators Target WuXi Bio and BGI; Aim to Prevent Transfer of US Genomic Data
- China Announces Plans to Facilitate Foreign Investments in its Biopharma Industry
- China Eases Rules for Hong Kong Biopharmas to List on Mainland Exchanges
- China to Ban Export of Cutting-Edge Cell Technologies
- EQRx Retracts Promise to Bring Low-Cost China Drugs to US
- China Blocks GSK Generic BPH Drug Due to Safety Concerns
- US Blocks Asymchem’s $58 Million Acquisition of Boston’s Snapdragon
- WSJ Says China and US are Close to Agreement on Auditing Standoff
- Shanghai Zai Lab Raises Hong Kong Listing to Primary Status
- China Changes Policy: US Auditors Can Examine US-Listed China Companies
- China and US May Solve De-Listing Problem
- I-Mab Expects Resolution of China-US Auditor Conflict without De-Listings
- Three China-Based Biopharmas Receive US De-listing Notices
- China to Require Companies to Seek Approval before IPOing Outside of China
- Shanghai Offers Financial Support for Novel Drugs, Devices and Services
- China Adds 119 New Drugs to NRDL after 51% Price Cuts
- US-China Trade Agreement Specifies Patent Protection Rules for Drugs
- Scientist Behind China CRISPR-Cas9 Scandal Sentenced to Three Years in Prison
- China Adds 70 Drugs to Insurance Reimbursement List; Negotiates 61% Average Price Cuts
- Changsheng Bio Delisted following Major Vaccine Scandal
- China Passes Comprehensive New Drug Administrative Law
- China Allows Importation of "Small" Amounts of Non-China-Approved Drugs
- China Adds 148 New Drugs to Basic Insurance List
- Shanghai Launches New Exchange for High-Tech Companies Including Biopharmas
- China to Audit 77 Pharmas after Kangmei Reports $4.4 Billion Fraud
- China Negotiates Shorter Exclusivity for US-Made Biologic Drugs
- FDA Official Tells China Biopharmas to Bring PD-1/PD-L1 Inhibitors to US
- US Government Forces US Healthcare Company to Divest Investment From China's iCarbonX
- China Finalizes IPO Listing Rules for Shanghai High-Tech Board
- China Strengthens Clinical Trial Approval Rules for Cell and Gene Therapies
- China Cuts Value Added Tax on Rare Disease Drugs to 3%
- China Proposes Rules for IPOs on New Shanghai Hi-Tech Stock Exchange
- China to Start Shanghai NASDAQ-like Exchange for Young Tech Companies
- China Conducts Drug Tenders for Shanghai Market; Prices Drop 46%
- Shanghai Stock Exchange to Set Up New Board for Innovative Science and Tech Companies
- China to Extend Drug Patent Protection to 25 Years, Up from 20
- US-China Trade War May Affect Life Science Products
- China Moves to Encourage Higher Quality China-made Generic Drugs
- China Proposes to Eliminate Tax on Imported Cancer Drugs
- China Plans to Move the CFDA into a New Agency
- China Sees Promise, not Danger in Crispr Gene-Editing Trials
- CFDA Plans to Double Drug Review Staff: From 800 to 1,600
- China's State Council Endorses CFDA's New Foreign Clinical Trial Data Policies
- China Adds 36 Drugs to NDRL Following Major Price Cuts
- After US Request, China Bans Four Synthetic Opioids
- Sea Change: China Joins ICH -- International Harmonization of Drug Rules
- China's FDA Issues Proposals to Speed Drug Approvals, Improve IP
- China FDA Proposes New Rules to Speed Foreign Drug Approvals
- China to Announce New National Drug Reimbursement List
- New China Policy Puts Pressure on Drug Distributors to Consolidate
- China Fines Medtronic $17 Million for Setting Minimum Prices
- CFDA: 80% of China's Drug Applications Utilized Faulty Data
- CFDA will Require Pharmas to Self-Report any Drug Manufacturing Changes
- World Bank Report: China Must Reform its Healthcare Delivery
- China Aims to Improve Healthcare for Rural Poor
- China Announces Overview for Healthcare Big Data Project
- China Begins Marketing Authorization Holder Pilot Program
- China Announces NDRC Investigation into Drug/Device Pricing
- Sinovac: China Vaccine Sales Drop Due to New Government Policies
- China's FDA Losing Experienced Staff to Private Companies
- China Cuts Prices on GSK, AstraZeneca and Beta Drugs by Up to Two-Thirds
- China Questions Pfizer about Anti-Competitive Practices
- CFDA Accepts HCV Treatments from Seven Companies for Accelerated Approval
- China's New Vaccine Scandal: $88 Million of Illegally Sourced Products
- China Negotiating 50% Discounts on Five Western Drugs
- CFDA Halts Alibaba-Run Drug Tracking Service
- China Eases Tech Transfer Rules; Researchers to Profit from Sales
- China Plans $9 Billion Precision Medicine Research Effort
- Shanghai Proposes Compensating Angel Investors for Losses
- CFDA Issues New Drug/Clinical Trial Approval Regulations
- China to Re-Start IPO Process
- CFDA is Hiring Drug Reviewers
- CFDA to Start 60-Day Approvals for INDs of Oncology Drugs
- China's State Council Says CFDA Must Set Deadlines for Drug Approvals
- CFDA Promises to Ease Rules for Approving Novel Foreign Drugs
- CFDA Proposes New Rules To Guarantee Drug Quality and Speed Up Approvals
- CFDA Requires Drugmakers to Verify Clinical Trial Data Filings
- Quality of Drugs Is Primary Issue Facing CFDA, Minister Says
- China Halts IPOs in Move to Stop Stock Market Decline
- Chronic Disease Rises Sharply in China
- In China, Big Pharma Faces Drug Pricing Pressure
- China's CFDA Raises Fees for Drug Review
- China's State Council Announces Healthcare Reform Policies
- China Establishes Biosimilar Approval Rules; Abandons Drug Price Controls
- China Centralizes Hospital Drug Procurement
- China Sets Plan to Increase Number of Rural Doctors
- China's State Council Announces Official $6.5 Billion VC Fund
- Multinational Pharmas Face Loss of Preferential Drug Pricing in China
- China Agrees to Accelerate Drug and Medical Device Approvals
- China Agrees to Cut Tariffs on Imported Medical Devices
- China Publishes Draft Guidelines for Biosimilars
- China to Allow 100% Foreign Ownership of Hospitals
- CFDA Plans Reforms to Speed up Drug Reviews
- China to Stage Only 100 IPOs During the Rest of 2014
- China to End Price Limits on 530 Drug Products
- China to Remove Price Limits on Some Essential Drugs
- US FDA Slow to Add Drug Inspectors in China
- China Announces New $3.2 Billion Drug Development Program
- CFDA Ups Scrutiny of Medical Devices to Promote Safety
- CFDA Establishes Priority Review for Innovative Medical Devices
- China Implements 30-Day Review for “Simple” M&A Transactions
- Big Four Accounting Firms Face Six-Month Suspension in China
- China Adds Regs to New IPO Process
- China Announces Blacklist for Medical Bribery and Substandard Products
- Hepatitis B Vaccines Cleared in Deaths of Young Children
- China Halts Imports of Pfizer Anti-Fungal
- US FDA Grants Exclusivity/Fast Track Designations to TaiGen Antibiotic
- China Arrests 1,300 in Raids on Fake-Drug Businesses
- China Agrees to Allow Ten Additional US FDA Inspectors
- China Launches New Probe into Pharma Corruption; Novartis Accused of Bribery
- J&J Fined for Illegal Price Controls in Suit with China Distributor
- China’s SIPO Voids Patent for Gilead’s Viread
- China Authorities: GSK Executives Admit to Bribing Scheme
- Problems with China Trial Data of BMS/Pfizer Blood Thinner Caused Delay in Approval
- China Investigates Pricing Practices of 60 Drugmakers
- China Talks to Johnson & Johnson about its Product Recalls
- China’s CDCP and Columbia University Join to Form Pathogen Lab in Beijing
- US FDA Requests $4.7 Million for China Drug Maker Inspections
- China’s New Essential Drug List: Quality + Price
- New Bird Flu Strain Surfaces in China; Two Dead
- China's MOH Issues New Essential Drug List with 520 Products
- SFDA to Monitor Food Safety; Will Remain Part of MOH
- China to Give SFDA Responsibility for Food as well as Drugs
- SFDA Proposes Further Reforms in China's Drug Approval Process
- China’s SFDA Wants to Cut Number of Drug Distribution Companies by 10,000
- China's State Council Issues Bio-Industry Development Plan
- China Proposes Fast-Track Approvals for Innovative Drugs
- China’s Latest Round of Price Cuts Hits Big Pharma Drugs
- India to Open Drug Inspection Office in China
- SFDA Releases 2011 Drug and Clinical Trial Approval Report
- China Announces Another Round of Drug Price Cuts
- China to Grant India Greater Access to its Pharma Market
- New Essential Drug List Now Expected to Include 700 Drugs
- Officials: Chronic Disease Threatens China’s Healthcare System
- SFDA Issues New Rules for Drug Excipients
- Beijing Starts Zero-Markup Policy on Drugs from Local Hospital
- China Earmarks $11.8 Billion for Drug Innovation in 2016-2020 Five-Year Plan
- China’s State Council Reiterates Support for Biotechnology
- Roche Cuts the Price of Cancer Drugs in India – Under Pressure?
- Beijing Closes Pharmacies in Two Hospitals
- China to Set Up Global Clinical Trial Center in Tianjin
- China Ups Science Budget for 2012
- China Raises Basic Healthcare Subsidy by 80%
- China Will Greatly Expand Essential Drug List
- Beijing FDA Speeds Up its Fast-Track Review
- China Announces Major Program for Biotechnology 2010-2020
- China Supports Foreign Direct Investment in Biotechnology
- China Will Regulate TCM Products to Improve Their Purity
- China's 12th Five-year Plan for Medical Technology
- WHO Certification a Shot-in-the-Arm for China Vaccine Makers
- PRC Increases Goals of Healthcare Reform
- China Plans $1.7 Trillion Investment in Hi-Tech, including Biotechnology
- SFDA Will Inspect Foreign Drug Makers
- The FDA Improves Tracking of Foreign-Sourced Drugs
- Gates Foundation and China Form $300 Million Drug and Agriculture Partnership
- China to Up Vaccine Protection against Epidemics
- China Attacks Antibiotic Overuse, Putting Pressure on Makers’ Stock Prices
- China’s Push for Low Prices Causes Drug Shortages
- Four China Vitamin C Makers to Face Price Fixing Charges in US
- China’s Government Spent $39 Billion on Healthcare in 1H of 2011
- SFDA Issues Anti-Counterfeiting Rules for CMOs
- New FDA Plan to Increase China Drugmaker Inspections
- NDRC Mandates Price Cuts on 82 Drugs
- China Takes Dramatic Step to Curb TCM Speculation
- China May Subject HIV/AIDS Treatments to Mandatory Licensing
- SFDA Orders China Recall of GlaxoSmithKline Antibiotic
- Foci Pharma Seeks EU Approval of TCM
- All 11 Defendants Plead Guilty in Fake Avastin Case
- China Stresses Consolidation in Five-Year Plan for Drug Distribution
- China Regulates Antibiotics to Curb Abuse
- China Orders More Price Cuts for Drugs
- China’s Vaccine Regulation Passes WHO Test
- China to Earmark $761 Million to Upgrade API Makers
- FDA to Outsource More Inspections of Foreign Drug Makers
- China Encourages Foreign Investment in Medical JVs
- Shanghai Bars Three Medical Device Firms for Bribery
- China and US to Set Up Joint Public-Private Healthcare Partnership
- New Five-Year Plan to Limit Healthcare Costs for Individuals
- Deputy Director of SFDA Fired for Bribery
- China to Accept Taiwan Clinical Trials for SFDA Approval
- NDRC Proposing 40% Cut in China’s Drug Prices
- China Orders Companies to Reduce Drug Prices
- China Considering $1.5 Trillion Plan to Stimulate Innovation
- China MOF Ups Spending for Healthcare Reform to $1.9 Billion
- China Targets Bribery in Healthcare System
- MicroConstants China Certified to Provide Bioanalytical CRO Services
- 12th Five-Year Plan for China Life Science to be Released Soon
- China's 12th Five-Year Plan May Contain $1.5 Billion for Biopharma
- SFDA to Set Up Monitoring System for Essential Drug List
- China Spent $11.8 Billion on Healthcare Reform in 2010's First Half
- Is Johnson & Johnson Involved in Most Recent SFDA Scandal?
- India Bans Imports from 10 China API Companies
- Deputy Director of SFDA Fired
- China Close to Five-Year Plan for Biotech Industry
- China Allocates $5.5 billion to Implement Healthcare Reform
- China’s State Council Reveals Hospital Reform Plan
- China Releases a New National Drug Reimbursement List
- China Reveals 2009 Medical Reform Plans
- China Unveils 11-Year Health Plan
- China Will Spend $123 Billion on Healthcare Reform
- China Will Experiment with Zero Markup on Drugs in Hospitals
- Final China Medical Reform Plan Expected In January
- China Proposes Universal Health Insurance
- Experts Discuss FDA Inspections in China
- FDA to Open China Office in October
- Waves of Changes in Chinese Patent Law and Regulations: An Update, Part II
- US and China to Explore TCM Together
- FDA to Open Three China Offices This Year
- Drug Deaths Prompt More Efficient SFDA Response
- China Sky One Granted Five Approvals
- China’s SFDA to Shorten IND Wait for Innovative Drugs
- SFDA Becomes Part of Ministry of Health Again
- China to Commit 11 Billion RMB ($1.5 Billion) to Drug Innovation
- China Submits Medical Reform Plan
- Multinational Pharma Wants More from China’s Drug Rules
- China Fine Tunes its VC/PE Rules
- Restrictions Lifted on Aida’s Antibiotic
- China Starts Special War for Safety
- China to Allow Investment in Hong Kong Stocks
- China Rejects St. Jude Pacemakers
- China Puts Money Behind Safety Pledge
- Transparency is Goal for Chinese FDA
- China Executes ex-SFDA Head
- China Gets Serious about Drug and Food Safety
- Week in Review
- Week in Review: Under Pressure from US Congress, WuXi AppTec Resigns from BIO
- Week in Review: EurekaBio Raises $40 Million to Support Lentiviral Vector Platform
- Week in Review: Mabwell Sells Ex-China Rights to Rare Disease Therapy in $412 Million Deal
- Week in Review: AlphaGen and ArtBio Form China-US Radioligand Partnership
- Week in Review: LianBio to Close Operations; Will Pay $528 Million to Shareholders
- Week in Review: I-Mab Morphs into US-Only Company; Sells China Assets for $80 Million
- Week in Review: Shanghai Inmagene Signs $230 Million Deal to Develop Two HutchMed Immunology Assets
- Week in Review: Arrivent BioPharma Raises $175 Million in IPO for In-licensings from China
- Week in Review: Lee’s Pharm Signs $138 Million Agreement for China Rights to Heart Failure Therapy
- Week in Review: China Biopharmas Book $9 Billion in Deals During JP Morgan Conference Week
- Week in Review: 2024 Kicks Off with Three Deals Worth a Total of $4 Billion
- Week in Review: $1.7 Billion Collaboration between Elpiscience and Astellas is Final 2023 Deal
- Week in Review: Two Billion-Dollar Deals as 2023 Nears End: Hansoh-GSK; Nona-Pfizer
- Week in Review: SystImmune Out-Licenses Global Rights for ADC to BMS in $8.4 Billion Deal
- Week in Review: Abbisko Sells China Rights for CSF-1R Inhibitor to Merck in $605 Million Deal
- Week in Review: Tang Capital Offers $465 Million for LianBio Plus 80% of any Licenses/Divestments
- Week in Review: BeiGene Signs $1.3 Billion Deal for Preclinical CDK2 Inhibitor from Boston’s Ensem
- Week in Review: Legend Partners DLL3 CAR-T Candidate with Novartis in $1.2 Billion Deal
- Week in Review: Eccogen Out-licenses GLP-1 Agonist to AstraZeneca in $2 Billion Deal
- Week in Review: Hengrui Out-Licenses Next-Gen PARP1 to Merck KGaA for $1.7 Billion
- Week in Review: Hansoh Sells ex-China ADC Rights to GSK in $1.6 Billion Deal
- Week in Review: China's Biopharmas Announce $2.5 Billion in Deals
- Week in Review: Two China Biopharmas Announce Billion Dollar Deals
- Week in Review: QYuns Plans Hong Kong IPO for Autoimmune/Allergic Disease Portfolio
- Week in Review: Adlai Nortye Stages $97.5 Million US IPO on NASDAQ
- Week in Review: Everest Acquires Novel Autoimmune Therapy in $132 Million Agreement
- Week in Review: Hasten Signs $325 Million Deal for China Rights to PCSK9 Cholesterol Therapy
- Week in Review: Grit Bio Raises $60 Million for Tumor-Infiltrating Lymphocyte Drugs
- Week in Review: GenFleet Out-Licenses Three Candidates to Verastem in $625 Million Deal
- Week in Review: A Consortium of China Drug Distributors Want to Acquire Poland's Neuca
- Week in Review: Hengrui Out-Licenses Novel Anti-Inflammatory to One Bio in $1 Billion Deal
- Week in Review: BeiGene and BMS Close BeiGene-Celgene PD-1 Partnership
- Week in Review: Mundipharma Considers $1 Billion Sale of China Operations
- Week in Review: Pyrotech Closes $97 Million Series A Round for Immunomodulator Drugs
- Week in Review: Novartis in $1 Billion Deal for DTx Pharma, a siRNA Company Incubated by Viva BioInnovator of San Diego and Shanghai
- Week in Review: BeiGene Options DualityBio ADC in $1.3 Billion Agreement
- Week in Review: Billion Dollar Deals: Moderna’s Shanghai Investment and F-star’s Takeda Collaboration
- Week in Review: CMBG Out-Licenses Two CAR-T Candidates to Janssen for $245 Million Upfront
- Week in Review: AstraZeneca Considers Spinning Off China Ops into Separate Company
- Week in Review: Cullgen Signs $1.9 Billion Protein Degrader Deal with Astellas
- Week in Review: Shanghai HighTide Therapeutics Files for Hong Kong IPO
- Week in Review: Betta Pharma Enters $392 Million Deal for C4 Therapeutics’ NSCLC Drug
- Week in Review: Allgenesis Posts Positive Data from US Trial of Bi-Specific for Diabetic Macular Edema
- Week in Review: LaNova Sells Pre-Clinical ADC to AstraZeneca in $600 Million Deal
- Week in Review: BlissBio Announces Potential $2 Billion Deal with Eisai for HER2 ADC
- Week in Review: Pfizer Picks Sinopharm to Market 12 of its Novel Drugs
- Week in Review: Suzhou Duality Out-Licenses Two ADCs to BioNTech in $1.7 Billion Deal
- Apollomics Merges with SPAC to Support Candidates Targeting Difficult-to-Treat Cancers
- Week in Review: Highlightll Pharma Out-licenses Parkinson's Treatment to Biohaven for $970 Million
- Week in Review: Livzon In-Licenses GERD Therapy in $127 Million Agreement
- Week in Review: Sino Biopharm Acquires F-Star for $161 Million after US Approval
- Week in Review: Abbisko Out-Licenses Rights to Precision NSCLC Medicine for $188 Million
- Week in Review: Keymed/Lepu Sign $1.2 Billion Deal Out-licensing Claudin 18.2 ADC to AstraZeneca
- Week in Review: China Biopharmas Announce Three Out-licensing Deals Totaling $2 Billion
- Week in Review: CANbridge In-Licenses Gene Therapy for Rare Disease from UMass
- Week in Review: Structure Stages $161 Million US IPO for AI/Structure-based Drug Development
- Week in Review: HutchMed Announces $1.1 Billion Deal with Takeda for Colorectal Cancer Drug
- Week in Review: Mabwell Out-Licenses Rare Disease Drug for $412.5 Million
- Week in Review: Qitan Raises $101 Million for Nanopore Sequencing Devices
- Week in Review: WuXi Biologics Out-Licenses Four TCE Antibodies to GSK in $1.5 Billion Pact
- Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion
- Week in Review: Kelun-Biotech in $9.5 Billion ADC Deal with Merck
- Week in Review: Boston Scientific Pays $523 million for Majority Stake in Beijing Acotec Scientific
- Week in Review: Akeso Out-Licenses PD-1/VEGF to Summit in $5 Billion Pact
- Week in Review: Full-Life Acquires Focus-X and its Eight Radioherapeutics in $245 Million Deal
- Week in Review: Three New/Expanded Collaborations in Holiday-Shortened Week
- Week in Review: Fosun Signs $840 Million Deal for US Rights to Henlius' PD-1
- Week in Review: Insilico Signs Six-Drug AI Discovery Deal with Sanofi Worth up to $1.2 Billion
- Week in Review: CBC Plans $137 Million Shanghai Biopharma Complex
- Week in Review: VectorBuilder Raises $57 Million for Gene Therapy Delivery CDMO
- Week in Review: Jemicare Out-licenses Prostate Cancer Therapy to Roche for $650 Million
- Week in Review: AIM Vaccine Stages $20 Million IPO on Hong Kong Exchange
- Week in Review: YishengBio to List on NASDAQ via SPAC Merger at an $834 Million Value
- Week in Review: Sino Biopharm Subsidiary Enters $307 Million Agreement for Rights to NASH Candidate
- Week in Review: METiS, a US-China AI biotech, Acquires Pan-RAF Inhibitor in $482 Million Deal
- Week in Review: Beijing BoomRay Closes $43 Million A Round for Novel Radionuclide Drugs
- Week in Review: Biocytogen, a Genetically Modified Animal Models Company, Stages $60 Million IPO
- Week in Review: China and the US May Settle De-Listing/Accounting Impasse
- Week in Review: Everest Sells Trodelvy Rights Back to Gilead for $455 Million
- Week in Review: Hansoh In-licenses Endometriosis/Fibroid Therapy in $170 Million Deal
- Week in Review: Innovent Lands $305 Million Investment from Sanofi; Will Partner Two Candidates in China
- Week in Review: China Biopharma Tops $2.8 Billion in Week's Dealmaking
- Week in Review: WuXi Biologics and WuXi AppTec Plan $2.8 Billion Investment in Singapore Facilities
- Week in Review: Qiming Closes $3.2 Billion for China Healthcare and Technology Investments
- Week in Review: Sequoia China Raises $9 Billion for Healthcare and Technology Investments
- Week in Review: Henlius Signs $196 Million Deal for Two Oncology Bifunctional Sialidase Candidates
- Week in Review: invoX, a Sino Biopharm Company, to Pay $161 Million to Acquire F-Star
- Week in Review: Joincare Plans $300-$400 Million IPO on Swiss Exchange
- Week in Review: Fosun Pays $158 Million for Controlling Stake in Singapore Medical Centers
- Week in Review: Vivo Raises $600 Million in First Tranche of China PE Fund
- Week in Review: Fosun Acquires VerImmune Cancer Immunotherapy in $125 Million Deal
- Week in Review: Hengrui Launches US Subsidiary to Bring Novel Medicines to Global Markets
- Week in Review: Zhaoke Signs $130 Million Deal for Vision-Improving Eyedrops
- Week in Review: OrbiMed Plans to Raise $1.1 Billion for Fifth Asia Fund
- Week in Review: I-Mab Files for Hong Kong SPAC IPO to Acquire Life Science Company
- Week in Review: Wuhan Binhui Raises $47 Million for Oncolytic Virus Products
- Week in Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO in Guangzhou
- Week in Review: Harbour BioMed Signs $350 Million Out-license Deal for Bispecific with AstraZeneca
- Week in Review: RemeGen Raises $410 Million in Shanghai IPO for mAb/Dual Therapies
- Week in Review: Nuance In-licenses RSV Vaccine in $225 Million Deal
- Week in Review: A Possible Solution to US De-listing of China Biopharmas?
- Week in Review: Adiso Breaks out of Stealth with $95 Million from Morningside
- Week in Review: Adagene Forms $2.5 Billion, Four-Drug Partnership with Sanofi
- Week in Review: Huadong Pharma Enters $662 Million Deal for Two Kiniksa Anti-Inflammatory Drugs
- Week in Review: Rights to ChinaBio® Partnership Forum Acquired by EBD Group
- Week in Review: US FDA Rejects Innovent/Lilly PD-1 NDA Based on China-only Trial Subjects
- Week in Review: Biopharma Deals Slow During China New Year Week
- Week in Review: Xbiome Acquires Diabetic Foot Ulcer Therapy in $139 Million Deal
- Week in Review: Mabwell Bio Raises $547 Million in Shanghai STAR IPO
- Week in Review: ChinaBio® at China Showcase: The Golden Age for China Life Science Investing
- Week in Review: China Biopharma Books $500 Million of Deals to Start 2022
- Week in Review: Tasly Pharma Acquires Sutro ADC in $385 Million Deal
- Week in Review: BeiGene Out-licenses TIGIT Inhibitor to Novartis in $2.8 Billion Pact
- Week in Review: BeiGene Completes $3.5 Billion IPO on Shanghai STAR Board
- Week in Review: Shanghai Regor to Discover Metabolic Therapies for Lilly in $1.55 Billion Deal
- Week in Review: BeiGene Raises $3.5 Billion in Shanghai STAR Board IPO
- Week in Review: Shanghai's Zenas Acquires CD19 Antibody from Xenco in $480 Million Deal
- Week in Review: BeiGene Cleared to Stage $3 Billion IPO on Shanghai STAR Exchange
- Week in Review: Zai Lab Announces Two In-Licensings with Total Value of $800 Million
- Week in Review: Two China Affiliated Biopharmas Raise $585 Million in IPOs
- Week in Review: Fosun Pharma Acquires Majority Stake in China Vaccine Company for $682 Million
- Week in Review: China's Hansoh Signs Two siRNA Deals Worth $1.7 Billion
- Week in Review: Hansoh Signs $456 Million Deal for siRNA Products
- Week in Review: MicroTech Medical Staging $245 Million HK IPO for Diabetes Products
- Week in Review: Innovent Acquires Novel Atopic Dermatitis Treatment in $267 Million Pact
- Week in Review: Broncus Stages $200 Million Hong Kong IPO for Pulmonary Devices
- Week in Review: Everest Announces Two In-Licensings with Total Value of $1 Billion
- Week in Review: Sanofi Acquires Kadmon, a US-China Pharma, for $1.9 Billion
- Week in Review: Innovent Acquires GenFleet's KRAS G12C Oncology Candidate in $312 Million Deal
- Week in Review: Suzhou Abogen Raises $700 Million for mRNA COVID Vaccine
- Week in Review: Sino Biological Stages $772 Million IPO on ChiNext Exchange
- Week in Review: RemeGen Out-Licenses Rights for HER2 ADC to Seagen in $2.6 Billion Deal
- Week in Review: China Life Science Posts $1.3 Billion in Deals
- Week in Review: Kumquat Signs $2 Billion US-China Deal with Lilly for Novel Immune Drugs
- Week in Review: Qiming Launches $500 Million Fund for Listed Healthcare Companies
- Week in Review: Innocare Strikes $937 Million Deal with Biogen for BTK Inhibitor
- Week in Review: Keymed Completes $378 Million IPO in Hong Kong for Antibody Drugs
- Week in Review: BeiGene Plans $3 Billion IPO on Shanghai STAR Market
- Week in Review: Insilico Closes $255 Million Round for AI Drug Discovery/Development
- Week in Review: Week's China Life Science Deals Total Over $2.5 Billion
- Week in Review: Shanghai CARsgen to Raise $400 Million in Hong Kong IPO
- Week in Review: Zai Lab Enters $338 Million Agreement to In-License KRAS Inhibitor
- Week in Review: Nikang Raises $200 Million from US and China Investors
- Week in Review: LianBio Acquires Two IBD Candidates in $218 Million Deal
- Week in Review: GenScript and its Legend Bio Subsidiary Raise $1 Billion from Hillhouse
- Week in Review: WHO Close to Approving Global Use for Two China COVID-19 Vaccines
- Week in Review: CANbridge Licenses LogicBio's Adeno-Associated Virus for Gene Therapies in $591 Million Deal
- Week in Review: Zai Lab Raises $750 Million in Public Offering for In-Licensed/Novel Drugs
- Week in Review: Sinopharm Transfers $4.6 Billion in Assets Including two COVID-19 Vaccines
- Week in Review: Sorrento Acquires ACEA in $488 Million Deal between Two San Diego-China Oncology Biopharmas
- Week in Review: Three China In-Licensing Deals Add up to $662 Million
- Week in Review: China Life Science Books $1 Billion in Ten Announced Deals
- Week in Review: $1.2 Billion in China Life Science Deals, IPOs and Financings
- Week in Review: Haohai Bio Enters $527 Million Deal for Dermatology Products
- Week in Review: OrbiMed Raises $800 Million for its Fourth Asia Fund
- Week in Review: China Life Science Scores over $1 Billion in Week's Deals
- Week in Review: Yuanxin Raises $465 Million for Online Healthcare Company Miaoshou Doctor
- Week in Review: Suzhou's Adagene Raises $140 Million in US IPO to Develop Oncology Drugs
- Week in Review: Junshi Signs $1.1 Billion Deal for US-Canada Rights to PD-1
- Week in Review: Matridx Raises $32 Million for AI/CRISPR-Cas Pathogen Metagenomics Diagnostic Devices
- Week in Review: Suzhou's Adagene to Stage $125 Million IPO on NASDAQ
- Week in Review: BeiGene Signs $2.2 Billion Deal with Novartis for PD-1
- Week in Review: China Biopharma Starts 2021 with Over $1 Billion in Deals and IPOs
- Week in Review: DXY Raises $500 Million for Online Consumer Healthcare Site
- Week in Review: Beijing's Jacobio Completes $174 Million Hong Kong IPO
- Week in Review: Week's China Life Science Investments Total $800 Million
- Week in Review: JD Health Raises $3.5 Billion in Hong Kong IPO; Climbs 56% on First Day
- Week in Review: CANbridge Closes $43 Million E Round for Rare Disease Drugs
- Week in Review: Eluminex Raises $50 Million for Ophthalmology Drugs
- Week in Review: BeiGene Plans $2.5 Billion IPO on Shanghai Star Exchange
- Week in Review: RemeGen, a Yantai Biologics Company, Completes $515 Million Hong Kong IPO
- Week in Review: Three $300 Million Deals for China Biopharma
- Week in Review: CStone Out-licenses Ex-China Rights to Two Immunotherapies in $1.3 Billion Deal
- Week in Review: Fosun's Gland Pharma Approved for $814 Million IPO in India
- Week in Review: Curon Bio Acquires Rights to Lymphoma Drug in $150 Million Deal
- Week in Review: $1.5 Billion Total in Week's China Deals
- Week in Review: Zai Lab Completes Second Listing with $761 Million HK IPO
- Week in Review: Illumina Pays $8 Billion to Acquire GRAIL, an Early-Stage Cancer Testing Company
- Week in Review: Zai Lab to Raise Up To $845 Million in Hong Kong IPO
- Week in Review: Baidu Raising $2 Billion for New China Biopharma
- Week in Review: I-Mab Partners CD47 with AbbVie in $2 Billion Deal
- Week in Review: Antengene Approved by Hong Kong Exchange for $200 Million IPO
- Week in Review: Innovent Out-licenses Ex-China Rights for PD-1 to Lilly in $1 Billion Deal
- Week in Review: $2.5 Billion in Deals including LianBio's Initial $719 Million in In-Licensings
- Week in Review: BioKangtai Acquires China Rights to AstraZeneca's COVID-19 Vaccine
- Week in Review: Shanghai Hansoh Enters $68 Million Deal for Leukemia Candidate
- Week in Review: BeiGene Signs $540 Million Deal for China Rights to Three HBV Candidates
- Week in Review: China Life Science Announces $5 Billion in Deals, a Weekly Record
- Week in Review: Ocumension Climbs to $2.5 Billion Market Cap after $184 Million Hong Kong IPO
- Week in Review: China Life Science Announces Deals Worth $1.3 Billion
- Week in Review: VistaGen Out-Licenses China/Asia Rights for Novel Anxiety Drug to EverInsight in $177 Million Deal
- Week in Review: Six China Biopharma Deals Raise a Total of $255 Million
- Week in Review: Suzhou Innovent Announces $2 Billion Immunotherapy Collaboration with Roche
- Week in Review: China Life Science Companies Raise Nearly $1 Billion Led by Legend's $424 Million US IPO
- Week in Review: Shenzhen's MGI Tech Raises $1 Billion to Develop Gene Sequencing Machines
- Week in Review: CanSino Publishes Positive Data from Trial of COVID-19 Vaccine
- Week in Review: Sorrento Announces mAb Inhibits 100% of SARS-CoV-2 Infection
- Week in Review: Junshi Out-Licenses Ex-China Rights for COVID-19 Therapeutic to Lilly
- Week in Review: I-Mab Seeking $2 Billion Deal for CD-47 Candidate
- Week in Review: Akeso Stages $335 Million HK IPO for Mono-/Bi-Specific Antibodies
- Week in Review: Leo Pharma Acquires Atopic Dermatitis Candidate from Taiwan-China Company in $570 Million Deal
- Week in Review: Qiming Venture Closes $1.1 Billion Fund for Healthcare/TMT Investments
- Week in Review: Signs of Life after Coronavirus -- China Biopharma Scores $721 Million in Deals
- Week in Review: Abbisko Raises $70 Million to Develop Cancer Drug Candidates
- Week in Review: InnoCare Prices Hong Kong IPO to Raise $288 Million
- Week in Review: Nanjing Legend Files to Stage IPO in the US
- Week in Review: Abpro Bio Signs $1.1 Billion Deal for China-Asian Rights to Two Bi-specifics
- Week in Review: CICC Capital Closes $229 Million China Fund for Biologics
- Week in Review: CANbridge Raises $98 Million for In-licensed Orphan Disease and Targeted Cancer Candidates
- Week in Review: Bio-Thera Raises $241 Million in Shanghai STAR IPO for Antibody Portfolio
- Week in Review: AkesoBio, a Zhongshan mAb Biopharma, Files for $300 Million Hong Kong IPO
- Week in Review: Sorrento Therapeutics Fights $933 Million Take-Private Bid
- Week in Review: South Korea's Celltrion Plans $513 Million Biologics Facility in Wuhan
- Week in Review: China's I-Mab Stages $104 Million NASDAQ IPO
- Week in Review: Four China Biopharmas Announce $100+ Million Deals in First Week of 2020
- Week in Review: Shanghai's I-Mab Plans $100 Million NASDAQ IPO on January 16
- Week in Review: Geneseeq and Elpiscience Close $100 Million VC Rounds; Zai Lab's PARP Inhibitor Approved for China Use
- Week in Review: Ally Bridge Leads $140 Million of Investments in Three Medical Device Companies
- Week in Review: AlphaMab Raises $234 Million in Hong Kong IPO; Climbs 35% in First Trading Session
- Week in Review: Alphamab Oncology Plans $350 Million Hong Kong IPO
- Week in Review: Pharmaron, a Beijing CRO, Stages $434 Million Hong Kong IPO
- Week in Review: Fosun Pharma Acquires Brain Cancer Immunotherapy in $148 Million Deal
- Week in Review: BeiGene's BTK Inhibitor Approved in US and China Approval for PD-1 Expected in Two Months
- Week in Review: AstraZeneca Announces $1 Billion Fund for China Life Science Startups
- Week in Review: BeiGene Forms Blockbuster $2.7 Billion Collaboration with Amgen
- Week in Review: Suzhou's Ascentage Pharma Stages $53 Million IPO in Hong Kong
- Week in Review: Taimei Raises $212 Million for AI Life Science Support Software
- Week in Review: Jiangsu's CTFH Signs $200 Million AI Drug Discovery Pact with Insilico
- Week in Review: Suzhou Innovent Raises $300 Million to Develop New Products
- Week in Review: Henlius Out-Licenses Southeast Asia Rights for PD-1 Candidate in $692 Million Deal
- Week in Review: Investor Group Bids $4.6 Billion to Acquire China Biologic
- Week in Review: Hansoh Signs $1.5 Billion Cross-Border Deal for AI-Drug Discovery with Atomwise
- Week in Review: PAG Pays $540 Million for 58% Stake in Hisun BioRay, a China Biotech
- Week in Review: HiFiBiO Raises $67 Million for Immune Modulator Portfolio
- Week in Review: Biotheus Acquires China Rights to Three Bi-Specifics in $142 Million Deal
- Week in Review: Chipscreen Gains 367% Following $148 Million Shanghai STAR IPO
- Week in Review: Nanjing King-Friend Invests $95 Million in US Partner, Meitheal Pharma
- Week in Review: United Healthcare, a China Hospital Chain, Acquired for $1.4 Billion
- Week in Review: Wild Trading on Opening Day at Shanghai STAR Exchange; Shenzhen Chipscreen to IPO on STAR Next Week
- Week in Review: Three China Biopharmas Announce Plans for Shanghai/Hong Kong IPOs
- Week in Review: SinoMab to IPO on Hong Kong Exchange
- Week in Review: Jibeier Pharma Files to Raise $100 Million in IPO on New Shanghai STAR Board
- Week in Review: Tasly Bio Files for $1 Billion Hong Kong IPO
- Week in Review: Immunotherapies Dominate the Week's China Biopharma News
- Week in Review: China Biopharma Announces Nearly $3 Billion in Deals
- Week in Review: Frontage, a US-China CRO, Stages $205 Million Hong Kong IPO
- Week in Review: Hansoh's Hong Kong IPO to Raise up to $1 Billion at $10 Billion Valuation
- Week in Review: WuXi Biologics Signs LOI for $3 Billion Vaccine Contract
- Week in Review: MGI Tech Raises $200 Million to Manufacture Genomic Sequencing Machines
- Week in Review: Human Gene Editing Scandal Revisited; Can China Biopharma Continue to Expand? News on Three China Life Science IPOs
- Week in Review: Everest In-licenses an ADC from Immunomedics in $835 Million Agreement, a China Record for a Single Asset
- Week in Review: Eddingpharm to Pay $375 Million for Two Lilly Antibiotics and a Suzhou Manufacturing Facility
- Week in Review: Chi-Med Plans $500 Million Hong Kong IPO
- Week in Review: Hansoh Plans Hong Kong IPO to Raise up to $1 Billion
- Week in Review: China's Cytovant Signs $1 Billion Deal for Four Medigene I-O Candidates
- Week in Review: CanSino Nears $1 Billion Valuation Following Hong Kong IPO
- Week in Review: Tianjin CanSino Staging $160.5 Million Hong Kong IPO
- Week in Review: Inventis Closes $70 Million Financing to Develop 30 Novel Therapeutics
- Week in Review: Grifols Pays $1.9 Billion for 26% Stake in Shanghai RAAS
- Week in Review: Nanjing's NJCTTQ Agrees to $4 Billion Package for Abpro Bi-Specific Immunotherapies
- Week in Review: Sciwind, a Hangzhou Biopharma, Raises $29.5 Million for NASH Treatments
- Week in Review: CStone's Hong Kong IPO to Raise $304 Million at $1.5 Billion Valuation Next Week
- Week in Review: China Resources and Charoen Pokphand Join to Launch $300 Million Life Science Fund
- Week in Review: New Shanghai Hi-Tech Exchange to IPO Pre-Revenue Companies
- Week in Review: China Green Lights NASDAQ-style Exchange for Young Companies
- Week in Review: Yantai's MabPlex Raises $59 Million to Expand CDMO Services
- Week in Review: China Life Science Starts off 2019 with $425 Million in Deals
- Week in Review: 2018 Results: China Life Science Investment Hits Record Levels
- Week in Review: Shanghai Industrial to Start $7.3 Billion Biomedical Fund in 2019
- Week in Review: $1.5 Billion in China Deals with One Week Left in 2018
- Week in Review: Two China Biopharmas Raise $1.4 Billion in Hong Kong IPOs
- Week in Review: China Pharmas Announce Deals Worth $1.5 Billion
- Week in Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal with Zymeworks
- Week in Review: Alphamab Closes $100 Million Series A for Oncology Candidates
- Week in Review: CStone Pharma, a Suzhou Oncology Company, Files for Hong Kong IPO
- Week in Review: bioMérieux Acquires Majority Stake in China Diagnostics Company for $114 Million
- Week in Review: Terns Raises $80 Million for China, Global Development of Drugs Licensed from Lilly
- Week in Review: Innovent Completes $421 Million Hong Kong IPO; Will Start Trading Next Week
- Week in Review: Innovent's Hong Kong IPO: Raising $422 Million at $2 Billion Valuation
- Week in Review: Biosense Exercises $75 Million Option for China Rights to Neovacs' Lupus Immunotherapy
- Week in Review: Shanghai Henlius to File for Hong Kong IPO at Valuation of Over $1 Billion
- Week in Review: Agilent Pays $250 Million to Acquire ACEA and its Cell Therapy Analyzer
- Week in Review: WuXi AppTec Files for $1 Billion+ Hong Kong IPO at $13 Billion Valuation
- Week in Review: $1.4 Billion in China Life Science Deals and Financings
- Week in Review: Jiangsu Hansoh to Raise Up to $3 Billion in Hong Kong IPO
- Week in Review: Nearly $1 Billion in Cross-Border China Biopharma Deals
- Week in Review: Three More China Biopharmas Planning Hong Kong IPOs
- Week in Review: Shanghai ChemPartner, a China CRO/CMO, Completes Reverse Merger
- Week in Review: Shanghai Junshi Biosciences Files for $500 Million Hong Kong IPO
- Week in Review: Two Hong Kong IPO - BeiGene and Ascletis - Raise a Combined $1.3 Billion
- Week in Review: Long Hill Capital Closes $265 Million Fund for China Healthcare
- Week in Review: Acletis Raising $457 Million in Hong Kong IPO at $2 Billion Valuation
- Week in Review: Tasly Biopharma Completes Pre-IPO Round at $1.9 Billion Valuation
- Week in Review: Suzhou Innovent Files for HK IPO -- $500 Million Raise Rumored
- Week in Review: CStone Acquires China Rights to Leukemia Drug in $424 Million Deal
- Week in Review: CITIC Offers $3.6 Billion to Acquire China Biologic
- Week in Review: Mevion Medical of Boston Closes $150 Million Financing from China Investors
- Week in Review: Hua Medicine Approved for $200 Million Hong Kong IPO
- Week in Review: Alibaba Transfers Assets to Ali Health in $1.4 Billion Deal
- Week in Review: Grail, an Oncology Diagnostics Company, Taps China Investors for $300 Million
- Week in Review: Fosun in $2 Billion Bidding War for US Rights to Novartis' Generic Drugs
- Week in Review: $3.4 Billion Week for China Life Science Deals
- Week in Review: Ping An Good Doctor Plans $1 Billion Hong Kong IPO in Mid-May
- Week in Review: Concord Medical Raises $240 Million for China Radiology Services
- Week in Review: WuXi AppTec Plans $910 Million Shanghai IPO
- Week in Review: James Watson to Lead New Shenzhen Biopharma Research Center
- Week in Review: Alibaba Bids $1.4 Billion for iKang, a Chain of China Healthcare Clinics
- Week in Review: China Pharma Deals Top $1.5 Billion for Week
- Week in Review: Grail Plans $500 Million Hong Kong IPO for Cancer Diagnostics
- Week in Review: Taiwan Liposome Files for $50 Million IPO in the US
- Week in Review: Harbin Pharma Invests $300 Million in US-based GNC; Forms China JV
- Week in Review: Tsinghua University Invests $276 Million in Cambridge UK Biohub
- Week in Review: C-Bridge Raising Another $650 Million for China Healthcare
- Week in Review: Luye May Stage $500 Million Singapore IPO of Healthcare Assets
- Week in Review: Sinocare Eyes $4 Billion Deal for J&J Diabetes Device Business
- Week in Review: Hua Medicine to Raise $200 Million Through Fundings and IPO for Oral Diabetes Drug
- Week in Review: China Life Science Starts 2018 with $2 Billion Week
- Week in Review: 2017 Was Record Investment Year for China Life Science; Final Week Adds $669 Million
- Week in Review: Nearly $2 Billion Late-December Week for China Pharma Deals
- Week in Review: Fosun Signs $125 Million Deal for Ardelyx IBS Treatment
- Week in Review: China Life Science Deals Total $550 Million
- Week in Review: Walgreens Boots Alliance Spends $420 Million for China Pharmacy Presence
- Week in Review: China Renaissance Sets $7 Billion Goal for New VC/PE Funds, Including Biotech/Healthcare
- Week in Review: Shanghai Pharma Acquires Cardinal's China Drug Distribution Network for $1.2 Billion
- Week in Review: China's Creat to Restructure $1.5 Billion Biotest Takeover
- Week in Review: Xynomic Signs $502 Million Deal for Boehringer's RAF Inhibitor
- Week in Review: China Resources Pharma Files for $369 Million China Life Science Investment Fund
- Week in Review: WuXi AppTec Acquires US-Global Clinical CRO
- Week in Review: Shanghai Pharma Bids in Cardinal China's $1.5 Billion Auction
- Week in Review: Fosun May Pay $350 Million for Second India Pharma Acquisition
- Week in Review: Another Billion Dollar Week for China Life Science Deals
- Week in Review: Zai Lab Completes $150 Million US IPO; Investors Push Valuation to $1.4 Billion
- Week in Review: Shanghai United Imaging Raises $500 Million in Series A; Zai Lab will IPO Next Week
- Week in Review: China Pharma Continues Record Deal Pace with $2 Billion in New Announcements
- Week in Review: This Week's China Pharma Deals Top $1 Billion
- Week in Review: Columbia China Building $150 Million Hospital in Jiaxing
- Week in Review: China's Life Science Deals Top $1.4 Billion for Week
- Week in Review: Zai Lab Targets $1 Billion Valuation in Planned US IPO
- Week in Review: China VC/PE Funds Raising Capital at $30 Billion Rate in 2017
- Week in Review: Vivace Details its Capital Efficient Plan to Develop Novel Cancer Therapies
- Week in Review: C-Bridge Raises $400 Million for Second China Healthcare Fund
- Week in Review: BGI Genomics Completes $81 Million Chi-Next IPO
- Week in Review: BeiGene Sets Record with $1.4 Billion Celgene Deal
- Week in Review: Sinovac's Privatization Offer Draws $459 Million Outside Bid
- Week in Review: BGI Genomics Plans $250 Million Shenzhen IPO
- Week in Review: IHH Building $1 Billion of China Hospitals; Seeks Deals for More
- Week in Review: WuXi Biologics Raises $511 Million in Hong Kong IPO
- Week in Review: Hong Kong's Cirina Merges with GRAIL for Early Stage Cancer Diagnostics
- Week in Review: China Life Science Venture Tie-up: WuXi and Frontline Merge
- Week in Review: Shanghai Pharma Considers $4 Billion Bid for Germany's Stada
- Week in Review: China Pharma Signs Cross-Border Deals
- Week in Review: Ping An Announces $1 Billion Fin-Tech/Healthcare VC Fund
- Week in Review: Cathay Fortune Pays $186 Million for German Diagnostic Company
- Week in Review: Tianjin CanSino Closes $65 Million Round for Vaccine Portfolio
- Week in Review: Dalian Wanda Plans $10 Billion Chengdu Healthcare Park
- Week in Review: Zai Lab Partners with GE on China Biologics Manufacturing
- Week in Review: Beijing's Creat Offers $1.3 Billion for Biotest of Germany
- Week in Review: BGI Genomics Plans $250 Million Shenzhen IPO
- Week in Review: Fosun Eyeing $4 Billion Bid for Germany's Stada Pharma
- Week in Review: OrbiMed Plans $450 Million Target for Third Asia Life Science Fund
- Week in Review: BioSense Signs $68 Million China Deal with Neovacs For Therapeutic Vaccine
- Week in Review: China to Add 300 Drugs to National Reimbursement Drug List
- Week in Review: China Investors Announce $4 Billion of Life Science Deals
- Week in Review: WuXi AppTec Acquires HD Biosciences in China CRO Tieup
- Week in Review: China's Sanpower Pays $820 for Provenge, a Prostate Immunotherapy
- Week in Review: China's New Century Healthcare Plans Hong Kong IPO
- Week in Review: Beijing's Berry Genomics Valued at $619 Million in Reverse Merger
- Week in Review: China Metallurgical Spending $531 Million to Build Two Kuwaiti Hospitals
- Week in Review: JHL Biotech Signs $257 Million Biosimilar Deal with Sanofi
- Week in Review: Suzhou's Innovent Biologics Announces Record $260 Million Funding
- Week in Review: Beijing's BeiGene Raises $185 Million for Clinical Trial Program
- Week in Review: Week's China Life Science Deals Total $795 Million
- Week in Review: Investors Embrace Future of Biologics Drugs in Samsung Biologics' $2 Billion IPO
- Week in Review: Chi-Next Exchange Rejects BGI's $260 Million IPO Application
- Week in Review: China Resources Pharma Stages $1.8 Billion Hong Kong IPO
- Week in Review: Over $850M in China Healthcare and Pharma Deals
- Week in Review: China Resources Pharma to Price $2 Billion Hong Kong IPO This Week
- Week in Review: Teva Pays $160 Million for US/Canada Rights to Celltrion Biosimilars
- Week in Review: Big Week for Cross-Border Life Science Deals
- Week in Review: Jacobson Pharma Raises $85 Million in Hong Kong IPO
- Week in Review: China's Luxin Invests in $215 Million Funding for Intarcia's Long-Term Diabetes Device
- Week in Review: China Resources Pharma to Raise $2 Billion in Hong Kong IPO
- Week in Review: New Deals Fund China Life Science Innovation
- Week in Review: Week's Deals Create New China Life Science Alliances
- Week in Review: China Group to Build $1.5 Billion Life Science Complex in South San Francisco
- Week in Review: Korea's Samsung BioLogics Files for $2.5 Billion IPO
- Week in Review: China Life Science Goes International for Deals
- Week in Review: CrownBio, a US-China CRO, Applies for Taiwan Listing
- Week in Review: Cross-Border Investments Rule the News
- Week in Review: China Bridge Capital Announces $1.5 Billion Precision Medicine Fund
- Week in Review: CStone Pharma to Develop Novel Drugs for China with $150 Million in Startup Capital
- Week in Review: Pfizer Building $350 Million China Biosimilar Facility
- Week in Review: Hengrui's US Spinoff Funded with $100 Million
- Week in Review: Gan & Lee to Raise $266 million in Shanghai IPO
- Week in Review: Sorrento Therapeutics Raises $150 Million from China Investors
- Week in Review: Novartis Opens $1 Billion Shanghai R&D Center
- Week in Review: HighLight Capital Raising $229 Million for China Healthcare
- Week in Review: Big Deals Headline This Week's Life Science News
- Week in Review: China Leads Global Pharma Innovation, Says Thomson Reuters
- Week in Review: Sinocare Acquires Second US Diagnostics Maker; Pays $200 Million
- Week in Review: Beijing's Dehaier Raises $20 Million for Smart Medical Devices
- Week in Review: iCarbonX Closes $155 Million Series A at $1 Billion Valuation
- Week in Review: BVCF Seeking $400 Million for Fourth China Life Science Fund
- Week in Review: WuXi AppTec and Juno Form China Immuno-Oncology JV
- Week in Review: Deals Dominate China Biopharma News
- Week in Review: Origin-Centrillion Offers $1.5 Billion for Affymetrix
- Week in Review: Bain Capital Enters China Healthcare Market with $150 Million Deal
- Week in Review: Chi-Med to Raise $100 Million in US Offering Next Week
- Week in Review: WuXi AppTec Raises $1.5 Billion for China Healthcare
- Week in Review: Three Months after Privatizing, WuXi PharmaTech Plans IPO for Biologics Unit
- Week in Review: Athenex Adds New York Oncology Facility to Two in China
- Week in Review: China Resource Plans $1 Billion Hong Kong IPO
- Week in Review: BeiGene Completes $158 Million IPO in the US
- Week in Review: China Pharma Financing Deals
- Week in Review: BeiGene Schedules $128 Million IPO for February
- Week in Review: China Pharma Cross-Border Deals
- Week in Review: China Pharma Starts New Year With Record Deals
- Week in Review: China Pharma Year-End Deals
- Week in Review: Fosun Plans Hong Kong IPO of IVD Subsidiary
- Week in Review: AstraZeneca Commits $800 Million to China
- Week in Review: BioAtla and Pfizer in $1 Billion Oncology Drug Deal
- Week in Review: 3SBio Uses M&A to Expand Portfolio of Biosimilars
- Week in Review: Hepalink Invests $13 Million in Canada's OncoQuest
- Week in Review: CFDA Begins Reform of China Drug Approval Process
- Week in Review: Korea's Hanmi Signs $960 Million Deal with Janssen
- Week in Review: Korea's Hanmi Signs $4.2 Billion Deal with Sanofi
- Week in Review: Suzhou's MabSpace Raises $15 Million for Antibody Program
- Week in Review: Beijing's Beigene Plans $100 Million IPO in the US
- Week in Review: Innovent and Lilly Sign $1 Billion Cancer Deal
- Week in Review: GuaHao Raises $395 Million for China Internet Healthcare
- Week in Review: ShangPharma Partners to Build Biologics Campus
- Week in Review: China Issues Rules for Trials of Stem Cell Treatments
- Week in Review: Hengrui Out-licenses Cancer Drug in $795 Million Deal
- Week in Review: Hepalink Pharma Buys US-based CMO Cytovance
- Week in Review: China to Set Time Limit on Drug Approval Process
- Week in Review: Roche Buys China-Backed GeneWEAVE for $425 Million
- Week in Review: China Cord Blood Receives Higher Takeover Offer
- Week in Review: Boehringer Signs $730 Million Deal for Hanmi SCLC Drug
- Week in Review: 3SBio Acquires Wansheng Pharma for $85 Million
- Week in Review: WuXi Healthcare Ventures II Files for $250 Million Fund
- Week in Review: WuXi's SynTheAll Subsidiary Raises $80 Million
- Week in Review: Zhongheng Pays $52 Million for Oramed's Diabetes Drugs
- Week in Review: 3SBio Snags Global Rights to mAb for Arthritis
- Week in Review: Livzon Leads $26 Million Funding of Cynvenio
- Week in Review: 3SBio Rises 5% After $711 Million IPO
- Week in Review: Management Offers $3.5 Billion to Privatize Mindray Medical
- Week in Review: 3SBio to Stage $712 Million Hong Kong IPO
- Week in Review: Fosun, WuXi PharmaTech Acquire San Diego's Ambrx
- Week in Review: BeiGene Raises $97 Million for Cancer Drugs
- Week in Review: Xinbang Pharma Acquires Chinese Peptide Co. for $323 Million
- Week in Review: Haohai Biological Schedules $305 Million Hong Kong IPO
- Week in Review: Menarini Acquires China Rights to Novel Cancer Drug for $100 Million
- Week in Review: aTyr Pharma to Raise $86 Million in IPO
- Week in Review: WuXi Sells Stake in CMO Subsidiary; Lists on China OTC Exchange
- Week in Review: ZAI Lab to Develop BMS Liver Cancer Drug in China
- Week in Review: China's Innovent and Lilly Form $456 Million Cancer Biologics Alliance
- Week in Review: Porton Fine Chemicals Buys Dongbang Pharma
- Week in Review: Rumor: Mindray Medical May Go Private
- Week in Review: Eddingpharm Pays $169 Million for China Rights to Omega-3 Drug
- Week in Review: 3SBio Files for $500 Million IPO in Hong Kong
- Week in Review: Cellular Biomedicine In-licenses Cancer Immunotherapy from China
- Week in Review: WuXi NextCode Leads $15 Million Financing in Claritas Genomics
- Week in Review: MicroConstants Pays $16 Million for Novel China Antibody
- Week in Review: China's Innovent Raises $100 Million for Biologics Portfolio
- Week in Review: Baiyunshan Pharma Raises $1.6 Billion
- Week in Review: WuXi PharmaTech Pays $65 Million for Genomics Company
- Week in Review: 2014 Pharma IPOs in China: Just Three
- Week in Review: Otsuka Pays $78 Million for Asian Rights to Ariad's Leukemia Drug
- Week in Review: China's Neusoft Raises $610 Million for Life Science Subsidiaries
- Week in Review: Suzhou's Adagene Raises $8 Million for Antibody Discovery
- Week in Review: WuXi PharmaTech to List Subsidiary on China's Third Board
- Week in Review: Cross-Border Deals Dominate the Week's News
- Week in Review: BeiGene Announces $75 Million Series A Fundraising
- Week in Review: China's Waterstone Pharma Acquires Global Rights to Anti-Viral
- Week in Review: Active Week for China Pharma Dealmaking
- Week in Review: Roche Seeks China Partners with First-in-Class, Best-in-Class Products
- Week in Review: MID Labs Raises $51 Million from China Investors
- Week in Review: Lee's Pharm Pays $50 Million for Novel Cancer Drug from Sorrento
- Week in Review: WuXi PharmaTech Acquires XenoBiotic, a US-China CRO
- Week in Review: GSK Ends China Bribery Investigation by Paying $489 Million Fine
- Week in Review: Beike Biotech In-Licenses Cancer Drug in $200 Million Deal
- Week in Review: DXY Receives $70 Million Investment from Tencent
- Week in Review: ZAI Laboratory Lands $30 Million in Initial Funding
- Week in Review: Luye Acquires Hanmi's Oncology Drug for $20 Million
- Week in Review: ZAI Lab In-Licenses Two Sanofi Drug Candidates
- Week in Review: PW Medtech Pays $130 Million for Fellow China Medical Device Company
- Week in Review: Lifetech Scientific to Form Pacemaker Partnership with Medtronic
- Week in Review: CFDA to Outsource Drug Reviews
- Week in Review: Luye Pharma Completes Successful IPO in Hong Kong
- Week in Review: Fosun Ends $531 Million Deal with Sellas
- Week in Review: Luye Pharma to Raise $764 Million in Hong Kong IPO
- Week in Review: JHL Biotech Raises $35 Million for Taiwan-China Operations
- Week in Review: BGI Raises $320 Million for Diagnostics Division
- Week in Review: MicroPort-Sorin $20 Million China JV to Begin Operations
- Week in Review: Crown Bioscience Raises $27 Million in Series D Round
- Week in Review: Aslan In-Licenses Novel Asthma mAb from CSL
- Week in Review: Tigermed, a China CRO, Buys Majority Stake in Frontage Labs
- Week in Review: Hisun and Ambrx Team Up to Develop Cancer Drugs
- Week in Review: Chindex Taken Private by Fosun and TPG for $434 Million
- Week in Review: Unnamed Entity Raises Chindex Bid to $23
- Week in Review: BVCF Closes $188 Million China Life Sciences Fund
- Week in Review: China is Asia’s Biggest Biotech Cluster
- Week in Review: RuiYi Raises $15 Million for mAb Development
- Week in Review: China Unveils New $3.2 Billion Drug Development Program
- Week in Review: Hainan Haiyo Invests $20 Million in VC Fund
- Week in Review: iKang Healthcare Planning $150 Million IPO in US
- Week in Review: BGI Tech to Stage Hong Kong IPO
- Week in Review: Luye Pharma to Raise $750 Million in Hong Kong IPO
- Week in Review: Sagent Pharma Opens Research Center in Chengdu
- Week in Review: Zhejiang Wolwo Bio-Pharm Stages $84 Million Shenzhen IPO
- Week in Review: Jiangsu Aosaikang Pharma Delays China IPO
- Week in Review: Eddingpharm Buys ACT Biotech Assets for $95 Million
- Week in Review: China Starting Up Revamped IPO System
- Week in Review: ChemPartner's Scientific Expertise
- Week in Review: First Novel China-Developed MAb Drug Gains CFDA Approval
- Week in Review: Consun Pharma to IPO in Hong Kong, Raising $141 Million
- Week in Review: China Pharmas Make Cross-Border Deals with the West
- Week in Review: BioPacific to Make Angel Investments in China/Asia
- Week in Review: Golden Meditech to Raise Capital from Shareholders
- Week in Review: BeiGene Out-Licenses Novel Cancer Drug to Merck Serono
- Week in Review: Lorem Vascular Signs $531 Million Deal with Cytori
- Week in Review: Three China In-Licensings and One Nixed Intra-China Deal
- Week in Review: Fosun Pharma Strikes $531 Million Deal for Two Pre-Clinical Drugs
- Week in Review: Eddingpharm In-licenses China Rights to Bone Drug for $2.7 Million Upfront
- Week in Review: Hutchison MediPharma Partners Cancer Drug with Lilly
- Week in Review: Tasly Buys Stake in TCM Maker for $25 Million
- Week in Review: Amgen Partners with ShanghaiTech on China R&D Center
- Week in Review: CanSino Lands $10 Million Investment from Lilly
- Week in Review: Walvax Rumored to Acquire Genor BioPharma Soon
- Week in Review: BGI Shenzhen Planning Partial IPO
- Week in Review: Simcere Pharma Accepts $495 Million Go-Private Deal
- Week in Review: MicuRx Raises $25 Million for Antibiotic Clinical Trial
- Week in Review: OrbiMed Announces $300 Million Asia Life Science Fund
- The Week in Review: Fundings for China-Affiliated Drug Companies
- Week in Review: China’s Rx Market to Total $315 Billion in 2020
- Week in Review: Hisun to Build Manufacturing Facility for Finished Drugs
- Week in Review: Mindray Closes Acquisition of US Ultrasound Company
- Week in Review: Kinex Gains China Rights to Hanmi’s Orascovery Program
- Week in Review: Glaxo Officials in China Detained for "Economic Crimes"
- Week in Review: Simcere Raises $65 Million by Selling Boda Subsidiary
- Week in Review: Zhejiang Medicine to Develop Ambrx Breast Cancer Drug
- Week in Review: Mindray Medical Buys US Ultrasound Company for $105 Million
- Week in Review: Boehringer Ingelheim to Build Biopharma CMO in Shanghai
- Week in Review: BeiGene Sells Novel Cancer Drug to Merck Serono
- Week in Review: Hisun-Pfizer and Merck-Simcere JVs Come Into Focus
- Week in Review: RuiYi Signs Up Shanghai’s Genor to Develop mAb in China
- The Week in Review: Sagent Buys Out China JV Partner for $25 Million
- Week in Review: Fosun Buys Israeli Laser Company for $240 Million
- Week in Review: WuXi PharmaTech Contributes to Syros Pharma Funding
- Week in Review: Ascletis Collaborates with Roche on HCV Treatment
- Week in Review: Lilly Invests $100 Million in China Animal Healthcare Ltd.
- Week in Review: Sanofi in the Hunt for China M&A
- Week in Review: Sinopharm Building M&A War Chest
- Week in Review: BGI’s CEO Says Science Drives Collaborations
- Week in Review: Simcere Receives $503 Million Privatization Offer
- The Week in Review: Sinopharm to Raise $640 Million through Bond Sale
- Week in Review: Sinopharm Pays $252 Million for Majority Stake in Winteam Pharma
- The Week in Review: Reckitt Benckiser Buys Anhui’s Golong Medicine
- Week in Review: Amgen to Build China Presence with Partnerships/M&A
- Week in Review: Cardinal Health Uses M&A to Add Drug Distribution Reach in China
- Week in Review: Hainan Haiyao Buys SinoMab Stake for $10 Million
- Week in Review: 2012 China Life Science VC, M&A, and Partnering Climb
- Week in Review: Stryker Pays $764 Million for China Orthopedic Maker
- Week in Review: China’s Joinn Labs Buys Major Biopharma Campus in San Francisco
- Week in Review: Cellular Biomedicine of China to Reverse Merger in US
- Week in Review: Unnamed China Pharma Buys Bayer’s Vacated Bay-Area Campus
- Week in Review: WuXi PharmaTech and PRA Form Clinical CRO JV
- Week in Review: China Leads Emerging Countries Pharma M&A
- Week in Review: Grupo Insud to Build China Veterinary Drug Facility
- Week in Review: Hutchison Chi-Med Forms Drug Development JV with Nestlé
- Week in Review: Henan Province Starts $40 Million Biological Fund
- Week in Review: PerkinElmer Buys Haoyuan Biotech, a Diagnostics Company
- Week in Review: Vivo Ventures Leads $30 Million Funding of Jingfeng Pharma
- Week in Review: Charles River Labs Buys China’s Vital River
- Week in Review: Fosun Pharma’s Hong Kong IPO Raises $512 Million
- Week in Review: Fosun Pharma to Spend $300 Million from Hong Kong IPO on M&A
- The Week in Review: SFDA Drug Approvals Drop in 2011
- The Week in Review: Fosun Pharma Schedules $600 Million Hong Kong IPO
- The Week in Review: China Kanghui Bought by Medtronic for $816 Million
- The Week in Review: China's BGI Acquires Complete Genomics of the US
- The Week in Review: WuXi AppTec and MedImmune Start Joint Venture
- Week in Review: China National Biotec Plans $1.6 Billion Hong Kong IPO
- The Week in Review: Sino Biological Partners with Life Technologies
- The Week in Review: Joincare to Invest $157 Million for Antibiotic Facility
- The Week in Review: Tigermed and Shuangcheng Pharma Complete IPOs
- Week in Review: Singapore’s S*BIO Sells Cancer Drug to US Pharma
- The Week in Review: Tigermed, clinical CRO, Plans IPO - FLASH: Pricing set
- Week in Review: Suzhou Connect Biopharma In-Licenses Anti-Inflammatories from Arena
- The Week in Review: Jinhe Biotech Stages $79 Million IPO in Shenzhen
- Week in Review: Ascletis In-Licenses China Rights to RNAi Cancer Drug
- The Week in Review: ShangPharma Receives Go-Private Offer from Chairman
- The Week in Review: China Pledges $18 Billion for Biopharma 2011-2020
- The Week in Review: Quintiles to Build China Headquarters in Shanghai
- The Week in Review: Shanghai Kinetic Medical Raises $59 Million in ChiNext IPO
- The Week in Review: Mindray Medical Continues on Acquisition Path
- The Week in Review: Roche Diagnostics Plans $310 Million China Effort
- The Week in Review: Hisun to Invest $163 Million into JV with Pfizer
- The Week in Review: Partnering Bootcamp Leads into ChinaBio® Partnering Forum
- The Week in Review: ChinaBio® Partnering Forum Expecting International Turnout
- The Week in Review: Watson Buys Actavis for $5.6 Billion Upfront in a Week of Big Deals
- The Week in Review: Fidelity Starts New VC Fund for China Healthcare
- The Week in Review: Fosun Pharma Given OK for Hong Kong IPO
- The Week in Review: Henan Taloph Pharma Raises $63 Million
- The Week in Review: Huapont Pharma Raises $146 Million
- The Week in Review: China Pharma -- From Local to Global
- The Week in Review: OriGene Technologies Acquires Zhongshan Biotech
- The Week in Review: Abcam Pays $170 Million for China-Connected Epitomics
- The Week in Review: Shaanxi Bicon Pharma Raises $250 Million
- The Week in Review: Newsummit to Stage $80 Million IPO on NYSE
- The Week in Review: ChinaBio® Partnering Forum 2012 Scheduled for Suzhou
- The Week in Review: Fosun Pharma Plans Large Hong Kong IPO
- The Week in Review: Are WuXi PharmaTech and ShangPharma Takeover Targets?
- The Week in Review: Seven China Researchers Land $650,000 Howard Hughes Research Grants
- The Week in Review: Xizang Haisco Pharma Completes $127 Million IPO
- The Week in Review: China Featured at J.P. Morgan Confab
- The Week in Review: China Unveils Biotech Development Plan 2010-2020
- The Week in Review: China Events at J.P. Morgan Healthcare Conference
- The Week in Review: Hutchison MediPharma and AstraZeneca Partner on Cancer Drug
- The Week in Review: Simcere and BMS Add Cardiovascular Drug to Partnership
- The Week in Review: Merck Plans Beijing R&D Center; $1.5 Billion China Investment
- The Week in Review: China’s 12th Five-year Plan for Medical Technology
- The Week in Review: Huge China Hi-Tech Stimulus Rumored
- The Week in Review: ASLAN Pharma – Leveraging Asia Pacific’s CROs
- The Week in Review: CNBG Schedules $2 Billion IPO in Hong Kong
- The Week in Review: Roche’s China Strategy
- The Week in Review: BioBay Park Forms Partnership with Roche and Harvard
- The Week in Review: SFDA Releases 2010 Approval Data
- The Week in Review: Pharma Execs Plan Future at ChinaBio® Leadership Retreat–Taicang
- The Week in Review: Bailing Group Pharma Acquires Zhengxin Pharma
- The Week in Review: Newsummit Announces $100 Million Medical Device Fund
- The Week in Review: BioBay Investor Forum Names Chiva Pharma and Suzhou Biologix as “Most Promising”
- The Week in Review: Avenue Capital Starts $313 Million Fund for China Medical City
- The Week in Review: Fosun to Pay $219 Million for 70% of Jinzhou Ahon
- The Week in Review: DSM and Sinochem Launch Antibiotic JV
- The Week in Review: China Spends $38 Billion on Healthcare in 1H of 2011
- The Week in Review: Shanghai Pharma Looking For Western Acquisitions
- The Week in Review: FDA to Step Up Inspections of China Drugmakers
- The Week in Review: Shionogi Pays $185 Million for Control of C&O Pharma
- The Week in Review: Boston Scientific Earmarks $150 Million for China Effort
- The Week in Review: ChinaBio® Investor Forum–Jinan Selects Two “Most Promising” Companies
- The Week in Review: Will Novartis IPO in Shanghai?
- The Week in Review: BeiGene to Raise up to $150 Million This Year
- The Week in Review: Support for China Pharma in Five-Year Plan
- The Week in Review: Sihuan Pharma Uses M&A to Add Vascular Drugs
- The Week in Review: GSK Buys Out China Vaccine JV Partner
- The Week in Review: Northeast Pharma of China to Raise $370 Million
- The Week in Review: Tasly Pharma to Build US Manufacturing Facility
- The Week in Review: Most Promising Technology Awards at ChinaBio® Partnering Forum
- The Week in Review: ChinaBio® Hosts Successful Partnering Forum
- The Week in Review: Chongqing Zhifei Bids for Dutch Vaccine Company
- The Week in Review: BeiGene Reports “Large” Investment from Merck
- The Week in Review: Edan Instruments Raises $146 Million in ChiNext Debut
- The Week in Review: US-based SciClone Buys NovaMed of Shanghai
- The Week in Review: Shanghai Pharma Schedules Hong Kong IPO for May
- The Week in Review: China Life Science Hit Record Levels in 2010
- The Week in Review: Shanghai Pharma May Increase HK IPO to $1.8 Billion
- The Week in Review: Fuan Pharma Completes $214 Million IPO
- The Week in Review: US Charges Four China API Makers with Price-Fixing
- The Week in Review: Shanghai Pharma Schedules Hong Kong IPO
- The Week in Review: Fosun Seeks $913 Million in Hong Kong Listing
- The Week in Review: Pharmaron Raises $40 Million in Venture Capital
- The Week in Review: Bayer to Expand Beijing R&D Center
- The Week in Review: China Puts CAS in Charge of Stem Cell Initiative
- The Week in Review: VCs Invest $1 Billion in China Life Science During 2010
- The Week in Review: Sinopharm's M&A Extends Drug Distribution Network
- The Week in Review: Investors Drawn to China Pharma
- The Week in Review: Shanghai Pharma Active in Drug Distribution Rollup
- The Week in Review: China Track at J.P. Morgan Conference
- The Week in Review: End of the Year Transactions
- The Week in Review: “Most Promising” Companies at ChinaBio® Event
- The Week in Review: Active Week for Pharma Deals
- The Week in Review: GSK Acquires MeiRui, a Urology Drugmaker
- The Week in Review: New Government Policies Affect Pharma
- The Week in Review: IPO and M&A Pipeline
- The Week in Review: Novo Nordisk Details China R&D Plans
- The Week in Review: China VC Investment to Hit a New High in 2010
- The Week in Review: Major Cross-Border Initiatives
- The Week in Review: Making Deals
- The Week in Review: Big Week for China Pharma IPOs
- The Week in Review: Burrill and Infinity Announce China Life Science Fund
- The Week in Review: Two Major IPOs Announced for China Life Science
- The Week in Review: Deals and Products
- The Week in Review: Eddingpharm Raises $24 Million to Buy Western Drugs
- The Week in Review: East/West Biopharma Alliances
- The Week in Review: Shanghai Pharma Plans $1.2 Billion IPO
- The Week in Review: New IPO in China
- The Week in Review: Golden Meditech Raises $40 Million
- The Week in Review: Upping the Stakes
- The Week in Review: China to Unveil More Support for Biopharma
- The Week in Review: China Orthopedic Device Maker Plans NYSE Debut
- The Week in Review: Charles River Cancels Merger with WuXi
- The Week in Review: China Pharma IPOs Raise $5.4 Billion in 12 Months
- The Week in Review: Charles River/Wuxi PharmaTech Back in the News
- The Week in Review: More CRO Consolidation
- The Week in Review: ChinaBio® Partnering Forum
- The Week in Review: Medical Device Company to IPO in Hong Kong
- The Week in Review: Deals and Other News
- The Week in Review: Transactions and Approvals
- The Week in Review: China Working on Biotech Development Plan
- The Week in Review: ChinaBio® Investor Forum Showcases Young Companies
- The Week in Review: A Week of Deals
- The Week in Review: M&A, Partnerships and Earnings
- The Week in Review: Shenzhen Hepalink Completes Big IPO
- The Week in Review: CROs Consolidating
- The Week in Review: Innovation
- The Week in Review: Raising Funds
- The Week in Review: Tigermed and ICON Form China CRO Partnership
- The Week in Review: Lilly Has Big Plans for China
- The Week in Review: Cross-Border Collaboration
- The Week in Review: China Offers Lion's Share of Emerging Market Growth
- The Week in Review: AutekBio Raises $100 Million for Biologic CMO
- The Week in Review: China Life Science to Grow 22% Per Year Through 2013
- The Week in Review: New Deals in China Life Science
- The Week in Review: China New Year’s News
- The Week in Review: 3SBio and Ascentage Form Cancer Partnership
- The Week in Review: New Investments in China Life Science
- The Week in Review: Suzhou Nanomed Funded by Softbank
- The Week in Review: China Pharma Investment, Company Progress
- The Week in Review: China Life Science Convergence
- The Week in Review: New Investments for a New Year
- The Week in Review: Year-End IPO Review
- The Week in Review: Holiday Transactions and Awards
- The Week in Review: Medical Device and Big Pharma Milestones
- The Week in Review: Deals and CRO News
- The Week in Review: ChinaBio® Investor Forum Held in Tianjin
- The Week in Review: Two More R&D Centers; One PE Fund; One IPO
- The Week in Review: CROs Consolidating
- The Week in Review: The Bull in China’s R&D Shop
- The Week in Review: Major Investments
- The Week in Review: Is CRO Consolidation a New Theme?
- The Week in Review: International Initiatives
- The Week in Review: Deals and Collaborations
- The Week in Review: Cross-Border Deals
- The Week in Review: IPOs, Patents, Investment Funds and More
- The Week in Review: Three Life Science Companies to IPO on GEM
- The Week in Review: Partnership Panels from ChinaBio® Day
- The Week in Review: Deals and Products
- The Week in Review: Flu’s News
- The Week in Review: US Clinical Trial of China Diabetes Drug
- The Week in Review: TCMs, Clinical Trials and Approvals
- The Week in Review: The Business of China Life Science
- The Week in Review: A New Cross-Border Clinical Trial
- The Week in Review: Pfizer Builds China Relationships
- The Week in Review: SFDA’s Green Channel Allows Speeded-up Approval
- The Week in Review: Marking Progress
- The Week in Review: Transactions and More
- The Week in Review: Doing Deals
- The Week in Review: New Developments
- The Week in Review: Moving Forward
- The Week in Review: A New Phase?
- The Week in Review: Deals and Earnings
- The Week in Review: Earnings Week
- The Week in Review: Invention and Design
- The Week in Review: Deals and Investments in China Life Science
- The Week in Review: China Life Science, Developing
- The Week in Review: Deals Dominate
- The Week in Review: China Releases Official Health Reform Plans
- The Week in Review: Investments, Partnerships, Deals, and Earnings
- The Week in Review: Innovative China Life Science Displayed in Hong Kong
- The Week in Review: Partnerships and Financials
- The Week in Review: Cross Border Collaborations
- The Week in Review: The Art of the Almost-Deal
- The Week in Review: Prestigious Pfizer Award Goes to HD Biosciences
- The Week in Review: China Biopharma Investment
- The Week in Review: Innovative Structures for Biopharma Deals
- The Week in Review: Cautious Optimism
- The Week in Review: Biopharma News from a Holiday Week
- The Week in Review: Systemic Changes in China Biopharma
- The Week in Review: A Second Major Deal for China Biopharma in 2009
- The Week in Review: January Off to a Slow Start
- The Week in Review: Looking Forward, Looking Back
- The Week in Review: No Vacation for China Biopharma News
- The Week in Review: China Biopharma Thrives Despite the Economy
- The Week in Review: Innovation in China Biopharma
- The Week in Review: New AIDS Vaccine Leads China Biopharma News
- The Week in Review: China Deals and Healthcare Stimulus
- The Week in Review: Biopharma News Back in the Forefront
- The Week in Review: Earnings Week
- The Week in Review: More Fallout from Economic Crisis
- The Week in Review: October is Finally Over
- The Week in Review: Broad Themes and Deals
- The Week in Review: The FDA, China Deals and Earnings
- The Week in Review: Economic Troubles
- The Week in Review: Deals, Earnings and a Profile of LEAD Therapeutics
- The Week in Review: Deals, Development and Financials
- The Week in Review: A Big Question
- The Week in Review: Broad Views, Individual Company Details
- The Week in Review: Trials and Deals in China Biopharma
- The Week in Review: An FDA Office in China and Deals/Financings
- The Week in Review: Earnings and Development
- The Week in Review: Earnings, Earnings, Earnings
- The Week in Review: Earnings and More in China Biopharma
- The Week in Review: Company Profiles and Drug Advancement
- The Week in Review: Summer Slump for News
- The Week in Review: China Biomedical Investment
- Week in Review: ChinaBio® Hosts Successful Investor Forum
- The Week in Review: China Biomedical Evolving
- The Week in Review: A Week of Collaborations in China
- The Week in Review: BIO Convention and More
- The Week in Review: Deals and Drugs in China Bio
- The Week in Review: Broad Trends, Individual Companies in China Bio
- The Week in Review: Earnings, Deals and Drug Development in China
- The Week in Review: The China Biopharma Beat
- The Week in Review: The Metrics of Growth in China Biopharma
- The Week in Review: What’s Not to Like in China Biopharma?
- The Week in Review: Investment Capital for China Biopharma
- The Week in Review: Investments in China Drug Development
- The Week in Review: Consolidation in China Life Science Companies
- The Week in Review: Deals and More in China Biotech
- The Week in Review: China Biotech Stocks Down; Activity Up
- The Week in Review: Consolidation and Growth in China Biotech
- The Week in Review: China Biotech Approvals, Deals and Company News
- The Week in Review: Earnings and More in China Biotech
- The Week in Review: SFDA To Become Part of Ministry of Health
- The Week in Review: Deals and Drugs in China Biopharma
- The Week in Review: New China Biopharma Investments
- The Week in Review: The Virtualization of Biopharma
- The Week in Review: CROs in the News
- The Week in Review: Looking Good for 2008 China Biopharma Investing
- The Week in Review: China Biopharma Investing
- The Week in Review: China Speed
- The Week in Review: Big Themes and Real Progress
- The Week in Review: 2007 a Good Year for US-listed China Life Science Companies
- The Week in Review: East-West Interdependence in 2007 China Biotech
- The Week in Review: East-West Pharma Interaction
- The Week in Review: Safety Regulation Improves; Drug Business Expands
- The Week in Review: What’s Happening with China Biopharma Investing?
- The Week in Review: Cross Border Pharma Activity
- The Week in Review: Progress in China BioPharma
- The Week in Review: China Biopharma Investing, Continued
- The Week in Review: Good Week for China BioPharma Investment
- The Week in Review: Regenerx Wins China Patent
- The Week in Review: The Evolution of China Biopharma
- The Week in Review: Large IPO Announced
- The Week in Review: Anesiva Forms JV with Fosun Pharma
- The Week in Review: China and Clinical Trials
- The Week in Review: Consolidation in China Biotech
- The Week in Review: Benda Qualifies for Nasdaq Listing
- The Week in Review: US Companies Increase Presence in China
- The Week in Review: US Pharmacopeia Opens Facility in Shanghai
- The Week in Review: China Steps Up Narcotics Monitoring
- The Week in Review: Covance Advances on its Shanghai Lab
- The Week in Review: Valuation of WuXi PharmaTech
- The Week in Review: WuXi PharmaTech Estimates Q2 Results
- The Week in Review: China Laughs Last
- The Week in Review: TCM Drug Investigated as Neuroprotector
- The Week in Review: Safety News Dominates
- The Week in Review: China Withdraws Leukemia Drug
- The Week In Review: China Strategy Evolves for AstraZeneca
- The Week in Review: TCM Goes Mainstream
- The Week In Review: Drug/Food Safety Still in the News
- Legal & IP Issues
- BrightGene Copying Gilead's Remdesivir, Says It Wants to In-License the Anti-Viral
- China Files for Patent to Gilead's Remdesivir, the Front-Runner for Coronavirus Treatment
- Gilead Loses Patent Fight in China for Pricey Hep C Drug
- China Revokes J&J’s Trademark for OneTouch Diabetes Monitoring Products
- Four China Vitamin C Producers Charged in US Antitrust Suit
- China and Taiwan Sign IP Agreement
- Allele Granted Broad RNAi Patents in China
- Novartis Says Weak IP Protection Makes India R&D Impossible
- New Patent Rules Take Effect on October 1
- Waves of Changes in Chinese Patent Law and Regulations: Final Update – Part III
- Waves of Changes in Chinese Patent Law and Regulations: Final Update -- Part II
- Waves of Changes in Chinese Patent Law and Regulations: Final Update, Part I
- China Will Lead Patent Filings in 2012
- Waves of Changes in Chinese Patent Law and Regulations: A Further Update--Part III
- Waves of Changes in Chinese Patent Law and Regulations: A Further Update Part II
- Waves of Changes in Chinese Patent Law and Regulations: A Further Update, Part I
- Waves of Changes in Chinese Patent Law and Regulations: An Update, Part I
- Waves of Changes in Chinese Patent Law and Regulations–Part IV
- Waves of Changes in Chinese Patent Law and Regulations – Part III
- Waves of Changes in Chinese Patent Law and Regulations – Part II
- Waves of Changes in Chinese Patent Law and Regulations -- Part I
- Sinobiomed Granted Patent in China
- Novartis Jilts India on Investment
- Big Pharma Chooses China over India
- Introgen Hints at Suit Against Benda/SiBiono
- In My Opinion
- China View: JP Morgan Healthcare Conference, 2013
- China at JP Morgan Conference - A Few Observations
- Charles River’s Decision Shows Misunderstanding of Pharma’s Future
- China’s Opportunity to Create Mega-Clusters
- In My Opinion: China vs. the Economy - Is it China's Time?
- FDA's Presence in China - A Momentous Event
- Quake Rocks China, Biotech Rocks On
- California Surfing – Silicon Valley vs. San Diego
- Behind the Great Wall of China Biotech
- Early Stage Biotechnology Investing – At China Speed
- Follow-on Biologics Revisited: Who’s on First?
- Could War with China be Imminent?
- Food and Drug Safety: Who is Really Responsible?
- Angel Investing in Life Science: The Best of Times, the Worst of Times
- "It's a Relationship Business"
- Rumors: SFDA to Speed INDs / US FDA OK with China Data
- IPO/Stock Watch
- PegBio Plans Hong Kong IPO to Support Long Acting GLP-1 for Diabetes/Obesity
- Xtalpi, a Quantum Physics-AI Drug Discovery Company, Files for Hong Kong IPO
- WuXi XDC Raises $520 Million in IPO; Climbs 39% in First Trading Session
- WuXi XDC, an ADC/Bioconjugates CRDMO, Stages $500 Million IPO
- Adlai Nortye Closes $97.5 Million Nasdaq IPO, Drops 27% Lower in Trading
- Kelun-Biotech Raises $174 Million in Hong Kong IPO for ADC Portfolio
- Kelun-Biotech Could Raise $208 Million in Hong Kong IPO for ADC Portfolio
- Laekna Raises $100 Million in Hong Kong IPO for Cancer, Liver Fibrosis Inhibitors
- Edding Group Files for Hong Kong IPO to Support its China In-licensing Operations
- Cutia Therapeutics Raises $65 Million in Hong Kong IPO for Dermatology Products
- Kelun Biotech Plans Hong Kong IPO to Develop ADCs and Other Products
- Structure Stages Expanded $161 Million IPO for Novel Small Molecules
- Structure, a US-China Company, Files for $100 Million NASDAQ IPO
- Boan Stages $20 Million Hong Kong IPO for Biosimilar/Novel mAb Drugs
- Hrain Biotech Plans $352 Million Shanghai STAR IPO for Novel CAR Candidates
- Beijing's AIM Vaccines Nets $10 Million in Small Hong Kong IPO
- YishengBio Announces Merger with NASDAQ SPAC Company at $834 Million Value
- Xuanzhu Biopharm, a Sihuan Subsidiary, Files to Raise $345 Million in Shanghai STAR IPO
- Apollomics, a US-China Biopharma, will Merge with SPAC to List on NASDAQ Exchange
- Lepu Medical, a Medical Device Company, Raises $224 Million by Listing on Swiss Exchange
- Biocytogen Closes $60 Million Hong Kong IPO for Animal Models and Drug Development
- Genuine Biotech Files for Hong Kong IPO to Support Novel Drug Portfolio
- InvestisBio Completes $296 Million IPO on the Shanghai STAR Board
- Joincare Plans IPO on the SIX Swiss Stock Exchange
- I-Mab and VMS Partner to IPO a SPAC in HK for a China Life Science Company
- RemeGen Stages $410 Million Shanghai IPO; Trades Lower
- OBiO Completes Shanghai IPO for Gene/Cell CDMO Services; Trades 67% Higher
- Recbio Plans to Raise $98 Million in a Hong Kong IPO for Vaccines
- Lepu Completes $116 Million HK IPO; Trades Flat in Opening Sessions
- Lepu Bio Seeks to Raise $115 Million in Hong Kong IPO
- BeiGene Begins Trading on Shanghai STAR Board; Slides 17% Lower
- CANbridge Raises $77 Million in Hong Kong IPO; Shares Trade Lower
- BeiGene Raises $3.5 Billion in Shanghai STAR Board IPO
- BeiGene Gets Green Light for $3 Billion Shanghai STAR IPO
- Shanghai AoHua Endoscope Raises $117 Million in IPO; Trades 71% Higher
- LianBio Completes $325 Million US IPO to Support China In-Licensing Program
- Microtech Medical Stages $233 Million Hong Kong IPO for Diabetes Devices
- Abbisko Raises $226 Million in Hong Kong IPO for Cancer Therapies
- MicroTech to Raise up to $254 Million in Hong Kong IPO for Diabetes Products
- LianBio Files for $100 Million IPO on NASDAQ
- Broncus Completes $200 Million Hong Kong IPO for Pulmonary Devices
- Cue Health Plans $180 Million US IPO for Home Healthcare Platform
- Sino Biological Raises $772 Million in Shenzhen ChiNext IPO
- I-Mab Plans Second Listing on Shanghai's STAR Board
- Sirnaomics Plans $300 Million Hong Kong IPO for RNAi Portfolio
- Mabworks Plans Hong Kong IPO to Support Antibody/Multi-Specifics Pipeline
- Keymed Stages $378 Million Hong Kong IPO for Antibody Portfolio
- BeiGene Approved to Stage $3 Billion IPO on Shanghai STAR Exchange
- HutchMed Completes $537 Million Hong Kong IPO for Oncology Drugs
- HutchMed to Raise $600 Million in Hong Kong IPO
- LinkDoc, a Beijing Cancer Data Company, to Raise up to $500 Million in US IPO
- CARsgen Therapeutics to Raise $400 Million in Hong Kong IPO
- Ambrx, a San Diego-Shanghai Biotech, Files for $100 Million US IPO
- Connect Bio Raises $191 Million in NASDAQ IPO for Autoimmune Portfolio
- Taicang's Connect Biopharma Files for $100 Million NASDAQ IPO
- SciClone IPOs on Hong Kong Exchange, Raising $279 Million
- New Horizon Stages $263 Million HK IPO for Cancer Screening Tests
- Microport Cardioflow Completes $324 Million HK IPO for Heart Valve Devices
- Adagene Completes $140 Million US IPO, Climbs 56% Higher
- Adagene of Suzhou Files for $125 Million US IPO
- Gracell Raises $209 Million in US IPO for Novel CAR-T Therapies
- APT Medical Closes $191 Million Shanghai STAR Board IPO
- Jacobio, a Beijing Biopharma, Raises $174 Million in Hong Kong IPO
- Harbour BioMed Raises $221 Million in Hong Kong IPO
- JD Health Completes $3.5 Billion HK IPO; Climbs 45% on First Day
- Antengene Completes $340 Million Hong Kong IPO for Oncology Drugs
- BeiGene Plans to Raise up to $2.5 Billion in Shanghai Star IPO
- RemeGen Raises $515 Million in Hong Kong IPO, Company Valued at $4.3 Billion
- JW Therapeutics Completes $300 Million Hong Kong IPO for CAR-T Products
- Gland Pharma, Fosun's Indian Subsidiary, Approved for $814 Million IPO
- Shanghai's Everest Medicines Stages $451 Million Hong Kong IPO
- Genor Completes $371 Million Hong Kong IPO; Market Cap Reaches $1.8 Billion
- Zai Lab Raises $761 Million in Hong Kong IPO; Climbs 8.5% Higher
- Genor Bio Conducting $370 Million IPO in Hong Kong
- JD Health, an Online Company, Plans $3 Billion Hong Kong IPO
- Zai Lab Conducting $845 Million IPO in Hong Kong
- Antengene Cleared to Stage $200 Million IPO in Hong Kong
- JW Therapeutics Files for $300 Million Hong Kong IPO
- CanSino Raises $748 Million in Shanghai STAR IPO for Vaccines, Including its COVID-19 Candidate
- Tigermed, a China Clinical CRO, Seeks up to $1 Billion in Hong Kong IPO
- Sunshine Guojian, a 3SBio Subsidiary, Plans $248 Million Shanghai STAR Board IPO
- Junshi Bio Stages $692 Million IPO on Shanghai's STAR Board
- Gland Pharma, a Fosun Subsidiary, Plans $650 Million IPO in India
- Ocumension Stages $184 Million HK IPO; Climbs 152% on First Day
- Hygeia Healthcare Stages $282 Million Hong Kong IPO for Radiotherapy Services
- Gan & Lee Raises $360 Million in Shanghai IPO; Trades up 44%
- SinocellTech Closes $181 Million IPO on STAR Board; Triples in Initial Trading
- Burning Rock Raises $223 Million In US IPO; Climbs 50% in Trading
- Simcere Plans to Raise a Rumored $500 Million in Hong Kong IPO
- Nanjing Legend Bio Completes $424 Million NASDAQ IPO; Shares Rise 60%
- Nanjing Legend Biotech Plans to Raise $350 Million in US IPO at $2.6 Billion Valuation
- Kintor Pharma Stages $240 Million Hong Kong IPO for Androgen Receptor Drugs
- Burning Rock of Guangzhou Plans $100 Million IPO on NASDAQ
- Peijia Medical Raises $302 Million in Hong Kong IPO for Medical Devices
- Nanjing Legend Approved for $100 Million US IPO on NASDAQ
- Ocumension Files for Hong Kong IPO to Advance Ophthalmology Portfolio
- AkesoBio Completes $335 Million Hong Kong IPO; Climbs 50% on First Trading Day
- Junshi Biosciences Approved for Shanghai STAR IPO, a Dual Listing with Hong Kong
- InnoCare (Beijing) Prices Hong Kong IPO at Top of Range, Raises $288 Million
- Legend, a Nanjing CAR-T Biotech, Files for a US IPO
- Bio-Thera, an Antibody Company, Prices $241 Million Shanghai STAR Board IPO
- AkesoBio Files for $300 Million Hong Kong IPO to Develop Antibody Portfolio
- I-Mab Completes $104 Million NASDAQ IPO to Develop Biologics Portfolio
- I-Mab Announces Terms for $100 Million US IPO; Starts China Trial of Immunoncology Drug
- Alphamab Oncology Closes $234 Million Hong Kong IPO; Climbs 35% in First Session
- Alphamab Oncology Tees Up $350 Million Hong Kong IPO
- Pharmaron Stages $434 Million Hong Kong IPO, after Completing Shenzhen IPO in January
- BrightGene Completes $74 Million Shanghai Star Board IPO; Trades 141% Higher
- Tot Biopharm Completes $66.5 Million Hong Kong IPO
- SinoMed, a Medical Device Company, Stages $50 Million IPO on the Shanghai STAR Exchange
- SinoMab is Raising $223 Million in a Hong Kong IPO
- I-Mab Files for $100 Million IPO on the NASDAQ Exchange
- Ascentage Pharma Rises 10% in First Trading Session after IPO
- China Aesthetics Company Completes $30 Million US IPO
- Ascentage Pharma Completes $53 Million Hong Kong IPO
- CanSino to Add Shanghai Star Board IPO to Hong Kong Listing
- Henlius Prices Hong Kong IPO at the Bottom of the Range, Raising $410 Million
- Henlius Biotech Prices Hong Kong IPO to Raise $477 Million
- Beijing's Immunotech Plans to Raise up to $200 Million in Hong Kong IPO
- BrightGene Plans $50 Million Shanghai STAR Board IPO
- Nanjing Frontier Biotech Plans $285 Million IPO on Shanghai STAR Exchange
- Chipscreen Bio Climbs 367% on First Trading Day following Shanghai IPO
- Shenzhen Chipscreen Raises $148 Million in Shanghai STAR IPO at $1.2 Billion Valuation
- Initial 25 IPOs on the Shanghai STAR Board Jump 140% Higher in First Session
- Chipscreen Poised to be One of the First IPOs on Shanghai's STAR Exchange
- Suzhou's Alphamab Oncology Approved to IPO on Hong Kong Exchange
- HitGen Approved for $97 Million IPO on Shanghai's STAR Board
- SinoMab Bioscience, a Hong Kong Biotech, to IPO on Hong Kong Exchange
- Jibeier Pharm Files for IPO on Shanghai's New Tech Innovation Board
- Tasly Biopharma Files for Hong Kong IPO That Could Raise $1 Billion
- Hansoh Completes $1 Billion Hong Kong IPO; Rises 37% in First Trading Session
- Frontage, a US-China CRO, Completes $205 Million Hong Kong IPO
- Hansoh Seeks to Raise $1 Billion at Top of Hong Kong IPO Range
- Mabpharm Hong Kong IPO to Raise $172 Million at $900 Million Valuation
- Viva Biotech Completes $194 Million Hong Kong IPO; Trades Higher
- Ally Bridge Leads $65 Million Round in Pulmonx, a COPD Device Company
- InnoCare Planning $250 Million IPO on Hong Kong Exchange
- Junshi Aims to Become First Company with Dual Hong Kong and Shanghai Listings
- Suzhou's Tot Biopharm, a Cancer Company, Plans Hong Kong IPO
- Hong Kong's Pre-Revenue China Biotech IPOs: A Tale of Two Markets
- Viva Biotech Raising $194 Million in Hong Kong IPO for CRO Operations
- Chi-Med Plans $500 Million IPO in Hong Kong, its Third Listing
- Hansoh Pharma Re-Files for $500 Million to $1 Billion Hong Kong IPO
- CanSino Biologics Climbs 58% Following $161 Million Hong Kong IPO
- Tianjin's CanSino to Raise $160.5 Million for Novel Vaccines in Hong Kong IPO
- CStone Pharma Completes $285 Million Hong Kong IPO; Trades Higher
- Suzhou's CStone Pharma Schedules $304 Million Hong Kong IPO for Next Week
- Junshi Biopharma Rises 22% Following $394 Million Hong Kong IPO
- Hong Kong's Aptorum Stages $12 Million US IPO for Drug Development
- WuXi AppTec Completes Hong Kong IPO; Finishes First Trading Session Unchanged
- Shanghai Junshi Bioscience to Raise $414 Million in Hong Kong IPO
- WuXi AppTec Raises $1 Billion in Hong Kong IPO
- WuXi AppTec to Price $1 Billion Hong Kong IPO on December 6
- CStone Pharma Files for Hong Kong IPO to Support its Oncology Portfolio
- Innovent Completes $421 Hong Kong IPO; Trading Begins in One Week
- Innovent to Raise $422 Million in Hong Kong IPO at $2 Billion Valuation
- Fosun Pharma Officially Announces Plan for Henlius IPO in Hong Kong
- Zhejiang Anglikang Pharma Approved for $87 Million IPO in Shenzhen
- WuXi AppTec Files for $1 Billion-Plus IPO in Hong Kong
- Hua Medicine Stages $110 Million Hong Kong IPO at $1.1 Billion Valuation
- Hansoh Pharma Plans Hong Kong IPO that Could Raise $1-$3 Billion
- Mabpharm Becomes 11th China Biotech to File for Hong Kong IPO
- Zai Lab Plans Hong Kong IPO to Raise up to $300 Million
- Ascentage Pharma Officially Announces its Hong Kong IPO
- Loncar Launches China BioPharma ETF on NASDAQ Exchange
- Ascletis and BeiGene Trade Lower Following Hong Kong IPOs
- Shanghai Junshi Files for $500 Million HK IPO; Has $2 Billion Valuation
- Ascletis Completes $400 Million IPO; Valuation is $2 Billion
- BeiGene Raised $900 Million in Hong Kong Debut Offering
- Ascletis' Hong Kong IPO to Raise $457 Million at $2 Billion Valuation
- CanSino Biologics Files for Hong Kong IPO
- Hua Medicine Files for Hong Kong IPO -- Rumors Predict a $200 Million Debut
- Ascletis, a Pre-Revenue China Biopharma, Files for Hong Kong IPO
- WuXi AppTec IPOs in Shanghai Exchange
- Hong Kong Aims to be IPO Venue of Choice for Young China Life Science Companies
- Ping An Healthcare and Technology Plans $1 Billion HK IPO for May
- Tasly Pharma Planning $1 Billion IPO in Hong Kong for Biologics Operations
- Grail, a US-Hong Kong Diagnostics Company, May Stage $500 Million Hong Kong IPO
- Mindray Medical Nixes Shenzhen IPO; Seeks New Venue
- Ping An Good Doctor Files for Hong Kong IPO Expected to Raise $1 Billion
- ARMO, Backed by China Investors, Completes $128 Million IPO in US
- Luye Considering $500 Million Singapore IPO for Healthcare Assets
- Sisram Medical, Majority-Owned by Fosun, Stages $125 Million Hong Kong IPO
- Zai Labs Completes $150 Million IPO; Stock Jumps 50% at Opening; Company Worth $1.4 Billion
- Berry Genomics Completes $648 Million Reverse Merger in Shenzhen
- Sinovac Prices Secondary Offering
- Sinovac Issues 2009 Guidance; Announces Secondary Stock Issue
- Mindray Medical Will Beat Analysts’ 2009 Predictions
- China-listed Life Science IPOs Are Hot
- Mixed Results for China Life Science US IPOs
- Anhui Anke Biotech Nearly Triples in ChiNext’s First Day
- The China IPO Window is Open for Pharma Companies
- ShanghaiBio Plans US IPO in 2008
- Jiaying Pharma to IPO in Shenzhen
- Insiders Sell Benda Shares despite Positive India News
- 3SBio Rises after Reporting Q3 Results
- China Nepstar Prices IPO at 30% Premium to Range
- Tongjitang Key Drug Flat in Q3
- Simcere Reports In-Line Q3; Takes Haircut
- Shares of China Pharma of Hainan on a Roll
- 3SBio Soars 23% on Analyst Comment
- Simcere and Tongjitang Attractively Priced
- Four Shanghai CROs To Go Public
- WuXi Reports 99% Increase in Q2 Revenue
- Bayer/Onyx Report Success in Asian Trial for Nexavar
- Aspreva Pays Roche for CellCept Development in China
- Optimer Pharma to Talk Collaboration with C&O
- China Shenghuo Announces Higher Q2 Results
- Lilly Partners with Chi-Med
- Sinovac Profitable in First Half
- China Biopharma Struggling with Enshi Acquisition
- Tongjitang Chinese Medicines Reports Higher Q2
- Sinobiomed Buys Distributor
- American Oriental Makes Another Acquisition
- 3SBio Hits its Q2 Targets
- WuXi Prices IPO above Range
- Mindray Medical Beats Street
- Simcere Posts Higher Revenues, Earnings for Q2
- IPO Watch: WuXi PharmaTech Files For NYSE IPO
- IPO Watch: WuXi PharmaTech Expected to Stage US IPO
- A Listing of Publicly Held Chinese Life Science Companies
- IPO Watch: WuXi PharmaTech Next?
- IPO Watch: Simcere Supplies High-End Generics In China
- Nasdaq To Start Chinese Stock Index
- IPO Watch: Tongjitang Chinese Medicines Prices at $10
- Cell & Gene Therapy
- Gritgen Advances Hemophilia A Gene Therapy; Completes Manufacturing Plant
- ImmVira Manufacturing Virus Vectors to Enable Solid Tumor CAR-T Products
- ImmVira Opens In-House Production Facility for Oncolytic Viruses
- Qihan Biotech Applies Genome Editing to Create Allogenic Stem Cells
- Wall Street Journal: Dr. Jiankui He, the Man Who Edited China Embryos, Was a Product of the System
- China Approves Merck's Keytruda, a PD-1 Drug, for First Line NSCLC
- Cellular Biomedicine Opens Shanghai CAR-T Facility
- CAS Announces Stem Cell Initiative
- Cellonis Uses Stem Cells to Treat Diabetes
- Beike Forms JV to Deliver Stem Cell Therapies throughout Asia
- Beike Reports Successful Test of Stem Cell Treatment for Lupus
- China Cord Blood Pays $20 Million for Stake in Shandong Cord Blood Bank
- Beike Biotech Given $1.8 Million Grant for Umbilical Cord Stem Cell Trial
- CRO/CMO Services
- WuXi Biologics’ Novel Bioprocessing Platform Offers Higher Yields, Lower Costs
- WuXi Biologics Pays $183 Million to Acquire Bayer German Manufacturing Facility
- PPD Plans Major Suzhou Lab to Offer China Drug Development Services
- Frontier Bio and Thermo Fisher to Collaborate on Novel HIV Candidate
- Harbour BioMed to Collaborate with PPD on Clinical Development
- GenScript Completes Phase I of Nanjing Biologics CDMO R&D/Production Center
- Harbour Antibodies Partners with Abveris, a Boston Drug Discovery CRO
- dMed and Target Join to Offer China-US Clinical CRO Services
- dMed, a Shanghai Clinical CRO, Opens Washington Office for US FDA Filings
- Boehringer Ingelheim Expands Shanghai Biologics CDMO Facility
- XingImaging Announces China Neuro-PET Scanning for Alzheimer's Trial
- WuXi Biologics Plans Another New CDMO Plant -- A $240 Million Facility in Shijiazhuang
- Sinobioway to Invest $471 Million Build a CMO Site in Hefei
- WuXi Biologics Opens Expanded $150 Million Biomanufacturing Facility
- WuXi Biologics Partners with Pall to Reduce mAb Production Costs
- Samsung BioLogics' New Plant Approved by FDA
- Germany's Merck Opens Biologics CRO/CMO in Shanghai
- WuXi AppTec Merges Formulation/Finishing Services into API Manufacturing Division
- Boehringer Ingelheim Opens $77 Million Shanghai Biologics CMO Plant; Establishes R&D Partnership with Peking University
- CrownBio Opens New CRO Facility in Louisiana
- ASLAN Signs up JHL to Provide Process Development for Asthma Treatment
- CANbridge Uses Boehringer Ingelheim China to Manufacture Novel Biologic
- WuXi's SynTheAll Manufacturing Subsidiary Opens San Diego Facility
- WuXi Biologics and Sartorius Open Joint Shanghai Lab for Biologic Drugs
- WuXi AppTec Begins Operations at $100 Million Changzhou Facility
- WuXi AppTec Announces $120 Million Shanghai Biologics Center
- Samsung Building $730 Million Biologics CMO Facility in Korea
- BIT Group Opens Second China CMO Facility in Shenzhen
- WuXi PharmaTech Launches App for Oncology Models
- Quintiles Opens New China Regional Headquarters in Shanghai
- WuXi PharmaTech: Q1 Revenues up 23%; Earnings Flat
- WuXi PharmaTech Starts Construction of $150 Million Biologics Facility
- PPD Opens Central Lab at Shanghai Clinical Research Center
- Sihuan Pharma and Covance Strike Global CRO Partnership Deal
- WuXi PharmaTech Building CAR T Facility in Philadelphia
- Shanghai Biotech Forms Genomic CRO Alliance with AKESOgen
- WuXi PharmaTech Unveils Mobile App to Order Chemical Synthesis
- WuXi PharmaTech Making Good on Biologics Investments
- Novotech, an Australian CRO, Opens Shanghai Office
- BeiGene Signs China CMO Deal with Boehringer Ingelheim
- ScinoPharm to Supply API for TaiGen’s Stem Cell Mobilizer
- WuXi PharmaTech Finishes Building a Biologics Biosafety Lab in Suzhou
- WuXi PharmaTech Starts Construction of $100 Million Plant in Changzhou
- WuXi PharmaTech Adds to Biologics Manufacturing Facility in Philadelphia
- WuXi’s Biologics Facility Wins International Award
- WuXi PharmaTech Expands Genomics with Illumina Sequencer
- JHL Biotech Offers Selexis's Technology for Biologics Development
- WuXi PharmaTech to Produce New Cancer Drug for Pharmacyclics
- A WuXi PharmaTech CMO Facility Attains US GMP Certification
- WuXi PharmaTech's Shanghai Lab Certified for Genomic Screening
- Siegfried Holdings Building China CMO Facility
- MicroConstants China to Manage Clinical Research Center at #307 Hospital
- Can-Fite Biopharma Shifts Drug Manufacturing to China
- Innovent Constructing Biologic Facility in Suzhou
- SLG-Giant Pharm, a China CRO, to Run China Arm of US NIH Trial
- New Beijing Facility for MicroConstants China Given GLP Cert
- WuXi PharmaTech Signs CMO Deal with TaiMed Biologics
- Tigermed and MSD China Sign LOI for Clinical Trial Services
- PRA, an International CRO, Opens Second Office in China
- WuXi PharmaTech Reports 29% Rise in Q2 Revenues
- ScinoPharm Building $37.6 Million Cancer Drug CMO in Tainan
- Suzhou Pharma Opens US Corporate Office
- Four Companies Join Forces to Form Pan-Asia Pacific Clinical CRO
- Hisun Pharma to Supply Celsion’s Proprietary Cancer Drug
- Hainan Haiyao Uses Knowshine to Develop Antibiotic Intermediate
- Novasep Opens New Shanghai Facility
- BioDuro Collaborates with Dow to Develop Crop Protection Products
- Frontage Labs Completes US Phase I Trial for China TCM Company
- Frontage Labs Opens Clinical-Stage CRO in Jilin Hospital
- Quintiles, a Clinical-Stage CRO, will Double China Headcount
- CRO ClinTec Making Push into China and Asia Pacific Region
- Shenogen Signs Up ShangPharma to Help Develop Cancer Drug
- Pharmaron Signs CMO Contract with Isis Pharma
- Bristol-Myers Squibb to Partner with WuXi PharmaTech
- ScinoPharm to Provide CMO Services for New Anti-Depressant
- American Oriental Signs Up with US CRO for Clinical Trials
- Charles River Labs Seeks Suitors for its Shanghai Facility
- START and Cenova Ventures Form JV for Cancer Phase I Trial Facility
- ShangPharma Opens cGMP Manufacturing Facility
- WuXi PharmaTech Announces Outstanding Q3 Numbers
- D-Pharm Selects Tigermed for Trial of Stroke Drug
- Fountain Medical and ICON Partner to Offer Central Lab Services
- Medpace Announces Accreditation for Central Labs in Beijing and Mumbai
- PPD Opens Vaccine Research Center in Taizhou
- PhytoMedical and Medicilon Seek China Partner for Cancer Drug
- Charles River Shanghai Is GLP Certified by OECD Member Country
- Tigermed Grows International Business through Partnership with ICON
- Quintiles' Beijing Lab to Offer Anatomic Pathology Services
- Pharmaron Acquires Bridge Labs China
- Shanghai ChemPartner Places Third in Fast 50 China
- AlphaRx Outsources Hepatitis Drug Manufacturing to Venturepharm
- Crown Bioscience Forms Cancer Collaboration with Pfizer
- Shanghai ChemPartner Aids Agios’ Cancer Research Breakthrough
- Shanghai ChemPartner Opens European Headquarters
- PharmaLegacy's First Year; Accredited by AAALAC
- Charles Rivers’ Shanghai Facility Receives Accreditations
- Shanghai ChemPartner and ELARA Pharma Extend Cancer Drug Work
- Express Clearance Cuts Customs Delay to One Day for CRO Sundia MediTech
- Shanghai ChemPartner and Agios Expand Cancer Drug Collaboration
- Sundia Acquires Protein Folding Technology
- Eurofins China Central Lab Receives Accreditation
- Asymchem Wins Pfizer Award: Opens New Plant;
- CRO XenoBiotic to Open Lab in Nanjing
- Charles River Labs Looking for 2nd China CRO Site
- ChinaBio® Publishes Proprietary China CRO/CMO List on goBalto
- Excel PharmaStudies Receives Asia Pacific CRO of the Year Award
- Excel PharmaStudies Opens Biometrics Center in Taizhou City
- Excel and GVK BIO Form China-India CRO Alliance
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China